Hercules Capital (HTGC) 10-Q 3 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Jul. 26, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Central Index Key	0001280784
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		144,602,208
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	814-00702
Entity Tax Identification Number	74-3113410
Entity Address, Address Line One	400 Hamilton Ave
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	289-3060
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MD
Document Quarterly Report	true
Document Transition Report	false
Common Stock Par Value $0.001 Per Share
Document Information [Line Items]
Title of 12(b) Security	Common Shares, par value $0.001 per share
Trading Symbol	HTGC
Security Exchange Name	NYSE
6.25% Notes Due 2033
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2033
Trading Symbol	HCXY
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF ASSE

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2023		Dec. 31, 2022
Assets
Total investments, at fair value	$ 3,112,789		$ 2,963,955
Cash and cash equivalents	61,695		15,797
Restricted cash (amounts related to a VIE $12,339 and $10,079, respectively)	12,339		10,079
Interest receivable	32,086		31,682
Right of use asset	3,783		4,986
Other assets	1,812		2,356
Total assets	3,224,504		3,028,855
Liabilities
Debt (net of debt issuance costs - Note 5; amounts related to a VIE $148,251 and $147,957, respectively)	1,588,608		1,574,351
Accounts payable and accrued liabilities	46,500		47,539
Operating lease liability	3,886		5,506
Total liabilities	1,638,994		1,627,396
Net assets consist of:
Common stock, par value	145		134
Capital in excess of par value	1,468,270		1,341,416
Total distributable earnings	117,095		59,909
Total net assets	1,585,510		1,401,459
Total liabilities and net assets	$ 3,224,504		$ 3,028,855
Shares of common stock outstanding ($0.001 par value and 200,000 authorized)	144,641		133,045
Net asset value per share	$ 10.96		$ 10.53
Investment, Unaffiliated Issuer [Member]
Assets
Total investments, at fair value	$ 3,021,866		$ 2,887,497
Investment, Affiliated Issuer, Controlled [Member]
Assets
Total investments, at fair value	$ 90,923	[1],[2]	$ 76,458	[3]
[1] All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 . All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

CONSOLIDATED STATEMENTS OF AS_2

CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Investment cost	$ 3,114,097	$ 3,005,696
Restricted cash (amounts related to a VIE $12,339 and $10,079, respectively)	12,339	10,079
Net of debt issuance costs	$ 1,588,608	$ 1,574,351
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Investment, Unaffiliated Issuer [Member]
Investment cost	$ 3,025,780	$ 2,918,425
Investment, Affiliated Issuer, Controlled [Member]
Investment cost	88,317	87,271
VIE
Investment cost	256,076	236,585
Restricted cash (amounts related to a VIE $12,339 and $10,079, respectively)	12,339	10,079
Net of debt issuance costs	$ 148,251	$ 147,957

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022
Investment income:
Total interest and dividend income		$ 108,986		$ 68,731		$ 208,883		$ 130,983
Fee Income		7,245		3,384		12,438		6,289
Gross Investment Income, Operating, Total		116,231		72,115		221,321		137,272
Operating expenses:
Interest		17,184	[1]	12,698	[2]	33,809	[1]	24,345	[2]
Loan fees		2,464		1,492		4,793		3,334
General and administrative		5,151		4,322		9,277		8,140
Investment Income, Operating, Tax Expense (Benefit)		1,980		1,821		3,367		2,533
Total gross operating expenses		42,945		35,054		85,215		65,826
Expenses allocated to the Adviser Subsidiary		(2,414)		(3,070)		(5,093)		(4,472)
Employee compensation:
Compensation and benefits		12,841		11,060		27,458		19,389
Employee benefits and share-based compensation		3,325		3,661		6,511		8,085
Employee compensation		16,166		14,721		33,969		27,474
Total net operating expenses		40,531		31,984		80,122		61,354
Net investment income		75,700		40,131		141,199		75,918
Net realized gain (loss):
Loss on debt extinguishment of debt		0		0		0		(3,686)
Total net realized gain (loss)		217		(2,133)		8,177		(4,514)
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		18,858		(48,316)		39,963		(85,058)
Total net realized gain (loss) and net change in unrealized appreciation (depreciation)		19,075		(50,449)		48,140		(89,572)
Net Income		$ 94,775		$ (10,318)		$ 189,339		$ (13,654)
Net investment income before investment gains and losses per common share:
Net investment income before investment gains and losses per common share: Basic		$ 0.53		$ 0.32		$ 1.01		$ 0.62
Change in net assets resulting from operations per common share:
Basic		0.66		(0.09)		1.35		(0.12)
Diluted		$ 0.66		$ (0.09)		$ 1.34		$ (0.12)
Weighted average shares outstanding
Basic		141,390		124,255		138,338		121,292
Diluted		142,084		124,255		139,587		121,292
Distributions paid per common share:
Basic		$ 0.47		$ 0.48		$ 0.94		$ 0.96
Investment, Affiliated Issuer [Member]
Investment income:
Total interest and dividend income		$ 0		$ 76		$ 0		$ 1,123
Gross Investment Income, Operating, Total	[3]							3,415
Net realized gain (loss):
Total net realized gain (loss)								3,772
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)								5,640
Investment, Unaffiliated Issuer [Member]
Investment income:
Fee Income		7,226		3,367		12,400		6,256
Net realized gain (loss):
Total net realized gain (loss)		217		(2,133)		8,177		(4,600)
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		14,285		(51,749)		26,544		(90,698)
Investment, Affiliated Issuer, Controlled [Member]
Investment income:
Total interest and dividend income	[4]	1,055		1,144		2,171		2,259
Fee Income	[4]	19		17		38		33
Gross Investment Income, Operating, Total						2,209	[5]	2,292	[3]
Net realized gain (loss):
Total net realized gain (loss)	[4]	0		0		0		0
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)	[4]	4,573		4,728		13,419		6,182
Investment, Affiliated Issuer, Noncontrolled [Member]
Investment income:
Total interest and dividend income		107,931		67,511		206,712		127,601
Gross Investment Income, Operating, Total	[3]							1,123
Net realized gain (loss):
Total net realized gain (loss)		0		0		0		3,772
Net change in unrealized appreciation (depreciation):
Total net change in unrealized appreciation (depreciation)		$ 0		$ (1,295)		$ 0		$ (542)
[1] Interest expense includes amortization of original issue discounts for the three months ended June 30, 2023 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2023, $ 83 thousand, $ 251 thousand, and $ 94 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the three months ended June 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 4 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2022, $ 23 thousand, $ 112 thousand, $ 84 thousand, $ 223 thousand, and $ 4 thousand, related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 . Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS - USD ($) $ in Thousands	3 Months Ended				6 Months Ended				12 Months Ended
	Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022		Dec. 31, 2022
Common stock, par value					$ 134
Capital in excess of par value					1,341,416
Distributable Earnings (loss)					59,909
Net assets at Beginning of period	$ 1,499,006		$ 1,333,448		1,401,459		$ 1,308,547		$ 1,308,547
Net Income (Loss)	94,775		(10,318)		189,339		(13,654)
Gross Proceeds	65,406		61,855		$ 130,748		$ 147,104
Public offering, net of offering expenses (Shares)					9,700,000		8,900,000
Shares retired on vesting of equity-based awards	(10,311)		(894)		$ (11,828)		$ (4,620)
Issuance of common stock under equity-based award plans	76		0		215		454
Distributions reinvested in common stock	939		921		$ 1,879		$ 1,946
Distributions reinvested in common stock (Shares)					133,142		121,471
Issuance of Convertible Notes							$ 0
Distributions	(67,379)		(59,993)		$ (132,153)		(117,875)		(249,077)
Stock-based compensation (1)	$ 2,998	[1]	$ 2,721	[2]	$ 5,851	[1]	$ 5,838	[2]
Ending Balance (Shares)	144,641,000		127,285,000		144,641,000		127,285,000
Common stock, par value	$ 145				$ 145				134
Capital in excess of par value	1,468,270				1,468,270				1,341,416
Distributable Earnings (loss)	117,095				117,095				59,909
Net assets at end of period	$ 1,585,510		$ 1,327,740		$ 1,585,510		$ 1,327,740		$ 1,401,459
Common Stock
Beginning Balance (Shares)	138,596,000		123,194,000		133,045,000		116,619,000		116,619,000
Common stock, par value	$ 139		$ 124		$ 134		$ 117		$ 117
Gross Proceeds	$ 5		$ 4		$ 9		$ 9
Public offering, net of offering expenses (Shares)	5,062,000		4,061,000		9,721,000		8,921,000
Shares retired on vesting of equity-based awards (Shares)	(44,000)		(54,000)		(160,000)		(182,000)
Issuance of common stock under equity-based award plans	$ 1				$ 2		$ 1
Issuance of common stock under equity-based award plans (Shares)	955,000		23,000		1,902,000		825,000
Distributions reinvested in common stock (Shares)	72,000		61,000		133,000		121,000
Issuance of Convertible Notes							$ 1
Issuance of Convertible Notes (Shares)							981,000
Distributions	$ 66,672		$ 59,431		$ 130,696		$ 116,693
Ending Balance (Shares)	144,641,000		127,285,000		144,641,000		127,285,000		133,045,000
Common stock, par value	$ 145		$ 128		$ 145		$ 128		$ 134
Capital in Excess of Par Value
Capital in excess of par value	1,409,168		1,178,019		1,341,416		1,091,907		1,091,907
Gross Proceeds	65,401		61,851		130,739		147,095
Shares retired on vesting of equity-based awards	(10,311)		(894)		(11,828)		(4,620)
Issuance of common stock under equity-based award plans	75				213		453
Distributions reinvested in common stock	939		921		1,879		1,946
Issuance of Convertible Notes							(1)
Stock-based compensation (1)	2,998	[1]	2,721	[2]	5,851	[1]	5,838	[2]
Capital in excess of par value	1,468,270		1,242,618		1,468,270		1,242,618		1,341,416
Distributable Earnings (Loss)
Distributable Earnings (loss)	89,699		155,305		59,909		216,523		216,523
Net Income (Loss)	94,775		(10,318)		189,339		(13,654)
Distributions	(67,379)		(59,993)		(132,153)		(117,875)
Distributable Earnings (loss)	$ 117,095		$ 84,994		$ 117,095		$ 84,994		$ 59,909
[1] Stock-based compensation includes $ 30 thousand and $ 50 thousand of restricted stock and option expense related to director compensation for the three and six months ended June 30, 2023 , respectively. Stock-based compensation includes $ 36 thousand and $ 76 thousand of restricted stock and option expense related to director compensation for the three and six months ended June 30, 2022 , respectively.

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]
APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition	$ 30	$ 36	$ 50	$ 76

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Cash flows provided by (used in) operating activities:
Net Income (Loss)		$ 189,339	$ (13,654)
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments		(834,759)	(790,706)
Fundings assigned to Adviser Funds		199,866	189,806
Net change in unrealized (appreciation) depreciation		(39,963)	85,058
Net realized (gain) loss		(8,177)	828
Accretion of paid-in-kind principal		(11,347)	(9,943)
Change in loan income, net of collections		12,421	7,119
Unearned fees related to unfunded commitments		(68)	1,819
Realized loss on debt extinguishment		0	364
Amortization of debt fees and issuance costs		3,474	2,570
Depreciation and amortization		108	110
Stock-based compensation and amortization of restricted stock grants (1)	[1]	5,851	5,838
Change in operating assets and liabilities:
Interest receivable		(393)	(4,768)
Other assets		7,546	482
Accrued liabilities		(2,574)	(12,630)
Net cash provided by (used in) operating activities		52,766	(306,707)
Cash flows provided by (used in) investing activities:
Purchases of capital equipment		(379)	(74)
Net cash provided by (used in) investing activities		(379)	(74)
Cash flows provided by (used in) financing activities:
Issuance of common stock		132,329	148,721
Offering expenses		(1,581)	(1,617)
Retirement of employee shares, net		(11,613)	(4,166)
Distributions paid		(130,274)	(115,929)
Issuance of debt		380,000	1,124,237
Repayment of debt		(368,000)	(854,374)
Debt issuance costs		0	(6,076)
Fees paid for credit facilities and debentures		(5,090)	(1,600)
Net cash provided by (used in) financing activities		(4,229)	289,196
Net increase (decrease) in cash, cash equivalents, and restricted cash		48,158	(17,585)
Cash, cash equivalents, and restricted cash at beginning of period		25,876	136,265
Cash, cash equivalents, and restricted cash at end of period		74,034	118,680
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid		33,664	22,642
Income tax, including excise tax, paid		5,151	7,281
Distributions reinvested		1,879	1,946
Equity and Warrant Investments [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Principal and fee repayments received and proceeds from the sale of debt investments		30,074	7,749
Debt Investment [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Principal and fee repayments received and proceeds from the sale of debt investments		516,535	237,178
Convertible Note Discounts - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion of loan discounts		0	112
Discounts - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion of loan discounts		(3,211)	(1,982)
Exit Fees - Amortization [Member]
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Accretion of loan discounts		$ (11,956)	$ (12,057)
[1] Stock-based compensation includes $ 50 thousand and $ 76 thousand of restricted stock and option expense related to director compensation for the six months ended June 30, 2023 and 2022 , respectively.

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Statement of Cash Flows [Abstract]
Restricted stock and option expense related to director compensation	$ 30	$ 36	$ 50	$ 76
Cash and cash equivalents	61,695	115,309	61,695	115,309	$ 15,797
Restricted cash	12,339	3,371	12,339	3,371	10,079
Total cash, cash equivalents, and restricted cash presented in the Consolidated Statements of Cash Flows	$ 74,034	$ 118,680	$ 74,034	$ 118,680	$ 25,876	$ 136,265

CONSOLIDATED SCHEDULE OF INVEST

CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands, $ in Thousands		Jun. 30, 2023 USD ($) shares		Jun. 30, 2023 GBP (£) shares		Dec. 31, 2022 USD ($) shares		Dec. 31, 2022 GBP (£) shares
Investment Holding [Line Items]
Investment, Basis Spread, Variable Rate		8.25%		8.25%		7.50%		7.50%
Investment cost		$ 3,114,097				$ 3,005,696
Investments at Fair Value		3,112,789				$ 2,963,955
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Class A Units
Investment Holding [Line Items]
Investment cost	[1],[2]	238
Investments at Fair Value	[1]	$ 222
Shares | shares	[1]	69,239		69,239
Investments Owned Acquisition Date	[1],[3]	Dec. 27, 2022		Dec. 27, 2022
Investment, Identifier [Axis]: Debt Investments (185.30%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	185.30%		185.30%
Investment cost	[2]	$ 2,936,952
Investments at Fair Value		$ 2,937,942
Investment, Identifier [Axis]: Debt Investments (199.47%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					199.47%		199.47%
Investment cost	[6]					$ 2,818,060
Investments at Fair Value						$ 2,795,444
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools (2.08%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.08%		2.08%
Investment cost	[2]	$ 32,724
Investments at Fair Value		$ 33,024
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools (2.31%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.31%		2.31%
Investment cost	[6]					$ 32,339
Investments at Fair Value						$ 32,339
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools and Alamar Biosciences, Inc. Senior Secured, Maturity Date June 2026, Prime + 3.00%, Floor rate 6.50%, PIK Interest 1.00%, 5.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-06	[7],[8],[9]	2026-06	[7],[8],[9]	2026-06	[10]	2026-06	[10]
Investments Maturity Month and Year		2026-06	[7],[8],[9]	2026-06	[7],[8],[9]	2026-06	[10]	2026-06	[10]
Investment, Basis Spread, Variable Rate		3%	[7],[8],[9],[11]	3%	[7],[8],[9],[11]	3%	[10],[12]	3%	[10],[12]
Investment, Interest Rate, Floor		6.50%	[7],[8],[9],[11]	6.50%	[7],[8],[9],[11]	6.50%	[10],[12]	6.50%	[10],[12]
Investment, Interest Rate, Paid in Kind		1%	[7],[8],[9],[11]	1%	[7],[8],[9],[11]	1%	[10],[12]	1%	[10],[12]
Principal Amount		$ 5,023	[7],[8],[9]			$ 5,000	[10]
Investment cost		5,028	[2],[7],[8],[9]			4,951	[6],[10]
Investments at Fair Value		$ 5,055	[7],[8],[9]			$ 4,951	[10]
Investment Exit Fee		5.95%	[7],[8],[9],[11]	5.95%	[7],[8],[9],[11]	5.95%	[10],[12]	5.95%	[10],[12]
Investment, Identifier [Axis]: Debt Investments Biotechnology Tools and PathAI, Inc., Senior Secured, Maturity Date January 2027, Prime + 2.15%, Floor rate 9.15%, 11.21% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-01	[9]	2027-01	[9]	2027-01	[10]	2027-01	[10]
Investments Maturity Month and Year		2027-01	[9]	2027-01	[9]	2027-01	[10]	2027-01	[10]
Investment, Basis Spread, Variable Rate		2.15%	[9],[11]	2.15%	[9],[11]	2.15%	[10],[12]	2.15%	[10],[12]
Investment, Interest Rate, Floor		9.15%	[9],[11]	9.15%	[9],[11]	9.15%	[10],[12]	9.15%	[10],[12]
Principal Amount		$ 28,000	[9]			$ 28,000	[10]
Investment cost		27,696	[2],[9]			27,388	[6],[10]
Investments at Fair Value		$ 27,969	[9]			$ 27,388	[10]
Investment Exit Fee		11.21%	[9],[11]	11.21%	[9],[11]	11.21%	[10],[12]	11.21%	[10],[12]
Investment, Identifier [Axis]: Debt Investments Communications & Networking (6.64%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	6.64%		6.64%
Investment cost	[2]	$ 104,713
Investments at Fair Value		$ 105,219
Investment, Identifier [Axis]: Debt Investments Communications & Networking (7.26%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					7.26%		7.26%
Investment cost	[6]					$ 99,167
Investments at Fair Value						$ 101,734
Investment, Identifier [Axis]: Debt Investments Communications & Networking and Aryaka Networks, Inc. Senior Secured, Maturity Date July 2026, Prime + 3.25%, Floor rate 6.75%, PIK Interest 1.05%, 3.55% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-07	[7],[9],[13]	2026-07	[7],[9],[13]	2026-07	[10],[14],[15]	2026-07	[10],[14],[15]
Investments Maturity Month and Year		2026-07	[7],[9],[13]	2026-07	[7],[9],[13]	2026-07	[10],[14],[15]	2026-07	[10],[14],[15]
Investment, Basis Spread, Variable Rate		3.25%	[7],[9],[11],[13]	3.25%	[7],[9],[11],[13]	3.25%	[10],[12],[14],[15]	3.25%	[10],[12],[14],[15]
Investment, Interest Rate, Floor		6.75%	[7],[9],[11],[13]	6.75%	[7],[9],[11],[13]	6.75%	[10],[12],[14],[15]	6.75%	[10],[12],[14],[15]
Investment, Interest Rate, Paid in Kind		1.05%	[7],[9],[11],[13]	1.05%	[7],[9],[11],[13]	1.05%	[10],[12],[14],[15]	1.05%	[10],[12],[14],[15]
Principal Amount		$ 15,073	[7],[9],[13]			$ 5,023	[10],[14],[15]
Investment cost		14,922	[2],[7],[9],[13]			4,969	[6],[10],[14],[15]
Investments at Fair Value		$ 15,407	[7],[9],[13]			$ 5,053	[10],[14],[15]
Investment Exit Fee		3.55%	[7],[9],[11],[13]	3.55%	[7],[9],[11],[13]	3.55%	[10],[12],[14],[15]	3.55%	[10],[12],[14],[15]
Investment, Identifier [Axis]: Debt Investments Communications & Networking and Cytracom Holdings LLC Senior Secured, Maturity Date February 2025, 3-month LIBOR + 9.31%, Floor rate 10.31%
Investment Holding [Line Items]
Maturity Date	[10],[16],[17]					2025-02		2025-02
Investments Maturity Month and Year	[10],[16],[17]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[10],[12],[16],[17]					9.31%		9.31%
Investment, Interest Rate, Floor	[10],[12],[16],[17]					10.31%		10.31%
Principal Amount	[10],[16],[17]					$ 8,910
Investment cost	[6],[10],[16],[17]					8,768
Investments at Fair Value	[10],[16],[17]					$ 8,748
Investment, Identifier [Axis]: Debt Investments Communications & Networking and Cytracom Holdings LLC Senior Secured, Maturity Date February 2025, 3-month SOFR + 9.62%, Floor rate 10.62%
Investment Holding [Line Items]
Maturity Date	[9],[18],[19]	2025-02		2025-02
Investments Maturity Month and Year	[9],[18],[19]	2025-02		2025-02
Investment, Basis Spread, Variable Rate	[9],[11],[18],[19]	9.62%		9.62%
Investment, Interest Rate, Floor	[9],[11],[18],[19]	10.62%		10.62%
Principal Amount	[9],[18],[19]	$ 3,284
Investment cost	[2],[9],[18],[19]	3,245
Investments at Fair Value	[9],[18],[19]	$ 3,266
Investment, Identifier [Axis]: Debt Investments Communications & Networking and Rocket Lab Global Services, LLC Senior Secured, Maturity Date June 2024, Prime + 4.90%, Floor rate 8.15%, PIK Interest 1.25%, 3.25% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-06	[7],[8],[18],[20],[21]	2024-06	[7],[8],[18],[20],[21]	2024-06	[15],[16],[22],[23],[24]	2024-06	[15],[16],[22],[23],[24]
Investments Maturity Month and Year		2024-06	[7],[8],[18],[20],[21]	2024-06	[7],[8],[18],[20],[21]	2024-06	[15],[16],[22],[23],[24]	2024-06	[15],[16],[22],[23],[24]
Investment, Basis Spread, Variable Rate		4.90%	[7],[8],[11],[18],[20],[21]	4.90%	[7],[8],[11],[18],[20],[21]	4.90%	[12],[15],[16],[22],[23],[24]	4.90%	[12],[15],[16],[22],[23],[24]
Investment, Interest Rate, Floor		8.15%	[7],[8],[11],[18],[20],[21]	8.15%	[7],[8],[11],[18],[20],[21]	8.15%	[12],[15],[16],[22],[23],[24]	8.15%	[12],[15],[16],[22],[23],[24]
Investment, Interest Rate, Paid in Kind		1.25%	[7],[8],[11],[18],[20],[21]	1.25%	[7],[8],[11],[18],[20],[21]	1.25%	[12],[15],[16],[22],[23],[24]	1.25%	[12],[15],[16],[22],[23],[24]
Principal Amount		$ 85,103	[7],[8],[18],[20],[21]			$ 84,581	[15],[16],[22],[23],[24]
Investment cost		86,546	[2],[7],[8],[18],[20],[21]			85,430	[6],[15],[16],[22],[23],[24]
Investments at Fair Value		$ 86,546	[7],[8],[18],[20],[21]			$ 87,933	[15],[16],[22],[23],[24]
Investment Exit Fee		3.25%	[7],[8],[11],[18],[20],[21]	3.25%	[7],[8],[11],[18],[20],[21]	3.25%	[12],[15],[16],[22],[23],[24]	3.25%	[12],[15],[16],[22],[23],[24]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services (28.15%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	28.15%		28.15%
Investment cost	[2]	$ 461,172
Investments at Fair Value		$ 446,342
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services (30.59%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					30.59%		30.59%
Investment cost	[6]					$ 444,703
Investments at Fair Value						$ 428,750
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and AppDirect, Inc. Senior Secured, Maturity Date April 2026, Prime + 5.50%, Floor rate 8.75%, 7.12% Exit Fee
Investment Holding [Line Items]
Maturity Date	[9],[20]	2026-04		2026-04
Investments Maturity Month and Year	[9],[20]	2026-04		2026-04
Investment, Basis Spread, Variable Rate	[11],[20]	5.50%		5.50%
Investment, Interest Rate, Floor	[9],[11],[20]	8.75%		8.75%
Principal Amount	[20]	$ 55,790
Investment cost	[2],[20]	57,154
Investments at Fair Value	[20]	$ 58,178
Investment Exit Fee	[9],[11],[20]	7.12%		7.12%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and AppDirect, Inc. Senior Secured, Maturity Date April 2026, Prime + 5.50%, Floor rate 8.75%, 8.29% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[23]					2026-04		2026-04
Investments Maturity Month and Year	[10],[23]					2026-04		2026-04
Investment, Basis Spread, Variable Rate	[10],[12],[23]					5.50%		5.50%
Investment, Interest Rate, Floor	[10],[12],[23]					8.70%		8.70%
Principal Amount	[10],[23]					$ 40,790
Investment cost	[6],[10],[23]					41,856
Investments at Fair Value	[10],[23]					$ 42,426
Investment Exit Fee	[10],[12],[23]					8.29%		8.29%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Carwow LTD Senior Secured, Maturity Date December 2024, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-12	[7],[9],[25],[26]	2024-12	[7],[9],[25],[26]	2024-12	[15],[27],[28]	2024-12	[15],[27],[28]
Investments Maturity Month and Year		2024-12	[7],[9],[25],[26]	2024-12	[7],[9],[25],[26]	2024-12	[15],[27],[28]	2024-12	[15],[27],[28]
Investment, Basis Spread, Variable Rate		4.70%	[7],[9],[11],[25],[26]	4.70%	[7],[9],[11],[25],[26]	4.70%	[12],[15],[27],[28]	4.70%	[12],[15],[27],[28]
Investment, Interest Rate, Floor		7.95%	[7],[9],[11],[25],[26]	7.95%	[7],[9],[11],[25],[26]	7.95%	[12],[15],[27],[28]	7.95%	[12],[15],[27],[28]
Investment, Interest Rate, Paid in Kind		1.45%	[7],[9],[11],[25],[26]	1.45%	[7],[9],[11],[25],[26]	1.45%	[12],[15],[27],[28]	1.45%	[12],[15],[27],[28]
Principal Amount | £				£ 19,327	[7],[9],[25],[26]			£ 18,890	[15],[27],[28]
Investment cost				26,412	[2],[7],[9],[25],[26]	$ 26,024	[6],[15],[27],[28]
Investments at Fair Value				£ 24,845	[7],[9],[25],[26]	$ 22,971	[15],[27],[28]
Investment Exit Fee		4.95%	[7],[9],[11],[25],[26]	4.95%	[7],[9],[11],[25],[26]	4.95%	[12],[15],[27],[28]	4.95%	[12],[15],[27],[28]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Collective Health, Inc. Senior Secured, Maturity Date September 2023, Prime + 4.75%, Floor rate 12.50%
Investment Holding [Line Items]
Maturity Date		2023-09		2023-09
Investments Maturity Month and Year		2023-09		2023-09
Investment, Basis Spread, Variable Rate	[11]	4.75%		4.75%
Investment, Interest Rate, Floor	[11]	12.50%		12.50%
Principal Amount		$ 4,000
Investment cost	[2]	3,985
Investments at Fair Value		$ 3,985
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Houzz, Inc. Convertible Debt, Maturity Date May 2028, PIK Interest 5.50%
Investment Holding [Line Items]
Maturity Date	[15],[29]					2028-05		2028-05
Investments Maturity Month and Year	[15],[29]					2028-05		2028-05
Investment, Interest Rate, Paid in Kind	[12],[15],[29]					5.50%		5.50%
Principal Amount	[15],[29]					$ 21,853
Investment cost	[6],[15],[29]					21,853
Investments at Fair Value	[15],[29]					$ 20,356
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Houzz, Inc. Convertible Debt, Maturity Date May 2028, PIK Interest 7.00%
Investment Holding [Line Items]
Maturity Date	[7],[30]	2028-05		2028-05
Investments Maturity Month and Year	[7],[30]	2028-05		2028-05
Investment, Interest Rate, Paid in Kind	[7],[11],[30]	7%		7%
Principal Amount	[7],[30]	$ 22,494
Investment cost	[2],[7],[30]	22,494
Investments at Fair Value	[7],[30]	$ 22,407
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Jobandtalent USA, Inc. Senior Secured, Maturity Date February 2025, 1-month SOFR + 8.75%, Floor rate 9.75%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[25],[26]	2025-02		2025-02
Investments Maturity Month and Year	[25],[26]	2025-02		2025-02
Investment, Basis Spread, Variable Rate	[11],[25],[26]	8.75%		8.75%
Investment, Interest Rate, Floor	[11],[25],[26]	9.75%		9.75%
Principal Amount	[25],[26]	$ 14,000
Investment cost	[2],[25],[26]	13,969
Investments at Fair Value	[25],[26]	$ 14,056
Investment Exit Fee	[11],[25],[26]	3%		3%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Jobandtalent USA, Inc. Senior Secured, Maturity Date February 2025, 1-month SOFR + 8.86%, Floor rate 9.75%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[27],[28]					2025-02		2025-02
Investments Maturity Month and Year	[27],[28]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[12],[27],[28]					8.86%		8.86%
Investment, Interest Rate, Floor	[12],[27],[28]					9.75%		9.75%
Principal Amount	[27],[28]					$ 14,000
Investment cost	[6],[27],[28]					13,853
Investments at Fair Value	[27],[28]					$ 13,904
Investment Exit Fee	[12],[27],[28]					3%		3%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Provi, Senior Secured, Maturity Date December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-12	[1]	2026-12	[1]	2026-12	[31]	2026-12	[31]
Investments Maturity Month and Year		2026-12	[1]	2026-12	[1]	2026-12	[31]	2026-12	[31]
Investment, Basis Spread, Variable Rate		4.40%	[1],[11]	4.40%	[1],[11]	4.40%	[12],[31]	4.40%	[12],[31]
Investment, Interest Rate, Floor		10.65%	[1],[11]	10.65%	[1],[11]	10.65%	[12],[31]	10.65%	[12],[31]
Principal Amount		$ 15,000	[1]			$ 15,000	[31]
Investment cost		14,819	[1],[2]			14,739	[6],[31]
Investments at Fair Value		$ 14,745	[1]			$ 14,739	[31]
Investment Exit Fee		2.95%	[1],[11]	2.95%	[1],[11]	2.95%	[12],[31]	2.95%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, Maturity Date December 2026, 3-month LIBOR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%
Investment Holding [Line Items]
Maturity Date		2026-12	[1],[7],[8],[9]	2026-12	[1],[7],[8],[9]	2026-12	[10],[15],[22],[31]	2026-12	[10],[15],[22],[31]
Investments Maturity Month and Year		2026-12	[1],[7],[8],[9]	2026-12	[1],[7],[8],[9]	2026-12	[10],[15],[22],[31]	2026-12	[10],[15],[22],[31]
Investment, Basis Spread, Variable Rate		5.50%	[1],[7],[8],[9],[11]	5.50%	[1],[7],[8],[9],[11]	5.50%	[10],[12],[15],[22],[31]	5.50%	[10],[12],[15],[22],[31]
Investment, Interest Rate, Floor		6.50%	[1],[7],[8],[9],[11]	6.50%	[1],[7],[8],[9],[11]	6.50%	[10],[12],[15],[22],[31]	6.50%	[10],[12],[15],[22],[31]
Investment, Interest Rate, Paid in Kind		4%	[1],[7],[8],[9],[11]	4%	[1],[7],[8],[9],[11]	4%	[10],[12],[15],[22],[31]	4%	[10],[12],[15],[22],[31]
Principal Amount		$ 28,296	[1],[7],[8],[9]			$ 27,730	[10],[15],[22],[31]
Investment cost		27,892	[1],[2],[7],[8],[9]			27,265	[6],[10],[15],[22],[31]
Investments at Fair Value		$ 28,114	[1],[7],[8],[9]			$ 27,256	[10],[15],[22],[31]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Rhino Labs, Inc. Senior Secured, Maturity Date March 2024, Prime + 5.50%, Floor rate 8.75%, PIK Interest 2.25%
Investment Holding [Line Items]
Maturity Date		2024-03	[1],[7]	2024-03	[1],[7]	2024-03	[15],[31]	2024-03	[15],[31]
Investments Maturity Month and Year		2024-03	[1],[7]	2024-03	[1],[7]	2024-03	[15],[31]	2024-03	[15],[31]
Investment, Basis Spread, Variable Rate		5.50%	[1],[7],[11]	5.50%	[1],[7],[11]	5.50%	[12],[15],[31]	5.50%	[12],[15],[31]
Investment, Interest Rate, Floor		8.75%	[1],[7],[11]	8.75%	[1],[7],[11]	8.75%	[12],[15],[31]	8.75%	[12],[15],[31]
Investment, Interest Rate, Paid in Kind		2.25%	[1],[7],[11]	2.25%	[1],[7],[11]	2.25%	[12],[15],[31]	2.25%	[12],[15],[31]
Principal Amount		$ 12,908	[1],[7]			$ 16,500	[15],[31]
Investment cost		12,841	[1],[2],[7]			16,328	[6],[15],[31]
Investments at Fair Value		12,841	[1],[7]			$ 16,496	[15],[31]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc.
Investment Holding [Line Items]
Principal Amount		83,260
Investment cost	[2]	82,697
Investments at Fair Value		$ 83,525
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc. Senior Secured, Maturity Date July 2025, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%
Investment Holding [Line Items]
Maturity Date	[9],[21]	2025-07		2025-07
Investments Maturity Month and Year	[9],[21]	2025-07		2025-07
Investment, Basis Spread, Variable Rate	[9],[11],[21]	2.50%		2.50%
Investment, Interest Rate, Floor	[9],[11],[21]	10.75%		10.75%
Investment, Interest Rate, Paid in Kind	[9],[11],[21]	0.50%		0.50%
Principal Amount	[9],[21]	$ 58,125
Investment cost	[2],[9],[21]	57,689
Investments at Fair Value	[9],[21]	$ 57,689
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc. Senior Secured, Maturity Date June 2023, Prime + 5.00%, Floor rate 10.50%, PIK Interest 0.50%
Investment Holding [Line Items]
Maturity Date	[15],[22],[23],[24]					2023-06		2023-06
Investments Maturity Month and Year	[15],[22],[23],[24]					2023-06		2023-06
Investment, Basis Spread, Variable Rate	[12],[15],[22],[23],[24]					5%		5%
Investment, Interest Rate, Floor	[12],[15],[22],[23],[24]					10.50%		10.50%
Investment, Interest Rate, Paid in Kind	[12],[15],[22],[23],[24]					0.50%		0.50%
Principal Amount	[15],[22],[23],[24]					$ 60,915
Investment cost	[6],[15],[22],[23],[24]					60,721
Investments at Fair Value	[15],[22],[23],[24]					$ 60,721
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc. Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%
Investment Holding [Line Items]
Maturity Date	[15],[16],[24]					2026-05		2026-05
Investments Maturity Month and Year	[15],[16],[24]					2026-05		2026-05
Investment, Basis Spread, Variable Rate	[12],[15],[16],[24]					7%		7%
Investment, Interest Rate, Floor	[12],[15],[16],[24]					10.50%		10.50%
Investment, Interest Rate, Paid in Kind	[12],[15],[16],[24]					0.50%		0.50%
Principal Amount	[15],[16],[24]					$ 25,071
Investment cost	[6],[15],[16],[24]					24,912
Investments at Fair Value	[15],[16],[24]					$ 25,823
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.05%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7],[9],[18],[21]	2026-05		2026-05
Investments Maturity Month and Year	[7],[9],[18],[21]	2026-05		2026-05
Investment, Basis Spread, Variable Rate	[7],[9],[11],[18],[21]	7%		7%
Investment, Interest Rate, Floor	[7],[9],[11],[18],[21]	10.50%		10.50%
Investment, Interest Rate, Cap	[7],[9],[11],[18],[21]	0.50%		0.50%
Principal Amount	[7],[9],[18],[21]	$ 25,135
Investment cost	[2],[7],[9],[18],[21]	25,008
Investments at Fair Value	[7],[9],[18],[21]	$ 25,836
Investment Exit Fee	[7],[9],[11],[18],[21]	1%		1%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Skyword, Inc. Senior Secured, Maturity Date November 2026, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-11	[7],[8]	2026-11	[7],[8]	2026-11	[15],[22]	2026-11	[15],[22]
Investments Maturity Month and Year		2026-11	[7],[8]	2026-11	[7],[8]	2026-11	[15],[22]	2026-11	[15],[22]
Investment, Basis Spread, Variable Rate		2.75%	[7],[8],[11]	2.75%	[7],[8],[11]	2.75%	[12],[15],[22]	2.75%	[12],[15],[22]
Investment, Interest Rate, Floor		9.25%	[7],[8],[11]	9.25%	[7],[8],[11]	9.25%	[12],[15],[22]	9.25%	[12],[15],[22]
Investment, Interest Rate, Paid in Kind		1.75%	[7],[8],[11]	1.75%	[7],[8],[11]	1.75%	[12],[15],[22]	1.75%	[12],[15],[22]
Principal Amount		$ 9,087	[7],[8]			$ 9,007	[15],[22]
Investment cost		9,051	[2],[7],[8]			8,918	[6],[15],[22]
Investments at Fair Value		$ 9,093	[7],[8]			$ 8,870	[15],[22]
Investment Exit Fee		3%	[7],[8],[11]	3%	[7],[8],[11]	3%	[12],[15],[22]	3%	[12],[15],[22]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date July 2024 One, PIK Interest 5.00%
Investment Holding [Line Items]
Maturity Date		2024-07	[7],[32],[33]	2024-07	[7],[32],[33]	2024-07	[15],[34],[35]	2024-07	[15],[34],[35]
Investments Maturity Month and Year		2024-07	[7],[32],[33]	2024-07	[7],[32],[33]	2024-07	[15],[34],[35]	2024-07	[15],[34],[35]
Investment, Interest Rate, Paid in Kind		5%	[7],[11],[32],[33]	5%	[7],[11],[32],[33]	5%	[12],[15],[34],[35]	5%	[12],[15],[34],[35]
Principal Amount		$ 23,703	[7],[32],[33]			$ 10,680	[15],[34],[35]
Investment cost		$ 13,263	[2],[7],[32],[33]			240	[6],[15],[34],[35]
Investments at Fair Value	[15],[34],[35]					$ 0
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date July 2024 Two, PIK Interest 5.00%
Investment Holding [Line Items]
Maturity Date	[15],[34],[35]					2024-07		2024-07
Investments Maturity Month and Year	[15],[34],[35]					2024-07		2024-07
Investment, Interest Rate, Paid in Kind	[12],[15],[34],[35]					5%		5%
Principal Amount	[15],[34],[35]					$ 13,023
Investment cost	[6],[15],[34],[35]					13,023
Investments at Fair Value	[15],[34],[35]					$ 0
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date July 2024, FIXED 8.25%
Investment Holding [Line Items]
Maturity Date		2024-07	[32]	2024-07	[32]	2024-07	[15],[34],[35]	2024-07	[15],[34],[35]
Investments Maturity Month and Year		2024-07	[32]	2024-07	[32]	2024-07	[15],[34],[35]	2024-07	[15],[34],[35]
Investment, Interest Rate, Paid in Cash		8.25%	[11],[32]	8.25%	[11],[32]	8.25%	[12],[15],[34],[35]	8.25%	[12],[15],[34],[35]
Principal Amount		$ 8,250	[32]			$ 8,250	[15],[34],[35]
Investment cost		8,250	[2],[32]			8,250	[6],[15],[34],[35]
Investments at Fair Value		$ 7,073	[32]			$ 8,042	[15],[34],[35]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Thumbtack, Inc. Senior Secured, Maturity Date April 2026, Prime + 4.95%, Floor rate 8.20%, PIK Interest 1.50%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-04	[7],[9],[20]	2026-04	[7],[9],[20]	2026-04	[10],[15],[23]	2026-04	[10],[15],[23]
Investments Maturity Month and Year		2026-04	[7],[9],[20]	2026-04	[7],[9],[20]	2026-04	[10],[15],[23]	2026-04	[10],[15],[23]
Investment, Basis Spread, Variable Rate		4.95%	[7],[9],[11],[20]	4.95%	[7],[9],[11],[20]	4.95%	[10],[12],[15],[23]	4.95%	[10],[12],[15],[23]
Investment, Interest Rate, Floor		8.20%	[7],[9],[11],[20]	8.20%	[7],[9],[11],[20]	8.20%	[10],[12],[15],[23]	8.20%	[10],[12],[15],[23]
Investment, Interest Rate, Paid in Kind		1.50%	[7],[9],[11],[20]	1.50%	[7],[9],[11],[20]	1.50%	[10],[12],[15],[23]	1.50%	[10],[12],[15],[23]
Principal Amount		$ 10,180	[7],[9],[20]			$ 10,103	[10],[15],[23]
Investment cost		10,180	[2],[7],[9],[20]			10,050	[6],[10],[15],[23]
Investments at Fair Value		$ 10,399	[7],[9],[20]			$ 10,167	[10],[15],[23]
Investment Exit Fee		3.95%	[7],[9],[11],[20]	3.95%	[7],[9],[11],[20]	3.95%	[10],[12],[15],[23]	3.95%	[10],[12],[15],[23]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Udacity, Inc. Senior Secured, Maturity Date September 2024, Prime + 4.50%, Floor rate 7.75%, PIK Interest 2.00%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-09	[7],[20]	2024-09	[7],[20]	2024-09	[15],[23]	2024-09	[15],[23]
Investments Maturity Month and Year		2024-09	[7],[20]	2024-09	[7],[20]	2024-09	[15],[23]	2024-09	[15],[23]
Investment, Basis Spread, Variable Rate		4.50%	[7],[11],[20]	4.50%	[7],[11],[20]	4.50%	[12],[15],[23]	4.50%	[12],[15],[23]
Investment, Interest Rate, Floor		7.75%	[7],[11],[20]	7.75%	[7],[11],[20]	7.75%	[12],[15],[23]	7.75%	[12],[15],[23]
Investment, Interest Rate, Paid in Kind		2%	[7],[11],[20]	2%	[7],[11],[20]	2%	[12],[15],[23]	2%	[12],[15],[23]
Principal Amount		$ 52,464	[7],[20]			$ 51,937	[15],[23]
Investment cost		53,106	[2],[7],[20]			52,265	[6],[15],[23]
Investments at Fair Value		$ 51,752	[7],[20]			$ 52,976	[15],[23]
Investment Exit Fee		3%	[7],[11],[20]	3%	[7],[11],[20]	3%	[12],[15],[23]	3%	[12],[15],[23]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.00%, Floor rate 7.25%, PIK Interest 1.25%, 4.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-03	[7],[8]	2025-03	[7],[8]	2025-03	[15],[22]	2025-03	[15],[22]
Investments Maturity Month and Year		2025-03	[7],[8]	2025-03	[7],[8]	2025-03	[15],[22]	2025-03	[15],[22]
Investment, Basis Spread, Variable Rate		4%	[7],[8],[11]	4%	[7],[8],[11]	4%	[12],[15],[22]	4%	[12],[15],[22]
Investment, Interest Rate, Floor		7.25%	[7],[8],[11]	7.25%	[7],[8],[11]	7.25%	[12],[15],[22]	7.25%	[12],[15],[22]
Investment, Interest Rate, Paid in Kind		1.25%	[7],[8],[11]	1.25%	[7],[8],[11]	1.25%	[12],[15],[22]	1.25%	[12],[15],[22]
Principal Amount		$ 5,075	[7],[8]			$ 5,043	[15],[22]
Investment cost		5,085	[2],[7],[8]			5,000	[6],[15],[22]
Investments at Fair Value		$ 5,124	[7],[8]			$ 5,042	[15],[22]
Investment Exit Fee		4.50%	[7],[8],[11]	4.50%	[7],[8],[11]	4.50%	[12],[15],[22]	4.50%	[12],[15],[22]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Veem, Inc. Senior Secured, Maturity Date March 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.50%, 4.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-03	[7]	2025-03	[7]	2025-03	[15]	2025-03	[15]
Investments Maturity Month and Year		2025-03	[7]	2025-03	[7]	2025-03	[15]	2025-03	[15]
Investment, Basis Spread, Variable Rate		4.70%	[7],[11]	4.70%	[7],[11]	4.70%	[12],[15]	4.70%	[12],[15]
Investment, Interest Rate, Floor		7.95%	[7],[11]	7.95%	[7],[11]	7.95%	[12],[15]	7.95%	[12],[15]
Investment, Interest Rate, Paid in Kind		1.50%	[7],[11]	1.50%	[7],[11]	1.50%	[12],[15]	1.50%	[12],[15]
Principal Amount		$ 5,071	[7]			$ 5,033	[15]
Investment cost		5,096	[2],[7]			4,988	[6],[15]
Investments at Fair Value		$ 5,194	[7]			$ 5,124	[15]
Investment Exit Fee		4.50%	[7],[11]	4.50%	[7],[11]	4.50%	[12],[15]	4.50%	[12],[15]
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited
Investment Holding [Line Items]
Principal Amount		$ 94,500
Investment cost	[2]	94,878
Investments at Fair Value		$ 95,011
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2025, 1-month SOFR + 9.25%, Floor rate 10.25%, 3.20% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13],[21],[25],[26]	2025-02		2025-02
Investments Maturity Month and Year	[13],[21],[25],[26]	2025-02		2025-02
Investment, Basis Spread, Variable Rate	[11],[13],[21],[25],[26]	9.25%		9.25%
Investment, Interest Rate, Floor	[11],[13],[21],[25],[26]	10.25%		10.25%
Principal Amount	[13],[21],[25],[26]	$ 6,250
Investment cost	[2],[13],[21],[25],[26]	6,252
Investments at Fair Value	[13],[21],[25],[26]	$ 6,270
Investment Exit Fee	[11],[13],[21],[25],[26]	3.20%		3.20%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2025, 3-month LIBOR + 9.25%, Floor rate 10.25%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[14],[16],[23],[24],[27],[28]					2025-02		2025-02
Investments Maturity Month and Year	[14],[16],[23],[24],[27],[28]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[12],[14],[16],[23],[24],[27],[28]					9.25%		9.25%
Investment, Interest Rate, Floor	[12],[14],[16],[23],[24],[27],[28]					10.25%		10.25%
Principal Amount	[14],[16],[23],[24],[27],[28]					$ 94,500
Investment cost	[6],[14],[16],[23],[24],[27],[28]					94,418
Investments at Fair Value	[14],[16],[23],[24],[27],[28]					$ 93,837
Investment Exit Fee	[12],[14],[16],[23],[24],[27],[28]					3%		3%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services and Worldremit Group Limited, Senior Secured, Maturity Date February 2025, 3-month SOFR + 9.25%, Floor rate 10.25%, 3.20% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13],[18],[20],[21],[25],[26]	2025-02		2025-02
Investments Maturity Month and Year	[13],[18],[20],[21],[25],[26]	2025-02		2025-02
Investment, Basis Spread, Variable Rate	[11],[13],[18],[20],[21],[25],[26]	9.25%		9.25%
Investment, Interest Rate, Floor	[11],[13],[18],[20],[21],[25],[26]	10.25%		10.25%
Principal Amount	[13],[18],[20],[21],[25],[26]	$ 88,250
Investment cost	[2],[13],[18],[20],[21],[25],[26]	88,626
Investments at Fair Value	[13],[18],[20],[21],[25],[26]	$ 88,741
Investment Exit Fee	[11],[13],[18],[20],[21],[25],[26]	3.20%		3.20%
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services, SeatGeek, Inc.
Investment Holding [Line Items]
Principal Amount						$ 85,986
Investment cost	[6]					85,633
Investments at Fair Value						86,544
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services, Tectura Corporation
Investment Holding [Line Items]
Principal Amount		$ 31,953				31,953
Investment cost		21,513	[2]			21,513	[6]
Investments at Fair Value		7,073				8,042
Investment, Identifier [Axis]: Debt Investments Consumer & Business Services, Veem, Inc.
Investment Holding [Line Items]
Principal Amount		10,146				10,076
Investment cost		10,181	[2]			9,988	[6]
Investments at Fair Value		$ 10,318				$ 10,166
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services (2.40%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.40%		2.40%
Investment cost	[6]					$ 36,567
Investments at Fair Value						$ 33,700
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services (2.94%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.94%		2.94%
Investment cost	[2]	$ 46,597
Investments at Fair Value		$ 46,597
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC (p.k.a. Gibraltar Business Capital, LLC), LLC, Unsecured, Maturity Date September 2026, FIXED 11.50%
Investment Holding [Line Items]
Maturity Date	[32],[36]	2026-09		2026-09
Investments Maturity Month and Year	[32],[36]	2026-09		2026-09
Investment, Interest Rate, Paid in Cash	[11],[32],[36]	11.50%		11.50%
Principal Amount	[32],[36]	$ 25,000
Investment cost	[2],[32],[36]	24,613
Investments at Fair Value	[32],[36]	$ 24,613
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Gibraltar Business Capital, LLC, Unsecured, Maturity Date September 2026, FIXED 11.50%
Investment Holding [Line Items]
Maturity Date	[34]					2026-09		2026-09
Investments Maturity Month and Year	[34]					2026-09		2026-09
Investment, Interest Rate, Paid in Cash	[12],[34]					11.50%		11.50%
Principal Amount	[34]					$ 10,000
Investment cost	[6],[34]					9,852
Investments at Fair Value	[34]					$ 8,898
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Gibraltar Business Capital, LLC, Unsecured, Maturity Date September 2026, FIXED 14.50%
Investment Holding [Line Items]
Maturity Date	[34]					2026-09		2026-09
Investments Maturity Month and Year	[34]					2026-09		2026-09
Investment, Interest Rate, Paid in Cash	[12],[34]					14.50%		14.50%
Principal Amount	[34]					$ 15,000
Investment cost	[6],[34]					14,715
Investments at Fair Value	[34]					$ 12,802
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Hercules Adviser LLC, Unsecured, Maturity Date June 2025, FIXED 5.00%
Investment Holding [Line Items]
Maturity Date		2025-06	[32]	2025-06	[32]	2025-06	[34]	2025-06	[34]
Investments Maturity Month and Year		2025-06	[32]	2025-06	[32]	2025-06	[34]	2025-06	[34]
Investment, Interest Rate, Paid in Cash		5%	[11],[32]	5%	[11],[32]	5%	[12],[34]	5%	[12],[34]
Principal Amount		$ 12,000	[32]			$ 12,000	[34]
Investment cost		12,000	[2],[32]			12,000	[6],[34]
Investments at Fair Value		$ 12,000	[32]			12,000	[34]
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services and Next Insurance, Inc, Senior Secured, Maturity Date February 2028, Prime + -1.50%, Floor rate 4.75%, PIK Interest 5.50%
Investment Holding [Line Items]
Maturity Date	[7],[9],[13]	2028-02		2028-02
Investments Maturity Month and Year	[7],[9],[13]	2028-02		2028-02
Investment, Basis Spread, Variable Rate	[7],[9],[11],[13]	(1.50%)		(1.50%)
Investment, Interest Rate, Floor	[7],[9],[11],[13]	4.75%		4.75%
Investment, Interest Rate, Paid in Kind	[7],[9],[11],[13]	5.50%		5.50%
Principal Amount	[7],[9],[13]	$ 10,181
Investment cost	[2],[7],[9],[13]	9,984
Investments at Fair Value	[7],[9],[13]	$ 9,984
Investment, Identifier [Axis]: Debt Investments Diversified Financial Services, Gibraltar Business Capital, LLC, Unsecured
Investment Holding [Line Items]
Principal Amount						25,000
Investment cost	[6]					24,567
Investments at Fair Value						$ 21,700
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development (68.62%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	68.62%		68.62%
Investment cost	[2]	$ 1,083,845
Investments at Fair Value		$ 1,087,991
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development (78.59%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					78.59%		78.59%
Investment cost	[6]					$ 1,107,352
Investments at Fair Value						$ 1,101,430
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and ATAI Life Sciences N.V. Senior Secured, Maturity Date August 2026, Prime + 4.55%, Floor rate 8.55%, 6.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-08	[9],[25],[26]	2026-08	[9],[25],[26]	2026-08	[27],[28]	2026-08	[27],[28]
Investments Maturity Month and Year		2026-08	[9],[25],[26]	2026-08	[9],[25],[26]	2026-08	[27],[28]	2026-08	[27],[28]
Investment, Basis Spread, Variable Rate		4.55%	[11],[25],[26]	4.55%	[11],[25],[26]	4.55%	[12],[27],[28]	4.55%	[12],[27],[28]
Investment, Interest Rate, Floor		8.55%	[11],[25],[26]	8.55%	[11],[25],[26]	8.55%	[12],[27],[28]	8.55%	[12],[27],[28]
Principal Amount		$ 10,500	[25],[26]			$ 10,500	[27],[28]
Investment cost		10,592	[2],[25],[26]			10,513	[6],[27],[28]
Investments at Fair Value		$ 10,633	[25],[26]			$ 10,513	[27],[28]
Investment Exit Fee		6.95%	[11],[25],[26]	6.95%	[11],[25],[26]	6.95%	[12],[27],[28]	6.95%	[12],[27],[28]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Akero Therapeutics, Inc. Senior Secured, Maturity Date January 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-01	[8],[9],[25]	2027-01	[8],[9],[25]	2027-01	[10],[22],[27]	2027-01	[10],[22],[27]
Investments Maturity Month and Year		2027-01	[8],[9],[25]	2027-01	[8],[9],[25]	2027-01	[10],[22],[27]	2027-01	[10],[22],[27]
Investment, Basis Spread, Variable Rate		3.65%	[8],[9],[11],[25]	3.65%	[8],[9],[11],[25]	3.65%	[10],[12],[22],[27]	3.65%	[10],[12],[22],[27]
Investment, Interest Rate, Floor		7.65%	[8],[9],[11],[25]	7.65%	[8],[9],[11],[25]	7.65%	[10],[12],[22],[27]	7.65%	[10],[12],[22],[27]
Principal Amount		$ 12,500	[8],[9],[25]			$ 5,000	[10],[22],[27]
Investment cost		12,385	[2],[8],[9],[25]			4,986	[6],[10],[22],[27]
Investments at Fair Value		$ 12,794	[8],[9],[25]			$ 5,039	[10],[22],[27]
Investment Exit Fee		5.85%	[8],[9],[11],[25]	5.85%	[8],[9],[11],[25]	5.85%	[10],[12],[22],[27]	5.85%	[10],[12],[22],[27]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc. Senior Secured, Maturity Date October 2024, Prime + 3.10%, Floor rate 8.60%, 8.90% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-10	[18]	2024-10	[18]	2024-10	[16]	2024-10	[16]
Investments Maturity Month and Year		2024-10	[18]	2024-10	[18]	2024-10	[16]	2024-10	[16]
Investment, Basis Spread, Variable Rate		3.10%	[11],[18]	3.10%	[11],[18]	3.10%	[12],[16]	3.10%	[12],[16]
Investment, Interest Rate, Floor		8.60%	[11],[18]	8.60%	[11],[18]	8.60%	[12],[16]	8.60%	[12],[16]
Principal Amount		$ 15,000	[18]			$ 15,000	[16]
Investment cost		16,047	[2],[18]			15,879	[6],[16]
Investments at Fair Value		$ 16,179	[18]			$ 15,974	[16]
Investment Exit Fee		8.90%	[11],[18]	8.90%	[11],[18]	8.90%	[12],[16]	8.90%	[12],[16]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Alladapt Immunotherapeutics Inc. Senior Secured, Maturity Date September 2026, Prime + 3.65%, Floor rate 8.40%, Cap rate 10.90%, 10.60% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[22]					2026-09		2026-09
Investments Maturity Month and Year	[10],[22]					2026-09		2026-09
Investment, Basis Spread, Variable Rate	[10],[12],[22]					3.65%		3.65%
Investment, Interest Rate, Floor	[10],[12],[22]					8.40%		8.40%
Investment, Interest Rate, Cap	[10],[12],[22]					10.90%		10.90%
Principal Amount	[10],[22]					$ 15,000
Investment cost	[6],[10],[22]					14,920
Investments at Fair Value	[10],[22]					$ 14,920
Investment Exit Fee	[10],[12],[22]					10.60%		10.60%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Alladapt Immunotherapeutics Inc. Senior Secured, Maturity Date September 2026, Prime + 3.65%, Floor rate 8.40%, Cap rate 10.90%, 5.30% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[9]	2026-09		2026-09
Investments Maturity Month and Year	[8],[9]	2026-09		2026-09
Investment, Basis Spread, Variable Rate	[8],[11]	3.65%		3.65%
Investment, Interest Rate, Floor	[8],[11]	8.40%		8.40%
Investment, Interest Rate, Cap	[8],[11]	10.90%		10.90%
Principal Amount	[8]	$ 30,000
Investment cost	[2],[8]	29,904
Investments at Fair Value	[8]	$ 29,747
Investment Exit Fee	[8],[11]	5.30%		5.30%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, Maturity Date January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-01	[1]	2027-01	[1]	2027-01	[31]	2027-01	[31]
Investments Maturity Month and Year		2027-01	[1]	2027-01	[1]	2027-01	[31]	2027-01	[31]
Investment, Basis Spread, Variable Rate		2.50%	[1],[11]	2.50%	[1],[11]	2.50%	[12],[31]	2.50%	[12],[31]
Investment, Interest Rate, Floor		9.50%	[1],[11]	9.50%	[1],[11]	9.50%	[12],[31]	9.50%	[12],[31]
Investment, Interest Rate, Cap		10.75%	[1],[11]	10.75%	[1],[11]	10.75%	[12],[31]	10.75%	[12],[31]
Principal Amount		$ 24,000	[1]			$ 24,000	[31]
Investment cost		23,883	[1],[2]			23,663	[6],[31]
Investments at Fair Value		$ 23,728	[1]			$ 23,663	[31]
Investment Exit Fee		5.85%	[1],[11]	5.85%	[1],[11]	5.85%	[12],[31]	5.85%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Aveo Pharmaceuticals, Inc. Senior Secured, Maturity Date September 2024, Prime + 6.40%, Floor rate 9.65%, Cap rate 15.00%, 6.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[16],[31]					2024-09		2024-09
Investments Maturity Month and Year	[16],[31]					2024-09		2024-09
Investment, Basis Spread, Variable Rate	[12],[16],[31]					6.40%		6.40%
Investment, Interest Rate, Floor	[12],[16],[31]					9.65%		9.65%
Investment, Interest Rate, Cap	[12],[16],[31]					15%		15%
Principal Amount	[16],[31]					$ 40,000
Investment cost	[6],[16],[31]					41,644
Investments at Fair Value	[16],[31]					$ 43,183
Investment Exit Fee	[12],[16],[31]					6.95%		6.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc. Senior Secured, Maturity Date January 2028 Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee
Investment Holding [Line Items]
Maturity Date	[9],[18],[20],[21],[25]	2028-01		2028-01
Investments Maturity Month and Year	[9],[18],[20],[21],[25]	2028-01		2028-01
Investment, Basis Spread, Variable Rate	[9],[11],[18],[20],[21],[25]	2.20%		2.20%
Investment, Interest Rate, Floor	[9],[11],[18],[20],[21],[25]	9.95%		9.95%
Investment, Interest Rate, Cap	[9],[11],[18],[20],[21],[25]	10.70%		10.70%
Principal Amount	[9],[18],[20],[21],[25]	$ 143,350
Investment cost	[2],[9],[18],[20],[21],[25]	142,818
Investments at Fair Value	[9],[18],[20],[21],[25]	$ 143,739
Investment Exit Fee	[9],[11],[18],[20],[21],[25]	5.78%		5.78%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc. Senior Secured, Maturity Date October 2026, Prime + 5.70%, Floor rate 8.95%, Cap rate 10.70%, 5.31% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[16],[23],[24],[27]					2026-10		2026-10
Investments Maturity Month and Year	[10],[16],[23],[24],[27]					2026-10		2026-10
Investment, Basis Spread, Variable Rate	[10],[12],[16],[23],[24],[27]					5.70%		5.70%
Investment, Interest Rate, Floor	[10],[12],[16],[23],[24],[27]					8.95%		8.95%
Investment, Interest Rate, Cap	[10],[12],[16],[23],[24],[27]					10.70%		10.70%
Principal Amount	[10],[16],[23],[24],[27]					$ 81,725
Investment cost	[6],[10],[16],[23],[24],[27]					81,631
Investments at Fair Value	[10],[16],[23],[24],[27]					$ 78,074
Investment Exit Fee	[10],[12],[16],[23],[24],[27]					5.31%		5.31%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Senior Secured, Maturity Date July 2025, Prime + 4.55%, Floor rate 8.05%, Cap rate 9.05%, 5.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-07	[18],[20],[25],[26]	2025-07	[18],[20],[25],[26]	2025-07	[16],[23],[27],[28]	2025-07	[16],[23],[27],[28]
Investments Maturity Month and Year		2025-07	[18],[20],[25],[26]	2025-07	[18],[20],[25],[26]	2025-07	[16],[23],[27],[28]	2025-07	[16],[23],[27],[28]
Investment, Basis Spread, Variable Rate		4.55%	[11],[18],[20],[25],[26]	4.55%	[11],[18],[20],[25],[26]	4.55%	[12],[16],[23],[27],[28]	4.55%	[12],[16],[23],[27],[28]
Investment, Interest Rate, Floor		8.05%	[11],[18],[20],[25],[26]	8.05%	[11],[18],[20],[25],[26]	8.05%	[12],[16],[23],[27],[28]	8.05%	[12],[16],[23],[27],[28]
Investment, Interest Rate, Cap		9.05%	[11],[18],[20],[25],[26]	9.05%	[11],[18],[20],[25],[26]	9.05%	[12],[16],[23],[27],[28]	9.05%	[12],[16],[23],[27],[28]
Principal Amount		$ 11,500	[18],[20],[25],[26]			$ 11,500	[16],[23],[27],[28]
Investment cost		11,818	[2],[18],[20],[25],[26]			11,757	[6],[16],[23],[27],[28]
Investments at Fair Value		$ 11,542	[18],[20],[25],[26]			$ 11,435	[16],[23],[27],[28]
Investment Exit Fee		5%	[11],[18],[20],[25],[26]	5%	[11],[18],[20],[25],[26]	5%	[12],[16],[23],[27],[28]	5%	[12],[16],[23],[27],[28]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and BiomX, INC, Senior Secured, Maturity Date September 2025, Prime + 5.70%, Floor rate 8.95%, 6.55% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-09	[18],[25],[26]	2025-09	[18],[25],[26]	2025-09	[16],[27],[28]	2025-09	[16],[27],[28]
Investments Maturity Month and Year		2025-09	[18],[25],[26]	2025-09	[18],[25],[26]	2025-09	[16],[27],[28]	2025-09	[16],[27],[28]
Investment, Basis Spread, Variable Rate		5.70%	[11],[18],[25],[26]	5.70%	[11],[18],[25],[26]	5.70%	[12],[16],[27],[28]	5.70%	[12],[16],[27],[28]
Investment, Interest Rate, Floor		8.95%	[11],[18],[25],[26]	8.95%	[11],[18],[25],[26]	8.95%	[12],[16],[27],[28]	8.95%	[12],[16],[27],[28]
Principal Amount		$ 8,008	[18],[25],[26]			$ 9,000	[16],[27],[28]
Investment cost		8,277	[2],[18],[25],[26]			9,174	[6],[16],[27],[28]
Investments at Fair Value		$ 8,246	[18],[25],[26]			$ 9,052	[16],[27],[28]
Investment Exit Fee		6.55%	[11],[18],[25],[26]	6.55%	[11],[18],[25],[26]	6.55%	[12],[16],[27],[28]	6.55%	[12],[16],[27],[28]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and BridgeBio Pharma, Inc. Senior Secured, Maturity Date November 2026, FIXED 9.00%, 2.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-11	[7],[8],[20]	2026-11	[7],[8],[20]	2026-11	[15],[22],[23]	2026-11	[15],[22],[23]
Investments Maturity Month and Year		2026-11	[7],[8],[20]	2026-11	[7],[8],[20]	2026-11	[15],[22],[23]	2026-11	[15],[22],[23]
Investment, Interest Rate, Paid in Cash		9%	[7],[8],[11],[20]	9%	[7],[8],[11],[20]	9%	[12],[15],[22],[23]	9%	[12],[15],[22],[23]
Interest rate	[12],[15],[22],[23]					2%		2%
Principal Amount		$ 37,880	[7],[8],[20]			$ 37,312	[15],[22],[23]
Investment cost		37,718	[2],[7],[8],[20]			37,039	[6],[15],[22],[23]
Investments at Fair Value		$ 34,033	[7],[8],[20]			$ 33,344	[15],[22],[23]
Investment Exit Fee	[7],[8],[11],[20]	2%		2%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Cellarity, Inc. Senior Secured, Maturity Date June 2026, Prime + 5.70%, Floor rate 8.95%, 3.75% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-06	[1],[8]	2026-06	[1],[8]	2026-06	[22],[31]	2026-06	[22],[31]
Investments Maturity Month and Year		2026-06	[1],[8]	2026-06	[1],[8]	2026-06	[22],[31]	2026-06	[22],[31]
Investment, Basis Spread, Variable Rate		5.70%	[1],[8],[11]	5.70%	[1],[8],[11]	5.70%	[12],[22],[31]	5.70%	[12],[22],[31]
Investment, Interest Rate, Floor		8.95%	[1],[8],[11]	8.95%	[1],[8],[11]	8.95%	[12],[22],[31]	8.95%	[12],[22],[31]
Principal Amount		$ 30,000	[1],[8]			$ 30,000	[22],[31]
Investment cost		30,056	[1],[2],[8]			29,841	[6],[22],[31]
Investments at Fair Value		$ 30,478	[1],[8]			$ 30,097	[22],[31]
Investment Exit Fee		3.75%	[1],[8],[11]	3.75%	[1],[8],[11]	3.75%	[12],[22],[31]	3.75%	[12],[22],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Century Therapeutics, Inc. Senior Secured, Maturity Date April 2024, Prime + 6.30%, Floor rate 9.55%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[16]					2024-04		2024-04
Investments Maturity Month and Year	[16]					2024-04		2024-04
Investment, Basis Spread, Variable Rate	[12],[16]					6.30%		6.30%
Investment, Interest Rate, Floor	[12],[16]					9.55%		9.55%
Principal Amount	[16]					$ 10,000
Investment cost	[6],[16]					10,235
Investments at Fair Value	[16]					$ 10,292
Investment Exit Fee	[12],[16]					3.95%		3.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Codiak Biosciences, Inc. Senior Secured, Maturity Date October 2025, Prime + 5.00%, Floor rate 8.25%, 5.50% Exit Fee
Investment Holding [Line Items]
Maturity Date	[16]					2025-10		2025-10
Investments Maturity Month and Year	[16]					2025-10		2025-10
Investment, Basis Spread, Variable Rate	[12],[16]					5%		5%
Investment, Interest Rate, Floor	[12],[16]					8.25%		8.25%
Principal Amount	[16]					$ 25,000
Investment cost	[6],[16]					25,759
Investments at Fair Value	[16]					$ 25,177
Investment Exit Fee	[12],[16]					5.50%		5.50%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Compass Pathways plc Senior Secured, Maturity Date June 2026, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee
Investment Holding [Line Items]
Maturity Date	[25],[26]	2027-07		2027-07
Investments Maturity Month and Year	[25],[26]	2027-07		2027-07
Investment, Basis Spread, Variable Rate	[11],[25],[26]	1.50%		1.50%
Investment, Interest Rate, Floor	[11],[25],[26]	9.75%		9.75%
Investment, Interest Rate, Paid in Kind	[11],[25],[26]	1.40%		1.40%
Principal Amount	[25],[26]	$ 24,000
Investment cost	[2],[25],[26]	23,443
Investments at Fair Value	[25],[26]	$ 23,443
Investment Exit Fee	[11],[25],[26]	4.75%		4.75%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Corium, Inc. Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-09	[8],[21]	2026-09	[8],[21]	2026-09	[22],[24]	2026-09	[22],[24]
Investments Maturity Month and Year		2026-09	[8],[21]	2026-09	[8],[21]	2026-09	[22],[24]	2026-09	[22],[24]
Investment, Basis Spread, Variable Rate		5.70%	[8],[11],[21]	5.70%	[8],[11],[21]	5.70%	[12],[22],[24]	5.70%	[12],[22],[24]
Investment, Interest Rate, Floor		8.95%	[8],[11],[21]	8.95%	[8],[11],[21]	8.95%	[12],[22],[24]	8.95%	[12],[22],[24]
Principal Amount		$ 132,675	[8],[21]			$ 132,675	[22],[24]
Investment cost		134,545	[2],[8],[21]			133,557	[6],[22],[24]
Investments at Fair Value		$ 136,450	[8],[21]			$ 135,619	[22],[24]
Investment Exit Fee		7.75%	[8],[11],[21]	7.75%	[8],[11],[21]	7.75%	[12],[22],[24]	7.75%	[12],[22],[24]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Curevo, Inc. Senior Secured, Maturity Date June 2027 Prime + 1.70%, Floor rate 9.70%, 6.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[1]	2027-06		2027-06
Investments Maturity Month and Year	[1]	2027-06		2027-06
Investment, Basis Spread, Variable Rate	[1],[11]	1.70%		1.70%
Investment, Interest Rate, Floor	[1],[11]	9.70%		9.70%
Principal Amount	[1]	$ 10,000
Investment cost	[1],[2]	9,674
Investments at Fair Value	[1]	$ 9,674
Investment Exit Fee	[1],[11]	6.95%		6.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Eloxx Pharmaceuticals, Inc. Senior Secured, Maturity Date April 2025, Prime + 6.25%, Floor rate 9.50%, 6.55% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-04	[1]	2025-04	[1]	2025-04	[31]	2025-04	[31]
Investments Maturity Month and Year		2025-04	[1]	2025-04	[1]	2025-04	[31]	2025-04	[31]
Investment, Basis Spread, Variable Rate		6.25%	[1],[11]	6.25%	[1],[11]	6.25%	[12],[31]	6.25%	[12],[31]
Investment, Interest Rate, Floor		9.50%	[1],[11]	9.50%	[1],[11]	9.50%	[12],[31]	9.50%	[12],[31]
Principal Amount		$ 5,000	[1]			$ 12,500	[31]
Investment cost		5,642	[1],[2]			12,753	[6],[31]
Investments at Fair Value		$ 5,552	[1]			$ 12,535	[31]
Investment Exit Fee		6.55%	[1],[11]	6.55%	[1],[11]	6.55%	[12],[31]	6.55%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Finch Therapeutics Group, Inc. Senior Secured, Maturity Date November 2026, Prime + 4.05%, Floor rate 7.55%, Cap rate 8.80%, 5.50% Exit Fee
Investment Holding [Line Items]
Maturity Date						2026-11		2026-11
Investments Maturity Month and Year						2026-11		2026-11
Investment, Basis Spread, Variable Rate	[12]					4.05%		4.05%
Investment, Interest Rate, Floor	[12]					7.55%		7.55%
Investment, Interest Rate, Cap	[12]					8.80%		8.80%
Principal Amount						$ 15,000
Investment cost	[6]					15,012
Investments at Fair Value						$ 13,940
Investment Exit Fee	[12]					5.50%		5.50%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and G1 Therapeutics, Inc. Senior Secured, Maturity Date November 2026, Prime + 5.65%, Floor rate 9.15%, 11.41% Exit Fee
Investment Holding [Line Items]
Maturity Date	[1],[18],[20]	2026-11		2026-11
Investments Maturity Month and Year	[1],[18],[20]	2026-11		2026-11
Investment, Basis Spread, Variable Rate	[1],[11],[18],[20]	5.65%		5.65%
Investment, Interest Rate, Floor	[1],[11],[18],[20]	9.15%		9.15%
Principal Amount	[1],[18],[20]	$ 38,750
Investment cost	[1],[2],[18],[20]	39,386
Investments at Fair Value	[1],[18],[20]	$ 39,500
Investment Exit Fee	[1],[11],[18],[20]	11.41%		11.41%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and G1 Therapeutics, Inc. Senior Secured, Maturity Date November 2026, Prime + 5.90%, Floor rate 9.15%, 9.86% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[16],[23],[31]					2026-11		2026-11
Investments Maturity Month and Year	[10],[16],[23],[31]					2026-11		2026-11
Investment, Basis Spread, Variable Rate	[10],[12],[16],[23],[31]					5.90%		5.90%
Investment, Interest Rate, Floor	[10],[12],[16],[23],[31]					9.15%		9.15%
Principal Amount	[10],[16],[23],[31]					$ 58,125
Investment cost	[6],[10],[16],[23],[31]					58,674
Investments at Fair Value	[10],[16],[23],[31]					$ 58,407
Investment Exit Fee	[10],[12],[16],[23],[31]					9.86%		9.86%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Geron Corporation, Senior Secured, Maturity Date April 2025, Prime + 5.75%, Floor rate 9.00%, 6.55% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[20],[25]	2025-04		2025-04
Investments Maturity Month and Year	[8],[20],[25]	2025-04		2025-04
Investment, Basis Spread, Variable Rate	[8],[11],[20],[25]	5.75%		5.75%
Investment, Interest Rate, Floor	[8],[11],[20],[25]	9%		9%
Principal Amount	[8],[20],[25]	$ 18,500
Investment cost	[2],[8],[20],[25]	19,243
Investments at Fair Value	[8],[20],[25]	$ 19,482
Investment Exit Fee	[8],[11],[20],[25]	6.55%		6.55%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Geron Corporation, Senior Secured, Maturity Date October 2024, Prime + 5.75%, Floor rate 9.00%, 6.55% Exit Fee
Investment Holding [Line Items]
Maturity Date	[22],[23],[27]					2024-10		2024-10
Investments Maturity Month and Year	[22],[23],[27]					2024-10		2024-10
Investment, Basis Spread, Variable Rate	[12],[22],[23],[27]					5.75%		5.75%
Investment, Interest Rate, Floor	[12],[22],[23],[27]					9%		9%
Principal Amount	[22],[23],[27]					$ 18,500
Investment cost	[6],[22],[23],[27]					19,109
Investments at Fair Value	[22],[23],[27]					$ 19,174
Investment Exit Fee	[12],[22],[23],[27]					6.55%		6.55%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Gritstone Bio, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 7.15%, Cap rate 8.65%, PIK Interest 2.00%, 5.75% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-07	[7],[8],[9]	2027-07	[7],[8],[9]	2027-07	[10],[15]	2027-07	[10],[15]
Investments Maturity Month and Year		2027-07	[7],[8],[9]	2027-07	[7],[8],[9]	2027-07	[10],[15]	2027-07	[10],[15]
Investment, Basis Spread, Variable Rate		3.15%	[7],[8],[9],[11]	3.15%	[7],[8],[9],[11]	3.15%	[10],[12],[15]	3.15%	[10],[12],[15]
Investment, Interest Rate, Floor		7.15%	[7],[8],[9],[11]	7.15%	[7],[8],[9],[11]	7.15%	[10],[12],[15]	7.15%	[10],[12],[15]
Investment, Interest Rate, Cap		8.65%	[7],[8],[9],[11]	8.65%	[7],[8],[9],[11]	8.65%	[10],[12],[15]	8.65%	[10],[12],[15]
Investment, Interest Rate, Paid in Kind		2%	[7],[8],[9],[11]	2%	[7],[8],[9],[11]	2%	[10],[12],[15]	2%	[10],[12],[15]
Principal Amount		$ 22,799	[7],[8],[9]			$ 15,113	[10],[15]
Investment cost		22,874	[2],[7],[8],[9]			15,109	[6],[10],[15]
Investments at Fair Value		$ 22,766	[7],[8],[9]			$ 15,109	[10],[15]
Investment Exit Fee		5.75%	[7],[8],[9],[11]	5.75%	[7],[8],[9],[11]	5.75%	[10],[12],[15]	5.75%	[10],[12],[15]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Hibercell, Inc. Senior Secured, Maturity Date May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-05	[1],[8]	2025-05	[1],[8]	2025-05	[22],[31]	2025-05	[22],[31]
Investments Maturity Month and Year		2025-05	[1],[8]	2025-05	[1],[8]	2025-05	[22],[31]	2025-05	[22],[31]
Investment, Basis Spread, Variable Rate		5.40%	[1],[8],[11]	5.40%	[1],[8],[11]	5.40%	[12],[22],[31]	5.40%	[12],[22],[31]
Investment, Interest Rate, Floor		8.65%	[1],[8],[11]	8.65%	[1],[8],[11]	8.65%	[12],[22],[31]	8.65%	[12],[22],[31]
Principal Amount		$ 16,386	[1],[8]			$ 17,000	[22],[31]
Investment cost		16,837	[1],[2],[8]			17,313	[6],[22],[31]
Investments at Fair Value		$ 16,770	[1],[8]			$ 17,265	[22],[31]
Investment Exit Fee		4.95%	[1],[8],[11]	4.95%	[1],[8],[11]	4.95%	[12],[22],[31]	4.95%	[12],[22],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and HilleVax, Inc. Senior Secured, Maturity Date May 2027, Prime + 1.05%, Floor rate 4.55%, Cap rate 6.05%, PIK Interest 2.85%, 7.15% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-05	[1],[7],[9]	2027-05	[1],[7],[9]	2027-05	[10],[15],[31]	2027-05	[10],[15],[31]
Investments Maturity Month and Year		2027-05	[1],[7],[9]	2027-05	[1],[7],[9]	2027-05	[10],[15],[31]	2027-05	[10],[15],[31]
Investment, Basis Spread, Variable Rate		1.05%	[1],[7],[11]	1.05%	[1],[7],[11]	1.05%	[10],[12],[15],[31]	1.05%	[10],[12],[15],[31]
Investment, Interest Rate, Floor		4.55%	[1],[7],[11]	4.55%	[1],[7],[11]	4.55%	[10],[12],[15],[31]	4.55%	[10],[12],[15],[31]
Investment, Interest Rate, Cap		6.05%	[1],[7],[11]	6.05%	[1],[7],[11]	6.05%	[10],[12],[15],[31]	6.05%	[10],[12],[15],[31]
Investment, Interest Rate, Paid in Kind		2.85%	[1],[7],[11]	2.85%	[1],[7],[11]	2.85%	[10],[12],[15],[31]	2.85%	[10],[12],[15],[31]
Principal Amount		$ 20,238	[1],[7]			$ 12,072	[10],[15],[31]
Investment cost		20,209	[1],[2],[7]			12,043	[6],[10],[15],[31]
Investments at Fair Value		$ 19,163	[1],[7]			$ 11,333	[10],[15],[31]
Investment Exit Fee		7.15%	[1],[7],[11]	7.15%	[1],[7],[11]	7.15%	[10],[12],[15],[31]	7.15%	[10],[12],[15],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Iveric Bio, Inc. Senior Secured, Maturity Date August 2027, Prime + 4.00%, Floor rate 8.75%, Cap rate 10.25%, 4.25% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-08	[9],[20],[25]	2027-08	[9],[20],[25]	2027-08	[23],[27]	2027-08	[23],[27]
Investments Maturity Month and Year		2027-08	[9],[20],[25]	2027-08	[9],[20],[25]	2027-08	[23],[27]	2027-08	[23],[27]
Investment, Basis Spread, Variable Rate		4%	[9],[11],[20],[25]	4%	[9],[11],[20],[25]	4%	[12],[23],[27]	4%	[12],[23],[27]
Investment, Interest Rate, Floor		8.75%	[9],[11],[20],[25]	8.75%	[9],[11],[20],[25]	8.75%	[12],[23],[27]	8.75%	[12],[23],[27]
Investment, Interest Rate, Cap		10.25%	[9],[11],[20],[25]	10.25%	[9],[11],[20],[25]	10.25%	[12],[23],[27]	10.25%	[12],[23],[27]
Principal Amount		$ 49,500	[9],[20],[25]			$ 49,500	[23],[27]
Investment cost		49,336	[2],[9],[20],[25]			49,090	[6],[23],[27]
Investments at Fair Value		$ 52,631	[9],[20],[25]			$ 49,090	[23],[27]
Investment Exit Fee		4.25%	[9],[11],[20],[25]	4.25%	[9],[11],[20],[25]	4.25%	[12],[23],[27]	4.25%	[12],[23],[27]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Kura Oncology, Inc. Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 15.13% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-11	[1],[9],[25]	2027-11	[1],[9],[25]	2027-11	[10],[27],[31]	2027-11	[10],[27],[31]
Investments Maturity Month and Year		2027-11	[1],[9],[25]	2027-11	[1],[9],[25]	2027-11	[10],[27],[31]	2027-11	[10],[27],[31]
Investment, Basis Spread, Variable Rate		2.40%	[1],[9],[11],[25]	2.40%	[1],[9],[11],[25]	2.40%	[10],[12],[27],[31]	2.40%	[10],[12],[27],[31]
Investment, Interest Rate, Floor		8.65%	[1],[9],[11],[25]	8.65%	[1],[9],[11],[25]	8.65%	[10],[12],[27],[31]	8.65%	[10],[12],[27],[31]
Principal Amount		$ 5,500	[1],[9],[25]			$ 5,500	[10],[27],[31]
Investment cost		5,489	[1],[2],[9],[25]			5,448	[6],[10],[27],[31]
Investments at Fair Value		$ 5,606	[1],[9],[25]			$ 5,448	[10],[27],[31]
Investment Exit Fee		15.13%	[1],[9],[11],[25]	15.13%	[1],[9],[11],[25]	15.13%	[10],[12],[27],[31]	15.13%	[10],[12],[27],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Locus Biosciences, Inc. Senior Secured, Maturity Date July 2025, Prime + 6.10%, Floor rate 9.35%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-07	[1]	2025-07	[1]	2025-07	[31]	2025-07	[31]
Investments Maturity Month and Year		2025-07	[1]	2025-07	[1]	2025-07	[31]	2025-07	[31]
Investment, Basis Spread, Variable Rate		6.10%	[1],[11]	6.10%	[1],[11]	6.10%	[12],[31]	6.10%	[12],[31]
Investment, Interest Rate, Floor		9.35%	[1],[11]	9.35%	[1],[11]	9.35%	[12],[31]	9.35%	[12],[31]
Principal Amount		$ 6,854	[1]			$ 8,000	[31]
Investment cost		7,042	[1],[2]			8,120	[6],[31]
Investments at Fair Value		$ 7,049	[1]			$ 8,085	[31]
Investment Exit Fee		4.95%	[1],[11]	4.95%	[1],[11]	4.95%	[12],[31]	4.95%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc. Senior Secured, Maturity Date May 2026, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee
Investment Holding [Line Items]
Maturity Date	[25]	2026-05		2026-05
Investments Maturity Month and Year	[25]	2026-05		2026-05
Investment, Basis Spread, Variable Rate	[11],[25]	2.45%		2.45%
Investment, Interest Rate, Floor	[11],[25]	8.25%		8.25%
Principal Amount	[25]	$ 68,000
Investment cost	[2],[25]	67,896
Investments at Fair Value	[25]	$ 68,481
Investment Exit Fee	[11],[25]	5.35%		5.35%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc. Senior Secured, Maturity Date May 2026, Prime + 3.95%, Floor rate 7.45%, 5.35% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[27]					2026-05		2026-05
Investments Maturity Month and Year	[10],[27]					2026-05		2026-05
Investment, Basis Spread, Variable Rate	[10],[12],[27]					3.95%		3.95%
Investment, Interest Rate, Floor	[10],[12],[27]					7.45%		7.45%
Principal Amount	[10],[27]					$ 34,000
Investment cost	[6],[10],[27]					33,945
Investments at Fair Value	[10],[27]					$ 33,987
Investment Exit Fee	[10],[12],[27]					5.35%		5.35%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Nabriva Therapeutics, Senior Secured, Maturity Date June 2023, Prime + 4.30%, Floor rate 9.80%, 9.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[22],[27],[28]					2023-06		2023-06
Investments Maturity Month and Year	[22],[27],[28]					2023-06		2023-06
Investment, Basis Spread, Variable Rate	[12],[22],[27],[28]					4.30%		4.30%
Investment, Interest Rate, Floor	[12],[22],[27],[28]					9.80%		9.80%
Principal Amount	[22],[27],[28]					$ 2,079
Investment cost	[6],[22],[27],[28]					2,734
Investments at Fair Value	[22],[27],[28]					$ 2,804
Investment Exit Fee	[12],[22],[27],[28]					9.95%		9.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc. Senior Secured, Maturity Date October 2026, Prime + 2.25%, Floor rate 5.50%, PIK Interest 3.35%, 7.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-10	[1],[7],[9],[20],[21],[25],[37]	2026-10	[1],[7],[9],[20],[21],[25],[37]	2026-10	[10],[15],[23],[24],[27],[31],[38]	2026-10	[10],[15],[23],[24],[27],[31],[38]
Investments Maturity Month and Year		2026-10	[1],[7],[9],[20],[21],[25],[37]	2026-10	[1],[7],[9],[20],[21],[25],[37]	2026-10	[10],[15],[23],[24],[27],[31],[38]	2026-10	[10],[15],[23],[24],[27],[31],[38]
Investment, Basis Spread, Variable Rate		2.25%	[1],[7],[9],[11],[20],[21],[25],[37]	2.25%	[1],[7],[9],[11],[20],[21],[25],[37]	2.25%	[10],[12],[15],[23],[24],[27],[31],[38]	2.25%	[10],[12],[15],[23],[24],[27],[31],[38]
Investment, Interest Rate, Floor		5.50%	[1],[7],[9],[11],[20],[21],[25],[37]	5.50%	[1],[7],[9],[11],[20],[21],[25],[37]	5.50%	[10],[12],[15],[23],[24],[27],[31],[38]	5.50%	[10],[12],[15],[23],[24],[27],[31],[38]
Investment, Interest Rate, Paid in Kind		3.35%	[1],[7],[9],[11],[20],[21],[25],[37]	3.35%	[1],[7],[9],[11],[20],[21],[25],[37]	3.35%	[10],[12],[15],[23],[24],[27],[31],[38]	3.35%	[10],[12],[15],[23],[24],[27],[31],[38]
Principal Amount		$ 96,262	[1],[7],[9],[20],[21],[25],[37]			$ 94,737	[10],[15],[23],[24],[27],[31],[38]
Investment cost		97,177	[1],[2],[7],[9],[20],[21],[25],[37]			95,032	[6],[10],[15],[23],[24],[27],[31],[38]
Investments at Fair Value		$ 96,827	[1],[7],[9],[20],[21],[25],[37]			$ 93,916	[10],[15],[23],[24],[27],[31],[38]
Investment Exit Fee		7.50%	[1],[7],[9],[11],[20],[21],[25],[37]	7.50%	[1],[7],[9],[11],[20],[21],[25],[37]	7.50%	[10],[12],[15],[23],[24],[27],[31],[38]	7.50%	[10],[12],[15],[23],[24],[27],[31],[38]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Provention Bio, Inc. Senior Secured, Maturity Date September 2027, Prime + 2.70%, Floor rate 8.20%, 6.60% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10]					2027-09		2027-09
Investments Maturity Month and Year	[10]					2027-09		2027-09
Investment, Basis Spread, Variable Rate	[10],[12]					2.70%		2.70%
Investment, Interest Rate, Floor	[10],[12]					8.20%		8.20%
Principal Amount	[10]					$ 25,000
Investment cost	[6],[10]					24,670
Investments at Fair Value	[10]					$ 24,670
Investment Exit Fee	[10],[12]					6.60%		6.60%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Redshift Bioanalytics, Inc. Senior Secured, Maturity Date January 2026, Prime + 4.25%, Floor rate 7.50%, 3.80% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-01	[1]	2026-01	[1]	2026-01	[31]	2026-01	[31]
Investments Maturity Month and Year		2026-01	[1]	2026-01	[1]	2026-01	[31]	2026-01	[31]
Investment, Basis Spread, Variable Rate		4.25%	[1],[11]	4.25%	[1],[11]	4.25%	[12],[31]	4.25%	[12],[31]
Investment, Interest Rate, Floor		7.50%	[1],[11]	7.50%	[1],[11]	7.50%	[12],[31]	7.50%	[12],[31]
Principal Amount		$ 5,000	[1]			$ 5,000	[31]
Investment cost		5,001	[1],[2]			4,957	[6],[31]
Investments at Fair Value		$ 5,027	[1]			$ 4,946	[31]
Investment Exit Fee		3.80%	[1],[11]	3.80%	[1],[11]	3.80%	[12],[31]	3.80%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Replimune Group, Inc. Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-10	[7],[25]	2027-10	[7],[25]	2027-10	[10],[15],[27]	2027-10	[10],[15],[27]
Investments Maturity Month and Year		2027-10	[7],[25]	2027-10	[7],[25]	2027-10	[10],[15],[27]	2027-10	[10],[15],[27]
Investment, Basis Spread, Variable Rate		1.75%	[7],[11],[25]	1.75%	[7],[11],[25]	1.75%	[10],[12],[15],[27]	1.75%	[10],[12],[15],[27]
Investment, Interest Rate, Floor		7.25%	[7],[11],[25]	7.25%	[7],[11],[25]	7.25%	[10],[12],[15],[27]	7.25%	[10],[12],[15],[27]
Investment, Interest Rate, Cap		9%	[7],[11],[25]	9%	[7],[11],[25]	9%	[10],[12],[15],[27]	9%	[10],[12],[15],[27]
Investment, Interest Rate, Paid in Kind		1.50%	[7],[11],[25]	1.50%	[7],[11],[25]	1.50%	[10],[12],[15],[27]	1.50%	[10],[12],[15],[27]
Principal Amount		$ 20,906	[7],[25]			$ 20,754	[10],[15],[27]
Investment cost		20,904	[2],[7],[25]			20,656	[6],[10],[15],[27]
Investments at Fair Value		$ 21,240	[7],[25]			$ 20,656	[10],[15],[27]
Investment Exit Fee		4.95%	[7],[11],[25]	4.95%	[7],[11],[25]	4.95%	[10],[12],[15],[27]	4.95%	[10],[12],[15],[27]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Scynexis, Inc. Senior Secured, Maturity Date March 2025, Prime + 5.80%, Floor rate 9.05%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[22],[23]					2025-03		2025-03
Investments Maturity Month and Year	[22],[23]					2025-03		2025-03
Investment, Basis Spread, Variable Rate	[12],[22],[23]					5.80%		5.80%
Investment, Interest Rate, Floor	[12],[22],[23]					9.05%		9.05%
Principal Amount	[22],[23]					$ 18,667
Investment cost	[6],[22],[23]					18,675
Investments at Fair Value	[22],[23]					$ 18,698
Investment Exit Fee	[12],[22],[23]					3.95%		3.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Seres Therapeutics, Inc. Senior Secured, Maturity Date October 2024, Prime + 6.40%, Floor rate 9.65%, 4.98% Exit Fee
Investment Holding [Line Items]
Maturity Date	[22],[23]					2024-10		2024-10
Investments Maturity Month and Year	[22],[23]					2024-10		2024-10
Investment, Basis Spread, Variable Rate	[12],[22],[23]					6.40%		6.40%
Investment, Interest Rate, Floor	[12],[22],[23]					9.65%		9.65%
Principal Amount	[22],[23]					$ 37,500
Investment cost	[6],[22],[23]					38,638
Investments at Fair Value	[22],[23]					$ 38,816
Investment Exit Fee	[12],[22],[23]					4.98%		4.98%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and TG Therapeutics, Inc. Senior Secured, Maturity Date January 2026, Prime + 1.20%, Floor rate 8.95%, PIK Interest 2.25%, 5.69% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7],[9],[18],[20],[25]	2026-01		2026-01
Investments Maturity Month and Year	[7],[9],[18],[20],[25]	2026-01		2026-01
Investment, Basis Spread, Variable Rate	[7],[9],[11],[18],[20],[25]	1.20%		1.20%
Investment, Interest Rate, Floor	[7],[9],[11],[18],[20],[25]	8.95%		8.95%
Investment, Interest Rate, Paid in Kind	[7],[9],[11],[18],[20],[25]	2.25%		2.25%
Principal Amount	[7],[9],[18],[20],[25]	$ 65,023
Investment cost	[2],[7],[9],[18],[20],[25]	65,045
Investments at Fair Value	[7],[9],[18],[20],[25]	$ 65,130
Investment Exit Fee	[7],[9],[11],[18],[20],[25]	5.69%		5.69%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and TG Therapeutics, Inc. Senior Secured, Maturity Date January 2026, Prime + 2.15%, Floor rate 5.40%, PIK Interest 3.45%, 5.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[15],[16],[23],[27]					2026-01		2026-01
Investments Maturity Month and Year	[15],[16],[23],[27]					2026-01		2026-01
Investment, Basis Spread, Variable Rate	[12],[15],[16],[23],[27]					2.15%		2.15%
Investment, Interest Rate, Floor	[12],[15],[16],[23],[27]					5.40%		5.40%
Investment, Interest Rate, Paid in Kind	[12],[15],[16],[23],[27]					3.45%		3.45%
Principal Amount	[15],[16],[23],[27]					$ 47,983
Investment cost	[6],[15],[16],[23],[27]					47,889
Investments at Fair Value	[15],[16],[23],[27]					$ 48,649
Investment Exit Fee	[12],[15],[16],[23],[27]					5.95%		5.95%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc. Senior Secured, Maturity Date February 2027, Prime + 4.45%, Floor rate 8.45%, Cap rate 11.45%, 4.75% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[9],[25]	2027-02		2027-02
Investments Maturity Month and Year	[8],[9],[25]	2027-02		2027-02
Investment, Basis Spread, Variable Rate	[8],[9],[11],[25]	4.45%		4.45%
Investment, Interest Rate, Floor	[8],[9],[11],[25]	8.45%		8.45%
Investment, Interest Rate, Cap	[8],[9],[11],[25]	11.45%		11.45%
Principal Amount	[8],[9],[25]	$ 10,313
Investment cost	[2],[8],[9],[25]	10,372
Investments at Fair Value	[8],[9],[25]	$ 10,434
Investment Exit Fee	[8],[9],[11],[25]	4.75%		4.75%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc. Senior Secured, Maturity Date February 2027, Prime + 5.20%, Floor rate 8.45%, 4.75% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[22],[27]					2027-02		2027-02
Investments Maturity Month and Year	[10],[22],[27]					2027-02		2027-02
Investment, Basis Spread, Variable Rate	[10],[12],[22],[27]					5.20%		5.20%
Investment, Interest Rate, Floor	[10],[12],[22],[27]					8.45%		8.45%
Principal Amount	[10],[22],[27]					$ 8,250
Investment cost	[6],[10],[22],[27]					8,274
Investments at Fair Value	[10],[22],[27]					$ 8,423
Investment Exit Fee	[10],[12],[22],[27]					4.75%		4.75%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Unity Biotechnology, Inc. Senior Secured, Maturity Date August 2024, Prime + 6.10%, Floor rate 9.35%, 6.25% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-08	[8]	2024-08	[8]	2024-08	[22]	2024-08	[22]
Investments Maturity Month and Year		2024-08	[8]	2024-08	[8]	2024-08	[22]	2024-08	[22]
Investment, Basis Spread, Variable Rate		6.10%	[8],[11]	6.10%	[8],[11]	6.10%	[12],[22]	6.10%	[12],[22]
Investment, Interest Rate, Floor		9.35%	[8],[11]	9.35%	[8],[11]	9.35%	[12],[22]	9.35%	[12],[22]
Principal Amount		$ 16,766	[8]			$ 20,000	[22]
Investment cost		18,014	[2],[8]			21,079	[6],[22]
Investments at Fair Value		$ 17,999	[8]			$ 20,967	[22]
Investment Exit Fee		6.25%	[8],[11]	6.25%	[8],[11]	6.25%	[12],[22]	6.25%	[12],[22]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Valo Health, LLC, Senior Secured, Maturity Date May 2024, Prime + 6.45%, Floor rate 9.70%, 3.85% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-05	[8],[18]	2024-05	[8],[18]	2024-05	[16],[22]	2024-05	[16],[22]
Investments Maturity Month and Year		2024-05	[8],[18]	2024-05	[8],[18]	2024-05	[16],[22]	2024-05	[16],[22]
Investment, Basis Spread, Variable Rate		6.45%	[8],[11],[18]	6.45%	[8],[11],[18]	6.45%	[12],[16],[22]	6.45%	[12],[16],[22]
Investment, Interest Rate, Floor		9.70%	[8],[11],[18]	9.70%	[8],[11],[18]	9.70%	[12],[16],[22]	9.70%	[12],[16],[22]
Principal Amount		$ 5,271	[8],[18]			$ 8,146	[16],[22]
Investment cost		5,621	[2],[8],[18]			8,416	[6],[16],[22]
Investments at Fair Value		$ 5,621	[8],[18]			$ 8,410	[16],[22]
Investment Exit Fee		3.85%	[8],[11],[18]	3.85%	[8],[11],[18]	3.85%	[12],[16],[22]	3.85%	[12],[16],[22]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc. Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 4.76% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[22],[27]					2026-10		2026-10
Investments Maturity Month and Year	[10],[22],[27]					2026-10		2026-10
Investment, Basis Spread, Variable Rate	[10],[12],[22],[27]					4.20%		4.20%
Investment, Interest Rate, Floor	[10],[12],[22],[27]					7.45%		7.45%
Investment, Interest Rate, Cap	[10],[12],[22],[27]					8.95%		8.95%
Principal Amount	[10],[22],[27]					$ 2,000
Investment cost	[6],[10],[22],[27]					2,012
Investments at Fair Value	[10],[22],[27]					$ 1,934
Investment Exit Fee	[10],[12],[22],[27]					4.76%		4.76%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc. Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[25]	2026-10		2026-10
Investments Maturity Month and Year	[8],[25]	2026-10		2026-10
Investment, Basis Spread, Variable Rate	[8],[11],[25]	4.20%		4.20%
Investment, Interest Rate, Floor	[8],[11],[25]	7.45%		7.45%
Investment, Interest Rate, Cap	[8],[11],[25]	8.95%		8.95%
Principal Amount	[8],[25]	$ 2,000
Investment cost	[2],[8],[25]	2,027
Investments at Fair Value	[8],[25]	$ 1,950
Investment Exit Fee	[8],[11],[25]	6%		6%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc. Senior Secured, Maturity Date April 2026, Prime + 3.15%, Floor rate 10.15%, 6.35% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[18],[20]	2026-04		2026-04
Investments Maturity Month and Year	[8],[18],[20]	2026-04		2026-04
Investment, Basis Spread, Variable Rate	[8],[11],[18],[20]	3.15%		3.15%
Investment, Interest Rate, Floor	[8],[11],[18],[20]	10.15%		10.15%
Principal Amount	[8],[18],[20]	$ 32,500
Investment cost	[2],[8],[18],[20]	32,658
Investments at Fair Value	[8],[18],[20]	$ 32,747
Investment Exit Fee	[8],[11],[18],[20]	6.35%		6.35%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc. Senior Secured, Maturity Date July 2024, Prime + 3.75%, Floor rate 8.75%, 8.80% Exit Fee
Investment Holding [Line Items]
Maturity Date	[16],[22],[23]					2024-07		2024-07
Investments Maturity Month and Year	[16],[22],[23]					2024-07		2024-07
Investment, Basis Spread, Variable Rate	[12],[16],[22],[23]					3.75%		3.75%
Investment, Interest Rate, Floor	[12],[16],[22],[23]					8.75%		8.75%
Principal Amount	[16],[22],[23]					$ 32,500
Investment cost	[6],[16],[22],[23]					33,705
Investments at Fair Value	[16],[22],[23]					$ 33,700
Investment Exit Fee	[12],[16],[22],[23]					8.80%		8.80%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and enGene, Inc. Senior Secured, Maturity Date July 2025, Prime + 5.00%, Floor rate 8.25%, 6.35% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-07	[8],[20],[25],[26]	2025-07	[8],[20],[25],[26]	2025-07	[22],[23],[27],[28]	2025-07	[22],[23],[27],[28]
Investments Maturity Month and Year		2025-07	[8],[20],[25],[26]	2025-07	[8],[20],[25],[26]	2025-07	[22],[23],[27],[28]	2025-07	[22],[23],[27],[28]
Investment, Basis Spread, Variable Rate		5%	[8],[11],[20],[25],[26]	5%	[8],[11],[20],[25],[26]	5%	[12],[22],[23],[27],[28]	5%	[12],[22],[23],[27],[28]
Investment, Interest Rate, Floor		8.25%	[8],[11],[20],[25],[26]	8.25%	[8],[11],[20],[25],[26]	8.25%	[12],[22],[23],[27],[28]	8.25%	[12],[22],[23],[27],[28]
Principal Amount		$ 11,000	[8],[20],[25],[26]			$ 11,000	[22],[23],[27],[28]
Investment cost		11,230	[2],[8],[20],[25],[26]			11,072	[6],[22],[23],[27],[28]
Investments at Fair Value		$ 11,264	[8],[20],[25],[26]			$ 11,067	[22],[23],[27],[28]
Investment Exit Fee		6.35%	[8],[11],[20],[25],[26]	6.35%	[8],[11],[20],[25],[26]	6.35%	[12],[22],[23],[27],[28]	6.35%	[12],[22],[23],[27],[28]
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and uniQure B.V. Senior Secured, Maturity Date December 2025, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee
Investment Holding [Line Items]
Maturity Date	[18],[20],[25],[26]	2027-01		2027-01
Investments Maturity Month and Year	[18],[20],[25],[26]	2027-01		2027-01
Investment, Basis Spread, Variable Rate	[11],[18],[20],[25],[26]	4.70%		4.70%
Investment, Interest Rate, Floor	[11],[18],[20],[25],[26]	7.95%		7.95%
Principal Amount	[18],[20],[25],[26]	$ 70,000
Investment cost	[2],[18],[20],[25],[26]	70,682
Investments at Fair Value	[18],[20],[25],[26]	$ 72,066
Investment Exit Fee	[11],[18],[20],[25],[26]	6.10%		6.10%
Investment, Identifier [Axis]: Debt Investments Drug Discovery & Development and uniQure B.V. Senior Secured, Maturity Date December 2025, Prime + 4.70%, Floor rate 7.95%, 7.28% Exit Fee
Investment Holding [Line Items]
Maturity Date	[16],[23],[24],[27],[28]					2025-12		2025-12
Investments Maturity Month and Year	[16],[23],[24],[27],[28]					2025-12		2025-12
Investment, Basis Spread, Variable Rate	[12],[16],[23],[24],[27],[28]					4.70%		4.70%
Investment, Interest Rate, Floor	[12],[16],[23],[24],[27],[28]					7.95%		7.95%
Principal Amount	[16],[23],[24],[27],[28]					$ 70,000
Investment cost	[6],[16],[23],[24],[27],[28]					72,329
Investments at Fair Value	[16],[23],[24],[27],[28]					$ 73,019
Investment Exit Fee	[12],[16],[23],[24],[27],[28]					7.28%		7.28%
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware (1.19%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	1.19%		1.19%
Investment cost	[2]	$ 18,256
Investments at Fair Value		$ 18,942
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware (1.34%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					1.34%		1.34%
Investment cost	[6]					$ 18,171
Investments at Fair Value						$ 18,723
Investment, Identifier [Axis]: Debt Investments Electronics & Computer Hardware and Locus Robotics Corp. Senior Secured, Maturity Date June 2026, Prime + 4.50%, Floor rate 8.00%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-06	[9],[13]	2026-06	[9],[13]	2026-06	[14]	2026-06	[14]
Investments Maturity Month and Year		2026-06	[9],[13]	2026-06	[9],[13]	2026-06	[14]	2026-06	[14]
Investment, Basis Spread, Variable Rate		4.50%	[9],[11],[13]	4.50%	[9],[11],[13]	4.50%	[12],[14]	4.50%	[12],[14]
Investment, Interest Rate, Floor		8%	[9],[11],[13]	8%	[9],[11],[13]	8%	[12],[14]	8%	[12],[14]
Principal Amount		$ 18,281	[9],[13]			$ 18,281	[14]
Investment cost		18,256	[2],[9],[13]			18,171	[6],[14]
Investments at Fair Value		$ 18,942	[9],[13]			$ 18,723	[14]
Investment Exit Fee		1%	[9],[11],[13]	1%	[9],[11],[13]	1%	[12],[14]	1%	[12],[14]
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other (13.76%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	13.76%		13.76%
Investment cost	[2]	$ 218,993
Investments at Fair Value		$ 218,185
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other (13.98%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					13.98%		13.98%
Investment cost	[6]					$ 196,342
Investments at Fair Value						$ 195,855
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Better Therapeutics, Inc. Senior Secured, Maturity Date August 2025, Prime + 5.70%, Floor rate 8.95%, 5.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-08	[1]	2025-08	[1]	2025-08	[31]	2025-08	[31]
Investments Maturity Month and Year		2025-08	[1]	2025-08	[1]	2025-08	[31]	2025-08	[31]
Investment, Basis Spread, Variable Rate		5.70%	[1],[11]	5.70%	[1],[11]	5.70%	[12],[31]	5.70%	[12],[31]
Investment, Interest Rate, Floor		8.95%	[1],[11]	8.95%	[1],[11]	8.95%	[12],[31]	8.95%	[12],[31]
Principal Amount		$ 11,314	[1]			$ 12,000	[31]
Investment cost		11,608	[1],[2]			12,162	[6],[31]
Investments at Fair Value		$ 11,500	[1]			$ 12,053	[31]
Investment Exit Fee		5.95%	[1],[11]	5.95%	[1],[11]	5.95%	[12],[31]	5.95%	[12],[31]
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc. Senior Secured, Maturity Date November 2026, 1-month LIBOR + 5.00%, Floor rate 6.00%, PIK Interest 4.45%
Investment Holding [Line Items]
Maturity Date	[15],[16],[22]					2026-11		2026-11
Investments Maturity Month and Year	[15],[16],[22]					2026-11		2026-11
Investment, Basis Spread, Variable Rate	[12],[15],[16],[22]					5%		5%
Investment, Interest Rate, Floor	[12],[15],[16],[22]					6%		6%
Investment, Interest Rate, Paid in Kind	[12],[15],[16],[22]					4.45%		4.45%
Principal Amount	[15],[16],[22]					$ 51,480
Investment cost	[6],[15],[16],[22]					50,813
Investments at Fair Value	[15],[16],[22]					$ 49,732
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc. Senior Secured, Maturity Date November 2026, 1-month SOFR + 5.00%, Floor rate 6.00%, PIK Interest 4.45%
Investment Holding [Line Items]
Maturity Date	[7],[8],[18]	2026-11		2026-11
Investments Maturity Month and Year	[7],[8],[18]	2026-11		2026-11
Investment, Basis Spread, Variable Rate	[7],[8],[11],[18]	5%		5%
Investment, Interest Rate, Floor	[7],[8],[11],[18]	6%		6%
Investment, Interest Rate, Paid in Kind	[7],[8],[11],[18]	4.45%		4.45%
Principal Amount	[7],[8],[18]	$ 57,658
Investment cost	[2],[7],[8],[18]	56,974
Investments at Fair Value	[7],[8],[18]	$ 55,819
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc. Senior Secured, Maturity Date March 2025, Prime + 5.60%, Floor rate 8.85%, 4.61% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-03	[8],[18]	2025-03	[8],[18]	2025-03	[14],[16],[22]	2025-03	[14],[16],[22]
Investments Maturity Month and Year		2025-03	[8],[18]	2025-03	[8],[18]	2025-03	[14],[16],[22]	2025-03	[14],[16],[22]
Investment, Basis Spread, Variable Rate		5.60%	[8],[11],[18]	5.60%	[8],[11],[18]	5.60%	[12],[14],[16],[22]	5.60%	[12],[14],[16],[22]
Investment, Interest Rate, Floor		8.85%	[8],[11],[18]	8.85%	[8],[11],[18]	8.85%	[12],[14],[16],[22]	8.85%	[12],[14],[16],[22]
Principal Amount		$ 46,125	[8],[18]			$ 46,125	[14],[16],[22]
Investment cost		46,859	[2],[8],[18]			46,552	[6],[14],[16],[22]
Investments at Fair Value		$ 47,142	[8],[18]			$ 46,548	[14],[16],[22]
Investment Exit Fee		4.61%	[8],[11],[18]	4.61%	[8],[11],[18]	4.61%	[12],[14],[16],[22]	4.61%	[12],[14],[16],[22]
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2026, Prime + 6.25%, Floor rate 9.50%, PIK Interest 1.55%
Investment Holding [Line Items]
Maturity Date		2026-02	[7],[18],[20]	2026-02	[7],[18],[20]	2026-02	[15],[23]	2026-02	[15],[23]
Investments Maturity Month and Year		2026-02	[7],[18],[20]	2026-02	[7],[18],[20]	2026-02	[15],[23]	2026-02	[15],[23]
Investment, Basis Spread, Variable Rate		6.25%	[7],[11],[18],[20]	6.25%	[7],[11],[18],[20]	6.25%	[12],[15],[23]	6.25%	[12],[15],[23]
Investment, Interest Rate, Floor		9.50%	[7],[11],[18],[20]	9.50%	[7],[11],[18],[20]	9.50%	[12],[15],[23]	9.50%	[12],[15],[23]
Investment, Interest Rate, Paid in Kind		1.55%	[7],[11],[18],[20]	1.55%	[7],[11],[18],[20]	1.55%	[12],[15],[23]	1.55%	[12],[15],[23]
Principal Amount		$ 53,999	[7],[18],[20]			$ 53,587	[15],[23]
Investment cost		53,646	[2],[7],[18],[20]			53,164	[6],[15],[23]
Investments at Fair Value		$ 54,269	[7],[18],[20]			$ 53,871	[15],[23]
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Main Street Rural, Inc. Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee
Investment Holding [Line Items]
Maturity Date	[1]	2027-07		2027-07
Investments Maturity Month and Year	[1]	2027-07		2027-07
Investment, Basis Spread, Variable Rate	[1],[11]	1.95%		1.95%
Investment, Interest Rate, Floor	[1],[11]	9.95%		9.95%
Principal Amount	[1]	$ 17,500
Investment cost	[1],[2]	17,331
Investments at Fair Value	[1]	$ 17,331
Investment Exit Fee	[1],[11]	6.85%		6.85%
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Modern Life, Inc. Senior Secured, Maturity Date February 2027, Prime + 2.75%, Floor rate 8.75%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[9]	2027-02		2027-02
Investments Maturity Month and Year	[8],[9]	2027-02		2027-02
Investment, Basis Spread, Variable Rate	[8],[9],[11]	2.75%		2.75%
Investment, Interest Rate, Floor	[8],[9],[11]	8.75%		8.75%
Principal Amount	[8],[9]	$ 13,000
Investment cost	[2],[8],[9]	12,765
Investments at Fair Value	[8],[9]	$ 12,765
Investment Exit Fee	[8],[9],[11]	3%		3%
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Oak Street Health, Inc. Senior Secured, Maturity Date October 2027, Prime + 2.45%, Floor rate 7.95%, Cap rate 9.45%, PIK Interest 1.00%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[15],[27]					2027-10		2027-10
Investments Maturity Month and Year	[10],[15],[27]					2027-10		2027-10
Investment, Basis Spread, Variable Rate	[10],[12],[15],[27]					2.45%		2.45%
Investment, Interest Rate, Floor	[10],[12],[15],[27]					7.95%		7.95%
Investment, Interest Rate, Cap	[10],[12],[15],[27]					9.45%		9.45%
Investment, Interest Rate, Paid in Kind	[10],[12],[15],[27]					1%		1%
Principal Amount	[10],[15],[27]					$ 33,808
Investment cost	[6],[10],[15],[27]					33,651
Investments at Fair Value	[10],[15],[27]					$ 33,651
Investment Exit Fee	[10],[12],[15],[27]					4.95%		4.95%
Investment, Identifier [Axis]: Debt Investments Healthcare Services, Other and Vida Health, Inc. Senior Secured, Maturity Date March 2026, Prime + 1.00%, Floor rate 9.20%, Cap rate 10.20%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[9],[18]	2026-03		2026-03
Investments Maturity Month and Year	[9],[18]	2026-03		2026-03
Investment, Basis Spread, Variable Rate	[9],[11],[18]	1%		1%
Investment, Interest Rate, Floor	[9],[11],[18]	9.20%		9.20%
Investment, Interest Rate, Cap	[9],[11],[18]	10.20%		10.20%
Principal Amount	[9],[18]	$ 20,000
Investment cost	[2],[9],[18]	19,810
Investments at Fair Value	[9],[18]	$ 19,359
Investment Exit Fee	[9],[11],[18]	4.95%		4.95%
Investment, Identifier [Axis]: Debt Investments Information Services (3.72%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					3.72%		3.72%
Investment cost	[6]					$ 52,619
Investments at Fair Value						$ 52,075
Investment, Identifier [Axis]: Debt Investments Information Services (4.25%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	4.25%		4.25%
Investment cost	[2]	$ 66,699
Investments at Fair Value		$ 67,371
Investment, Identifier [Axis]: Debt Investments Information Services and Capella Space Corp. Senior Secured, Maturity Date November 2025, Prime + 5.00%, Floor rate 8.25%, PIK Interest 1.10%, 7.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-11	[1],[7],[13]	2025-11	[1],[7],[13]	2025-11	[14],[15],[31]	2025-11	[14],[15],[31]
Investments Maturity Month and Year		2025-11	[1],[7],[13]	2025-11	[1],[7],[13]	2025-11	[14],[15],[31]	2025-11	[14],[15],[31]
Investment, Basis Spread, Variable Rate		5%	[1],[7],[11]	5%	[1],[7],[11]	5%	[12],[14],[15],[31]	5%	[12],[14],[15],[31]
Investment, Interest Rate, Floor		8.25%	[1],[7],[11]	8.25%	[1],[7],[11]	8.25%	[12],[14],[15],[31]	8.25%	[12],[14],[15],[31]
Investment, Interest Rate, Paid in Kind		1.10%	[1],[7],[11]	1.10%	[1],[7],[11]	1.10%	[12],[14],[15],[31]	1.10%	[12],[14],[15],[31]
Principal Amount		$ 20,362	[1],[7]			$ 20,250	[14],[15],[31]
Investment cost		20,826	[1],[2],[7]			20,506	[6],[14],[15],[31]
Investments at Fair Value		$ 20,949	[1],[7]			$ 20,574	[14],[15],[31]
Investment Exit Fee		7%	[1],[7],[11]	7%	[1],[7],[11]	7%	[12],[14],[15],[31]	7%	[12],[14],[15],[31]
Investment, Identifier [Axis]: Debt Investments Information Services and Saama Technologies, LLC Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[9]	2027-07		2027-07
Investments Maturity Month and Year	[9]	2027-07		2027-07
Investment, Basis Spread, Variable Rate	[9],[11]	0.70%		0.70%
Investment, Interest Rate, Floor	[9],[11]	8.95%		8.95%
Investment, Interest Rate, Paid in Kind	[9],[11]	2%		2%
Principal Amount	[9]	$ 11,625
Investment cost	[2],[9]	11,480
Investments at Fair Value	[9]	$ 11,480
Investment Exit Fee	[9],[11]	2.95%		2.95%
Investment, Identifier [Axis]: Debt Investments Information Services and Signal Media Limited, Senior Secured, Maturity Date June 2025, Prime + 5.50%, Floor rate 9.00%, Cap rate 12.00%, 3.45% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-06	[9],[25],[26]	2025-06	[9],[25],[26]	2025-06	[10],[27],[28]	2025-06	[10],[27],[28]
Investments Maturity Month and Year		2025-06	[9],[25],[26]	2025-06	[9],[25],[26]	2025-06	[10],[27],[28]	2025-06	[10],[27],[28]
Investment, Basis Spread, Variable Rate		5.50%	[9],[11],[25],[26]	5.50%	[9],[11],[25],[26]	5.50%	[10],[12],[27],[28]	5.50%	[10],[12],[27],[28]
Investment, Interest Rate, Floor		9%	[9],[11],[25],[26]	9%	[9],[11],[25],[26]	9%	[10],[12],[27],[28]	9%	[10],[12],[27],[28]
Investment, Interest Rate, Cap		12%	[9],[11],[25],[26]	12%	[9],[11],[25],[26]	12%	[10],[12],[27],[28]	12%	[10],[12],[27],[28]
Principal Amount		$ 3,000	[9],[25],[26]			$ 750	[10],[27],[28]
Investment cost		2,970	[2],[9],[25],[26]			742	[6],[10],[27],[28]
Investments at Fair Value		$ 2,955	[9],[25],[26]			$ 738	[10],[27],[28]
Investment Exit Fee		3.45%	[9],[11],[25],[26]	3.45%	[9],[11],[25],[26]	3.45%	[10],[12],[27],[28]	3.45%	[10],[12],[27],[28]
Investment, Identifier [Axis]: Debt Investments Information Services and Yipit, LLC, Senior Secured, Maturity Date September 2026, 1-month SOFR + 9.03%, Floor rate 10.13%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2026-09		2026-09
Investments Maturity Month and Year	[9],[19]	2026-09		2026-09
Investment, Basis Spread, Variable Rate	[9],[11],[19]	9.03%		9.03%
Investment, Interest Rate, Floor	[9],[11],[19]	10.03%		10.03%
Principal Amount	[9],[19]	$ 31,875
Investment cost	[2],[9],[19]	31,423
Investments at Fair Value	[9],[19]	$ 31,987
Investment, Identifier [Axis]: Debt Investments Information Services and Yipit, LLC, Senior Secured, Maturity Date September 2026, 1-month SOFR + 9.08%, Floor rate 10.08%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2026-09		2026-09
Investments Maturity Month and Year	[10],[17]					2026-09		2026-09
Investment, Basis Spread, Variable Rate	[10],[12],[17]					9.08%		9.08%
Investment, Interest Rate, Floor	[10],[12],[17]					10.08%		10.08%
Principal Amount	[10],[17]					$ 31,875
Investment cost	[6],[10],[17]					31,371
Investments at Fair Value	[10],[17]					$ 30,763
Investment, Identifier [Axis]: Debt Investments Manufacturing Technology (2.94%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.94%		2.94%
Investment cost	[2]	$ 44,357
Investments at Fair Value		$ 46,549
Investment, Identifier [Axis]: Debt Investments Manufacturing Technology (2.99%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.99%		2.99%
Investment cost	[6]					$ 41,568
Investments at Fair Value						$ 41,953
Investment, Identifier [Axis]: Debt Investments Manufacturing Technology and Bright Machines, Inc. Senior Secured, Maturity Date April 2025, Prime + 4.00%, Floor rate 9.50%, 5.00% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-04	[8]	2025-04	[8]	2025-04	[22]	2025-04	[22]
Investments Maturity Month and Year		2025-04	[8]	2025-04	[8]	2025-04	[22]	2025-04	[22]
Investment, Basis Spread, Variable Rate		4%	[8],[11]	4%	[8],[11]	4%	[12],[22]	4%	[12],[22]
Investment, Interest Rate, Floor		9.50%	[8],[11]	9.50%	[8],[11]	9.50%	[12],[22]	9.50%	[12],[22]
Principal Amount		$ 10,231	[8]			$ 11,050	[22]
Investment cost		10,252	[2],[8]			10,832	[6],[22]
Investments at Fair Value		$ 10,356	[8]			$ 10,832	[22]
Investment Exit Fee		5%	[8],[11]	5%	[8],[11]	5%	[12],[22]	5%	[12],[22]
Investment, Identifier [Axis]: Debt Investments Manufacturing Technology and MacroFab, Inc. Senior Secured, Maturity Date March 2026, Prime + 4.35%, Floor rate 7.60%, PIK Interest 1.25%, 4.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-03	[7]	2026-03	[7]	2026-03	[10],[15]	2026-03	[10],[15]
Investments Maturity Month and Year		2026-03	[7]	2026-03	[7]	2026-03	[10],[15]	2026-03	[10],[15]
Investment, Basis Spread, Variable Rate		4.35%	[7],[11]	4.35%	[7],[11]	4.35%	[10],[12],[15]	4.35%	[10],[12],[15]
Investment, Interest Rate, Floor		7.60%	[7],[11]	7.60%	[7],[11]	7.60%	[10],[12],[15]	7.60%	[10],[12],[15]
Investment, Interest Rate, Paid in Kind		1.25%	[7],[11]	1.25%	[7],[11]	1.25%	[10],[12],[15]	1.25%	[10],[12],[15]
Principal Amount		$ 20,254	[7]			$ 17,137	[10],[15]
Investment cost		19,995	[2],[7]			16,766	[6],[10],[15]
Investments at Fair Value		$ 21,608	[7]			$ 16,917	[10],[15]
Investment Exit Fee		4.50%	[7],[11]	4.50%	[7],[11]	4.50%	[10],[12],[15]	4.50%	[10],[12],[15]
Investment, Identifier [Axis]: Debt Investments Manufacturing Technology and Ouster, Inc. Senior Secured, Maturity Date May 2026, Prime + 6.15%, Floor rate 9.40%, 7.45% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-05	[8],[25]	2026-05	[8],[25]	2026-05	[22],[27]	2026-05	[22],[27]
Investments Maturity Month and Year		2026-05	[8],[25]	2026-05	[8],[25]	2026-05	[22],[27]	2026-05	[22],[27]
Investment, Basis Spread, Variable Rate		6.15%	[8],[11],[25]	6.15%	[8],[11],[25]	6.15%	[12],[22],[27]	6.15%	[12],[22],[27]
Investment, Interest Rate, Floor		9.40%	[8],[11],[25]	9.40%	[8],[11],[25]	9.40%	[12],[22],[27]	9.40%	[12],[22],[27]
Principal Amount		$ 14,000	[8],[25]			$ 14,000	[22],[27]
Investment cost		14,110	[2],[8],[25]			13,970	[6],[22],[27]
Investments at Fair Value		$ 14,585	[8],[25]			$ 14,204	[22],[27]
Investment Exit Fee		7.45%	[8],[11],[25]	7.45%	[8],[11],[25]	7.45%	[12],[22],[27]	7.45%	[12],[22],[27]
Investment, Identifier [Axis]: Debt Investments Media/Content/Info (0.73%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.73%		0.73%
Investment cost	[2]	$ 11,418
Investments at Fair Value		11,497
Investment, Identifier [Axis]: Debt Investments Media/Content/Info and Fever Labs, Inc.
Investment Holding [Line Items]
Principal Amount		11,501
Investment cost	[2]	11,418
Investments at Fair Value		$ 11,497
Investment, Identifier [Axis]: Debt Investments Media/Content/Info and Fever Labs, Inc. Senior Secured, Maturity Date December 2025, Prime + 3.50%, Floor rate 9.00%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13]	2025-12		2025-12
Investments Maturity Month and Year	[13]	2025-12		2025-12
Investment, Basis Spread, Variable Rate	[11],[13]	3.50%		3.50%
Investment, Interest Rate, Floor	[11],[13]	9%		9%
Principal Amount	[13]	$ 1,667
Investment cost	[2],[13]	1,656
Investments at Fair Value	[13]	$ 1,664
Investment Exit Fee	[11],[13]	1%		1%
Investment, Identifier [Axis]: Debt Investments Media/Content/Info and Fever Labs, Inc. Senior Secured, Maturity Date March 2026, Prime + 3.50%, Floor rate 9.00%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13]	2026-03		2026-03
Investments Maturity Month and Year	[13]	2026-03		2026-03
Investment, Basis Spread, Variable Rate	[11],[13]	3.50%		3.50%
Investment, Interest Rate, Floor	[11],[13]	9%		9%
Principal Amount	[13]	$ 1,667
Investment cost	[2],[13]	1,648
Investments at Fair Value	[13]	$ 1,648
Investment Exit Fee	[11],[13]	1%		1%
Investment, Identifier [Axis]: Debt Investments Media/Content/Info and Fever Labs, Inc. Senior Secured, Maturity Date September 2025, Prime + 3.50%, Floor rate 9.00%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13]	2025-09		2025-09
Investments Maturity Month and Year	[13]	2025-09		2025-09
Investment, Basis Spread, Variable Rate	[11],[13]	3.50%		3.50%
Investment, Interest Rate, Floor	[11],[13]	9%		9%
Principal Amount	[13]	$ 1,500
Investment cost	[2],[13]	1,495
Investments at Fair Value	[13]	$ 1,503
Investment Exit Fee	[11],[13]	1%		1%
Investment, Identifier [Axis]: Debt Investments Media/Content/Info and Fever Labs, Inc. Senior Secured, Maturity Date September 2026, Prime + 3.50%, Floor rate 9.00%, 1.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[13]	2026-09		2026-09
Investments Maturity Month and Year	[13]	2026-09		2026-09
Investment, Basis Spread, Variable Rate	[11],[13]	3.50%		3.50%
Investment, Interest Rate, Floor	[11],[13]	9%		9%
Principal Amount	[13]	$ 6,667
Investment cost	[2],[13]	6,619
Investments at Fair Value	[13]	$ 6,682
Investment Exit Fee	[11],[13]	1%		1%
Investment, Identifier [Axis]: Debt Investments Semiconductors (1.51%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					1.51%		1.51%
Investment cost	[6]					$ 19,639
Investments at Fair Value						$ 21,192
Investment, Identifier [Axis]: Debt Investments Semiconductors and Fungible, Inc. Senior Secured, Maturity Date December 2024, Prime + 5.00%, Floor rate 8.25%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[14],[31]					2024-12		2024-12
Investments Maturity Month and Year	[14],[31]					2024-12		2024-12
Investment, Basis Spread, Variable Rate	[12],[14],[31]					5%		5%
Investment, Interest Rate, Floor	[12],[14],[31]					8.25%		8.25%
Principal Amount	[14],[31]					$ 20,000
Investment cost	[6],[14],[31]					19,639
Investments at Fair Value	[14],[31]					$ 21,192
Investment Exit Fee	[12],[14],[31]					4.95%		4.95%
Investment, Identifier [Axis]: Debt Investments Software (53.63%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	53.63%		53.63%
Investment cost	[2]	$ 842,249
Investments at Fair Value		$ 850,278
Investment, Identifier [Axis]: Debt Investments Software (54.28%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					54.28%		54.28%
Investment cost	[6]					$ 762,371
Investments at Fair Value						760,679
Investment, Identifier [Axis]: Debt Investments Software and 3GTMS, LLC
Investment Holding [Line Items]
Principal Amount						13,176
Investment cost	[6]					13,035
Investments at Fair Value						$ 12,998
Investment, Identifier [Axis]: Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month LIBOR + 6.57%, Floor rate 7.57%
Investment Holding [Line Items]
Maturity Date	[17]					2025-02		2025-02
Investments Maturity Month and Year	[17]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[12],[17]					6.57%		6.57%
Investment, Interest Rate, Floor	[12],[17]					7.57%		7.57%
Principal Amount	[17]					$ 2,750
Investment cost	[6],[17]					2,744
Investments at Fair Value	[17]					$ 2,681
Investment, Identifier [Axis]: Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month LIBOR + 9.28%, Floor rate 10.28%
Investment Holding [Line Items]
Maturity Date	[16],[17]					2025-02		2025-02
Investments Maturity Month and Year	[16],[17]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[12],[16],[17]					9.28%		9.28%
Investment, Interest Rate, Floor	[12],[16],[17]					10.28%		10.28%
Principal Amount	[16],[17]					$ 10,426
Investment cost	[6],[16],[17]					10,291
Investments at Fair Value	[16],[17]					$ 10,317
Investment, Identifier [Axis]: Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 6-month SOFR + 9.27%, Floor rate 10.27%
Investment Holding [Line Items]
Maturity Date	[9],[18],[19]	2025-02		2025-02
Investments Maturity Month and Year	[9],[18],[19]	2025-02		2025-02
Investment, Basis Spread, Variable Rate	[9],[11],[18],[19]	9.27%		9.27%
Investment, Interest Rate, Floor	[9],[11],[18],[19]	10.27%		10.27%
Principal Amount	[9],[18],[19]	$ 13,174
Investment cost	[2],[9],[18],[19]	13,061
Investments at Fair Value	[9],[18],[19]	$ 13,016
Investment, Identifier [Axis]: Debt Investments Software and Agilence, Inc. Senior Secured, Maturity Date October 2026, 1-month BSBY + 9.00%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date		2026-10	[9],[19],[20]	2026-10	[9],[19],[20]	2026-10	[10],[17],[23]	2026-10	[10],[17],[23]
Investments Maturity Month and Year		2026-10	[9],[19],[20]	2026-10	[9],[19],[20]	2026-10	[10],[17],[23]	2026-10	[10],[17],[23]
Investment, Basis Spread, Variable Rate		9%	[9],[11],[19],[20]	9%	[9],[11],[19],[20]	9%	[10],[12],[17],[23]	9%	[10],[12],[17],[23]
Investment, Interest Rate, Floor		10%	[9],[11],[19],[20]	10%	[9],[11],[19],[20]	10%	[10],[12],[17],[23]	10%	[10],[12],[17],[23]
Principal Amount		$ 9,259	[9],[19],[20]			$ 9,306	[10],[17],[23]
Investment cost		9,063	[2],[9],[19],[20]			9,088	[6],[10],[17],[23]
Investments at Fair Value		$ 9,093	[9],[19],[20]			$ 8,977	[10],[17],[23]
Investment, Identifier [Axis]: Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 7.89%, Floor rate 8.89%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2028-05		2028-05
Investments Maturity Month and Year	[10],[17]					2028-05		2028-05
Investment, Basis Spread, Variable Rate	[10],[12],[17]					7.89%		7.89%
Investment, Interest Rate, Floor	[10],[12],[17]					8.89%		8.89%
Principal Amount	[10],[17]					$ 20,463
Investment cost	[6],[10],[17]					19,999
Investments at Fair Value	[10],[17]					$ 20,123
Investment, Identifier [Axis]: Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%
Investment Holding [Line Items]
Maturity Date	[8],[9],[19]	2028-05		2028-05
Investments Maturity Month and Year	[8],[9],[19]	2028-05		2028-05
Investment, Basis Spread, Variable Rate	[8],[9],[11],[19]	8.14%		8.14%
Investment, Interest Rate, Floor	[8],[9],[11],[19]	9.14%		9.14%
Principal Amount	[8],[9],[19]	$ 20,908
Investment cost	[2],[8],[9],[19]	20,475
Investments at Fair Value	[8],[9],[19]	$ 21,158
Investment, Identifier [Axis]: Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 1-month BSBY + 8.99%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date	[10],[22]					2027-02		2027-02
Investments Maturity Month and Year	[10],[22]					2027-02		2027-02
Investment, Basis Spread, Variable Rate	[10],[12],[22]					8.99%		8.99%
Investment, Interest Rate, Floor	[10],[12],[22]					10%		10%
Principal Amount	[10],[22]					$ 8,500
Investment cost	[6],[10],[22]					8,292
Investments at Fair Value	[10],[22]					$ 8,176
Investment, Identifier [Axis]: Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 1-month BSBY + 8.99%, Floor rate 9.99%
Investment Holding [Line Items]
Maturity Date	[8],[9]	2027-02		2027-02
Investments Maturity Month and Year	[8],[9]	2027-02		2027-02
Investment, Basis Spread, Variable Rate	[8],[9],[11]	8.99%		8.99%
Investment, Interest Rate, Floor	[8],[9],[11]	9.99%		9.99%
Principal Amount	[8],[9]	$ 8,479
Investment cost	[2],[8],[9]	8,290
Investments at Fair Value	[8],[9]	$ 8,319
Investment, Identifier [Axis]: Debt Investments Software and Automation Anywhere, Inc. Senior Secured, Maturity Date September 2027, Prime + 4.25%, Floor rate 9.00%, 2.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2027-09	[9],[13],[18]	2027-09	[9],[13],[18]	2027-09	[10],[14],[16]	2027-09	[10],[14],[16]
Investments Maturity Month and Year		2027-09	[9],[13],[18]	2027-09	[9],[13],[18]	2027-09	[10],[14],[16]	2027-09	[10],[14],[16]
Investment, Basis Spread, Variable Rate		4.25%	[9],[11],[13],[18]	4.25%	[9],[11],[13],[18]	4.25%	[10],[12],[14],[16]	4.25%	[10],[12],[14],[16]
Investment, Interest Rate, Floor		9%	[9],[11],[13],[18]	9%	[9],[11],[13],[18]	9%	[10],[12],[14],[16]	9%	[10],[12],[14],[16]
Principal Amount		$ 19,600	[9],[13],[18]			$ 19,600	[10],[14],[16]
Investment cost		19,197	[2],[9],[13],[18]			19,059	[6],[10],[14],[16]
Investments at Fair Value		$ 19,782	[9],[13],[18]			$ 19,059	[10],[14],[16]
Investment Exit Fee		2.50%	[9],[11],[13],[18]	2.50%	[9],[11],[13],[18]	2.50%	[10],[12],[14],[16]	2.50%	[10],[12],[14],[16]
Investment, Identifier [Axis]: Debt Investments Software and Babel Street, Senior Secured, Maturity Date December 2027, 3-month SOFR + 7.89%, Floor rate 8.89%
Investment Holding [Line Items]
Maturity Date		2027-12	[1],[9],[19]	2027-12	[1],[9],[19]	2027-12	[10],[17],[31]	2027-12	[10],[17],[31]
Investments Maturity Month and Year		2027-12	[1],[9],[19]	2027-12	[1],[9],[19]	2027-12	[10],[17],[31]	2027-12	[10],[17],[31]
Investment, Basis Spread, Variable Rate		7.89%	[1],[9],[11],[19]	7.89%	[1],[9],[11],[19]	7.89%	[10],[12],[17],[31]	7.89%	[10],[12],[17],[31]
Investment, Interest Rate, Floor		8.89%	[1],[9],[11],[19]	8.89%	[1],[9],[11],[19]	8.89%	[10],[12],[17],[31]	8.89%	[10],[12],[17],[31]
Principal Amount		$ 45,000	[1],[9],[19]			$ 45,000	[10],[17],[31]
Investment cost		43,889	[1],[2],[9],[19]			43,801	[6],[10],[17],[31]
Investments at Fair Value		$ 44,387	[1],[9],[19]			$ 43,801	[10],[17],[31]
Investment, Identifier [Axis]: Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date April 2025, PRIME + 3.70%, Floor rate 6.95%, PIK Interest 1.00%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[15],[22],[31]					2025-04		2025-04
Investments Maturity Month and Year	[10],[15],[22],[31]					2025-04		2025-04
Investment, Basis Spread, Variable Rate	[10],[12],[15],[22],[31]					3.70%		3.70%
Investment, Interest Rate, Floor	[10],[12],[15],[22],[31]					6.95%		6.95%
Investment, Interest Rate, Paid in Kind	[10],[12],[15],[22],[31]					1%		1%
Principal Amount	[10],[15],[22],[31]					$ 20,166
Investment cost	[6],[10],[15],[22],[31]					20,242
Investments at Fair Value	[10],[15],[22],[31]					$ 20,138
Investment Exit Fee	[10],[12],[15],[22],[31]					3.95%		3.95%
Investment, Identifier [Axis]: Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date April 2026, PRIME + 3.70%, Floor rate 9.20%, PIK Interest 1.00%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[1],[7],[8],[9]	2026-04		2026-04
Investments Maturity Month and Year	[1],[7],[8],[9]	2026-04		2026-04
Investment, Basis Spread, Variable Rate	[1],[7],[8],[9],[11]	3.70%		3.70%
Investment, Interest Rate, Floor	[1],[7],[8],[9],[11]	9.20%		9.20%
Investment, Interest Rate, Paid in Kind	[1],[7],[8],[9],[11]	1%		1%
Principal Amount	[1],[7],[8],[9]	$ 30,268
Investment cost	[1],[2],[7],[8],[9]	30,313
Investments at Fair Value	[1],[7],[8],[9]	$ 30,184
Investment Exit Fee	[1],[7],[8],[9],[11]	3.95%		3.95%
Investment, Identifier [Axis]: Debt Investments Software and Campaign Monitor Limited, Senior Secured, Maturity Date November 2025, 3-month SOFR + 8.90%, Floor rate 9.90%
Investment Holding [Line Items]
Maturity Date	[8],[13]	2025-11		2025-11
Investments Maturity Month and Year	[8],[13]	2025-11		2025-11
Investment, Basis Spread, Variable Rate	[8],[11],[13]	8.90%		8.90%
Investment, Interest Rate, Floor	[8],[11],[13]	9.90%		9.90%
Principal Amount	[8],[13]	$ 33,000
Investment cost	[2],[8],[13]	32,640
Investments at Fair Value	[8],[13]	$ 33,000
Investment, Identifier [Axis]: Debt Investments Software and Campaign Monitor Limited, Senior Secured, Maturity Date November 2025, 6-month SOFR + 8.90%, Floor rate 9.90%
Investment Holding [Line Items]
Maturity Date	[14],[22]					2025-11		2025-11
Investments Maturity Month and Year	[14],[22]					2025-11		2025-11
Investment, Basis Spread, Variable Rate	[12],[14],[22]					8.90%		8.90%
Investment, Interest Rate, Floor	[12],[14],[22]					9.90%		9.90%
Principal Amount	[14],[22]					$ 33,000
Investment cost	[6],[14],[22]					32,578
Investments at Fair Value	[14],[22]					$ 33,000
Investment, Identifier [Axis]: Debt Investments Software and Catchpoint Systems, Inc., Senior Secured, Maturity Date June 2026, 1-month SOFR + 8.76%, Floor rate 9.76%
Investment Holding [Line Items]
Maturity Date	[19]	2026-06		2026-06
Investments Maturity Month and Year	[19]	2026-06		2026-06
Investment, Basis Spread, Variable Rate	[11],[19]	8.76%		8.76%
Investment, Interest Rate, Floor	[11],[19]	9.76%		9.76%
Principal Amount	[19]	$ 10,124
Investment cost	[2],[19]	9,952
Investments at Fair Value	[19]	$ 10,081
Investment, Identifier [Axis]: Debt Investments Software and Catchpoint Systems, Inc., Senior Secured, Maturity Date June 2026, 3-month SOFR + 8.86%, Floor rate 9.76%
Investment Holding [Line Items]
Maturity Date	[17]					2026-06		2026-06
Investments Maturity Month and Year	[17]					2026-06		2026-06
Investment, Basis Spread, Variable Rate	[12],[17]					8.86%		8.86%
Investment, Interest Rate, Floor	[12],[17]					9.76%		9.76%
Principal Amount	[17]					$ 10,175
Investment cost	[6],[17]					9,980
Investments at Fair Value	[17]					$ 9,996
Investment, Identifier [Axis]: Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 6-month LIBOR + 8.89%, Floor rate 9.89%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2026-09		2026-09
Investments Maturity Month and Year	[9],[19]	2026-09		2026-09
Investment, Basis Spread, Variable Rate	[9],[11],[19]	8.89%		8.89%
Investment, Interest Rate, Floor	[9],[11],[19]	9.89%		9.89%
Principal Amount	[9],[19]	$ 22,973
Investment cost	[2],[9],[19]	22,547
Investments at Fair Value	[9],[19]	$ 23,145
Investment, Identifier [Axis]: Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 6-month LIBOR + 9.67%, Floor rate 10.67%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2026-09		2026-09
Investments Maturity Month and Year	[10],[17]					2026-09		2026-09
Investment, Basis Spread, Variable Rate	[10],[12],[17]					9.67%		9.67%
Investment, Interest Rate, Floor	[10],[12],[17]					10.67%		10.67%
Principal Amount	[10],[17]					$ 21,445
Investment cost	[6],[10],[17]					21,003
Investments at Fair Value	[10],[17]					$ 21,050
Investment, Identifier [Axis]: Debt Investments Software and CloudBolt Software, Inc., Senior Secured, Maturity Date October 2024, Prime + 6.70%, Floor rate 9.95%, 3.45% Exit Fee
Investment Holding [Line Items]
Maturity Date	[14],[16]					2024-10		2024-10
Investments Maturity Month and Year	[14],[16]					2024-10		2024-10
Investment, Basis Spread, Variable Rate	[12],[14],[16]					6.70%		6.70%
Investment, Interest Rate, Floor	[12],[14],[16]					9.95%		9.95%
Principal Amount	[14],[16]					$ 10,000
Investment cost	[6],[14],[16]					10,069
Investments at Fair Value	[14],[16]					$ 10,498
Investment Exit Fee	[12],[14],[16]					3.45%		3.45%
Investment, Identifier [Axis]: Debt Investments Software and Constructor Corporation, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%
Investment Holding [Line Items]
Maturity Date	[8],[9],[19]	2027-07		2027-07
Investments Maturity Month and Year	[8],[9],[19]	2027-07		2027-07
Investment, Basis Spread, Variable Rate	[8],[9],[11],[19]	8.44%		8.44%
Investment, Interest Rate, Floor	[8],[9],[11],[19]	9.44%		9.44%
Principal Amount	[8],[9],[19]	$ 4,688
Investment cost	[2],[8],[9],[19]	4,582
Investments at Fair Value	[8],[9],[19]	$ 4,736
Investment, Identifier [Axis]: Debt Investments Software and Constructor.io Corporation, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.44%, Floor rate 9.44%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2027-07		2027-07
Investments Maturity Month and Year	[10],[17]					2027-07		2027-07
Investment, Basis Spread, Variable Rate	[10],[12],[17]					8.44%		8.44%
Investment, Interest Rate, Floor	[10],[12],[17]					9.44%		9.44%
Principal Amount	[10],[17]					$ 4,688
Investment cost	[6],[10],[17]					4,573
Investments at Fair Value	[10],[17]					$ 4,573
Investment, Identifier [Axis]: Debt Investments Software and Convoy, Inc., Senior Secured, Maturity Date March 2026, Prime + 3.20%, Floor rate 6.45%, PIK Interest 1.95%, 4.55% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-03	[7],[13]	2026-03	[7],[13]	2026-03	[14],[15],[24]	2026-03	[14],[15],[24]
Investments Maturity Month and Year		2026-03	[7],[13]	2026-03	[7],[13]	2026-03	[14],[15],[24]	2026-03	[14],[15],[24]
Investment, Basis Spread, Variable Rate		3.20%	[7],[11],[13]	3.20%	[7],[11],[13]	3.20%	[12],[14],[15],[24]	3.20%	[12],[14],[15],[24]
Investment, Interest Rate, Floor		6.45%	[7],[11],[13]	6.45%	[7],[11],[13]	6.45%	[12],[14],[15],[24]	6.45%	[12],[14],[15],[24]
Investment, Interest Rate, Paid in Kind		1.95%	[7],[11],[13]	1.95%	[7],[11],[13]	1.95%	[12],[14],[15],[24]	1.95%	[12],[14],[15],[24]
Principal Amount		$ 74,719	[7],[13]			$ 73,987	[14],[15],[24]
Investment cost		74,304	[2],[7],[13]			73,060	[6],[14],[15],[24]
Investments at Fair Value		$ 74,805	[7],[13]			$ 73,498	[14],[15],[24]
Investment Exit Fee		4.55%	[7],[11],[13]	4.55%	[7],[11],[13]	4.55%	[12],[14],[15],[24]	4.55%	[12],[14],[15],[24]
Investment, Identifier [Axis]: Debt Investments Software and Copper CRM, Inc, Senior Secured, Maturity Date March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.32% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7],[18]	2025-03		2025-03
Investments Maturity Month and Year	[7],[18]	2025-03		2025-03
Investment, Basis Spread, Variable Rate	[7],[11],[18]	4.50%		4.50%
Investment, Interest Rate, Floor	[7],[11],[18]	8.25%		8.25%
Investment, Interest Rate, Cap	[7],[11],[18]	10.25%		10.25%
Investment, Interest Rate, Paid in Kind	[7],[11],[18]	1.95%		1.95%
Principal Amount	[7],[18]	$ 9,848
Investment cost	[2],[7],[18]	9,937
Investments at Fair Value	[7],[18]	$ 9,645
Investment Exit Fee	[7],[11],[18]	4.32%		4.32%
Investment, Identifier [Axis]: Debt Investments Software and Copper CRM, Inc, Senior Secured, Maturity Date March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee
Investment Holding [Line Items]
Maturity Date	[15],[16]					2025-03		2025-03
Investments Maturity Month and Year	[15],[16]					2025-03		2025-03
Investment, Basis Spread, Variable Rate	[12],[15],[16]					4.50%		4.50%
Investment, Interest Rate, Floor	[12],[15],[16]					8.25%		8.25%
Investment, Interest Rate, Cap	[12],[15],[16]					10.25%		10.25%
Investment, Interest Rate, Paid in Kind	[12],[15],[16]					1.95%		1.95%
Principal Amount	[15],[16]					$ 10,144
Investment cost	[6],[15],[16]					10,150
Investments at Fair Value	[15],[16]					$ 9,820
Investment Exit Fee	[12],[15],[16]					4.50%		4.50%
Investment, Identifier [Axis]: Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-10	[9],[20],[25],[26]	2025-10	[9],[20],[25],[26]	2025-10	[10],[23],[27],[28]	2025-10	[10],[23],[27],[28]
Investments Maturity Month and Year		2025-10	[9],[20],[25],[26]	2025-10	[9],[20],[25],[26]	2025-10	[10],[23],[27],[28]	2025-10	[10],[23],[27],[28]
Investment, Basis Spread, Variable Rate		5.20%	[9],[11],[20],[25],[26]	5.20%	[9],[11],[20],[25],[26]	5.20%	[10],[12],[23],[27],[28]	5.20%	[10],[12],[23],[27],[28]
Investment, Interest Rate, Floor		9.95%	[9],[11],[20],[25],[26]	9.95%	[9],[11],[20],[25],[26]	9.95%	[10],[12],[23],[27],[28]	9.95%	[10],[12],[23],[27],[28]
Principal Amount		$ 5,500	[9],[20],[25],[26]			$ 5,000	[10],[23],[27],[28]
Investment cost		5,489	[2],[9],[20],[25],[26]			4,949	[6],[10],[23]
Investments at Fair Value		$ 5,629	[9],[20],[25],[26]			$ 4,949	[10],[23],[27],[28]
Investment Exit Fee		4.95%	[9],[11],[20],[25],[26]	4.95%	[9],[11],[20],[25],[26]	4.95%	[10],[12],[23],[27],[28]	4.95%	[10],[12],[23],[27],[28]
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc.
Investment Holding [Line Items]
Principal Amount		$ 10,528
Investment cost	[2]	10,323
Investments at Fair Value		$ 10,161
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 12.11%, Floor rate 13.11%
Investment Holding [Line Items]
Maturity Date	[9]	2026-08		2026-08
Investments Maturity Month and Year	[9]	2026-08		2026-08
Investment, Basis Spread, Variable Rate	[9],[11]	12.11%		12.11%
Investment, Interest Rate, Floor	[9],[11]	13.11%		13.11%
Principal Amount	[9]	$ 2,553
Investment cost	[2],[9]	2,493
Investments at Fair Value	[9]	$ 2,604
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 8.38%, Floor rate 9.38%
Investment Holding [Line Items]
Maturity Date	[8],[9]	2026-08		2026-08
Investments Maturity Month and Year	[8],[9]	2026-08		2026-08
Investment, Basis Spread, Variable Rate	[8],[9],[11]	8.38%		8.38%
Investment, Interest Rate, Floor	[8],[9],[11]	9.38%		9.38%
Principal Amount	[8],[9]	$ 7,975
Investment cost	[2],[8],[9]	7,830
Investments at Fair Value	[8],[9]	$ 7,557
Investment, Identifier [Axis]: Debt Investments Software and Cybermaxx Intermediate Holdings, Inc., Senior Secured, Maturity Date August 2026, 6-month SOFR + 9.53%, Floor rate 10.28%
Investment Holding [Line Items]
Maturity Date	[10],[22]					2026-08		2026-08
Investments Maturity Month and Year	[10],[22]					2026-08		2026-08
Investment, Basis Spread, Variable Rate	[10],[12],[22]					9.53%		9.53%
Investment, Interest Rate, Floor	[10],[12],[22]					10.28%		10.28%
Principal Amount	[10],[22]					$ 10,528
Investment cost	[6],[10],[22]					10,298
Investments at Fair Value	[10],[22]					$ 10,114
Investment, Identifier [Axis]: Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date July 2025, Prime + 3.05%, Floor rate 7.55%, PIK Interest 1.10%, 2.39% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[13],[18]	2025-07		2025-07
Investments Maturity Month and Year	[8],[13],[18]	2025-07		2025-07
Investment, Basis Spread, Variable Rate	[7],[8],[11],[13],[18]	3.05%		3.05%
Investment, Interest Rate, Floor	[7],[8],[11],[13],[18]	7.55%		7.55%
Investment, Interest Rate, Paid in Kind	[7],[8],[11],[13],[18]	1.10%		1.10%
Principal Amount	[7],[8],[13],[18]	$ 42,611
Investment cost	[2],[7],[8],[13],[18]	42,648
Investments at Fair Value	[7],[8],[13],[18]	$ 42,749
Investment Exit Fee	[7],[8],[11],[13],[18]	2.39%		2.39%
Investment, Identifier [Axis]: Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date July 2025, Prime + 3.05%, Floor rate 7.55%, PIK Interest 1.10%, 4.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[14],[15],[16],[22]					2025-07		2025-07
Investments Maturity Month and Year	[10],[14],[15],[16],[22]					2025-07		2025-07
Investment, Basis Spread, Variable Rate	[10],[12],[14],[15],[16],[22]					3.05%		3.05%
Investment, Interest Rate, Floor	[10],[12],[14],[15],[16],[22]					7.55%		7.55%
Investment, Interest Rate, Paid in Kind	[10],[12],[14],[15],[16],[22]					1.10%		1.10%
Principal Amount	[10],[14],[15],[16],[22]					$ 31,930
Investment cost	[6],[10],[14],[15],[16],[22]					32,346
Investments at Fair Value	[10],[14],[15],[16],[22]					$ 32,012
Investment Exit Fee	[10],[12],[14],[15],[16],[22]					4.95%		4.95%
Investment, Identifier [Axis]: Debt Investments Software and Demandbase, Inc., Senior Secured, Maturity Date August 2025, Prime + 2.25%, Floor rate 5.50%, PIK Interest 3.00%, 5.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[14],[15],[22]					2025-08		2025-08
Investments Maturity Month and Year	[10],[14],[15],[22]					2025-08		2025-08
Investment, Basis Spread, Variable Rate	[10],[12],[14],[15],[22]					2.25%		2.25%
Investment, Interest Rate, Floor	[10],[12],[14],[15],[22]					5.50%		5.50%
Investment, Interest Rate, Paid in Kind	[10],[12],[14],[15],[22]					3%		3%
Principal Amount	[10],[14],[15],[22]					$ 28,503
Investment cost	[6],[10],[14],[15],[22]					28,442
Investments at Fair Value	[10],[14],[15],[22]					$ 28,664
Investment Exit Fee	[10],[12],[14],[15],[22]					5%		5%
Investment, Identifier [Axis]: Debt Investments Software and Dispatch Technologies, Inc., Senior Secured, Maturity Date April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%
Investment Holding [Line Items]
Maturity Date		2028-04	[9],[19]	2028-04	[9],[19]	2028-04	[10],[17]	2028-04	[10],[17]
Investments Maturity Month and Year		2028-04	[9],[19]	2028-04	[9],[19]	2028-04	[10],[17]	2028-04	[10],[17]
Investment, Basis Spread, Variable Rate		8.01%	[9],[11],[19]	8.01%	[9],[11],[19]	8.01%	[10],[12],[17]	8.01%	[10],[12],[17]
Investment, Interest Rate, Floor		8.76%	[9],[11],[19]	8.76%	[9],[11],[19]	8.76%	[10],[12],[17]	8.76%	[10],[12],[17]
Principal Amount		$ 7,500	[9],[19]			$ 7,500	[10],[17]
Investment cost		7,309	[2],[9],[19]			7,295	[6],[10],[17]
Investments at Fair Value		$ 7,414	[9],[19]			$ 7,339	[10],[17]
Investment, Identifier [Axis]: Debt Investments Software and Eigen Technologies Ltd., Senior Secured, Maturity Date April 2025, Prime + 5.10%, Floor rate 8.35%, 2.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-04	[25],[26]	2025-04	[25],[26]	2025-04	[27],[28]	2025-04	[27],[28]
Investments Maturity Month and Year		2025-04	[25],[26]	2025-04	[25],[26]	2025-04	[27],[28]	2025-04	[27],[28]
Investment, Basis Spread, Variable Rate		5.10%	[11],[25],[26]	5.10%	[11],[25],[26]	5.10%	[12],[27],[28]	5.10%	[12],[27],[28]
Investment, Interest Rate, Floor		8.35%	[11],[25],[26]	8.35%	[11],[25],[26]	8.35%	[12],[27],[28]	8.35%	[12],[27],[28]
Principal Amount		$ 3,750	[25],[26]			$ 3,750	[27],[28]
Investment cost		3,772	[2],[25],[26]			3,744	[6],[27],[28]
Investments at Fair Value		$ 3,746	[25],[26]			$ 3,746	[27],[28]
Investment Exit Fee		2.95%	[11],[25],[26]	2.95%	[11],[25],[26]	2.95%	[12],[27],[28]	2.95%	[12],[27],[28]
Investment, Identifier [Axis]: Debt Investments Software and Elation Health, Inc., Senior Secured, Maturity Date March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2026-03	[7],[9],[13]	2026-03	[7],[9],[13]	2026-03	[10],[14],[15]	2026-03	[10],[14],[15]
Investments Maturity Month and Year		2026-03	[7],[9],[13]	2026-03	[7],[9],[13]	2026-03	[10],[14],[15]	2026-03	[10],[14],[15]
Investment, Basis Spread, Variable Rate		4.25%	[7],[9],[11],[13]	4.25%	[7],[9],[11],[13]	4.25%	[10],[12],[14],[15]	4.25%	[10],[12],[14],[15]
Investment, Interest Rate, Floor		9%	[7],[9],[11],[13]	9%	[7],[9],[11],[13]	9%	[10],[12],[14],[15]	9%	[10],[12],[14],[15]
Investment, Interest Rate, Paid in Kind		1.95%	[7],[9],[11],[13]	1.95%	[7],[9],[11],[13]	1.95%	[10],[12],[14],[15]	1.95%	[10],[12],[14],[15]
Principal Amount		$ 5,071	[7],[9],[13]			$ 5,021	[10],[14],[15]
Investment cost		4,935	[2],[7],[9],[13]			4,839	[6],[10],[14],[15]
Investments at Fair Value		$ 5,059	[7],[9],[13]			$ 4,839	[10],[14],[15]
Investment Exit Fee		3.95%	[7],[9],[11],[13]	3.95%	[7],[9],[11],[13]	3.95%	[10],[12],[14]	3.95%	[10],[12],[14]
Investment, Identifier [Axis]: Debt Investments Software and Enmark Systems, Inc., Senior Secured, Maturity Date September 2026, 3-month LIBOR + 6.77%, Floor rate 7.77%, PIK Interest 2.16%
Investment Holding [Line Items]
Maturity Date	[10],[15],[16],[17]					2026-09		2026-09
Investments Maturity Month and Year	[10],[15],[16],[17]					2026-09		2026-09
Investment, Basis Spread, Variable Rate	[10],[12],[15],[16],[17]					6.77%		6.77%
Investment, Interest Rate, Floor	[10],[12],[15],[16],[17]					7.77%		7.77%
Investment, Interest Rate, Paid in Kind	[10],[12],[15],[16],[17]					2.16%		2.16%
Principal Amount	[10],[15],[16],[17]					$ 8,223
Investment cost	[6],[10],[15],[16],[17]					8,054
Investments at Fair Value	[10],[15],[16],[17]					$ 8,043
Investment, Identifier [Axis]: Debt Investments Software and Enmark Systems, Inc., Senior Secured, Maturity Date September 2026, 3-month SOFR + 6.75%, Floor rate 7.75%, PIK Interest 2.14%
Investment Holding [Line Items]
Maturity Date	[7],[9],[18],[19]	2026-09		2026-09
Investments Maturity Month and Year	[7],[9],[18],[19]	2026-09		2026-09
Investment, Basis Spread, Variable Rate	[7],[9],[11],[18],[19]	6.75%		6.75%
Investment, Interest Rate, Floor	[7],[9],[11],[18],[19]	7.75%		7.75%
Investment, Interest Rate, Paid in Kind	[7],[9],[11],[18],[19]	2.14%		2.14%
Principal Amount	[7],[9],[18],[19]	$ 8,313
Investment cost	[2],[7],[9],[18],[19]	8,161
Investments at Fair Value	[7],[9],[18],[19]	$ 8,263
Investment, Identifier [Axis]: Debt Investments Software and Esentire, Inc., Senior Secured, Maturity Date May 2024, 3-month LIBOR + 9.96%, Floor rate 10.96%
Investment Holding [Line Items]
Maturity Date	[16],[17],[27],[28]					2024-05		2024-05
Investments Maturity Month and Year	[16],[17],[27],[28]					2024-05		2024-05
Investment, Basis Spread, Variable Rate	[12],[16],[17],[27],[28]					9.96%		9.96%
Investment, Interest Rate, Floor	[12],[16],[17],[27],[28]					10.96%		10.96%
Principal Amount	[16],[17],[27],[28]					$ 8,436
Investment cost	[6],[16],[17],[27]					8,361
Investments at Fair Value	[16],[17],[27],[28]					$ 8,376
Investment, Identifier [Axis]: Debt Investments Software and Esme Learning Solutions, Inc., Senior Secured, Maturity Date February 2025, Prime + 5.50%, Floor rate 8.75%, PIK Interest 1.50%, 3.00% Exit Fee
Investment Holding [Line Items]
Maturity Date	[15],[35]					2025-02		2025-02
Investments Maturity Month and Year	[15],[35]					2025-02		2025-02
Investment, Basis Spread, Variable Rate	[12],[15],[35]					5.50%		5.50%
Investment, Interest Rate, Floor	[12],[15],[35]					8.75%		8.75%
Investment, Interest Rate, Paid in Kind	[12],[15],[35]					1.50%		1.50%
Principal Amount	[15],[35]					$ 4,892
Investment cost	[6],[15],[35]					4,737
Investments at Fair Value	[15],[35]					$ 1,671
Investment Exit Fee	[12],[15],[35]					3%		3%
Investment, Identifier [Axis]: Debt Investments Software and Flight Schedule Pro, LLC, Senior Secured, Maturity Date October 2027, 1-month SOFR + 7.70%, Floor rate 8.70%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2027-10		2027-10
Investments Maturity Month and Year	[9],[19]	2027-10		2027-10
Investment, Basis Spread, Variable Rate	[9],[11],[19]	7.70%		7.70%
Investment, Interest Rate, Floor	[9],[11],[19]	8.70%		8.70%
Principal Amount	[9],[19]	$ 5,948
Investment cost	[2],[9],[19]	5,785
Investments at Fair Value	[9],[19]	$ 5,859
Investment, Identifier [Axis]: Debt Investments Software and Flight Schedule Pro, LLC, Senior Secured, Maturity Date October 2027, 1-month SOFR + 7.79%, Floor rate 8.70%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2027-10		2027-10
Investments Maturity Month and Year	[10],[17]					2027-10		2027-10
Investment, Basis Spread, Variable Rate	[10],[12],[17]					7.79%		7.79%
Investment, Interest Rate, Floor	[10],[12],[17]					8.70%		8.70%
Principal Amount	[10],[17]					$ 5,948
Investment cost	[6],[10],[17]					5,771
Investments at Fair Value	[10],[17]					$ 5,771
Investment, Identifier [Axis]: Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 6-month SOFR + 7.54%, Floor rate 8.54%
Investment Holding [Line Items]
Maturity Date	[9],[19],[20]	2027-12		2027-12
Investments Maturity Month and Year	[9],[19],[20]	2027-12		2027-12
Investment, Basis Spread, Variable Rate	[9],[11],[19],[20]	7.54%		7.54%
Investment, Interest Rate, Floor	[9],[11],[19],[20]	8.54%		8.54%
Principal Amount	[9],[18],[19]	$ 7,000
Investment cost	[2],[9],[18],[19]	6,837
Investments at Fair Value	[9],[18],[19]	$ 6,796
Investment, Identifier [Axis]: Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 6-month SOFR + 7.79%, Floor rate 8.54%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2027-12		2027-12
Investments Maturity Month and Year	[10],[17]					2027-12		2027-12
Investment, Basis Spread, Variable Rate	[10],[12],[17]					7.79%		7.79%
Investment, Interest Rate, Floor	[10],[12],[17]					8.54%		8.54%
Principal Amount	[10],[17]					$ 7,000
Investment cost	[6],[10],[17]					6,824
Investments at Fair Value	[10],[17]					$ 6,824
Investment, Identifier [Axis]: Debt Investments Software and Ikon Science Limited, Senior Secured, Maturity Date October 2024, 3-month Eurodollar + 9.00%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date		2024-10	[9],[19],[25],[26]	2024-10	[9],[19],[25],[26]	2024-10	[10],[17],[27],[28]	2024-10	[10],[17],[27],[28]
Investments Maturity Month and Year		2024-10	[9],[19],[25],[26]	2024-10	[9],[19],[25],[26]	2024-10	[10],[17],[27],[28]	2024-10	[10],[17],[27],[28]
Investment, Basis Spread, Variable Rate		9%	[9],[11],[19],[25],[26]	9%	[9],[11],[19],[25],[26]	9%	[10],[12],[17],[27],[28]	9%	[10],[12],[17],[27],[28]
Investment, Interest Rate, Floor		10%	[9],[11],[19],[25],[26]	10%	[9],[11],[19],[25],[26]	10%	[10],[12],[17],[27],[28]	10%	[10],[12],[17],[27],[28]
Principal Amount		$ 6,388	[9],[19],[25],[26]			$ 6,563	[10],[17],[27],[28]
Investment cost		6,284	[2],[9],[19],[25],[26]			6,422	[6],[10],[17],[27],[28]
Investments at Fair Value		$ 6,363	[9],[19],[25],[26]			$ 6,484	[10],[17],[27],[28]
Investment, Identifier [Axis]: Debt Investments Software and Imperva, Inc., Senior Secured, Maturity Date January 2027, 3-month LIBOR + 7.75%, Floor rate 8.75%
Investment Holding [Line Items]
Maturity Date		2027-01	[13]	2027-01	[13]	2027-01	[14]	2027-01	[14]
Investments Maturity Month and Year		2027-01	[13]	2027-01	[13]	2027-01	[14]	2027-01	[14]
Investment, Basis Spread, Variable Rate		7.75%	[11],[13]	7.75%	[11],[13]	7.75%	[12],[14]	7.75%	[12],[14]
Investment, Interest Rate, Floor		8.75%	[11],[13]	8.75%	[11],[13]	8.75%	[12],[14]	8.75%	[12],[14]
Principal Amount		$ 20,000	[13]			$ 20,000	[14]
Investment cost		19,887	[2],[13]			19,875	[6],[14]
Investments at Fair Value		$ 20,200	[13]			$ 20,200	[14]
Investment, Identifier [Axis]: Debt Investments Software and Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.), Senior Secured, Maturity Date July 2023, 3-month SOFR + 10.14%, Floor rate 11.14%
Investment Holding [Line Items]
Maturity Date	[17]					2023-07		2023-07
Investments Maturity Month and Year	[17]					2023-07		2023-07
Investment, Basis Spread, Variable Rate	[12],[17]					10.14%		10.14%
Investment, Interest Rate, Floor	[12],[17]					11.14%		11.14%
Principal Amount	[17]					$ 10,681
Investment cost	[6],[17]					10,593
Investments at Fair Value	[17]					$ 10,593
Investment, Identifier [Axis]: Debt Investments Software and Khoros (p.k.a Lithium Technologies), Senior Secured, Maturity Date January 2024, 3-month SOFR + 8.00%, Floor rate 9.00%
Investment Holding [Line Items]
Maturity Date		2024-01	[9]	2024-01	[9]	2024-01	[10]	2024-01	[10]
Investments Maturity Month and Year		2024-01	[9]	2024-01	[9]	2024-01	[10]	2024-01	[10]
Investment, Basis Spread, Variable Rate		8%	[9],[11]	8%	[9],[11]	8%	[10],[12]	8%	[10],[12]
Investment, Interest Rate, Floor		9%	[9],[11]	9%	[9],[11]	9%	[10],[12]	9%	[10],[12]
Principal Amount		$ 57,113	[9]			$ 56,208	[10]
Investment cost		57,037	[2],[9]			56,062	[6],[10]
Investments at Fair Value		$ 57,037	[9]			$ 55,520	[10]
Investment, Identifier [Axis]: Debt Investments Software and Kore.ai, Inc., Senior Secured, Maturity Date April 2027, Prime + 1.50%, Floor rate 9.25%, PIK Interest 2.20%, 2.25% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7]	2027-04		2027-04
Investments Maturity Month and Year	[7]	2027-04		2027-04
Investment, Basis Spread, Variable Rate	[7],[11]	1.50%		1.50%
Investment, Interest Rate, Floor	[7],[11]	9.25%		9.25%
Investment, Interest Rate, Paid in Kind	[7],[11]	2.20%		2.20%
Principal Amount	[7]	$ 30,114
Investment cost	[2],[7]	29,707
Investments at Fair Value	[7]	$ 29,503
Investment Exit Fee	[7],[11]	2.25%		2.25%
Investment, Identifier [Axis]: Debt Investments Software and Leapwork ApS., Senior Secured, Maturity Date February 2026, Prime + 0.25%, Floor rate 7.25%, PIK Interest 1.95%, 2.70% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7],[9],[20],[25],[26]	2026-02		2026-02
Investments Maturity Month and Year	[7],[9],[20],[25],[26]	2026-02		2026-02
Investment, Basis Spread, Variable Rate	[7],[9],[11],[20],[25],[26]	0.25%		0.25%
Investment, Interest Rate, Floor	[7],[9],[11],[20],[25],[26]	7.25%		7.25%
Investment, Interest Rate, Paid in Kind	[7],[9],[11],[20],[25],[26]	1.95%		1.95%
Principal Amount	[7],[9],[20],[25],[26]	$ 3,776
Investment cost	[2],[7],[9],[20],[25],[26]	3,751
Investments at Fair Value	[7],[9],[20],[25],[26]	$ 3,751
Investment Exit Fee	[7],[9],[11],[20],[25],[26]	2.70%		2.70%
Investment, Identifier [Axis]: Debt Investments Software and Loftware, Inc., Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2028-03		2028-03
Investments Maturity Month and Year	[9],[19]	2028-03		2028-03
Investment, Basis Spread, Variable Rate	[9],[11],[19]	7.88%		7.88%
Investment, Interest Rate, Floor	[9],[11],[19]	8.88%		8.88%
Principal Amount	[9],[19]	$ 25,900
Investment cost	[2],[9],[19]	25,278
Investments at Fair Value	[9],[19]	$ 25,278
Investment, Identifier [Axis]: Debt Investments Software and LogicSource, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.93%, Floor rate 9.93%
Investment Holding [Line Items]
Maturity Date		2027-07	[9]	2027-07	[9]	2027-07	[10]	2027-07	[10]
Investments Maturity Month and Year		2027-07	[9]	2027-07	[9]	2027-07	[10]	2027-07	[10]
Investment, Basis Spread, Variable Rate		8.93%	[9],[11]	8.93%	[9],[11]	8.93%	[10],[12]	8.93%	[10],[12]
Investment, Interest Rate, Floor		9.93%	[9],[11]	9.93%	[9],[11]	9.93%	[10],[12]	9.93%	[10],[12]
Principal Amount		$ 13,300	[9]			$ 13,300	[10]
Investment cost		13,050	[2],[9]			13,028	[6],[10]
Investments at Fair Value		$ 13,287	[9]			$ 13,028	[10]
Investment, Identifier [Axis]: Debt Investments Software and Logicworks, Senior Secured, Maturity Date January 2024, Prime + 7.50%, Floor rate 10.75%
Investment Holding [Line Items]
Maturity Date	[23]					2024-01		2024-01
Investments Maturity Month and Year	[23]					2024-01		2024-01
Investment, Basis Spread, Variable Rate	[12],[23]					7.50%		7.50%
Investment, Interest Rate, Floor	[12],[23]					10.75%		10.75%
Principal Amount	[23]					$ 14,500
Investment cost	[6],[23]					14,398
Investments at Fair Value	[23]					$ 14,473
Investment, Identifier [Axis]: Debt Investments Software and Mobile Solutions Services, Senior Secured, Maturity Date December 2025, 3-month LIBOR + 9.06%, Floor rate 10.06%
Investment Holding [Line Items]
Maturity Date		2025-12	[19]	2025-12	[19]	2025-12	[10],[17]	2025-12	[10],[17]
Investments Maturity Month and Year		2025-12	[19]	2025-12	[19]	2025-12	[10],[17]	2025-12	[10],[17]
Investment, Basis Spread, Variable Rate		9.06%	[11],[19]	9.06%	[11],[19]	9.06%	[10],[12],[17]	9.06%	[10],[12],[17]
Investment, Interest Rate, Floor		10.06%	[11],[19]	10.06%	[11],[19]	10.06%	[10],[12],[17]	10.06%	[10],[12],[17]
Principal Amount		$ 18,366	[19]			$ 17,915	[10],[17]
Investment cost		18,059	[2],[19]			17,556	[6],[10],[17]
Investments at Fair Value		$ 17,821	[19]			$ 17,474	[10],[17]
Investment, Identifier [Axis]: Debt Investments Software and Nextroll, Inc., Senior Secured, Maturity Date July 2023, Prime + 3.75%, Floor rate 7.75%, PIK Interest 2.95%, 1.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[15],[23]					2023-07		2023-07
Investments Maturity Month and Year	[15],[23]					2023-07		2023-07
Investment, Basis Spread, Variable Rate	[12],[15],[23]					3.75%		3.75%
Investment, Interest Rate, Floor	[12],[15],[23]					7.75%		7.75%
Investment, Interest Rate, Paid in Kind	[12],[15],[23]					2.95%		2.95%
Principal Amount	[15],[23]					$ 22,211
Investment cost	[6],[15],[23]					22,284
Investments at Fair Value	[15],[23]					$ 22,284
Investment Exit Fee	[12],[15],[23]					1.95%		1.95%
Investment, Identifier [Axis]: Debt Investments Software and Nuvolo Technologies Corporation, Senior Secured, Maturity Date July 2025, Prime + 5.25%, Floor rate 8.50%, 2.42% Exit Fee
Investment Holding [Line Items]
Maturity Date	[10],[14],[22],[23]					2025-07		2025-07
Investments Maturity Month and Year	[10],[14],[22],[23]					2025-07		2025-07
Investment, Basis Spread, Variable Rate	[10],[12],[14],[22],[23]					5.25%		5.25%
Investment, Interest Rate, Floor	[10],[12],[14],[22],[23]					8.50%		8.50%
Principal Amount	[10],[14],[22],[23]					$ 22,500
Investment cost	[6],[10],[14],[22],[23]					22,508
Investments at Fair Value	[10],[14],[22],[23]					$ 22,817
Investment Exit Fee	[10],[12],[14],[22],[23]					2.42%		2.42%
Investment, Identifier [Axis]: Debt Investments Software and Nuvolo Technologies Corporation, Senior Secured, Maturity Date July 2026, Prime + 5.25%, Floor rate 8.50%, 2.42% Exit Fee
Investment Holding [Line Items]
Maturity Date	[8],[9],[13],[20]	2026-07		2026-07
Investments Maturity Month and Year	[8],[9],[13],[20]	2026-07		2026-07
Investment, Basis Spread, Variable Rate	[8],[9],[11],[13],[20]	5.25%		5.25%
Investment, Interest Rate, Floor	[8],[9],[11],[13],[20]	8.50%		8.50%
Principal Amount	[8],[9],[13],[20]	$ 22,500
Investment cost	[2],[8],[9],[13],[20]	22,644
Investments at Fair Value	[8],[9],[13],[20]	$ 22,975
Investment Exit Fee	[8],[9],[11],[13],[20]	2.42%		2.42%
Investment, Identifier [Axis]: Debt Investments Software and Omeda Holdings, LLC, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%
Investment Holding [Line Items]
Maturity Date		2027-07	[9],[18],[19]	2027-07	[9],[18],[19]	2027-07	[10],[17]	2027-07	[10],[17]
Investments Maturity Month and Year		2027-07	[9],[18],[19]	2027-07	[9],[18],[19]	2027-07	[10],[17]	2027-07	[10],[17]
Investment, Basis Spread, Variable Rate		8.05%	[9],[11],[18],[19]	8.05%	[9],[11],[18],[19]	8.05%	[10],[12],[17]	8.05%	[10],[12],[17]
Investment, Interest Rate, Floor		9.05%	[9],[11],[18],[19]	9.05%	[9],[11],[18],[19]	9.05%	[10],[12],[17]	9.05%	[10],[12],[17]
Principal Amount		$ 7,519	[9],[18],[19]			$ 7,500	[10],[17]
Investment cost		7,299	[2],[9],[18],[19]			7,261	[6],[10],[17]
Investments at Fair Value		$ 7,398	[9],[18],[19]			$ 7,261	[10],[17]
Investment, Identifier [Axis]: Debt Investments Software and Riviera Partners LLC, Senior Secured, Maturity Date April 2027, 6-month SOFR + 7.53%, Floor rate 8.53%
Investment Holding [Line Items]
Maturity Date		2027-04	[9],[19]	2027-04	[9],[19]	2027-04	[10],[17]	2027-04	[10],[17]
Investments Maturity Month and Year		2027-04	[9],[19]	2027-04	[9],[19]	2027-04	[10],[17]	2027-04	[10],[17]
Investment, Basis Spread, Variable Rate		7.53%	[9],[11],[19]	7.53%	[9],[11],[19]	7.53%	[10],[12],[17]	7.53%	[10],[12],[17]
Investment, Interest Rate, Floor		8.53%	[9],[11],[19]	8.53%	[9],[11],[19]	8.53%	[10],[12],[17]	8.53%	[10],[12],[17]
Principal Amount		$ 25,988	[9],[19]			$ 26,184	[10],[17]
Investment cost		25,477	[2],[9],[19]			25,622	[6],[10],[17]
Investments at Fair Value		$ 24,871	[9],[19]			$ 25,487	[10],[17]
Investment, Identifier [Axis]: Debt Investments Software and Salary.com, LLC, Senior Secured, Maturity Date September 2027, 3-month SOFR + 8.00%, Floor rate 9.00%
Investment Holding [Line Items]
Maturity Date	[19]	2027-09		2027-09
Investments Maturity Month and Year	[19]	2027-09		2027-09
Investment, Basis Spread, Variable Rate	[11],[19]	8%		8%
Investment, Interest Rate, Floor	[11],[19]	9%		9%
Principal Amount	[19]	$ 17,910
Investment cost	[2],[19]	17,591
Investments at Fair Value	[19]	$ 17,577
Investment, Identifier [Axis]: Debt Investments Software and Salary.com, LLC, Senior Secured, Maturity Date September 2027, 6-month SOFR + 8.00%, Floor rate 9.00%
Investment Holding [Line Items]
Maturity Date	[17]					2027-09		2027-09
Investments Maturity Month and Year	[17]					2027-09		2027-09
Investment, Basis Spread, Variable Rate	[12],[17]					8%		8%
Investment, Interest Rate, Floor	[12],[17]					9%		9%
Principal Amount	[17]					$ 18,000
Investment cost	[6],[17]					17,654
Investments at Fair Value	[17]					$ 17,654
Investment, Identifier [Axis]: Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 3-month LIBOR + 9.00%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2026-12		2026-12
Investments Maturity Month and Year	[10],[17]					2026-12		2026-12
Investment, Basis Spread, Variable Rate	[10],[12],[17]					9%		9%
Investment, Interest Rate, Floor	[10],[12],[17]					10%		10%
Principal Amount	[10],[17]					$ 5,985
Investment cost	[6],[10],[17]					5,841
Investments at Fair Value	[10],[17]					$ 5,830
Investment, Identifier [Axis]: Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 6-month SOFR + 8.95%, Floor rate 9.95%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2026-12		2026-12
Investments Maturity Month and Year	[9],[19]	2026-12		2026-12
Investment, Basis Spread, Variable Rate	[9],[11],[19]	8.95%		8.95%
Investment, Interest Rate, Floor	[9],[11],[19]	9.95%		9.95%
Principal Amount	[9],[19]	$ 6,000
Investment cost	[2],[9],[19]	5,868
Investments at Fair Value	[9],[19]	$ 5,739
Investment, Identifier [Axis]: Debt Investments Software and Simon Data, Inc., Senior Secured, Maturity Date March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7]	2027-03		2027-03
Investments Maturity Month and Year	[7]	2027-03		2027-03
Investment, Basis Spread, Variable Rate	[7],[11]	1%		1%
Investment, Interest Rate, Floor	[7],[11]	8.75%		8.75%
Investment, Interest Rate, Paid in Kind	[7],[11]	1.95%		1.95%
Principal Amount	[7]	$ 15,058
Investment cost	[2],[7]	14,980
Investments at Fair Value	[7]	$ 14,962
Investment Exit Fee	[7],[11]	2.95%		2.95%
Investment, Identifier [Axis]: Debt Investments Software and Sisense Ltd., Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 2.55% Exit Fee
Investment Holding [Line Items]
Maturity Date	[25],[26]	2027-07		2027-07
Investments Maturity Month and Year	[25],[26]	2027-07		2027-07
Investment, Basis Spread, Variable Rate	[11],[25],[26]	1.50%		1.50%
Investment, Interest Rate, Floor	[11],[25],[26]	9.50%		9.50%
Investment, Interest Rate, Paid in Kind	[11],[25],[26]	1.95%		1.95%
Principal Amount	[25],[26]	$ 34,500
Investment cost	[2],[25],[26]	33,984
Investments at Fair Value	[25],[26]	$ 33,984
Investment Exit Fee	[11],[25],[26]	2.55%		2.55%
Investment, Identifier [Axis]: Debt Investments Software and Streamline Healthcare Solutions, Senior Secured, Maturity Date March 2028, 1-month SOFR + 7.25%, Floor rate 8.25%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2028-03		2028-03
Investments Maturity Month and Year	[9],[19]	2028-03		2028-03
Investment, Basis Spread, Variable Rate	[9],[11],[19]	7.25%		7.25%
Investment, Interest Rate, Floor	[9],[11],[19]	8.25%		8.25%
Principal Amount	[9],[19]	$ 13,200
Investment cost	[2],[9],[19]	12,931
Investments at Fair Value	[9],[19]	$ 12,932
Investment, Identifier [Axis]: Debt Investments Software and Sumo Logic, Inc., Senior Secured, Maturity Date May 2030, 3-month SOFR + 6.50%, Floor rate 7.50%
Investment Holding [Line Items]
Maturity Date	[9]	2030-05		2030-05
Investments Maturity Month and Year	[9]	2030-05		2030-05
Investment, Basis Spread, Variable Rate	[9],[11]	6.50%		6.50%
Investment, Interest Rate, Floor	[9],[11]	7.50%		7.50%
Principal Amount	[9]	$ 23,000
Investment cost	[2],[9]	22,432
Investments at Fair Value	[9]	$ 22,432
Investment, Identifier [Axis]: Debt Investments Software and Tact.ai Technologies, Inc., Senior Secured, Maturity Date February 2024, Prime + 4.00%, Floor rate 8.75%, PIK Interest 2.00%, 5.50% Exit Fee
Investment Holding [Line Items]
Maturity Date		2024-02	[7]	2024-02	[7]	2024-02	[15]	2024-02	[15]
Investments Maturity Month and Year		2024-02	[7]	2024-02	[7]	2024-02	[15]	2024-02	[15]
Investment, Basis Spread, Variable Rate		4%	[7],[11]	4%	[7],[11]	4%	[12],[15]	4%	[12],[15]
Investment, Interest Rate, Floor		8.75%	[7],[11]	8.75%	[7],[11]	8.75%	[12],[15]	8.75%	[12],[15]
Investment, Interest Rate, Paid in Kind		2%	[7],[11]	2%	[7],[11]	2%	[12],[15]	2%	[12],[15]
Principal Amount		$ 2,672	[7]			$ 4,250	[15]
Investment cost		2,657	[2],[7]			4,481	[6],[15]
Investments at Fair Value		$ 2,657	[7]			$ 4,446	[15]
Investment Exit Fee		5.50%	[7],[11]	5.50%	[7],[11]	5.50%	[12],[15]	5.50%	[12],[15]
Investment, Identifier [Axis]: Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 6-month LIBOR + 9.00%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date	[10],[17]					2026-05		2026-05
Investments Maturity Month and Year	[10],[17]					2026-05		2026-05
Investment, Basis Spread, Variable Rate	[10],[12],[17]					9%		9%
Investment, Interest Rate, Floor	[10],[12],[17]					10%		10%
Principal Amount	[10],[17]					$ 11,032
Investment cost	[6],[10],[17]					10,778
Investments at Fair Value	[10],[17]					$ 10,793
Investment, Identifier [Axis]: Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 6-month SOFR + 9.00%, Floor rate 10.00%
Investment Holding [Line Items]
Maturity Date	[9],[19]	2026-05		2026-05
Investments Maturity Month and Year	[9],[19]	2026-05		2026-05
Investment, Basis Spread, Variable Rate	[9],[11],[19]	9%		9%
Investment, Interest Rate, Floor	[9],[11],[19]	10%		10%
Principal Amount	[9],[19]	$ 10,976
Investment cost	[2],[9],[19]	10,753
Investments at Fair Value	[9],[19]	$ 10,823
Investment, Identifier [Axis]: Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2027, Prime + 0.45%, Floor rate 7.95%, PIK Interest 2.00%, 3.75% Exit Fee
Investment Holding [Line Items]
Maturity Date	[7],[9],[25],[26]	2027-04		2027-04
Investments Maturity Month and Year	[7],[9],[25],[26]	2027-04		2027-04
Investment, Basis Spread, Variable Rate	[7],[9],[11],[25],[26]	0.45%		0.45%
Investment, Interest Rate, Floor	[7],[9],[11],[25],[26]	7.95%		7.95%
Investment, Interest Rate, Paid in Kind	[7],[9],[11],[25],[26]	2%		2%
Principal Amount	[7],[9],[25],[26]	$ 10,541
Investment cost	[2],[7],[9],[25],[26]	10,416
Investments at Fair Value	[7],[9],[25],[26]	$ 10,416
Investment Exit Fee	[7],[9],[11],[25],[26]	3.75%		3.75%
Investment, Identifier [Axis]: Debt Investments Software and VideoAmp, Inc., Senior Secured, Maturity Date February 2025, Prime + 3.70%, Floor rate 6.95%, PIK Interest 1.25%, 5.25% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-02	[1],[7],[13]	2025-02	[1],[7],[13]	2025-02	[14],[15],[31]	2025-02	[14],[15],[31]
Investments Maturity Month and Year		2025-02	[1],[7],[13]	2025-02	[1],[7],[13]	2025-02	[14],[15],[31]	2025-02	[14],[15],[31]
Investment, Basis Spread, Variable Rate		3.70%	[1],[7],[11],[13]	3.70%	[1],[7],[11],[13]	3.70%	[12],[14],[15],[31]	3.70%	[12],[14],[15],[31]
Investment, Interest Rate, Floor		6.95%	[1],[7],[11],[13]	6.95%	[1],[7],[11],[13]	6.95%	[12],[14],[15],[31]	6.95%	[12],[14],[15],[31]
Investment, Interest Rate, Paid in Kind		1.25%	[1],[7],[11],[13]	1.25%	[1],[7],[11],[13]	1.25%	[12],[14],[15],[31]	1.25%	[12],[14],[15],[31]
Principal Amount		$ 63,585	[1],[7],[13]			$ 63,187	[14],[15],[31]
Investment cost		63,830	[1],[2],[7],[13]			62,640	[6],[14],[31]
Investments at Fair Value		$ 68,207	[1],[7],[13]			$ 63,429	[14],[15],[31]
Investment Exit Fee		5.25%	[1],[7],[11],[13]	5.25%	[1],[7],[11],[13]	5.25%	[12],[14],[15],[31]	5.25%	[12],[14],[15],[31]
Investment, Identifier [Axis]: Debt Investments Software and Zappi, Inc., Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%
Investment Holding [Line Items]
Maturity Date		2027-12	[9],[19],[25],[26]	2027-12	[9],[19],[25],[26]	2027-12	[10],[17],[27],[28]	2027-12	[10],[17],[27],[28]
Investments Maturity Month and Year		2027-12	[9],[19],[25],[26]	2027-12	[9],[19],[25],[26]	2027-12	[10],[17],[27],[28]	2027-12	[10],[17],[27],[28]
Investment, Basis Spread, Variable Rate		8.03%	[9],[11],[19],[25],[26]	8.03%	[9],[11],[19],[25],[26]	8.03%	[10],[12],[17],[27],[28]	8.03%	[10],[12],[17],[27],[28]
Investment, Interest Rate, Floor		9.03%	[9],[11],[19],[25],[26]	9.03%	[9],[11],[19],[25],[26]	9.03%	[10],[12],[17],[27],[28]	9.03%	[10],[12],[17],[27],[28]
Principal Amount		$ 9,000	[9],[19],[25],[26]			$ 9,000	[10],[17],[27],[28]
Investment cost		8,797	[2],[9],[19],[25],[26]			8,779	[6],[10],[17],[27],[28]
Investments at Fair Value		$ 8,803	[9],[19],[25],[26]			$ 8,779	[10],[17],[27],[28]
Investment, Identifier [Axis]: Debt Investments Software and Zimperium, Inc., Senior Secured, Maturity Date May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%
Investment Holding [Line Items]
Maturity Date		2027-05	[9],[19]	2027-05	[9],[19]	2027-05	[10],[17]	2027-05	[10],[17]
Investments Maturity Month and Year		2027-05	[9],[19]	2027-05	[9],[19]	2027-05	[10],[17]	2027-05	[10],[17]
Investment, Basis Spread, Variable Rate		8.31%	[9],[11],[19]	8.31%	[9],[11],[19]	8.31%	[10],[12],[17]	8.31%	[10],[12],[17]
Investment, Interest Rate, Floor		9.31%	[9],[11],[19]	9.31%	[9],[11],[19]	9.31%	[10],[12],[17]	9.31%	[10],[12],[17]
Principal Amount		$ 16,313	[9],[19]			$ 16,313	[10],[17]
Investment cost		16,028	[2],[9],[19]			16,000	[6],[10],[17]
Investments at Fair Value		$ 16,235	[9],[19]			$ 16,072	[10],[17]
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology (0.38%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.38%		0.38%
Investment cost	[2]	$ 5,929
Investments at Fair Value		$ 5,947
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology (0.50%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.50%		0.50%
Investment cost	[6]					$ 7,222
Investments at Fair Value						$ 7,014
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, Maturity Date May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee
Investment Holding [Line Items]
Maturity Date		2025-05	[7],[8]	2025-05	[7],[8]	2025-05	[15],[22]	2025-05	[15],[22]
Investments Maturity Month and Year		2025-05	[7],[8]	2025-05	[7],[8]	2025-05	[15],[22]	2025-05	[15],[22]
Investment, Basis Spread, Variable Rate		4.70%	[7],[8],[11]	4.70%	[7],[8],[11]	4.70%	[12],[15],[22]	4.70%	[12],[15],[22]
Investment, Interest Rate, Floor		7.95%	[7],[8],[11]	7.95%	[7],[8],[11]	7.95%	[12],[15],[22]	7.95%	[12],[15],[22]
Investment, Interest Rate, Paid in Kind		1.45%	[7],[8],[11]	1.45%	[7],[8],[11]	1.45%	[12],[15],[22]	1.45%	[12],[15],[22]
Principal Amount		$ 4,067	[7],[8]			$ 4,037	[15],[22]
Investment cost		4,053	[2],[7],[8]			3,985	[6],[15],[22]
Investments at Fair Value		$ 4,091	[7],[8]			$ 4,008	[15],[22]
Investment Exit Fee		3.95%	[7],[8],[11]	3.95%	[7],[8],[11]	3.95%	[12],[15],[22]	3.95%	[12],[15],[22]
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, Maturity Date December 2024, PIK Interest 10.00%
Investment Holding [Line Items]
Maturity Date	[15]					2024-12		2024-12
Investments Maturity Month and Year	[15]					2024-12		2024-12
Investment, Interest Rate, Paid in Kind	[12],[15]					10%		10%
Principal Amount	[15]					$ 3,237
Investment cost	[6],[15]					3,237
Investments at Fair Value	[15]					$ 3,006
Investment, Identifier [Axis]: Debt Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Senior Secured, Maturity Date June 2027, FIXED 10.00%
Investment Holding [Line Items]
Maturity Date	[7]	2027-06		2027-06
Investments Maturity Month and Year	[7]	2027-06		2027-06
Investment, Interest Rate, Paid in Kind	[11]	10%		10%
Principal Amount	[7]	$ 1,876
Investment cost	[2],[7]	1,876
Investments at Fair Value	[7]	$ 1,856
Investment, Identifier [Axis]: Equity Investments (8.59%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	8.59%		8.59%
Investment cost	[2]	$ 140,925
Investments at Fair Value		$ 136,180
Investment, Identifier [Axis]: Equity Investments (9.56%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					9.56%		9.56%
Investment cost	[6]					$ 153,173
Investments at Fair Value						$ 133,972
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products (0.02%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.02%		0.02%
Investment cost	[2]	$ 663
Investments at Fair Value		325
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.04%		0.04%
Investment cost	[6]					$ 663
Investments at Fair Value						498
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock
Investment Holding [Line Items]
Investment cost		433	[2],[39]			433	[6],[40]
Investments at Fair Value		$ 22	[39]			$ 24	[40]
Shares | shares		12,260	[39]	12,260	[39]	61,300	[40]	61,300	[40]
Investments Owned Acquisition Date		Apr. 30, 2021	[3]	Apr. 30, 2021	[3]	Apr. 30, 2021	[40]	Apr. 30, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units
Investment Holding [Line Items]
Investment cost		$ 13	[2]			$ 13	[6]
Investments at Fair Value		$ 144				$ 226
Shares | shares		42,137		42,137		42,137		42,137
Investments Owned Acquisition Date		Apr. 30, 2010	[3]	Apr. 30, 2010	[3]	Apr. 30, 2010	[40]	Apr. 30, 2010	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and TFG Holding, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 89	[2]			$ 89	[6]
Investments at Fair Value		$ 72				$ 116
Shares | shares		42,989		42,989		42,989		42,989
Investments Owned Acquisition Date		Apr. 30, 2010	[3]	Apr. 30, 2010	[3]	Apr. 30, 2010	[40]	Apr. 30, 2010	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Products and TechStyle, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 128	[2]			$ 128	[6]
Investments at Fair Value		$ 87				$ 132
Shares | shares		42,989		42,989		42,989		42,989
Investments Owned Acquisition Date		Apr. 30, 2010	[3]	Apr. 30, 2010	[3]	Apr. 30, 2010	[40]	Apr. 30, 2010	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services (0.57%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.57%		0.57%
Investment cost	[6]					$ 13,488
Investments at Fair Value						7,995
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services (0.61%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.61%		0.61%
Investment cost	[2]	$ 13,171
Investments at Fair Value		9,737
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-4
Investment Holding [Line Items]
Investment cost		1,151	[2],[25],[26]			1,151	[6],[27],[28]
Investments at Fair Value		$ 511	[25],[26]			$ 257	[27],[28]
Shares | shares		199,742	[25],[26]	199,742	[25],[26]	199,742	[27],[28]	199,742	[27],[28]
Investments Owned Acquisition Date		Dec. 15, 2021	[25],[26],[39]	Dec. 15, 2021	[25],[26],[39]	Dec. 15, 2021	[27],[28],[40]	Dec. 15, 2021	[27],[28],[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and DoorDash, Inc., Equity, Acquisition Date 12/20/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 946	[2],[39]			$ 945	[6],[40]
Investments at Fair Value		$ 6,267	[39]			$ 4,003	[40]
Shares | shares		81,996	[39]	81,996	[39]	81,996	[40]	81,996	[40]
Investments Owned Acquisition Date		Dec. 20, 2018	[3],[39]	Dec. 20, 2018	[3],[39]	Dec. 20, 2018	[40]	Dec. 20, 2018	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 5,263	[2],[39]			$ 5,263	[6],[40]
Investments at Fair Value		$ 966	[39]			$ 1,110	[40]
Shares | shares		100,738	[39]	100,738	[39]	100,738	[40]	100,738	[40]
Investments Owned Acquisition Date		Dec. 26, 2018	[3],[39]	Dec. 26, 2018	[3],[39]	Dec. 26, 2018	[40]	Dec. 26, 2018	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,000	[2],[39]			$ 1,000	[6],[40]
Investments at Fair Value		$ 417	[39]			$ 225	[40]
Shares | shares		100,000	[39]	100,000	[39]	100,000	[40]	100,000	[40]
Investments Owned Acquisition Date		Sep. 17, 2021	[3],[39]	Sep. 17, 2021	[3],[39]	Sep. 17, 2021	[40]	Sep. 17, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A
Investment Holding [Line Items]
Investment cost		$ 1,663	[2]			$ 1,663	[6]
Investments at Fair Value		$ 450				$ 372
Shares | shares		286,080		286,080		286,080		286,080
Investments Owned Acquisition Date		Oct. 25, 2016	[3]	Oct. 25, 2016	[3]	Oct. 25, 2016	[40]	Oct. 25, 2016	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-1
Investment Holding [Line Items]
Investment cost		$ 632	[2]			$ 632	[6]
Investments at Fair Value		$ 171				$ 141
Shares | shares		108,710		108,710		108,710		108,710
Investments Owned Acquisition Date		Oct. 25, 2016	[3]	Oct. 25, 2016	[3]	Oct. 25, 2016	[40]	Oct. 25, 2016	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 577	[2],[39]			$ 577	[6],[40]
Investments at Fair Value		$ 289	[39]			$ 266	[40]
Shares | shares		48,365	[39]	48,365	[39]	48,365	[40]	48,365	[40]
Investments Owned Acquisition Date		Jun. 28, 2013	[3],[39]	Jun. 28, 2013	[3],[39]	Jun. 28, 2013	[40]	Jun. 28, 2013	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Reischling Press, Inc., Acquisition Date 7/31/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 39	[2]			$ 39	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		3,095		3,095		3,095		3,095
Investments Owned Acquisition Date		Jul. 31, 2020	[3]	Jul. 31, 2020	[3]	Jul. 31, 2020	[40]	Jul. 31, 2020	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Preferred Series B-2
Investment Holding [Line Items]
Investment cost		$ 1,000	[2]			$ 1,000	[6]
Investments at Fair Value		$ 666				$ 805
Shares | shares		7,063		7,063		7,063		7,063
Investments Owned Acquisition Date		Jan. 24, 2022	[3]	Jan. 24, 2022	[3]	Jan. 24, 2022	[40]	Jan. 24, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Acquisition Date 5/23/2018, Series Common Stock
Investment Holding [Line Items]
Investments at Fair Value						$ 0
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 900	[2],[32]			$ 900	[6],[34]
Investments at Fair Value	[32]	$ 0
Shares | shares		414,994,863	[32]	414,994,863	[32]	414,994,863	[34]	414,994,863	[34]
Investments Owned Acquisition Date		May 23, 2018	[3],[32]	May 23, 2018	[3],[32]	May 23, 2018	[34],[40]	May 23, 2018	[34],[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB
Investment Holding [Line Items]
Investment cost		$ 0	[2],[32]			$ 0	[6],[34]
Investments at Fair Value						$ 0
Shares | shares		1,000,000	[32]	1,000,000	[32]	1,000,000	[34]	1,000,000	[34]
Investments Owned Acquisition Date		Jun. 06, 2016	[3],[32]	Jun. 06, 2016	[3],[32]	Jun. 06, 2016	[34],[40]	Jun. 06, 2016	[34],[40]
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Total OfferUp, Inc.
Investment Holding [Line Items]
Investment cost		$ 2,295	[2]			$ 2,295	[6]
Investments at Fair Value		$ 621				$ 513
Shares | shares		394,790		394,790		394,790		394,790
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Total Tectura Corporation
Investment Holding [Line Items]
Investment cost		$ 900	[2]			$ 900	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		415,994,863		415,994,863		415,994,863		415,994,863
Investment, Identifier [Axis]: Equity Investments Consumer & Business Services and Uber Technologies, Inc., Acquisition Date 12/1/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 318
Investments at Fair Value	[40]					$ 816
Shares | shares	[40]					32,991		32,991
Investments Owned Acquisition Date	[40]					Dec. 01, 2020		Dec. 01, 2020
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services (2.49%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.49%		2.49%
Investment cost	[6]					$ 28,444
Investments at Fair Value						34,869
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services (2.98%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.98%		2.98%
Investment cost	[2]	$ 29,444
Investments at Fair Value		47,313
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Gibraltar Business Capital, LLC, Equity, Acquisition Date 3/1/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[34]					1,884
Investments at Fair Value	[34]					$ 1,107
Shares | shares	[34]					830,000		830,000
Investments Owned Acquisition Date	[34],[40]					Mar. 01, 2018		Mar. 01, 2018
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Gibraltar Business Capital, LLC, Equity, Acquisition Date 3/1/2018, Series Preferred Series A
Investment Holding [Line Items]
Investment cost	[6],[34]					$ 26,122
Investments at Fair Value	[34]					$ 14,137
Shares | shares	[34]					10,602,752		10,602,752
Investments Owned Acquisition Date	[34],[40]					Mar. 01, 2018		Mar. 01, 2018
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/1/2018, Series Member Units
Investment Holding [Line Items]
Investment cost	[2],[32],[36]	29,006
Investments at Fair Value	[32],[36]	$ 19,779
Shares | shares	[32],[36]	1		1
Investments Owned Acquisition Date	[3],[32],[36]	Mar. 01, 2018		Mar. 01, 2018
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units
Investment Holding [Line Items]
Investment cost		$ 35	[2],[32]			$ 35	[6],[34]
Investments at Fair Value		$ 27,161	[32]			$ 19,153	[34]
Shares | shares		1	[32]	1	[32]	1	[34]	1	[34]
Investments Owned Acquisition Date		Mar. 26, 2021	[3],[32]	Mar. 26, 2021	[3],[32]	Mar. 26, 2021	[34],[40]	Mar. 26, 2021	[34],[40]
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-2
Investment Holding [Line Items]
Investment cost		$ 403	[2]			$ 403	[6]
Investments at Fair Value		$ 373				$ 472
Shares | shares		210,282		210,282		210,282		210,282
Investments Owned Acquisition Date		Sep. 30, 2021	[3]	Sep. 30, 2021	[3]	Sep. 30, 2021	[40]	Sep. 30, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Diversified Financial Services, Gibraltar Business Capital, LLC
Investment Holding [Line Items]
Investment cost	[6]					$ 28,006
Investments at Fair Value						$ 15,244
Shares | shares						11,432,752		11,432,752
Investment, Identifier [Axis]: Equity Investments Drug Delivery (0.00%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0%		0%
Investment cost	[2]	$ 3,638
Investments at Fair Value		23
Investment, Identifier [Axis]: Equity Investments Drug Delivery (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.01%		0.01%
Investment cost	[6]					$ 3,638
Investments at Fair Value						89
Investment, Identifier [Axis]: Equity Investments Drug Delivery and AcelRx Pharmaceuticals, Inc., Equity, Acquisition Date 12/10/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		1,329	[2],[39]			1,329	[6],[40]
Investments at Fair Value		$ 10	[39]			$ 20	[40]
Shares | shares		8,836	[39]	8,836	[39]	8,836	[40]	8,836	[40]
Investments Owned Acquisition Date		Dec. 10, 2018	[3],[39]	Dec. 10, 2018	[3],[39]	Dec. 10, 2018	[40]	Dec. 10, 2018	[40]
Investment, Identifier [Axis]: Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,500	[2],[39]			$ 1,500	[6],[40]
Investments at Fair Value		$ 1	[39]			$ 3	[40]
Shares | shares		680	[39]	680	[39]	13,600	[40]	13,600	[40]
Investments Owned Acquisition Date		Mar. 28, 2014	[3],[39]	Mar. 28, 2014	[3],[39]	Mar. 28, 2014	[40]	Mar. 28, 2014	[40]
Investment, Identifier [Axis]: Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 500	[2]			$ 500	[6]
Investments at Fair Value						$ 33
Shares | shares		165,000		165,000		165,000		165,000
Investments Owned Acquisition Date		Dec. 08, 2015	[3]	Dec. 08, 2015	[3]	Dec. 08, 2015	[40]	Dec. 08, 2015	[40]
Investment, Identifier [Axis]: Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 309	[2],[39]			$ 309	[6],[40]
Investments at Fair Value		$ 12	[39]			$ 33	[40]
Shares | shares		2,498	[39]	2,498	[39]	2,498	[40]	2,498	[40]
Investments Owned Acquisition Date		Apr. 06, 2015	[3],[39]	Apr. 06, 2015	[3],[39]	Apr. 06, 2015	[40]	Apr. 06, 2015	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development (2.20%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.20%		2.20%
Investment cost	[2]	$ 40,305
Investments at Fair Value		34,933
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development (2.66%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.66%		2.66%
Investment cost	[6]					$ 43,971
Investments at Fair Value						37,315
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 9/19/2022, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[40]					1,000
Investments at Fair Value	[27],[40]					$ 2,108
Shares | shares	[27],[40]					38,461		38,461
Investments Owned Acquisition Date	[27],[40]					Sep. 19, 2022		Sep. 19, 2022
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Albireo Pharma, Inc., Equity, Acquisition Date 9/14/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[40]					$ 1,000
Investments at Fair Value	[27],[40]					$ 540
Shares | shares	[27],[40]					25,000		25,000
Investments Owned Acquisition Date	[27],[40]					Sep. 14, 2020		Sep. 14, 2020
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Applied Molecular Transport, Equity, Acquisition Date 4/6/2021, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 42	[2],[25],[39]			$ 42	[6],[27],[40]
Investments at Fair Value	[27],[40]					$ 0
Shares | shares		1,000	[25],[39]	1,000	[25],[39]	1,000	[27],[40]	1,000	[27],[40]
Investments Owned Acquisition Date		Apr. 06, 2021	[3],[25],[39]	Apr. 06, 2021	[3],[25],[39]	Apr. 06, 2021	[27],[40]	Apr. 06, 2021	[27],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,000	[2],[39]			$ 1,000	[6],[40]
Investments at Fair Value		$ 4	[39]			$ 50	[40]
Shares | shares		9,923	[39]	9,923	[39]	9,924	[40]	9,924	[40]
Investments Owned Acquisition Date		Aug. 19, 2014	[3],[39]	Aug. 19, 2014	[3],[39]	Aug. 19, 2014	[40]	Aug. 19, 2014	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Aveo Pharmaceuticals, Inc., Equity, Acquisition Date 7/31/2011, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 1,715
Investments at Fair Value	[40]					$ 2,843
Shares | shares	[40]					190,179		190,179
Investments Owned Acquisition Date	[40]					Jul. 31, 2011		Jul. 31, 2011
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 4,165	[2],[21],[25],[39]			$ 4,165	[6],[24],[27],[40]
Investments at Fair Value		$ 9,128	[21],[25],[39]			$ 9,797	[24],[27],[40]
Shares | shares		127,021	[21],[25],[39]	127,021	[21],[25],[39]	127,021	[24],[27],[40]	127,021	[24],[27],[40]
Investments Owned Acquisition Date		May 09, 2022	[3],[21],[25],[39]	May 09, 2022	[3],[21],[25],[39]	May 09, 2022	[24],[27],[40]	May 09, 2022	[24],[27],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,871	[2],[25],[26],[39]			$ 1,871	[6],[27],[28],[40]
Investments at Fair Value		$ 2,503	[25],[26],[39]			$ 2,904	[27],[28],[40]
Shares | shares		98,100	[25],[26],[39]	98,100	[25],[26],[39]	98,100	[27],[28],[40]	98,100	[27],[28],[40]
Investments Owned Acquisition Date		Oct. 05, 2020	[3],[25],[26],[39]	Oct. 05, 2020	[3],[25],[26],[39]	Oct. 05, 2020	[28],[40]	Oct. 05, 2020	[28],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost	[2],[39]	$ 2,255
Investments at Fair Value	[39]	$ 3,979
Shares | shares	[39]	231,329		231,329
Investments Owned Acquisition Date	[3],[39]	Jun. 21, 2018		Jun. 21, 2018
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Concert Pharmaceuticals, Inc., Equity, Acquisition Date 2/13/2019, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[40]					$ 1,367
Investments at Fair Value	[27],[40]					$ 413
Shares | shares	[27],[40]					70,796		70,796
Investments Owned Acquisition Date	[27],[40]					Feb. 13, 2019		Feb. 13, 2019
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 1,000
Investments at Fair Value	[40]					$ 11
Shares | shares	[40]					13,550		13,550
Investments Owned Acquisition Date	[40]					Jan. 08, 2015		Jan. 08, 2015
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 550	[2],[25],[39]			$ 550	[6],[27],[40]
Investments at Fair Value		$ 258	[25],[39]			$ 213	[27],[40]
Shares | shares		20,000	[25],[39]	20,000	[25],[39]	20,000	[27],[40]	20,000	[27],[40]
Investments Owned Acquisition Date		Jul. 22, 2015	[3],[25],[39]	Jul. 22, 2015	[3],[25],[39]	Jul. 22, 2015	[27],[40]	Jul. 22, 2015	[27],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Gritstone Bio, Inc., Equity, Acquisition Date 10/26/2022, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,000	[2],[39]			$ 1,000	[6],[40]
Investments at Fair Value		$ 863	[39]			$ 1,527	[40]
Shares | shares		442,477	[39]	442,477	[39]	442,477	[40]	442,477	[40]
Investments Owned Acquisition Date		Oct. 26, 2022	[3],[39]	Oct. 26, 2022	[3],[39]	Oct. 26, 2022	[40]	Oct. 26, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 4,250	[1],[2]			$ 4,250	[6],[31]
Investments at Fair Value		$ 1,131	[1]			$ 2,233	[31]
Shares | shares		3,466,840	[1]	3,466,840	[1]	3,466,840	[31]	3,466,840	[31]
Investments Owned Acquisition Date		May 07, 2021	[1],[3]	May 07, 2021	[1],[3]	May 07, 2021	[31],[40]	May 07, 2021	[31],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 4,000	[2],[39]			$ 4,000	[6],[40]
Investments at Fair Value		$ 4,044	[39]			$ 3,937	[40]
Shares | shares		235,295	[39]	235,295	[39]	235,295	[40]	235,295	[40]
Investments Owned Acquisition Date		May 03, 2022	[3],[39]	May 03, 2022	[3],[39]	May 03, 2022	[40]	May 03, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Humanigen, Inc., Equity, Acquisition Date 3/31/2021, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 800	[2],[25],[39]			$ 800	[6],[27],[40]
Investments at Fair Value		$ 7	[25],[39]			$ 5	[27],[40]
Shares | shares		43,243	[25],[39]	43,243	[25],[39]	43,243	[27],[40]	43,243	[27],[40]
Investments Owned Acquisition Date		Mar. 31, 2021	[3],[25],[39]	Mar. 31, 2021	[3],[25],[39]	Mar. 31, 2021	[27],[40]	Mar. 31, 2021	[27],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock
Investment Holding [Line Items]
Investment cost	[2],[25],[39]	$ 550
Investments at Fair Value	[25],[39]	$ 506
Shares | shares	[25],[39]	47,826		47,826
Investments Owned Acquisition Date	[3],[39]	Jun. 16, 2023		Jun. 16, 2023
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 2,000	[2],[25],[26]			$ 2,000	[6],[27],[28]
Investments at Fair Value		$ 763	[25],[39]			$ 1,476	[27],[28]
Shares | shares		983	[25],[26]	983	[25],[26]	983	[27],[28]	983	[27],[28]
Investments Owned Acquisition Date		Dec. 15, 2021	[3],[25],[26]	Dec. 15, 2021	[3],[25],[26]	Dec. 15, 2021	[27],[28],[40]	Dec. 15, 2021	[27],[28],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Paratek Pharmaceuticals, Inc., Equity, Acquisition Date 2/26/2007, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 2,744	[2],[39]			$ 2,744	[6],[40]
Investments at Fair Value		$ 169	[39]			$ 143	[40]
Shares | shares		76,362	[39]	76,362	[39]	76,362	[40]	76,362	[40]
Investments Owned Acquisition Date		Feb. 26, 2007	[3],[39]	Feb. 26, 2007	[3],[39]	Feb. 26, 2007	[40]	Feb. 26, 2007	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock
Investment Holding [Line Items]
Investment cost	[2],[21],[25],[39]	$ 1,730
Investments at Fair Value	[21],[25],[39]	$ 2,108
Shares | shares	[21],[25],[39]	147,233		147,233
Investments Owned Acquisition Date	[3],[39]	Jun. 09, 2023		Jun. 09, 2023
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,500	[2],[39]			$ 1,500	[6],[40]
Investments at Fair Value		$ 19	[39]			$ 18	[40]
Shares | shares		944	[39]	944	[39]	944	[40]	944	[40]
Investments Owned Acquisition Date		Aug. 22, 2007	[3],[39]	Aug. 22, 2007	[3],[39]	Aug. 22, 2007	[40]	Aug. 22, 2007	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 202	[2],[39]			$ 203	[6],[40]
Investments at Fair Value		$ 36	[39]			$ 17	[40]
Shares | shares		11,119	[39]	11,119	[39]	11,119	[40]	11,119	[40]
Investments Owned Acquisition Date		Aug. 11, 2015	[3],[39]	Aug. 11, 2015	[3],[39]	Aug. 11, 2015	[40]	Aug. 11, 2015	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Sio Gene Therapies, Inc., Equity, Acquisition Date 2/2/2017, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,269	[2],[39]			$ 1,269	[6],[40]
Investments at Fair Value		$ 7	[39]			$ 7	[40]
Shares | shares		16,228	[39]	16,228	[39]	16,228	[40]	16,228	[40]
Investments Owned Acquisition Date		Feb. 02, 2017	[3],[39]	Feb. 02, 2017	[3],[39]	Feb. 02, 2017	[40]	Feb. 02, 2017	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Tarsus Pharmaceuticals, Inc., Equity, Acquisition Date 5/5/2022, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 2,100	[2],[25],[39]			$ 2,100	[6],[27],[40]
Investments at Fair Value		$ 2,811	[25],[39]			$ 2,280	[27],[40]
Shares | shares		155,555	[25],[39]	155,555	[25],[39]	155,555	[27],[40]	155,555	[27],[40]
Investments Owned Acquisition Date		May 05, 2022	[3],[25],[39]	May 05, 2022	[3],[25],[39]	May 05, 2022	[27],[40]	May 05, 2022	[27],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Tricida, Inc., Equity, Acquisition Date 2/28/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 863
Investments at Fair Value	[40]					$ 11
Shares | shares	[40]					68,816		68,816
Investments Owned Acquisition Date	[40]					Feb. 28, 2018		Feb. 28, 2018
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 1,000	[2]			$ 1,000	[6]
Investments at Fair Value		$ 1,070				$ 1,012
Shares | shares		170,102		170,102		170,102		170,102
Investments Owned Acquisition Date		Oct. 31, 2022	[3]	Oct. 31, 2022	[3]	Oct. 31, 2022	[40]	Oct. 31, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 3,000	[2]			$ 3,000	[6]
Investments at Fair Value		$ 2,280				$ 2,063
Shares | shares		510,308		510,308		510,308		510,308
Investments Owned Acquisition Date		Dec. 11, 2020	[3]	Dec. 11, 2020	[3]	Dec. 11, 2020	[40]	Dec. 11, 2020	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 2,945	[2],[39]			$ 2,945	[6],[40]
Investments at Fair Value		$ 3,038	[39]			$ 1,555	[40]
Shares | shares		1,566,064	[39]	1,566,064	[39]	1,566,064	[40]	1,566,064	[40]
Investments Owned Acquisition Date		Nov. 26, 2019	[3],[39]	Nov. 26, 2019	[3],[39]	Nov. 26, 2019	[40]	Nov. 26, 2019	[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 332	[2],[25],[26],[39]			$ 332	[6],[24],[27],[28],[40]
Investments at Fair Value		$ 197	[25],[26],[39]			$ 389	[24],[27],[28],[40]
Shares | shares		17,175	[25],[26],[39]	17,175	[25],[26],[39]	17,175	[24],[27],[28],[40]	17,175	[24],[27],[28],[40]
Investments Owned Acquisition Date		Jan. 31, 2019	[3],[25],[26],[39]	Jan. 31, 2019	[3],[25],[26],[39]	Jan. 31, 2019	[24],[27],[28],[40]	Jan. 31, 2019	[24],[27],[28],[40]
Investment, Identifier [Axis]: Equity Investments Drug Discovery & Development, Valo Health LLC
Investment Holding [Line Items]
Investment cost		$ 4,000	[2]			$ 4,000	[6]
Investments at Fair Value		$ 3,350				$ 3,075
Shares | shares		680,410		680,410		680,410		680,410
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware (0.07%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.07%		0.07%
Investment cost	[2]	$ 2,150
Investments at Fair Value		1,123
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware (0.11%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.11%		0.11%
Investment cost	[6]					$ 2,150
Investments at Fair Value						1,521
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F
Investment Holding [Line Items]
Investment cost		650	[2]			650	[6]
Investments at Fair Value		$ 512				$ 606
Shares | shares		15,116		15,116		15,116		15,116
Investments Owned Acquisition Date		Nov. 17, 2022	[3]	Nov. 17, 2022	[3]	Nov. 17, 2022	[40]	Nov. 17, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 1,500	[2]			$ 1,500	[6]
Investments at Fair Value		$ 611				$ 915
Shares | shares		248,900		248,900		248,900		248,900
Investments Owned Acquisition Date		Mar. 08, 2022	[3]	Mar. 08, 2022	[3]	Mar. 08, 2022	[40]	Mar. 08, 2022	[40]
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other (0.15%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.15%		0.15%
Investment cost	[2]	$ 6,782
Investments at Fair Value		2,313
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other (0.21%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.21%		0.21%
Investment cost	[6]					$ 6,781
Investments at Fair Value						2,894
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock
Investment Holding [Line Items]
Investment cost		5,095	[2],[39]			5,094	[6],[40]
Investments at Fair Value		$ 1,446	[39]			$ 1,784	[40]
Shares | shares		825,732	[39]	825,732	[39]	825,732	[40]	825,732	[40]
Investments Owned Acquisition Date		Mar. 11, 2019	[3],[39]	Mar. 11, 2019	[3],[39]	Mar. 11, 2019	[40]	Mar. 11, 2019	[40]
Investment, Identifier [Axis]: Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 1,687	[2]			$ 1,687	[6]
Investments at Fair Value		$ 867				$ 1,110
Shares | shares		217,880		217,880		217,880		217,880
Investments Owned Acquisition Date		Mar. 30, 2021	[3]	Mar. 30, 2021	[3]	Mar. 30, 2021	[40]	Mar. 30, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Information Services (0.34%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.34%		0.34%
Investment cost	[2]	$ 4,440
Investments at Fair Value		5,469
Investment, Identifier [Axis]: Equity Investments Information Services (0.58%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.58%		0.58%
Investment cost	[6]					$ 4,440
Investments at Fair Value						8,175
Investment, Identifier [Axis]: Equity Investments Information Services and Planet Labs, Inc., Equity, Acquisition Date 6/21/2019, Series Common Stock
Investment Holding [Line Items]
Investment cost		615	[2],[39]			615	[6],[40]
Investments at Fair Value		$ 1,764	[39]			$ 2,383	[40]
Shares | shares		547,880	[39]	547,880	[39]	547,880	[40]	547,880	[40]
Investments Owned Acquisition Date		Jun. 21, 2019	[3],[39]	Jun. 21, 2019	[3],[39]	Jun. 21, 2019	[40]	Jun. 21, 2019	[40]
Investment, Identifier [Axis]: Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 3,825	[2]			$ 3,825	[6]
Investments at Fair Value		$ 3,705				$ 3,375
Shares | shares		41,021		41,021		41,021		41,021
Investments Owned Acquisition Date		Dec. 30, 2021	[3],[39]	Dec. 30, 2021	[3],[39]	Dec. 30, 2021	[40]	Dec. 30, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Information Services and Zeta Global Corp., Equity, Acquisition Date 11/20/2007, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 0
Investments at Fair Value	[40]					$ 2,417
Shares | shares	[40]					295,861		295,861
Investments Owned Acquisition Date	[40]					Nov. 20, 2007		Nov. 20, 2007
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment (0.02%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.02%		0.02%
Investment cost	[2]	$ 2,953
Investments at Fair Value		369
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment (0.07%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.07%		0.07%
Investment cost	[6]					$ 2,953
Investments at Fair Value						915
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units
Investment Holding [Line Items]
Investment cost	[6],[34]					0
Investments at Fair Value		$ 5	[32]			$ 6	[34]
Shares | shares		180,000	[32]	180,000	[32]	180,000	[34]	180,000	[34]
Investments Owned Acquisition Date		Oct. 15, 2021	[3],[32]	Oct. 15, 2021	[3],[32]	Oct. 15, 2021	[34],[40]	Oct. 15, 2021	[34],[40]
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-2
Investment Holding [Line Items]
Investment cost	[2],[32]	$ 250
Investments at Fair Value	[32]	$ 292
Shares | shares	[32]	5,000,000		5,000,000
Investments Owned Acquisition Date	[3],[32]	Oct. 15, 2021		Oct. 15, 2021
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Flowonix Medical Incorporated, Equity, Acquisition Date 11/3/2014, Series Preferred Series AA
Investment Holding [Line Items]
Investment cost		$ 1,500	[2]			$ 1,499	[6]
Investments at Fair Value						$ 0
Shares | shares		221,893		221,893		221,893		221,893
Investments Owned Acquisition Date		Nov. 03, 2014	[3]	Nov. 03, 2014	[3]	Nov. 03, 2014	[40]	Nov. 03, 2014	[40]
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and Gelesis, Inc., Equity, Acquisition Date 11/30/2009, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 871	[2],[39]			$ 871	[6],[40]
Investments at Fair Value		$ 59	[39]			$ 433	[40]
Shares | shares		1,490,700	[39]	1,490,700	[39]	1,490,700	[40]	1,490,700	[40]
Investments Owned Acquisition Date		Nov. 30, 2009	[3]	Nov. 30, 2009	[3]	Nov. 30, 2009	[40]	Nov. 30, 2009	[40]
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment and ViewRay, Inc., Equity, Acquisition Date 12/16/2013, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 332	[2],[39]			$ 333	[6],[40]
Investments at Fair Value		$ 13	[39]			$ 163	[40]
Shares | shares		36,457	[39]	36,457	[39]	36,457	[40]	36,457	[40]
Investments Owned Acquisition Date		Dec. 16, 2013	[3]	Dec. 16, 2013	[3]	Dec. 16, 2013	[40]	Dec. 16, 2013	[40]
Investment, Identifier [Axis]: Equity Investments Medical Devices & Equipment, Coronado Aesthetics, LLC
Investment Holding [Line Items]
Investment cost		$ 250	[2]			$ 250	[6]
Investments at Fair Value		$ 297				$ 319
Shares | shares		5,180,000		5,180,000		5,180,000		5,180,000
Investment, Identifier [Axis]: Equity Investments Semiconductors (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.01%		0.01%
Investment cost	[6]					$ 160
Investments at Fair Value						205
Investment, Identifier [Axis]: Equity Investments Semiconductors (0.02%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.02%		0.02%
Investment cost	[2]	$ 160
Investments at Fair Value		368
Investment, Identifier [Axis]: Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C
Investment Holding [Line Items]
Investment cost		160	[2]			160	[6]
Investments at Fair Value		$ 368				$ 205
Shares | shares		277,995		277,995		277,995		277,995
Investments Owned Acquisition Date		Jul. 01, 2011	[3]	Jul. 01, 2011	[3]	Jul. 01, 2011	[40]	Jul. 01, 2011	[40]
Investment, Identifier [Axis]: Equity Investments Software (1.83%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	1.83%		1.83%
Investment cost	[2]	$ 25,711
Investments at Fair Value		28,941
Investment, Identifier [Axis]: Equity Investments Software (2.07%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.07%		2.07%
Investment cost	[6]					$ 32,498
Investments at Fair Value						28,966
Investment, Identifier [Axis]: Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock
Investment Holding [Line Items]
Investment cost		1,000	[2]			1,000	[6]
Investments at Fair Value		$ 965				$ 793
Shares | shares		1,000,000		1,000,000		1,000,000		1,000,000
Investments Owned Acquisition Date		Aug. 09, 2021	[3]	Aug. 09, 2021	[3]	Aug. 09, 2021	[40]	Aug. 09, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note
Investment Holding [Line Items]
Investment cost		$ 2,406	[2],[41]			$ 3,000	[6],[42]
Investments at Fair Value		$ 2,406	[41]			$ 3,000	[42]
Shares | shares		3	[41]	3	[41]	3	[42]	3	[42]
Investments Owned Acquisition Date		Mar. 24, 2021	[3],[41]	Mar. 24, 2021	[3],[41]	Mar. 24, 2021	[40],[42]	Mar. 24, 2021	[40],[42]
Investment, Identifier [Axis]: Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-3
Investment Holding [Line Items]
Investment cost		$ 51	[2]			$ 51	[6]
Investments at Fair Value		$ 0				$ 6
Shares | shares		53,614		53,614		53,614		53,614
Investments Owned Acquisition Date		Oct. 26, 2012	[3]	Oct. 26, 2012	[3]	Oct. 26, 2012	[40]	Oct. 26, 2012	[40]
Investment, Identifier [Axis]: Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 500	[2],[25],[26]			$ 500	[6],[27],[28]
Investments at Fair Value		$ 736	[25],[26]			$ 732	[27],[28]
Shares | shares		108,500	[25],[26]	108,500	[25],[26]	108,500	[27],[28]	108,500	[27],[28]
Investments Owned Acquisition Date		Nov. 20, 2018	[3],[25],[26]	Nov. 20, 2018	[3],[25],[26]	Nov. 20, 2018	[27],[28],[40]	Nov. 20, 2018	[27],[28],[40]
Investment, Identifier [Axis]: Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 138	[2],[25],[26]			$ 138	[6],[27],[28]
Investments at Fair Value		$ 263	[25],[26]			$ 258	[27],[28]
Shares | shares		41,000	[25],[26]	41,000	[25],[26]	41,000	[27],[28]	41,000	[27],[28]
Investments Owned Acquisition Date		Dec. 22, 2020	[3],[25],[26]	Dec. 22, 2020	[3],[25],[26]	Dec. 22, 2020	[27],[28],[40]	Dec. 22, 2020	[27],[28],[40]
Investment, Identifier [Axis]: Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 4,284	[2]			$ 4,284	[6]
Investments at Fair Value		$ 565				$ 503
Shares | shares		20,000		20,000		20,000		20,000
Investments Owned Acquisition Date		Nov. 29, 2018	[3]	Nov. 29, 2018	[3]	Nov. 29, 2018	[40]	Nov. 29, 2018	[40]
Investment, Identifier [Axis]: Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 2
Investment Holding [Line Items]
Investment cost		$ 1,000	[2]			$ 1,000	[6]
Investments at Fair Value		$ 1,706				$ 1,764
Shares | shares		458,841		458,841		458,841		458,841
Investments Owned Acquisition Date		Oct. 22, 2015	[3]	Oct. 22, 2015	[3]	Oct. 22, 2015	[40]	Oct. 22, 2015	[40]
Investment, Identifier [Axis]: Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 3
Investment Holding [Line Items]
Investment cost		$ 300	[2]			$ 300	[6]
Investments at Fair Value		$ 377				$ 395
Shares | shares		93,620		93,620		93,620		93,620
Investments Owned Acquisition Date		Aug. 24, 2017	[3]	Aug. 24, 2017	[3]	Aug. 24, 2017	[40]	Aug. 24, 2017	[40]
Investment, Identifier [Axis]: Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 307	[2]			$ 307	[6]
Investments at Fair Value						$ 0
Shares | shares		190		190		190		190
Investments Owned Acquisition Date		Jan. 18, 2013	[3]	Jan. 18, 2013	[3]	Jan. 18, 2013	[40]	Jan. 18, 2013	[40]
Investment, Identifier [Axis]: Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 265	[2]			$ 265	[6]
Investments at Fair Value		$ 18				$ 24
Shares | shares		38,461		38,461		38,461		38,461
Investments Owned Acquisition Date		Dec. 04, 2020	[3]	Dec. 04, 2020	[3]	Dec. 04, 2020	[40]	Dec. 04, 2020	[40]
Investment, Identifier [Axis]: Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 4,854	[2],[39]			$ 4,854	[6],[40]
Investments at Fair Value		$ 3,323	[39]			$ 2,100	[40]
Shares | shares		1,019,255	[39]	1,019,255	[39]	1,019,255	[40]	1,019,255	[40]
Investments Owned Acquisition Date		Aug. 01, 2018	[3],[39]	Aug. 01, 2018	[3],[39]	Aug. 01, 2018	[40]	Aug. 01, 2018	[40]
Investment, Identifier [Axis]: Equity Investments Software and Palantir Technologies, Equity, Acquisition Date 9/23/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 6,225	[2],[39]			$ 8,670	[6],[40]
Investments at Fair Value		$ 15,611	[39]			$ 9,106	[40]
Shares | shares		1,018,337	[39]	1,018,337	[39]	1,418,337	[40]	1,418,337	[40]
Investments Owned Acquisition Date		Sep. 23, 2020	[3],[39]	Sep. 23, 2020	[3],[39]	Sep. 23, 2020	[40]	Sep. 23, 2020	[40]
Investment, Identifier [Axis]: Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 2,000	[2]			$ 2,000	[6]
Investments at Fair Value		$ 1,922				$ 1,940
Shares | shares		580,983		580,983		580,983		580,983
Investments Owned Acquisition Date		Nov. 25, 2020	[3]	Nov. 25, 2020	[3]	Nov. 25, 2020	[40]	Nov. 25, 2020	[40]
Investment, Identifier [Axis]: Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F
Investment Holding [Line Items]
Investment cost		$ 280	[2]			$ 280	[6]
Investments at Fair Value		$ 211				$ 221
Shares | shares		52,956		52,956		52,956		52,956
Investments Owned Acquisition Date		Aug. 12, 2021	[3]	Aug. 12, 2021	[3]	Aug. 12, 2021	[40]	Aug. 12, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Software and Sprinklr, Inc., Equity, Acquisition Date 3/22/2017, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 3,748
Investments at Fair Value	[40]					$ 5,719
Shares | shares	[40]					700,000		700,000
Investments Owned Acquisition Date	[40]					Mar. 22, 2017		Mar. 22, 2017
Investment, Identifier [Axis]: Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 2,000	[2]			$ 2,000	[6]
Investments at Fair Value		$ 548				$ 1,023
Shares | shares		952,562		952,562		952,562		952,562
Investments Owned Acquisition Date		Jul. 08, 2021	[3]	Jul. 08, 2021	[3]	Jul. 08, 2021	[40]	Jul. 08, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Software and ZeroFox, Inc., Equity, Acquisition Date 5/7/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 101	[2],[39]			$ 101	[6],[40],[43]
Investments at Fair Value		$ 290	[39]			$ 1,382	[40],[43]
Shares | shares		289,992	[39]	289,992	[39]	289,992	[40],[43]	289,992	[40],[43]
Investments Owned Acquisition Date		May 07, 2020	[3],[39]	May 07, 2020	[3],[39]	May 07, 2020	[40],[43]	May 07, 2020	[40],[43]
Investment, Identifier [Axis]: Equity Investments Software, Contentful Global, Inc.
Investment Holding [Line Items]
Investment cost		$ 638	[2]			$ 638	[6]
Investments at Fair Value		$ 999				$ 990
Shares | shares		149,500		149,500		149,500		149,500
Investment, Identifier [Axis]: Equity Investments Software, Druva Holdings, Inc.
Investment Holding [Line Items]
Investment cost		$ 1,300	[2]			$ 1,300	[6]
Investments at Fair Value		$ 2,083				$ 2,159
Shares | shares		552,461		552,461		552,461		552,461
Investment, Identifier [Axis]: Equity Investments Software, SingleStore, Inc.
Investment Holding [Line Items]
Investment cost		$ 2,280	[2]			$ 2,280	[6]
Investments at Fair Value		$ 2,133				$ 2,161
Shares | shares		633,939		633,939		633,939		633,939
Investment, Identifier [Axis]: Equity Investments Surgical Devices (0.18%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.18%		0.18%
Investment cost	[6]					$ 2,479
Investments at Fair Value						2,546
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 1/18/2007, Series Preferred Series B
Investment Holding [Line Items]
Investment cost	[6]					250
Investments at Fair Value						$ 0
Shares | shares						219,298		219,298
Investments Owned Acquisition Date	[40]					Jan. 18, 2007		Jan. 18, 2007
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 12/18/2018, Series Preferred Series F
Investment Holding [Line Items]
Investment cost	[6]					$ 118
Investments at Fair Value						$ 0
Shares | shares						1,523,693		1,523,693
Investments Owned Acquisition Date	[40]					Dec. 18, 2018		Dec. 18, 2018
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 12/18/2018, Series Preferred Series F-1
Investment Holding [Line Items]
Investment cost	[6]					$ 150
Investments at Fair Value						$ 0
Shares | shares						2,418,125		2,418,125
Investments Owned Acquisition Date	[40]					Dec. 18, 2018		Dec. 18, 2018
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 2/8/2013, Series Preferred Series D
Investment Holding [Line Items]
Investment cost	[6]					$ 712
Investments at Fair Value						$ 0
Shares | shares						1,991,157		1,991,157
Investments Owned Acquisition Date	[40]					Feb. 08, 2013		Feb. 08, 2013
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 6/16/2010, Series Preferred Series C
Investment Holding [Line Items]
Investment cost	[6]					$ 282
Investments at Fair Value						$ 0
Shares | shares						656,538		656,538
Investments Owned Acquisition Date	[40]					Jun. 16, 2010		Jun. 16, 2010
Investment, Identifier [Axis]: Equity Investments Surgical Devices and Gynesonics, Inc., Equity, Acquisition Date 7/14/2015, Series Preferred Series E
Investment Holding [Line Items]
Investment cost	[6]					$ 429
Investments at Fair Value						$ 0
Shares | shares						2,786,367		2,786,367
Investments Owned Acquisition Date	[40]					Jul. 14, 2015		Jul. 14, 2015
Investment, Identifier [Axis]: Equity Investments Surgical Devices and TransMedics Group, Inc., Equity, Acquisition Date 11/7/2012, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 538
Investments at Fair Value	[40]					$ 2,546
Shares | shares	[40]					50,000		50,000
Investments Owned Acquisition Date	[40]					Nov. 07, 2012		Nov. 07, 2012
Investment, Identifier [Axis]: Equity Investments Surgical Devices, Gynesonics, Inc.
Investment Holding [Line Items]
Investment cost	[6]					$ 1,941
Investments at Fair Value						$ 0
Shares | shares						9,595,178		9,595,178
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology (0.33%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.33%		0.33%
Investment cost	[2]	$ 11,508
Investments at Fair Value		5,266
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology (0.57%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.57%		0.57%
Investment cost	[6]					$ 11,508
Investments at Fair Value						7,984
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Fulcrum Bioenergy, Inc., Equity, Acquisition Date 9/13/2012, Series Preferred Series C-1
Investment Holding [Line Items]
Investment cost		711	[2]			711	[6]
Investments at Fair Value		$ 1,024				$ 995
Shares | shares		187,265		187,265		187,265		187,265
Investments Owned Acquisition Date		Sep. 13, 2012	[3]	Sep. 13, 2012	[3]	Sep. 13, 2012	[40]	Sep. 13, 2012	[40]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-1
Investment Holding [Line Items]
Investment cost		$ 2,000	[2]			$ 2,000	[6]
Investments at Fair Value		$ 867				$ 2,173
Shares | shares		188,611		188,611		188,611		188,611
Investments Owned Acquisition Date		May 10, 2019	[3]	May 10, 2019	[3]	May 10, 2019	[40]	May 10, 2019	[40]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 500	[2]			$ 500	[6]
Investments at Fair Value						$ 0
Shares | shares		1,035		1,035		1,035		1,035
Investments Owned Acquisition Date		Jun. 01, 2015	[3]	Jun. 01, 2015	[3]	Jun. 01, 2015	[40]	Jun. 01, 2015	[40]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and NantEnergy, LLC, Equity, Acquisition Date 8/31/2013, Series Common Units
Investment Holding [Line Items]
Investment cost		$ 102	[2]			$ 102	[6]
Investments at Fair Value						$ 0
Shares | shares		59,665		59,665		59,665		59,665
Investments Owned Acquisition Date		Aug. 31, 2013	[3]	Aug. 31, 2013	[3]	Aug. 31, 2013	[40]	Aug. 31, 2013	[40]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Pineapple Energy LLC, Equity, Acquisition Date 12/10/2020, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 3,153	[2],[39]			$ 3,153	[6],[40],[43]
Investments at Fair Value		$ 417	[39]			$ 634	[40],[43]
Shares | shares		304,487	[39]	304,487	[39]	304,486	[40],[43]	304,486	[40],[43]
Investments Owned Acquisition Date		Dec. 10, 2020	[3],[39]	Dec. 10, 2020	[3],[39]	Dec. 10, 2020	[40],[43]	Dec. 10, 2020	[40],[43]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 4,500	[2]			$ 4,500	[6]
Investments at Fair Value		$ 2,409				$ 2,456
Shares | shares		593,080		593,080		593,080		593,080
Investments Owned Acquisition Date		Jun. 28, 2021	[3]	Jun. 28, 2021	[3]	Jun. 28, 2021	[40]	Jun. 28, 2021	[40]
Investment, Identifier [Axis]: Equity Investments Sustainable and Renewable Technology and Proterra, Inc., Equity, Acquisition Date 5/28/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost		$ 542	[2],[39]			$ 542	[6],[40]
Investments at Fair Value		$ 549	[39]			$ 1,726	[40]
Shares | shares		457,841	[39]	457,841	[39]	457,841	[40]	457,841	[40]
Investments Owned Acquisition Date		May 28, 2015	[3],[39]	May 28, 2015	[3],[39]	May 28, 2015	[40]	May 28, 2015	[40]
Investment, Identifier [Axis]: Equity Investments and Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 2,255
Investments at Fair Value	[40]					$ 1,763
Shares | shares	[40]					231,329		231,329
Investments Owned Acquisition Date	[40]					Jun. 21, 2018		Jun. 21, 2018
Investment, Identifier [Axis]: Equity Investments and Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock
Investment Holding [Line Items]
Investment cost	[2],[39]	$ 1,000
Investments at Fair Value	[39]	$ 12
Shares | shares	[39]	13,550		13,550
Investments Owned Acquisition Date	[3],[39]	Jan. 08, 2015		Jan. 08, 2015
Investment, Identifier [Axis]: Equity Investments and Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-2
Investment Holding [Line Items]
Investment cost	[6],[34]					$ 250
Investments at Fair Value	[34]					$ 313
Shares | shares	[34]					5,000,000		5,000,000
Investments Owned Acquisition Date	[34],[40]					Oct. 15, 2021		Oct. 15, 2021
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments (0.27%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.27%		0.27%
Investment cost	[2]	$ 4,135
Investments at Fair Value		$ 4,353
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments (0.28%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.28%		0.28%
Investment cost	[6]					$ 3,499
Investments at Fair Value						$ 3,893
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development (0.25%)
Investment Holding [Line Items]
Investment owned, percent of net assets		0.25%	[4]	0.25%	[4]	0.25%	[5]	0.25%	[5]
Investment cost		$ 3,754	[2]			$ 3,118	[6]
Investments at Fair Value		4,004				3,518
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/2020
Investment Holding [Line Items]
Investment cost		3,271	[2],[9],[25],[26]			2,699	[6],[10],[27],[28]
Investments at Fair Value		$ 3,239	[9],[25],[26]			$ 3,080	[10],[27],[28]
Investments Owned Acquisition Date		Nov. 16, 2020	[3],[9],[25],[26]	Nov. 16, 2020	[3],[9],[25],[26]	Nov. 16, 2020	[10],[27],[28],[40]	Nov. 16, 2020	[10],[27],[28],[40]
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/2022
Investment Holding [Line Items]
Investment cost		$ 483	[2],[9],[25],[26]			$ 419	[6],[10],[27],[28]
Investments at Fair Value		$ 765	[9],[25],[26]			$ 438	[10],[27],[28]
Investments Owned Acquisition Date		Jun. 23, 2022	[3],[9],[25],[26]	Jun. 23, 2022	[3],[9],[25],[26]	Jun. 23, 2022	[10],[27],[28],[40]	Jun. 23, 2022	[10],[27],[28],[40]
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Software (0.02%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.02%		0.02%
Investment cost	[2]	$ 381
Investments at Fair Value		349
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Software (0.03%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.03%		0.03%
Investment cost	[6]					$ 381
Investments at Fair Value						$ 375
Investment, Identifier [Axis]: Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/2022
Investment Holding [Line Items]
Investment cost	[2],[25],[26]	381
Investments at Fair Value	[25],[26]	$ 349
Investments Owned Acquisition Date	[3],[25],[26]	Jul. 21, 2022		Jul. 21, 2022
Investment, Identifier [Axis]: Investments (196.33%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	196.33%		196.33%
Investment cost	[2]	$ 3,114,097
Investments at Fair Value		$ 3,112,789
Investment, Identifier [Axis]: Investments (211.49%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					211.49%		211.49%
Investment cost	[6]					$ 3,005,696
Investments at Fair Value						$ 2,963,955
Investment, Identifier [Axis]: Investments in Securities (196.05%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	196.05%		196.05%
Investment cost	[2]	$ 3,109,962
Investments at Fair Value		$ 3,108,436
Investment, Identifier [Axis]: Investments in Securities (211.21%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					211.21%		211.21%
Investment cost	[6]					$ 3,002,197
Investments at Fair Value						$ 2,960,062
Investment, Identifier [Axis]: Warrant Investments (2.16%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	2.16%		2.16%
Investment cost	[2]	$ 32,085
Investments at Fair Value		$ 34,314
Investment, Identifier [Axis]: Warrant Investments (2.19%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					2.19%		2.19%
Investment cost	[6]					$ 30,964
Investments at Fair Value						$ 30,646
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools (0.03%)
Investment Holding [Line Items]
Investment owned, percent of net assets		0.03%	[4]	0.03%	[4]	0.03%	[5]	0.03%	[5]
Investment cost		$ 485	[2]			$ 485	[6]
Investments at Fair Value		441				486
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Preferred Series B
Investment Holding [Line Items]
Investment cost		24	[2]			24	[6]
Investments at Fair Value		$ 11				$ 23
Shares | shares		15,399		15,399		15,399		15,399
Investments Owned Acquisition Date		Jun. 21, 2022	[3]	Jun. 21, 2022	[3]	Jun. 21, 2022	[40]	Jun. 21, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 461	[2]			$ 461	[6]
Investments at Fair Value		$ 430				$ 463
Shares | shares		53,418		53,418		53,418		53,418
Investments Owned Acquisition Date		Dec. 23, 2022	[3]	Dec. 23, 2022	[3]	Dec. 23, 2022	[40]	Dec. 23, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets		0.01%	[4]	0.01%	[4]	0.01%	[5]	0.01%	[5]
Investment cost		$ 123	[2]			$ 541	[6]
Investments at Fair Value		124				99
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Common Stock
Investment Holding [Line Items]
Investment cost		123	[2]			123	[6]
Investments at Fair Value		$ 124				$ 99
Shares | shares		229,611		229,611		229,611		229,611
Investments Owned Acquisition Date		Jun. 28, 2022	[3]	Jun. 28, 2022	[3]	Jun. 28, 2022	[40]	Jun. 28, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Communications & Networking and Spring Mobile Solutions, Inc., Warrant, Acquisition Date 4/19/2013, Common Stock
Investment Holding [Line Items]
Investment cost	[6]					$ 418
Investments at Fair Value						$ 0
Shares | shares						2,834,375		2,834,375
Investments Owned Acquisition Date	[40]					Apr. 19, 2013		Apr. 19, 2013
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products (0.06%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.06%		0.06%
Investment cost	[2]	$ 1,712
Investments at Fair Value		969
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products (0.17%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.17%		0.17%
Investment cost	[6]					$ 1,712
Investments at Fair Value						2,323
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 228	[2]			228	[6]
Investments at Fair Value						$ 0
Shares | shares		1,662,441		1,662,441		1,662,441		1,662,441
Investments Owned Acquisition Date		Jun. 03, 2014	[3]	Jun. 03, 2014	[3]	Jun. 03, 2014	[40]	Jun. 03, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and Savage X Holding, LLC, Warrant, Acquisition Date 6/27/2014, Class A Units
Investment Holding [Line Items]
Investment cost	[6]					$ 0
Investments at Fair Value		$ 60				$ 1,103
Shares | shares		206,185		206,185		206,185		206,185
Investments Owned Acquisition Date		Jun. 27, 2014	[3]	Jun. 27, 2014	[3]	Jun. 27, 2014	[40]	Jun. 27, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and TFG Holding, Inc., Warrant, Acquisition Date 6/27/2014, Common Stock
Investment Holding [Line Items]
Investment cost	[6]					$ 0
Investments at Fair Value						$ 0
Shares | shares		206,185		206,185		206,185		206,185
Investments Owned Acquisition Date		Jun. 27, 2014	[3]	Jun. 27, 2014	[3]	Jun. 27, 2014	[40]	Jun. 27, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and TechStyle, Inc., Warrant, Acquisition Date 7/16/2013, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 1,101	[2]			$ 1,101	[6]
Investments at Fair Value		$ 513				$ 745
Shares | shares		206,185		206,185		206,185		206,185
Investments Owned Acquisition Date		Jul. 16, 2013	[3]	Jul. 16, 2013	[3]	Jul. 16, 2013	[40]	Jul. 16, 2013	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and The Neat Company, Warrant, Acquisition Date 8/13/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 365	[2]			$ 365	[6]
Investments at Fair Value						$ 0
Shares | shares		54,054		54,054		54,054		54,054
Investments Owned Acquisition Date		Aug. 13, 2014	[3]	Aug. 13, 2014	[3]	Aug. 13, 2014	[40]	Aug. 13, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 18	[2]			$ 18	[6]
Investments at Fair Value		$ 396				$ 475
Shares | shares		686,270		686,270		686,270		686,270
Investments Owned Acquisition Date		Jun. 27, 2018	[3]	Jun. 27, 2018	[3]	Jun. 27, 2018	[40]	Jun. 27, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services (0.19%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.19%		0.19%
Investment cost	[6]					$ 4,248
Investments at Fair Value						2,639
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services (0.20%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.20%		0.20%
Investment cost	[2]	$ 4,175
Investments at Fair Value		3,197
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Common Stock
Investment Holding [Line Items]
Investment cost		164	[2],[25],[26]			164	[6],[27],[28]
Investments at Fair Value		$ 53	[25],[26]			$ 34	[27],[28]
Shares | shares		174,163	[25],[26]	174,163	[25],[26]	174,163	[27],[28]	174,163	[27],[28]
Investments Owned Acquisition Date		Dec. 14, 2021	[3],[25],[26]	Dec. 14, 2021	[3],[25],[26]	Dec. 14, 2021	[27],[28],[40]	Dec. 14, 2021	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 20	[2]			$ 20	[6]
Investments at Fair Value						$ 0
Shares | shares		529,661		529,661		529,661		529,661
Investments Owned Acquisition Date		Oct. 29, 2019	[3]	Oct. 29, 2019	[3]	Oct. 29, 2019	[40]	Oct. 29, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 116	[1],[2]			$ 116	[6],[31]
Investments at Fair Value		$ 147	[1]			$ 127	[31]
Shares | shares		11,806	[1]	11,806	[1]	11,806	[31]	11,806	[31]
Investments Owned Acquisition Date		Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[31],[40]	Mar. 12, 2021	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 39	[2]			$ 39	[6]
Investments at Fair Value		$ 40				$ 19
Shares | shares		127,032		127,032		127,032		127,032
Investments Owned Acquisition Date		Mar. 29, 2019	[3]	Mar. 29, 2019	[3]	Mar. 29, 2019	[40]	Mar. 29, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 166	[1],[2]			$ 166	[6],[31]
Investments at Fair Value		$ 143	[1]			$ 155	[31]
Shares | shares		117,042	[1]	117,042	[1]	117,042	[31]	117,042	[31]
Investments Owned Acquisition Date		Dec. 22, 2022	[1],[3]	Dec. 22, 2022	[1],[3]	Dec. 22, 2022	[31],[40]	Dec. 22, 2022	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 470	[1],[2]			$ 470	[6],[31]
Investments at Fair Value		$ 143	[1]			$ 308	[31]
Shares | shares		13,106	[1]	13,106	[1]	13,106	[31]	13,106	[31]
Investments Owned Acquisition Date		Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[1],[3]	Mar. 12, 2021	[31],[40]	Mar. 12, 2021	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and RumbleON, Inc., Warrant, Acquisition Date 10/30/2018, Common Stock
Investment Holding [Line Items]
Investment cost	[2],[39]	$ 15
Shares | shares	[39]	1,048		1,048
Investments Owned Acquisition Date	[3],[39]	Oct. 30, 2018		Oct. 30, 2018
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and RumbleON, Inc., Warrant, Acquisition Date 4/30/2018, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 88
Investments at Fair Value	[40]					$ 0
Shares | shares	[40]					5,139		5,139
Investments Owned Acquisition Date	[40]					Apr. 30, 2018		Apr. 30, 2018
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 842	[2],[20],[21]			$ 842	[6],[23],[24]
Investments at Fair Value		$ 2,122	[20],[21]			$ 1,332	[23],[24]
Shares | shares		1,379,761	[20],[21]	1,379,761	[20],[21]	1,379,761	[23],[24]	1,379,761	[23],[24]
Investments Owned Acquisition Date		Jun. 12, 2019	[3],[20],[21]	Jun. 12, 2019	[3],[20],[21]	Jun. 12, 2019	[23],[24],[40]	Jun. 12, 2019	[23],[24],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Skyword, Inc.
Investment Holding [Line Items]
Investment cost		$ 140	[2]			$ 140	[6]
Investments at Fair Value		$ 30				$ 43
Shares | shares		2,051,587		2,051,587		2,051,587		2,051,587
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 57	[2]			$ 57	[6]
Investments at Fair Value		$ 27				$ 43
Shares | shares		1,607,143		1,607,143		1,607,143		1,607,143
Investments Owned Acquisition Date		Nov. 14, 2022	[3]	Nov. 14, 2022	[3]	Nov. 14, 2022	[40]	Nov. 14, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 83	[2]			$ 83	[6]
Investments at Fair Value		$ 3				$ 0
Shares | shares		444,444		444,444		444,444		444,444
Investments Owned Acquisition Date		Aug. 23, 2019	[3]	Aug. 23, 2019	[3]	Aug. 23, 2019	[40]	Aug. 23, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc.
Investment Holding [Line Items]
Investment cost		$ 860	[2]			$ 860	[6]
Investments at Fair Value		$ 45				$ 118
Shares | shares		3,611,537		3,611,537		3,611,537		3,611,537
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 16	[2]			$ 16	[6]
Investments at Fair Value		$ 15				$ 43
Shares | shares		600,000		600,000		600,000		600,000
Investments Owned Acquisition Date		Apr. 20, 2020	[3]	Apr. 20, 2020	[3]	Apr. 20, 2020	[40]	Apr. 20, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Preferred Series A
Investment Holding [Line Items]
Investment cost		$ 782	[2]			$ 782	[6]
Investments at Fair Value		$ 20				$ 50
Shares | shares		1,800,000		1,800,000		1,800,000		1,800,000
Investments Owned Acquisition Date		Jun. 30, 2016	[3]	Jun. 30, 2016	[3]	Jun. 30, 2016	[40]	Jun. 30, 2016	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 62	[2]			$ 62	[6]
Investments at Fair Value		$ 10				$ 25
Shares | shares		1,211,537		1,211,537		1,211,537		1,211,537
Investments Owned Acquisition Date		Aug. 01, 2018	[3]	Aug. 01, 2018	[3]	Aug. 01, 2018	[40]	Aug. 01, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Common Stock
Investment Holding [Line Items]
Investment cost		$ 844	[2],[20]			$ 844	[6],[23]
Investments at Fair Value		$ 401	[20]			$ 280	[23]
Shares | shares		267,225	[20]	267,225	[20]	267,225	[23]	267,225	[23]
Investments Owned Acquisition Date		May 01, 2018	[3],[20]	May 01, 2018	[3],[20]	May 01, 2018	[23],[40]	May 01, 2018	[23],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Udacity, Inc., Warrant, Acquisition Date 9/25/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 218	[2],[20]			$ 218	[6],[23]
Investments at Fair Value	[23]					$ 4
Shares | shares		486,359	[20]	486,359	[20]	486,359	[23]	486,359	[23]
Investments Owned Acquisition Date		Sep. 25, 2020	[3],[20]	Sep. 25, 2020	[3],[20]	Sep. 25, 2020	[23],[40]	Sep. 25, 2020	[23],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 126	[2]			$ 126	[6]
Investments at Fair Value		$ 21				$ 25
Shares | shares		98,428		98,428		98,428		98,428
Investments Owned Acquisition Date		Mar. 31, 2022	[3]	Mar. 31, 2022	[3]	Mar. 31, 2022	[40]	Mar. 31, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Worldremit Group Limited
Investment Holding [Line Items]
Investment cost		$ 155	[2]			$ 155	[6]
Investments at Fair Value		$ 52				$ 194
Shares | shares		79,083		79,083		79,083		79,083
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 129	[2],[20],[21],[25],[26]			$ 129	[6],[23],[24],[27],[28]
Investments at Fair Value		$ 52	[20],[21],[25],[26]			$ 192	[23],[24],[27],[28]
Shares | shares		77,215	[20],[21],[25],[26]	77,215	[20],[21],[25],[26]	77,215	[23],[24],[27],[28]	77,215	[23],[24],[27],[28]
Investments Owned Acquisition Date		Feb. 11, 2021	[3],[20],[21],[25],[26]	Feb. 11, 2021	[3],[20],[21],[25],[26]	Feb. 11, 2021	[23],[24],[27],[28],[40]	Feb. 11, 2021	[23],[24],[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 26	[2],[21],[25],[26]			$ 26	[6],[24],[27],[28]
Investments at Fair Value	[24],[27],[28]					$ 2
Shares | shares		1,868	[21],[25],[26]	1,868	[21],[25],[26]	1,868	[24],[27],[28]	1,868	[24],[27],[28]
Investments Owned Acquisition Date		Aug. 27, 2021	[3],[21],[25],[26]	Aug. 27, 2021	[3],[21],[25],[26]	Aug. 27, 2021	[24],[27],[28],[40]	Aug. 27, 2021	[24],[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Diversified Financial Services (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	(0.01%)		(0.01%)
Investment cost	[2]	$ 214
Investments at Fair Value		167
Investment, Identifier [Axis]: Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[2]	214
Investments at Fair Value		$ 167
Shares | shares		522,930		522,930
Investments Owned Acquisition Date	[3]	Feb. 03, 2023		Feb. 03, 2023
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery (0.00%)
Investment Holding [Line Items]
Investment owned, percent of net assets		0%	[4]	0%	[4]	0%	[5]	0%	[5]
Investment cost		$ 465	[2]			$ 465	[6]
Investments at Fair Value		0				1
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and Aerami Therapeutics Holdings, Inc., Warrant, Acquisition Date 9/30/2015, Common Stock
Investment Holding [Line Items]
Investment cost		74	[2]			74	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		110,882		110,882		110,882		110,882
Investments Owned Acquisition Date		Sep. 30, 2015	[3]	Sep. 30, 2015	[3]	Sep. 30, 2015	[40]	Sep. 30, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and BioQ Pharma Incorporated, Warrant, Acquisition Date 10/27/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 1	[2]			$ 1	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		459,183		459,183		459,183		459,183
Investments Owned Acquisition Date		Oct. 27, 2014	[3]	Oct. 27, 2014	[3]	Oct. 27, 2014	[40]	Oct. 27, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Delivery and PDS Biotechnology Corporation, Warrant, Acquisition Date 8/28/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 390	[2],[39]			$ 390	[6],[40]
Investments at Fair Value		$ 0	[39]			$ 1	[40]
Shares | shares		3,929	[39]	3,929	[39]	3,929	[40]	3,929	[40]
Investments Owned Acquisition Date		Aug. 28, 2014	[3],[39]	Aug. 28, 2014	[3],[39]	Aug. 28, 2014	[40]	Aug. 28, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development (0.60%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.60%		0.60%
Investment cost	[6]					$ 7,466
Investments at Fair Value						8,444
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development (0.68%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.68%		0.68%
Investment cost	[2]	$ 7,710
Investments at Fair Value		10,797
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and ADMA Biologics, Inc., Warrant, Acquisition Date 2/24/2014, Common Stock
Investment Holding [Line Items]
Investment cost		166	[2],[39]			166	[6],[40]
Investments at Fair Value		$ 7	[39]			$ 10	[40]
Shares | shares		58,000	[39]	58,000	[39]	58,000	[40]	58,000	[40]
Investments Owned Acquisition Date		Feb. 24, 2014	[3],[39]	Feb. 24, 2014	[3],[39]	Feb. 24, 2014	[40]	Feb. 24, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Acacia Pharma Inc., Warrant, Acquisition Date 6/29/2018, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[28]					$ 304
Investments at Fair Value	[27],[28]					$ 0
Shares | shares	[27],[28]					201,330		201,330
Investments Owned Acquisition Date	[27],[28],[40]					Jun. 29, 2018		Jun. 29, 2018
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 175	[2],[25],[39]			$ 56	[6],[27],[40]
Investments at Fair Value		$ 702	[25],[39]			$ 674	[27],[40]
Shares | shares		22,949	[25],[39]	22,949	[25],[39]	18,360	[27],[40]	18,360	[27],[40]
Investments Owned Acquisition Date		Jun. 15, 2022	[3],[25],[39]	Jun. 15, 2022	[3],[25],[39]	Jun. 15, 2022	[27],[40]	Jun. 15, 2022	[27],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Albireo Pharma, Inc., Warrant, Acquisition Date 6/8/2020, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[40]					$ 61
Investments at Fair Value	[27],[40]					$ 31
Shares | shares	[27],[40]					5,311		5,311
Investments Owned Acquisition Date	[27],[40]					Jun. 08, 2020		Jun. 08, 2020
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Class A Units
Investment Holding [Line Items]
Investment cost	[6],[31]					$ 238
Investments at Fair Value	[31]					$ 256
Shares | shares	[31]					69,239		69,239
Investments Owned Acquisition Date	[31],[40]					Dec. 27, 2022		Dec. 27, 2022
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,289	[2],[20],[21],[25],[39]			$ 880	[6],[23],[24],[27],[40]
Investments at Fair Value		$ 1,707	[20],[21],[25],[39]			$ 1,590	[23],[24],[27],[40]
Shares | shares		61,004	[20],[21],[25],[39]	61,004	[20],[21],[25],[39]	40,396	[23],[24],[27],[40]	40,396	[23],[24],[27],[40]
Investments Owned Acquisition Date		Sep. 25, 2020	[3],[20],[21],[25]	Sep. 25, 2020	[3],[20],[21],[25]	Sep. 25, 2020	[23],[24],[27],[40]	Sep. 25, 2020	[23],[24],[27],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Ordinary Shares
Investment Holding [Line Items]
Investment cost	[2],[25],[26],[39]	$ 278
Investments at Fair Value	[25],[26],[39]	$ 278
Shares | shares	[25],[26],[39]	75,376		75,376
Investments Owned Acquisition Date	[3],[25],[26],[39]	Jun. 30, 2023		Jun. 30, 2023
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 287	[1],[2]			$ 287	[6],[31]
Investments at Fair Value		$ 226	[1]			$ 318	[31]
Shares | shares		100,000	[1]	100,000	[1]	100,000	[31]	100,000	[31]
Investments Owned Acquisition Date		Dec. 08, 2021	[1],[3]	Dec. 08, 2021	[1],[3]	Dec. 08, 2021	[31],[40]	Dec. 08, 2021	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 37	[2],[39]			$ 37	[6],[40]
Investments at Fair Value	[40]					$ 3
Shares | shares		16,112	[39]	16,112	[39]	16,112	[40]	16,112	[40]
Investments Owned Acquisition Date		Sep. 14, 2020	[3],[39]	Sep. 14, 2020	[3],[39]	Sep. 14, 2020	[40]	Sep. 14, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[1],[2]	$ 233
Investments at Fair Value	[1]	$ 219
Shares | shares	[1]	95,221		95,221
Investments Owned Acquisition Date	[1],[3]	Jun. 09, 2023		Jun. 09, 2023
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Dermavant Sciences Ltd., Warrant, Acquisition Date 5/31/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 101	[2],[25],[26]			$ 101	[6],[27],[28]
Investments at Fair Value		$ 94	[25],[26]			$ 199	[27],[28]
Shares | shares		223,642	[25],[26]	223,642	[25],[26]	223,642	[27],[28]	223,642	[27],[28]
Investments Owned Acquisition Date		May 31, 2019	[3],[25],[26]	May 31, 2019	[3],[25],[26]	May 31, 2019	[27],[28],[40]	May 31, 2019	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Evofem Biosciences, Inc., Warrant, Acquisition Date 6/11/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 266	[2],[39]			$ 266	[6],[40]
Investments at Fair Value	[40]					$ 0
Shares | shares		3	[39]	3	[39]	520	[40]	520	[40]
Investments Owned Acquisition Date		Jun. 11, 2014	[3],[39]	Jun. 11, 2014	[3],[39]	Jun. 11, 2014	[40]	Jun. 11, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.), Warrant, Acquisition Date 2/18/2016, Common Stock
Investment Holding [Line Items]
Investment cost		$ 119	[2],[39]			$ 119	[6],[40]
Investments at Fair Value	[40]					$ 0
Shares | shares		201	[39]	201	[39]	200	[40]	200	[40]
Investments Owned Acquisition Date		Feb. 18, 2016	[3],[39]	Feb. 18, 2016	[3],[39]	Feb. 18, 2016	[40]	Feb. 18, 2016	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 110	[2],[39]			$ 110	[6],[40]
Investments at Fair Value	[40]					$ 0
Shares | shares		2,202	[39]	2,202	[39]	2,202	[40]	2,202	[40]
Investments Owned Acquisition Date		Dec. 20, 2019	[3],[39]	Dec. 20, 2019	[3],[39]	Dec. 20, 2019	[40]	Dec. 20, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 88	[1],[2],[25],[39]			$ 88	[6],[27],[31],[40]
Investments at Fair Value		$ 41	[1],[25],[39]			$ 59	[27],[31],[40]
Shares | shares		14,342	[1],[25],[39]	14,342	[1],[25],[39]	14,342	[27],[31],[40]	14,342	[27],[31],[40]
Investments Owned Acquisition Date		Nov. 02, 2022	[1],[3],[25],[39]	Nov. 02, 2022	[1],[3],[25],[39]	Nov. 02, 2022	[27],[31],[40]	Nov. 02, 2022	[27],[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 517	[2],[25],[39]			$ 177	[6],[27],[40]
Investments at Fair Value		$ 1,806	[25],[39]			$ 1,977	[27],[40]
Shares | shares		12,514	[25],[39]	12,514	[25],[39]	10,131	[27],[40]	10,131	[27],[40]
Investments Owned Acquisition Date		May 09, 2022	[3],[25],[39]	May 09, 2022	[3],[25],[39]	May 09, 2022	[27],[40]	May 09, 2022	[27],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Myovant Sciences, Ltd., Warrant, Acquisition Date 10/16/2017, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[27],[28],[40]					$ 460
Investments at Fair Value	[27],[28],[40]					$ 958
Shares | shares	[27],[28],[40]					73,710		73,710
Investments Owned Acquisition Date	[27],[28],[40]					Oct. 16, 2017		Oct. 16, 2017
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Paratek Pharmaceuticals, Inc., Warrant, Acquisition Date 8/1/2018, Common Stock
Investment Holding [Line Items]
Investment cost		$ 520	[2],[39]			$ 520	[6],[40]
Investments at Fair Value		$ 86	[39]			$ 34	[40]
Shares | shares		426,866	[39]	426,866	[39]	426,866	[40]	426,866	[40]
Investments Owned Acquisition Date		Aug. 01, 2018	[3],[39]	Aug. 01, 2018	[3],[39]	Aug. 01, 2018	[40]	Aug. 01, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 848	[1],[2],[20],[21],[25],[39]			$ 848	[6],[23],[24],[27],[31],[40]
Investments at Fair Value		$ 216	[1],[20],[21],[25],[39]			$ 101	[23],[24],[27],[31],[40]
Shares | shares		64,687	[1],[20],[21],[25],[39]	64,687	[1],[20],[21],[25],[39]	64,687	[23],[24],[27],[31],[40]	64,687	[23],[24],[27],[31],[40]
Investments Owned Acquisition Date		Sep. 17, 2021	[1],[3],[20],[21],[25],[39]	Sep. 17, 2021	[1],[3],[20],[21],[25],[39]	Sep. 17, 2021	[23],[24],[27],[31],[40]	Sep. 17, 2021	[23],[24],[27],[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Provention Bio, Inc., Warrant, Acquisition Date 9/15/2022, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 281
Investments at Fair Value	[40]					$ 677
Shares | shares	[40]					111,934		111,934
Investments Owned Acquisition Date	[40]					Sep. 15, 2022		Sep. 15, 2022
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Preferred Series E
Investment Holding [Line Items]
Investment cost		$ 20	[1],[2]			$ 20	[6],[31]
Investments at Fair Value		$ 9	[1]			$ 21	[31]
Shares | shares		475,510	[1]	475,510	[1]	475,510	[31]	475,510	[31]
Investments Owned Acquisition Date		Mar. 23, 2022	[1],[3],[39]	Mar. 23, 2022	[1],[3],[39]	Mar. 23, 2022	[31],[40]	Mar. 23, 2022	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 296	[2],[20],[39]			$ 296	[6],[23],[40]
Investments at Fair Value		$ 65	[20],[39]			$ 15	[23],[40]
Shares | shares		106,035	[20],[39]	106,035	[20],[39]	106,035	[23],[40]	106,035	[23],[40]
Investments Owned Acquisition Date		May 14, 2021	[3],[20],[39]	May 14, 2021	[3],[20],[39]	May 14, 2021	[23],[40]	May 14, 2021	[23],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 2/28/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,284	[2],[20],[25],[39]			$ 1,033	[6],[23],[27],[40]
Investments at Fair Value		$ 4,046	[20],[25],[39]			$ 1,084	[23],[27],[40]
Shares | shares		264,226	[20],[25],[39]	264,226	[20],[25],[39]	231,613	[23],[27],[40]	231,613	[23],[27],[40]
Investments Owned Acquisition Date		Feb. 28, 2019	[3],[20],[25],[39]	Feb. 28, 2019	[3],[20],[25],[39]	Feb. 28, 2019	[23],[27],[40]	Feb. 28, 2019	[23],[27],[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Tricida, Inc., Warrant, Acquisition Date 3/27/2019, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 280
Investments at Fair Value	[40]					$ 1
Shares | shares	[40]					31,352		31,352
Investments Owned Acquisition Date	[40]					Mar. 27, 2019		Mar. 27, 2019
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Common Units
Investment Holding [Line Items]
Investment cost		$ 256	[2]			$ 256	[6]
Investments at Fair Value		$ 142				$ 127
Shares | shares		102,216		102,216		102,216		102,216
Investments Owned Acquisition Date		Jun. 15, 2020	[3]	Jun. 15, 2020	[3]	Jun. 15, 2020	[40]	Jun. 15, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 12/9/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 510	[2],[39]			$ 510	[6],[40]
Investments at Fair Value		$ 931	[39]			$ 281	[40]
Shares | shares		1,392,787	[39]	1,392,787	[39]	1,392,787	[40]	1,392,787	[40]
Investments Owned Acquisition Date		Dec. 09, 2022	[3],[39]	Dec. 09, 2022	[3],[39]	Dec. 09, 2022	[40]	Dec. 09, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/30/2021, Preferred Series 3
Investment Holding [Line Items]
Investment cost		$ 72	[2],[20],[25],[26]			$ 72	[6],[23],[27],[28]
Investments at Fair Value	[23],[27],[28]					$ 28
Shares | shares		133,692	[20],[25],[26]	133,692	[20],[25],[26]	133,692	[23],[27],[28]	133,692	[23],[27],[28]
Investments Owned Acquisition Date		Dec. 30, 2021	[3],[20],[25],[26]	Dec. 30, 2021	[3],[20],[25],[26]	Dec. 30, 2021	[23],[27],[28],[40]	Dec. 30, 2021	[23],[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.04%		0.04%
Investment cost	[2]	$ 692
Investments at Fair Value		662
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware (0.09%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.09%		0.09%
Investment cost	[6]					$ 692
Investments at Fair Value						1,273
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Common Stock
Investment Holding [Line Items]
Investment cost		101	[2],[39]			101	[6],[40]
Investments at Fair Value		$ 60	[39]			$ 86	[40]
Shares | shares		49,078	[39]	49,078	[39]	49,078	[40]	49,078	[40]
Investments Owned Acquisition Date		Mar. 15, 2017	[3],[39]	Mar. 15, 2017	[3],[39]	Mar. 15, 2017	[40]	Mar. 15, 2017	[40]
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 34	[2]			$ 34	[6]
Investments at Fair Value		$ 152				$ 212
Shares | shares		8,503		8,503		8,511		8,511
Investments Owned Acquisition Date		Jun. 21, 2022	[3]	Jun. 21, 2022	[3]	Jun. 21, 2022	[40]	Jun. 21, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 557	[2]			$ 557	[6]
Investments at Fair Value		$ 450				$ 975
Shares | shares		622,255		622,255		622,255		622,255
Investments Owned Acquisition Date		Nov. 08, 2021	[3]	Nov. 08, 2021	[3]	Nov. 08, 2021	[40]	Nov. 08, 2021	[40]
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other (0.00%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0%		0%
Investment cost	[6]					$ 114
Investments at Fair Value						14
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.01%		0.01%
Investment cost	[2]	$ 284
Investments at Fair Value		175
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[2]	164
Investments at Fair Value		$ 171
Shares | shares		37,618		37,618
Investments Owned Acquisition Date	[3]	Mar. 30, 2023		Mar. 30, 2023
Investment, Identifier [Axis]: Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 120	[2]			114	[6]
Investments at Fair Value		$ 4				$ 14
Shares | shares		150,926		150,926		100,618		100,618
Investments Owned Acquisition Date		Mar. 28, 2022	[3]	Mar. 28, 2022	[3]	Mar. 28, 2022	[40]	Mar. 28, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Information Services (0.03%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.03%		0.03%
Investment cost	[2]	$ 680
Investments at Fair Value		466
Investment, Identifier [Axis]: Warrant Investments and Information Services (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.04%		0.04%
Investment cost	[6]					$ 680
Investments at Fair Value						509
Investment, Identifier [Axis]: Warrant Investments and Information Services and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Common Stock
Investment Holding [Line Items]
Investment cost		207	[1],[2]			207	[6],[31]
Investments at Fair Value		$ 90	[1]			$ 114	[31]
Shares | shares		176,200	[1]	176,200	[1]	176,200	[31]	176,200	[31]
Investments Owned Acquisition Date		Oct. 21, 2021	[1],[3]	Oct. 21, 2021	[1],[3]	Oct. 21, 2021	[31],[40]	Oct. 21, 2021	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Information Services and INMOBI Inc., Warrant, Acquisition Date 11/19/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 82	[2],[25],[26]			$ 82	[6],[27],[28]
Investments at Fair Value		$ 0	[25],[26]			$ 0	[27],[28]
Shares | shares		65,587	[25],[26]	65,587	[25],[26]	65,587	[27],[28]	65,587	[27],[28]
Investments Owned Acquisition Date		Nov. 19, 2014	[3],[25],[26]	Nov. 19, 2014	[3],[25],[26]	Nov. 19, 2014	[27],[28],[40]	Nov. 19, 2014	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Information Services and NetBase Solutions, Inc., Warrant, Acquisition Date 8/22/2017, Preferred Series 1
Investment Holding [Line Items]
Investment cost		$ 356	[2]			$ 356	[6]
Investments at Fair Value		$ 357				$ 380
Shares | shares		60,000		60,000		60,000		60,000
Investments Owned Acquisition Date		Aug. 22, 2017	[3]	Aug. 22, 2017	[3]	Aug. 22, 2017	[40]	Aug. 22, 2017	[40]
Investment, Identifier [Axis]: Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 35	[2],[25],[26]			$ 35	[6],[27],[28]
Investments at Fair Value		$ 19	[25],[26]			$ 15	[27],[28]
Shares | shares		94,857	[25],[26]	94,857	[25],[26]	94,857	[27],[28]	94,857	[27],[28]
Investments Owned Acquisition Date		Jun. 29, 2022	[3],[25],[26]	Jun. 29, 2022	[3],[25],[26]	Jun. 29, 2022	[27],[28],[40]	Jun. 29, 2022	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology (0.19%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.19%		0.19%
Investment cost	[2]	$ 1,112
Investments at Fair Value		3,047
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology (0.30%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.30%		0.30%
Investment cost	[6]					$ 1,112
Investments at Fair Value						4,156
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Common Stock
Investment Holding [Line Items]
Investment cost		537	[2]			537	[6]
Investments at Fair Value		$ 726				$ 1,154
Shares | shares		392,308		392,308		392,308		392,308
Investments Owned Acquisition Date		Mar. 31, 2022	[3]	Mar. 31, 2022	[3]	Mar. 31, 2022	[40]	Mar. 31, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 528	[2]			$ 528	[6]
Investments at Fair Value		$ 1,242				$ 1,202
Shares | shares		1,111,111		1,111,111		1,111,111		1,111,111
Investments Owned Acquisition Date		Mar. 23, 2022	[3]	Mar. 23, 2022	[3]	Mar. 23, 2022	[40]	Mar. 23, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Manufacturing Technology and Xometry, Inc., Warrant, Acquisition Date 5/9/2018, Common Stock
Investment Holding [Line Items]
Investment cost		$ 47	[2],[39]			$ 47	[6],[40]
Investments at Fair Value		$ 1,079	[39]			$ 1,800	[40]
Shares | shares		87,784	[39]	87,784	[39]	87,784	[40]	87,784	[40]
Investments Owned Acquisition Date		May 09, 2018	[3],[39]	May 09, 2018	[3],[39]	May 09, 2018	[40]	May 09, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Media/Content/Info (0.00%)
Investment Holding [Line Items]
Investment owned, percent of net assets		0%	[4]	0%	[4]	0%	[5]	0%	[5]
Investment cost		$ 56	[2]			$ 35	[6]
Investments at Fair Value		45				35
Investment, Identifier [Axis]: Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Preferred Series E-1
Investment Holding [Line Items]
Investment cost		56	[2]			35	[6]
Investments at Fair Value		$ 45				$ 35
Shares | shares		350,902		350,902		221,622		221,622
Investments Owned Acquisition Date		Dec. 30, 2022	[3]	Dec. 30, 2022	[3]	Dec. 30, 2022	[40]	Dec. 30, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.04%		0.04%
Investment cost	[2]	$ 1,925
Investments at Fair Value		683
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment (0.07%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.07%		0.07%
Investment cost	[6]					$ 2,034
Investments at Fair Value						919
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Aspire Bariatrics, Inc., Warrant, Acquisition Date 1/28/2015, Common Stock
Investment Holding [Line Items]
Investment cost		455	[2]			455	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		22,572		22,572		22,572		22,572
Investments Owned Acquisition Date		Jan. 28, 2015	[3]	Jan. 28, 2015	[3]	Jan. 28, 2015	[40]	Jan. 28, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Flowonix Medical Incorporated
Investment Holding [Line Items]
Investment cost		$ 714	[2]			$ 713	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		836,752		836,752		836,752		836,752
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Flowonix Medical Incorporated, Warrant, Acquisition Date 11/3/2014, Preferred Series AA
Investment Holding [Line Items]
Investment cost		$ 362	[2]			$ 362	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		110,946		110,946		110,946		110,946
Investments Owned Acquisition Date		Nov. 03, 2014	[3]	Nov. 03, 2014	[3]	Nov. 03, 2014	[40]	Nov. 03, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Flowonix Medical Incorporated, Warrant, Acquisition Date 9/21/2018, Preferred Series BB
Investment Holding [Line Items]
Investment cost		$ 352	[2]			$ 351	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		725,806		725,806		725,806		725,806
Investments Owned Acquisition Date		Sep. 21, 2018	[3]	Sep. 21, 2018	[3]	Sep. 21, 2018	[40]	Sep. 21, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Intuity Medical, Inc., Warrant, Acquisition Date 12/29/2017, Preferred Series B-1
Investment Holding [Line Items]
Investment cost		$ 294	[2]			$ 294	[6]
Investments at Fair Value		$ 0				$ 54
Shares | shares		3,076,323		3,076,323		3,076,323		3,076,323
Investments Owned Acquisition Date		Dec. 29, 2017	[3]	Dec. 29, 2017	[3]	Dec. 29, 2017	[40]	Dec. 29, 2017	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Lucira Health, Inc., Warrant, Acquisition Date 2/4/2022, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[40]					$ 110
Investments at Fair Value	[40]					$ 0
Shares | shares	[40]					59,642		59,642
Investments Owned Acquisition Date	[40]					Feb. 04, 2022		Feb. 04, 2022
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Common Stock
Investment Holding [Line Items]
Investment cost		$ 401	[2],[39]			$ 401	[6],[40]
Investments at Fair Value		$ 683	[39]			$ 864	[40]
Shares | shares		62,794	[39]	62,794	[39]	62,794	[40]	62,794	[40]
Investments Owned Acquisition Date		Sep. 27, 2013	[3],[39]	Sep. 27, 2013	[3],[39]	Sep. 27, 2013	[40]	Sep. 27, 2013	[40]
Investment, Identifier [Axis]: Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Common Stock
Investment Holding [Line Items]
Investment cost		$ 61	[2],[39]			$ 61	[6],[40]
Investments at Fair Value		$ 0	[39]			$ 1	[40]
Shares | shares		15,712	[39]	15,712	[39]	15,712	[40]	15,712	[40]
Investments Owned Acquisition Date		Mar. 31, 2017	[3],[39]	Mar. 31, 2017	[3],[39]	Mar. 31, 2017	[40]	Mar. 31, 2017	[40]
Investment, Identifier [Axis]: Warrant Investments and Semiconductors (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.04%		0.04%
Investment cost	[6]					$ 850
Investments at Fair Value						524
Investment, Identifier [Axis]: Warrant Investments and Semiconductors (0.05%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.05%		0.05%
Investment cost	[2]	$ 99
Investments at Fair Value		820
Investment, Identifier [Axis]: Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Preferred Series D-2
Investment Holding [Line Items]
Investment cost		99	[2]			99	[6]
Investments at Fair Value		$ 820				$ 524
Shares | shares		750,000		750,000		750,000		750,000
Investments Owned Acquisition Date		Jun. 26, 2015	[3]	Jun. 26, 2015	[3]	Jun. 26, 2015	[40]	Jun. 26, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Semiconductors and Fungible, Inc., Warrant, Acquisition Date 12/16/2021, Common Stock
Investment Holding [Line Items]
Investment cost	[6],[31]					$ 751
Investments at Fair Value	[31]					$ 0
Shares | shares	[31]					800,000		800,000
Investments Owned Acquisition Date	[31],[40]					Dec. 16, 2021		Dec. 16, 2021
Investment, Identifier [Axis]: Warrant Investments and Software (0.59%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.59%		0.59%
Investment cost	[6]					$ 9,761
Investments at Fair Value						8,244
Investment, Identifier [Axis]: Warrant Investments and Software (0.75%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.75%		0.75%
Investment cost	[2]	$ 11,775
Investments at Fair Value		11,870
Investment, Identifier [Axis]: Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Preferred Series G
Investment Holding [Line Items]
Investment cost		74	[2]			74	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		231,535		231,535		231,535		231,535
Investments Owned Acquisition Date		May 22, 2015	[3]	May 22, 2015	[3]	May 22, 2015	[40]	May 22, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 448	[2]			$ 448	[6]
Investments at Fair Value		$ 542				$ 365
Shares | shares		254,778		254,778		254,778		254,778
Investments Owned Acquisition Date		Sep. 23, 2022	[3]	Sep. 23, 2022	[3]	Sep. 23, 2022	[40]	Sep. 23, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 284	[2]			$ 284	[6]
Investments at Fair Value		$ 514				$ 398
Shares | shares		29,691		29,691		29,691		29,691
Investments Owned Acquisition Date		Nov. 18, 2020	[3]	Nov. 18, 2020	[3]	Nov. 18, 2020	[40]	Nov. 18, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 165	[1],[2]			$ 165	[6],[31]
Investments at Fair Value		$ 72	[1]			$ 61	[31]
Shares | shares		194,629	[1]	194,629	[1]	194,629	[31]	194,629	[31]
Investments Owned Acquisition Date		Oct. 04, 2021	[1],[3]	Oct. 04, 2021	[1],[3]	Oct. 04, 2021	[31],[40]	Oct. 04, 2021	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 117	[2]			$ 117	[6]
Investments at Fair Value		$ 16				$ 1
Shares | shares		211,342		211,342		211,342		211,342
Investments Owned Acquisition Date		Sep. 30, 2020	[3]	Sep. 30, 2020	[3]	Sep. 30, 2020	[40]	Sep. 30, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Common Stock
Investment Holding [Line Items]
Investment cost		$ 71	[2]			$ 71	[6]
Investments at Fair Value		$ 46				$ 14
Shares | shares		477,454		477,454		477,454		477,454
Investments Owned Acquisition Date		Nov. 06, 2018	[3]	Nov. 06, 2018	[3]	Nov. 06, 2018	[40]	Nov. 06, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 54	[2],[25],[26]			$ 54	[6],[27],[28]
Investments at Fair Value		$ 611	[25],[26]			$ 400	[27],[28]
Shares | shares		6,763	[25],[26]	6,763	[25],[26]	6,763	[27],[28]	6,763	[27],[28]
Investments Owned Acquisition Date		Apr. 10, 2018	[3],[25],[26]	Apr. 10, 2018	[3],[25],[26]	Apr. 10, 2018	[27],[28],[40]	Apr. 10, 2018	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Convoy, Inc., Warrant, Acquisition Date 3/30/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 974	[2]			$ 974	[6],[24]
Investments at Fair Value		$ 330				$ 364	[24]
Shares | shares		165,456		165,456		165,456	[24]	165,456	[24]
Investments Owned Acquisition Date		Mar. 30, 2022	[3]	Mar. 30, 2022	[3]	Mar. 30, 2022	[24],[40]	Mar. 30, 2022	[24],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 462	[2],[39]			$ 462	[6],[40]
Investments at Fair Value		$ 695	[39]			$ 488	[40]
Shares | shares		105,350	[39]	105,350	[39]	105,350	[40]	105,350	[40]
Investments Owned Acquisition Date		Apr. 25, 2019	[3]	Apr. 25, 2019	[3]	Apr. 25, 2019	[40]	Apr. 25, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 26	[2],[20],[25],[26]			$ 26	[6],[23],[27],[28]
Investments at Fair Value		$ 28	[20],[25],[26]			$ 19	[23],[27],[28]
Shares | shares		102,898	[20],[25],[26]	102,898	[20],[25],[26]	102,898	[23],[27],[28]	102,898	[23],[27],[28]
Investments Owned Acquisition Date		Sep. 21, 2022	[3],[20],[25],[26]	Sep. 21, 2022	[3],[20],[25],[26]	Sep. 21, 2022	[23],[27],[28],[40]	Sep. 21, 2022	[23],[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and DNAnexus, Inc., Warrant, Acquisition Date 3/21/2014, Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 97	[2]			$ 97	[6]
Investments at Fair Value		$ 181				$ 131
Shares | shares		909,091		909,091		909,091		909,091
Investments Owned Acquisition Date		Mar. 21, 2014	[3]	Mar. 21, 2014	[3]	Mar. 21, 2014	[40]	Mar. 21, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 353	[2]			$ 353	[6]
Investments at Fair Value		$ 202				$ 168
Shares | shares		453,641		453,641		453,641		453,641
Investments Owned Acquisition Date		Mar. 11, 2019	[3]	Mar. 11, 2019	[3]	Mar. 11, 2019	[40]	Mar. 11, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Delphix Corp., Warrant, Acquisition Date 10/8/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,594	[2]			$ 1,594	[6]
Investments at Fair Value		$ 2,485				$ 2,657
Shares | shares		718,898		718,898		718,898		718,898
Investments Owned Acquisition Date		Oct. 08, 2019	[3]	Oct. 08, 2019	[3]	Oct. 08, 2019	[40]	Oct. 08, 2019	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Common Stock
Investment Holding [Line Items]
Investment cost		$ 545	[2]			$ 545	[6]
Investments at Fair Value		$ 334				$ 180
Shares | shares		727,047		727,047		727,047		727,047
Investments Owned Acquisition Date		Aug. 02, 2021	[3]	Aug. 02, 2021	[3]	Aug. 02, 2021	[40]	Aug. 02, 2021	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[2]	$ 1,453
Investments at Fair Value		$ 1,452
Shares | shares		49,309		49,309
Investments Owned Acquisition Date	[3]	Jun. 28, 2023		Jun. 28, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 278	[2]			$ 278	[6]
Investments at Fair Value		$ 374				$ 300
Shares | shares		95,911		95,911		95,911		95,911
Investments Owned Acquisition Date		Jun. 30, 2022	[3]	Jun. 30, 2022	[3]	Jun. 30, 2022	[40]	Jun. 30, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Eigen Technologies Ltd., Warrant, Acquisition Date 4/13/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 8	[2],[25],[26]			$ 8	[6],[27],[28]
Investments at Fair Value		$ 5	[25],[26]			$ 6	[27],[28]
Shares | shares		522	[25],[26]	522	[25],[26]	522	[27],[28]	522	[27],[28]
Investments Owned Acquisition Date		Apr. 13, 2022	[3],[25],[26]	Apr. 13, 2022	[3],[25],[26]	Apr. 13, 2022	[27],[28],[40]	Apr. 13, 2022	[27],[28],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 583	[2]			$ 583	[6]
Investments at Fair Value		$ 307				$ 382
Shares | shares		362,837		362,837		362,837		362,837
Investments Owned Acquisition Date		Sep. 12, 2022	[3]	Sep. 12, 2022	[3]	Sep. 12, 2022	[40]	Sep. 12, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Esme Learning Solutions, Inc., Warrant, Acquisition Date 1/27/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 198	[2]			$ 198	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		56,765		56,765		56,765		56,765
Investments Owned Acquisition Date		Jan. 27, 2022	[3]	Jan. 27, 2022	[3]	Jan. 27, 2022	[40]	Jan. 27, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Evernote Corporation, Warrant, Acquisition Date 9/30/2016, Common Stock
Investment Holding [Line Items]
Investment cost	[6]					$ 107
Investments at Fair Value						$ 6
Shares | shares						62,500		62,500
Investments Owned Acquisition Date	[40]					Sep. 30, 2016		Sep. 30, 2016
Investment, Identifier [Axis]: Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 96	[2]			$ 96	[6]
Investments at Fair Value		$ 55				$ 39
Shares | shares		75,917		75,917		75,917		75,917
Investments Owned Acquisition Date		May 10, 2018	[3]	May 10, 2018	[3]	May 10, 2018	[40]	May 10, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 325	[2]			$ 325	[6]
Investments at Fair Value		$ 408				$ 314
Shares | shares		84,995		84,995		84,995		84,995
Investments Owned Acquisition Date		Jul. 29, 2022	[3]	Jul. 29, 2022	[3]	Jul. 29, 2022	[40]	Jul. 29, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Preferred Series C
Investment Holding [Line Items]
Investment cost	[2]	$ 208
Investments at Fair Value		$ 273
Shares | shares		64,293		64,293
Investments Owned Acquisition Date	[3]	Mar. 31, 2023		Mar. 31, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[2],[20],[25],[26]	$ 16
Investments at Fair Value	[20],[25],[26]	$ 16
Shares | shares	[20],[25],[26]	39,948		39,948
Investments Owned Acquisition Date	[3],[20],[25],[26]	Jan. 23, 2023		Jan. 23, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 131	[2]			$ 131	[6]
Investments at Fair Value		$ 37				$ 1
Shares | shares		89,685		89,685		89,685		89,685
Investments Owned Acquisition Date		Feb. 14, 2018	[3]	Feb. 14, 2018	[3]	Feb. 14, 2018	[40]	Feb. 14, 2018	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 252	[2]			$ 252	[6]
Investments at Fair Value		$ 299				$ 225
Shares | shares		82,362		82,362		82,362		82,362
Investments Owned Acquisition Date		Sep. 30, 2020	[3]	Sep. 30, 2020	[3]	Sep. 30, 2020	[40]	Sep. 30, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Nuvolo Technologies Corporation, Warrant, Acquisition Date 3/29/2019, Common Stock
Investment Holding [Line Items]
Investment cost		$ 172	[2],[20]			$ 172	[6],[23]
Investments at Fair Value		$ 156	[20]			$ 175	[23]
Shares | shares		70,000	[20]	70,000	[20]	70,000	[23]	70,000	[23]
Investments Owned Acquisition Date		Mar. 29, 2019	[3],[20]	Mar. 29, 2019	[3],[20]	Mar. 29, 2019	[23],[40]	Mar. 29, 2019	[23],[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Poplicus, Inc., Warrant, Acquisition Date 5/28/2014, Common Stock
Investment Holding [Line Items]
Investment cost		$ 0	[2]			$ 0	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		132,168		132,168		132,168		132,168
Investments Owned Acquisition Date		May 28, 2014	[3]	May 28, 2014	[3]	May 28, 2014	[40]	May 28, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 215	[2]			$ 215	[6]
Investments at Fair Value		$ 383				$ 298
Shares | shares		69,120		69,120		69,120		69,120
Investments Owned Acquisition Date		Jun. 30, 2020	[3]	Jun. 30, 2020	[3]	Jun. 30, 2020	[40]	Jun. 30, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and SignPost, Inc., Warrant, Acquisition Date 1/13/2016, Series Junior 1 Preferred
Investment Holding [Line Items]
Investment cost		$ 314	[2]			$ 314	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		474,019		474,019		474,019		474,019
Investments Owned Acquisition Date		Jan. 13, 2016	[3]	Jan. 13, 2016	[3]	Jan. 13, 2016	[40]	Jan. 13, 2016	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Common Stock
Investment Holding [Line Items]
Investment cost	[2]	$ 96
Investments at Fair Value		$ 73
Shares | shares		77,934		77,934
Investments Owned Acquisition Date	[3]	Mar. 22, 2023		Mar. 22, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Preferred Series D
Investment Holding [Line Items]
Investment cost		$ 103	[2]			$ 103	[6]
Investments at Fair Value		$ 513				$ 426
Shares | shares		312,596		312,596		312,596		312,596
Investments Owned Acquisition Date		Apr. 28, 2020	[3]	Apr. 28, 2020	[3]	Apr. 28, 2020	[40]	Apr. 28, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Ordinary Shares
Investment Holding [Line Items]
Investment cost	[25],[26]	$ 174
Investments at Fair Value	[25],[26]	$ 169
Shares | shares	[25],[26]	321,956		321,956
Investments Owned Acquisition Date	[3],[25],[26]	Jun. 08, 2023		Jun. 08, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and Tact.ai Technologies, Inc., Warrant, Acquisition Date 2/13/2020, Common Stock
Investment Holding [Line Items]
Investment cost		$ 206	[2]			$ 206	[6]
Investments at Fair Value		$ 35				$ 69
Shares | shares		1,041,667		1,041,667		1,041,667		1,041,667
Investments Owned Acquisition Date		Feb. 13, 2020	[3]	Feb. 13, 2020	[3]	Feb. 13, 2020	[40]	Feb. 13, 2020	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and The Faction Group LLC, Warrant, Acquisition Date 11/3/2014, Preferred Series AA
Investment Holding [Line Items]
Investment cost		$ 234	[2]			$ 234	[6]
Investments at Fair Value		$ 730				$ 436
Shares | shares		8,076		8,076		8,076		8,076
Investments Owned Acquisition Date		Nov. 03, 2014	[3]	Nov. 03, 2014	[3]	Nov. 03, 2014	[40]	Nov. 03, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Ordinary Shares
Investment Holding [Line Items]
Investment cost	[2],[25],[26]	$ 174
Investments at Fair Value	[25],[26]	$ 204
Shares | shares	[25],[26]	254,877		254,877
Investments Owned Acquisition Date	[3],[25],[26]	Mar. 22, 2023		Mar. 22, 2023
Investment, Identifier [Axis]: Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Common Stock
Investment Holding [Line Items]
Investment cost		$ 1,275	[1],[2]			$ 1,275	[6],[31]
Investments at Fair Value		$ 325	[1]			$ 321	[31]
Shares | shares		152,048	[1]	152,048	[1]	152,048	[31]	152,048	[31]
Investments Owned Acquisition Date		Jan. 21, 2022	[1],[3]	Jan. 21, 2022	[1],[3]	Jan. 21, 2022	[31],[40]	Jan. 21, 2022	[31],[40]
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices (0.04%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.04%		0.04%
Investment cost	[6]					$ 46
Investments at Fair Value						492
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices (0.05%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.05%		0.05%
Investment cost	[2]	$ 39
Investments at Fair Value		731
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices and Gynesonics, Inc., Warrant, Acquisition Date 1/16/2013, Preferred Series C
Investment Holding [Line Items]
Investment cost	[6]					7
Investments at Fair Value						$ 0
Shares | shares						16,835		16,835
Investments Owned Acquisition Date	[40]					Jan. 16, 2013		Jan. 16, 2013
Investment, Identifier [Axis]: Warrant Investments and Surgical Devices and TransMedics Group, Inc., Warrant, Acquisition Date 9/11/2015, Common Stock
Investment Holding [Line Items]
Investment cost		39	[2],[39]			$ 39	[6],[40]
Investments at Fair Value		$ 731	[39]			$ 492	[40]
Shares | shares		14,440	[39]	14,440	[39]	14,440	[40]	14,440	[40]
Investments Owned Acquisition Date		Sep. 11, 2015	[3],[39]	Sep. 11, 2015	[3],[39]	Sep. 11, 2015	[40]	Sep. 11, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology (0.01%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[4]	0.01%		0.01%
Investment cost	[2]	$ 539
Investments at Fair Value		120
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology (0.03%)
Investment Holding [Line Items]
Investment owned, percent of net assets	[5]					0.03%		0.03%
Investment cost	[6]					$ 723
Investments at Fair Value						488
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Common Stock
Investment Holding [Line Items]
Investment cost		52	[2]			52	[6]
Investments at Fair Value		$ 45				$ 44
Shares | shares		18,472		18,472		18,472		18,472
Investments Owned Acquisition Date		Apr. 15, 2022	[3]	Apr. 15, 2022	[3]	Apr. 15, 2022	[40]	Apr. 15, 2022	[40]
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Fulcrum Bioenergy, Inc., Warrant, Acquisition Date 4/30/2013, Preferred Series C-1
Investment Holding [Line Items]
Investment cost	[6]					$ 64
Investments at Fair Value						$ 275
Shares | shares						93,632		93,632
Investments Owned Acquisition Date	[40]					Apr. 30, 2013		Apr. 30, 2013
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc.
Investment Holding [Line Items]
Investment cost		$ 218	[2]			$ 218	[6]
Investments at Fair Value		$ 75				$ 169
Shares | shares		456,883		456,883		456,883		456,883
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/22/2014, Preferred Series A
Investment Holding [Line Items]
Investment cost		$ 155	[2]			$ 155	[6]
Investments at Fair Value		$ 57				$ 126
Shares | shares		325,000		325,000		325,000		325,000
Investments Owned Acquisition Date		Apr. 22, 2014	[3]	Apr. 22, 2014	[3]	Apr. 22, 2014	[40]	Apr. 22, 2014	[40]
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Preferred Series B
Investment Holding [Line Items]
Investment cost		$ 63	[2]			$ 63	[6]
Investments at Fair Value		$ 18				$ 43
Shares | shares		131,883		131,883		131,883		131,883
Investments Owned Acquisition Date		Apr. 07, 2015	[3]	Apr. 07, 2015	[3]	Apr. 07, 2015	[40]	Apr. 07, 2015	[40]
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and IngredientWerks Holdings, Inc. (p.k.a Agrivida, Inc.), Warrant, Acquisition Date 6/20/2013, Preferred Series D
Investment Holding [Line Items]
Investment cost	[6]					$ 120
Investments at Fair Value						$ 0
Shares | shares						471,327		471,327
Investments Owned Acquisition Date	[40]					Jun. 20, 2013		Jun. 20, 2013
Investment, Identifier [Axis]: Warrant Investments and Sustainable and Renewable Technology and Polyera Corporation, Warrant, Acquisition Date 3/24/2015, Preferred Series C
Investment Holding [Line Items]
Investment cost		$ 269	[2]			$ 269	[6]
Investments at Fair Value		$ 0				$ 0
Shares | shares		150,036		150,036		150,036		150,036
Investments Owned Acquisition Date		Mar. 24, 2015	[3]	Mar. 24, 2015	[3]	Mar. 24, 2015	[40]	Mar. 24, 2015	[40]
Investment, Identifier [Axis]: nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/2022
Investment Holding [Line Items]
Investment cost	[6],[27],[28]					$ 381
Investments at Fair Value	[27],[28]					$ 375
Investments Owned Acquisition Date	[27],[28],[40]					Jul. 21, 2022		Jul. 21, 2022
[1] Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company. Gross unrealized appreciation, gross unrealized depreciation, and net unrealized appreciation for federal income tax purposes totaled $ 92.5 million, $ 92.0 million and $ 0.5 million, respectively. The tax cost of investments is $ 3.1 billion. Unless otherwise noted, all securities are restricted as of June 30, 2023 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”). Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies. Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $ 72.2 million, $ 112.0 39.8 million, respectively. The tax cost of investments is $ 3.0 billion. Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”). Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of June 30, 2023 (Refer to “Note 11 - Commitments and Contingencies”). Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2022 (Refer to “Note 11 — Interest rate PRIME represents 8.25 % as of June 30, 2023. 1-month LIBOR, 3-month LIBOR and 6-month LIBOR represent 5.22 % , 5.55 % , and 5.76 % , respectively, as of June 30, 2023. 1-month SOFR, 3-month SOFR and 6-month SOFR represent 5.07 % , 5.00 % , and 4.78 % , respectively, as of June 30, 2023 . Interest rate PRIME represents 7.50 % as of December 31, 2022. 1-month LIBOR, 3-month LIBOR, and 6-month LIBOR represent 4.40 %, 4.77 %, and 5.14 %, Denotes second lien senior secured debt. Denotes second lien senior secured debt. Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments. Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”). Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition. Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”). Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of June 30, 2023 . Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”). Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”). Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets. Non-U.S. company or the company’s principal place of business is outside the United States. Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Non-U.S. company or the company’s principal place of business is outside the United States. Denotes that all or a portion of the debt investment is convertible debt. Denotes that all or a portion of the debt investment is convertible debt. Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board. Debt is on non-accrual status as of June 30, 2023, and is therefore considered non-income producing. Note that as of June 30, 2023 , only the PIK, or payment-in-kind, portion is on non-accrual for the Company’s debt investment in Tectura Corporation. Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% Debt is on non-accrual status as of December 31, 2022, and is therefore considered non-income producing. Note that as of December 31, 2022, only the PIK, or Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $ 4.6 million and $ 3.1 million, respectively. Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the 4.6 million and $ 3.4 million, respectively. Denotes an investment in common stock or warrants of a publicly traded company. None of the publicly traded company securities are restricted securities as defined under the Securities Act of 1933 ("Securities Act") as of June 30, 2023 . Except for warrants in 27 publicly traded companies and common stock in 43 publicly traded companies, all investments are restricted as of December 31, 2022 Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of June 30, 2023 , the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $ 2.4 million. Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of 3.0 million. Denotes all or a portion of the public equity or warrant investment was acquired in a transaction exempt from registration under the Securities Act of 1933

CONSOLIDATED SCHEDULE OF INVE_2

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical) $ in Thousands	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($) Firm
Investment Holding [Line Items]
Investment, Basis Spread, Variable Rate	8.25%	7.50%
Tax basis of investments, gross, unrealized appreciation	$ 92,500	$ 72,200
Tax basis of investments, gross, unrealized depreciation	92,000	112,000
Tax basis of investments, unrealized appreciation (depreciation), net	500	39,800
Tax basis of investments, cost for income tax purposes	3,100,000	3,000,000
Investment Owned, Cost	3,114,097	3,005,696
Investment Owned, Fair Value	$ 3,112,789	$ 2,963,955
1-month LIBOR
Investment Holding [Line Items]
Interest rate	5.22%	4.40%
3-month LIBOR
Investment Holding [Line Items]
Interest rate	5.55%	4.77%
6-month LIBOR
Investment Holding [Line Items]
Interest rate	5.76%	5.14%
1-month SOFR
Investment Holding [Line Items]
Interest rate	5.07%
3-month SOFR
Investment Holding [Line Items]
Interest rate	5%
6-month SOFR
Investment Holding [Line Items]
Interest rate	4.78%
Common Stock | Fair Value, Inputs, Level 1 [Member]
Investment Holding [Line Items]
Number of publicly traded companies | Firm		43
Warrants | Fair Value, Inputs, Level 1 [Member]
Investment Holding [Line Items]
Number of publicly traded companies | Firm		27
Biotechnology Tools
Investment Holding [Line Items]
Investment Owned, Fair Value	$ 33,465	$ 32,825
Media/Content/Info
Investment Holding [Line Items]
Investment Owned, Fair Value	11,542	35
Surgical Devices
Investment Holding [Line Items]
Investment Owned, Fair Value	731	3,038
Consumer & Business Products
Investment Holding [Line Items]
Investment Owned, Fair Value	1,294	2,821
Communications & Networking
Investment Holding [Line Items]
Investment Owned, Fair Value	105,343	101,833
Drug Delivery
Investment Holding [Line Items]
Investment Owned, Fair Value	23	90
Drug Discovery & Development
Investment Holding [Line Items]
Investment Owned, Fair Value	1,137,725	1,150,707
Medical Devices & Equipment
Investment Holding [Line Items]
Investment Owned, Fair Value	1,052	1,834
Information Services
Investment Holding [Line Items]
Investment Owned, Fair Value	73,306	60,759
Semiconductors
Investment Holding [Line Items]
Investment Owned, Fair Value	1,188	21,921
Healthcare Services Other
Investment Holding [Line Items]
Investment Owned, Fair Value	220,673	198,763
Manufacturing Technology
Investment Holding [Line Items]
Investment Owned, Fair Value	49,596	46,109
Diversified Financial Services
Investment Holding [Line Items]
Investment Owned, Fair Value	94,077	68,569
Sustainable And Renewable Technology
Investment Holding [Line Items]
Investment Owned, Fair Value	11,333	15,486
Software
Investment Holding [Line Items]
Investment Owned, Fair Value	891,438	798,264
Consumer And Business Services [Member]
Investment Holding [Line Items]
Investment Owned, Fair Value	459,276	439,384
Electronics & Computer Hardware
Investment Holding [Line Items]
Investment Owned, Fair Value	20,727	21,517
Phathom Pharmaceuticals, Inc. | Royalty Contract
Investment Holding [Line Items]
Investment Owned, Cost	4,600	4,600
Investment Owned, Fair Value	3,100	3,400
Black Crow AI, Inc. affiliates | Promissory Notes [Member]
Investment Holding [Line Items]
Investment Owned, Balance, Principal Amount	2,400	3,000
Senior Secured
Investment Holding [Line Items]
Investment Owned, Fair Value	$ 2,878,923	$ 2,741,388

Consolidated Schedule of Inve_3

Consolidated Schedule of Investments - Forward Foreign Currency Exchange Contracts £ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)		Jun. 30, 2023 GBP (£)
Open Forward Foreign Currency Contract, Identifier [Axis]: Foreign Currency Exchange Contracts Counterparty Goldman Sachs Bank USA Settlement Date 6/3/2024
Schedule of Investments [Line Items]
Derivative, Contract End Date	Jun. 03, 2024
Cumulative Unrealized Gain Loss On Derivatives | £			£ (554)
Derivative Liability, Notional Amount	$ 19,288
Derivative Asset, Notional Amount | £			£ 23,810
Open Forward Foreign Currency Contract, Identifier [Axis]: Total Foreign Currency Forward (-0.03%*)
Schedule of Investments [Line Items]
Cumulative Unrealized Gain Loss On Derivatives	(554)
Derivative Asset, Notional Amount	$ 23,810
Investment owned, percent of net assets	(0.03%)	[1]	(0.03%)	[1]
[1] Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 94,775	$ (10,318)	$ 189,339	$ (13,654)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Rule 10b5-1 Trading Plans During the fiscal quarter ended June 30, 2023, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
Non-Rule 10b5-1 Arrangement Adopted		false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, San Diego, CA, Denver, CO, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003. The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a Business Development Company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a Regulated Investment Company (“RIC”) under Subchapter M of the Code (see “Note 6 - Income Taxes”). The Company is not registered with the Commodity Futures Trading Commission (“CFTC”). The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. The Company is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA. Hercules Capital IV, L.P. (“HC IV”) is our wholly owned Delaware limited partnership that was formed in December 2010. HC IV received a license to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020. SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC (“HTM”), is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV. The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or Limited Liability Companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Certain of the subsidiaries are taxable and not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. The Company formed Hercules Adviser LLC (the “Adviser Subsidiary”) in 2020 as a wholly owned Delaware limited liability subsidiary to provide investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary receives fee income for the services provided to the Adviser Funds. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow the Adviser Subsidiary to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions. Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit. Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company. Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. As of June 30, 2023, approximately 96.5 % of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820. Derivative Instruments The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of June 30, 2023, the Company held $ 2,258 thousa nd (Cost basis $ 2,204 thousand) of foreign cash. As of December 31, 2022, the Company held $ 1,178 thousand (Cost basis $ 1,168 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”). Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables. Escrow Receivables Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”. Investment Income Recognition The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID. The OID received upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term. The Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal. Realized Gains or Losses Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries. Secured Borrowings The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value. Equity Offering Expenses The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities. Debt The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”. Debt Issuance Costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Int

N-2

N-2 - $ / shares	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Cover [Abstract]
Entity Central Index Key	0001280784
Amendment Flag	false
Securities Act File Number	814-00702
Document Type	10-Q
Entity Registrant Name	HERCULES CAPITAL, INC.
Entity Address, Address Line One	400 Hamilton Ave
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	289-3060
Entity Emerging Growth Company	false
General Description of Registrant [Abstract]
Risk Factors [Table Text Block]	ITEM 1A. RISK FACTORS In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 16, 2023 (the “Annual Report”) and Part II, Item 1A “Risk Factors” of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC on May 4, 2022. Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of June 30, 2023 that represent greater than 5% of our net assets: (in thousands) June 30, 2023 Fair Value Percentage of Net Assets Axsome Therapeutics, Inc. $ 154,574 9.7 % Corium, Inc. $ 136,450 8.6 % Phathom Pharmaceuticals, Inc. $ 99,152 6.3 % Worldremit Group Limited $ 95,063 6.0 % Rocket Lab Global Services, LLC $ 86,546 5.5 % SeatGeek, Inc. $ 85,647 5.4 % • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Worldremit Group Limited is a global online money transfer business. • Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected. Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then-current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock. The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. On July 20, 2023, we obtained authorization from our stockholders to issue common stock at a price below our then-current NAV per share for a twelve-month period expiring on July 20, 2024. We may seek to obtain this authorization again in the future. Our stockholders have previously approved a proposal to authorize us to issue securities to subscribe to, convert to, or purchase shares of our common stock in one or more offerings. Even though we have obtained authorization from our stockholders to issue common stock at a price below our then-current NAV, we cannot predict whether we will make any Below-NAV Sales under the prospectus supplement, as supplemented by the amendment. Any decision to sell shares of our common stock below the then-current NAV per share of our common stock or securities to subscribe to, convert to, or purchase shares of our common stock would be subject to the determination by our Board that such issuance is in our and our stockholders’ best interests. If we were to sell shares of our common stock below NAV per share, such sales would result in an immediate dilution to the NAV per share. This dilution would occur as a result of the sale of shares at a price below the then-current NAV per share of our common stock and a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance. In addition, if we issue securities to subscribe to, convert to or purchase shares of common stock, the exercise or conversion of such securities would increase the number of outstanding shares of our common stock. Any such exercise would be dilutive on the voting power of existing stockholders and could be dilutive with regard to dividends and our NAV, and other economic aspects of the common stock. Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect cannot be predicted; however, the example below illustrates the effect of dilution to existing stockholders resulting from the sale of common stock at prices below the NAV of such shares. Illustration: Example of Dilutive Effect of the Issuance of Shares Below NAV . Assume that Company XYZ has 1,000,000 total shares outstanding, $15,000,000 in total assets and $5,000,000 in total liabilities. The NAV per share of the common stock of Company XYZ is $10.00. The following table illustrates the reduction to NAV and the dilution experienced by Stockholder A following the sale of 40,000 shares of the common stock of Company XYZ at $9.50 per share, a price below its NAV per share. Prior to Sale Following Sale Percentage Below NAV Below NAV Change Reduction to NAV Total Shares Outstanding 1,000,000 1,040,000 0.04 % NAV per share $ 10.00 $ 9.98 (0.2 )% Dilution to Existing Stockholder Shares Held by Stockholder A 10,000 10,000 (1) 0.00 % Percentage Held by Stockholder A 1.00 % 0.96 % (4.0 )% Total Interest of Stockholder A in NAV $ 100,000 $ 99,808 (0.2 )% (1) Assumes that Stockholder A does not purchase additional shares in the sale of shares below NAV. In addition, all distributions in cash payable to stockholders who participate in our dividend reinvestment plan are automatically reinvested in shares of our common stock. As a result, stockholders who opt out of our dividend reinvestment plan will experience dilution of their ownership percentage of our common stock over time .
Share Price	$ 14.8		$ 13.49
NAV Per Share	$ 10.96	$ 10.53	$ 10.43	$ 11.22
Significant Portfolio Investment [Member]
General Description of Registrant [Abstract]
Risk [Text Block]	Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected. Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of June 30, 2023 that represent greater than 5% of our net assets: (in thousands) June 30, 2023 Fair Value Percentage of Net Assets Axsome Therapeutics, Inc. $ 154,574 9.7 % Corium, Inc. $ 136,450 8.6 % Phathom Pharmaceuticals, Inc. $ 99,152 6.3 % Worldremit Group Limited $ 95,063 6.0 % Rocket Lab Global Services, LLC $ 86,546 5.5 % SeatGeek, Inc. $ 85,647 5.4 % • Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options. • Corium, Inc. develops, engineers, and manufactures drug delivery products and devices that utilize the skin and mucosa as a primary means of transport. • Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. • Worldremit Group Limited is a global online money transfer business. • Rocket Lab Global Services, LLC is a commercial space provider of high-frequency, low-cost launches. • SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.
Valuation Risk [Member]
General Description of Registrant [Abstract]
Risk [Text Block]	Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then-current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock. The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. On July 20, 2023, we obtained authorization from our stockholders to issue common stock at a price below our then-current NAV per share for a twelve-month period expiring on July 20, 2024. We may seek to obtain this authorization again in the future. Our stockholders have previously approved a proposal to authorize us to issue securities to subscribe to, convert to, or purchase shares of our common stock in one or more offerings. Even though we have obtained authorization from our stockholders to issue common stock at a price below our then-current NAV, we cannot predict whether we will make any Below-NAV Sales under the prospectus supplement, as supplemented by the amendment. Any decision to sell shares of our common stock below the then-current NAV per share of our common stock or securities to subscribe to, convert to, or purchase shares of our common stock would be subject to the determination by our Board that such issuance is in our and our stockholders’ best interests. If we were to sell shares of our common stock below NAV per share, such sales would result in an immediate dilution to the NAV per share. This dilution would occur as a result of the sale of shares at a price below the then-current NAV per share of our common stock and a proportionately greater decrease in a stockholder’s interest in our earnings and assets and voting interest in us than the increase in our assets resulting from such issuance. In addition, if we issue securities to subscribe to, convert to or purchase shares of common stock, the exercise or conversion of such securities would increase the number of outstanding shares of our common stock. Any such exercise would be dilutive on the voting power of existing stockholders and could be dilutive with regard to dividends and our NAV, and other economic aspects of the common stock. Because the number of shares of common stock that could be so issued and the timing of any issuance is not currently known, the actual dilutive effect cannot be predicted; however, the example below illustrates the effect of dilution to existing stockholders resulting from the sale of common stock at prices below the NAV of such shares. Illustration: Example of Dilutive Effect of the Issuance of Shares Below NAV . Assume that Company XYZ has 1,000,000 total shares outstanding, $15,000,000 in total assets and $5,000,000 in total liabilities. The NAV per share of the common stock of Company XYZ is $10.00. The following table illustrates the reduction to NAV and the dilution experienced by Stockholder A following the sale of 40,000 shares of the common stock of Company XYZ at $9.50 per share, a price below its NAV per share. Prior to Sale Following Sale Percentage Below NAV Below NAV Change Reduction to NAV Total Shares Outstanding 1,000,000 1,040,000 0.04 % NAV per share $ 10.00 $ 9.98 (0.2 )% Dilution to Existing Stockholder Shares Held by Stockholder A 10,000 10,000 (1) 0.00 % Percentage Held by Stockholder A 1.00 % 0.96 % (4.0 )% Total Interest of Stockholder A in NAV $ 100,000 $ 99,808 (0.2 )% (1) Assumes that Stockholder A does not purchase additional shares in the sale of shares below NAV. In addition, all distributions in cash payable to stockholders who participate in our dividend reinvestment plan are automatically reinvested in shares of our common stock. As a result, stockholders who opt out of our dividend reinvestment plan will experience dilution of their ownership percentage of our common stock over time .

Fair Value of Financial Instrum

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of June 30, 2023 and December 31, 2022. (in thousands) Balance as of Quoted Prices in Significant Significant Description 2023 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 803 $ — $ — $ 803 Investments Senior Secured Debt $ 2,878,923 $ — $ — $ 2,878,923 Unsecured Debt 59,019 — — 59,019 Preferred Stock 41,249 — — 41,249 Common Stock (1) 94,931 61,144 — 33,787 Warrants 34,314 — 13,134 21,180 $ 3,108,436 $ 61,144 $ 13,134 $ 3,034,158 Investment Funds & Vehicles measured at Net Asset Value (2) 4,353 Total Investments, at fair value $ 3,112,789 Derivative Instruments (3) $ ( 554 ) Total Investments, at fair value including derivative instruments $ 3,112,235 (in thousands) Balance as of Quoted Prices in Significant Significant Description 2022 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 875 $ — $ — $ 875 Investments Senior Secured Debt $ 2,741,388 $ — $ — $ 2,741,388 Unsecured Debt 54,056 — — 54,056 Preferred Stock 41,488 — — 41,488 Common Stock 92,484 66,027 1,398 25,059 Warrants 30,646 — 11,227 19,419 $ 2,960,062 $ 66,027 $ 12,625 $ 2,881,410 Investment Funds & Vehicles measured at Net Asset Value (2) 3,893 Total Investments, at fair value $ 2,963,955 (1) Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock. (2) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities. (3) Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy. The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the six months ended June 30, 2023 and 2022. (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (3) Gross (3) Balance as of Investments Senior Secured Debt $ 2,741,388 $ ( 5,845 ) $ 19,330 $ 648,729 $ — $ ( 524,679 ) $ — $ — $ 2,878,923 Unsecured Debt 54,056 — 4,276 687 — — — — 59,019 Preferred Stock 41,488 ( 1,941 ) 1,702 — — — — — 41,249 Common Stock 25,059 — 8,322 1,000 ( 594 ) — — — 33,787 Warrants 19,419 ( 1,763 ) 722 2,809 ( 7 ) — — — 21,180 Other Assets Escrow Receivable 875 80 — — ( 152 ) — — — 803 Total $ 2,882,285 $ ( 9,469 ) $ 34,352 $ 653,225 $ ( 753 ) $ ( 524,679 ) $ — $ — $ 3,034,961 (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (4) Gross (4) Balance as of Investments Senior Secured Debt $ 2,156,709 $ ( 1,883 ) $ ( 16,525 ) $ 599,596 $ ( 73,500 ) $ ( 164,254 ) $ — $ ( 3,504 ) $ 2,496,639 Unsecured Debt 52,890 — ( 2,025 ) 3,362 — — — — 54,227 Preferred Stock 69,439 2,867 ( 14,157 ) 2,903 ( 4,772 ) — — ( 6,422 ) 49,858 Common Stock 21,968 ( 93 ) 10,240 — — — 207 ( 3,942 ) 28,380 Warrants 27,477 409 ( 8,120 ) 4,391 ( 2,167 ) — — — 21,990 Other Assets Escrow Receivable 561 312 — 167 ( 398 ) — — — 642 Total $ 2,329,044 $ 1,612 $ ( 30,587 ) $ 610,419 $ ( 80,837 ) $ ( 164,254 ) $ 207 $ ( 13,868 ) $ 2,651,736 (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the ac companying Consoli dated Statements of Operations. (3) There were no transfers into or out of Level 3 during the six months ended June 30, 2023. (4) Transfers out of Level 3 during the six months ended June 30, 2022, related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the six months ended June 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares. (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. For the six months ended June 30, 2023, approximately $ 1.7 million in net unrealized depreciation and $ 8.3 million in net unrealized appreciation relating to assets still held at the reporting date were recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $ 23.0 million in net unrealized appreciation and $ 0.8 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. For the six months ended June 30, 2022, approximately $ 14.9 million in net unrealized depreciation and $ 10.2 million in net unrealized appreciation relating to assets still held at the reporting date were recorded for preferred stock and common stock Level 3 investments, respectively. For the same period, approximately $ 17.7 million and $ 8.6 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date. The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of June 30, 2023 and December 31, 2022. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 1,046,205 Market Comparable Companies Hypothetical Market Yield 11.72 % - 18.25 % 14.52 % Premium/(Discount) ( 1.00 )% - 3.50 % 0.10 % Technology 1,047,563 Market Comparable Companies Hypothetical Market Yield 12.87 % - 20.20 % 15.57 % Premium/(Discount) ( 0.75 )% - 3.00 % 0.39 % 22,407 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.22 % Sustainable and Renewable Technology 1,856 Market Comparable Companies Hypothetical Market Yield 11.10 % 11.10 % Premium/(Discount) 0.75 % 0.75 % Lower Middle Market 252,658 Market Comparable Companies Hypothetical Market Yield 14.07 % - 17.36 % 13.96 % Premium/(Discount) ( 0.75 )% - 1.75 % 0.23 % 7,073 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 255,144 Debt Investments originated within 6 months 142,446 Imminent Payoffs (4) 162,590 Debt Investments Maturing in Less than One Year $ 2,937,942 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Fair Value as of Valuation Techniques/Methodologies Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 903,427 Market Comparable Companies Hypothetical Market Yield 11.74 % - 19.04 % 15.17 % Premium/(Discount) ( 0.75 )% - 1.75 % 0.01 % Technology 967,108 Market Comparable Companies Hypothetical Market Yield 12.05 % - 18.53 % 15.21 % Premium/(Discount) ( 1.00 )% - 1.50 % 0.20 % 20,356 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.79 % 1,671 Liquidation (3) Probability weighting of alternative outcomes 5.00 % - 80.00 % 48.29 % Sustainable and Renewable Technology 3,006 Market Comparable Companies Hypothetical Market Yield 14.71 % - 14.71 % 14.71 % Premium/(Discount) 0.75 % - 0.75 % 0.75 % Lower Middle Market 328,393 Market Comparable Companies Hypothetical Market Yield 13.68 % - 18.49 % 14.82 % Premium/(Discount) ( 2.00 )% - 0.75 % ( 0.43 )% 8,042 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 392,168 Debt Investments originated within 6 months 77,676 Imminent Payoffs (4) 93,597 Debt Investments Maturing in Less than One Year $ 2,795,444 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 35,966 Market Comparable Companies EBITDA Multiple (2) 13.3 x - 13.3 x 13.3 x Revenue Multiple (2) 0.6 x - 18.0 x 7.9 x Tangible Book Value Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 5.47 % - 32.11 % 23.35 % 8,882 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 83.47 )% - 13.33 % ( 13.31 )% 27,161 Discounted Cash Flow Discount Rate (7) 19.95 % - 31.68 % 26.14 % — Liquidation Revenue Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 83.00 % - 83.00 % 83.00 % 3,027 Other (6) Warrant Investments 15,936 Market Comparable Companies EBITDA Multiple (2) 13.3 x - 13.3 x 13.3 x Revenue Multiple (2) 0.7 x - 9.9 x 3.9 x Discount for Lack of Marketability (3) 5.47 % - 32.50 % 22.91 % 5,244 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 63.49 )% - 23.93 % 6.56 % Total Level 3 Equity and Warrant Investments $ 96,216 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 30,086 Market Comparable Companies EBITDA Multiple (2) 12.4 x - 12.4 x 12.4 x Revenue Multiple (2) 0.7 x - 16.1 x 7.4 x Tangible Book Value Multiple (2) 1.6 x - 1.6 x 1.6 x Discount for Lack of Marketability (3) 8.11 % - 28.90 % 19.79 % 13,795 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.82 )% - 16.34 % ( 16.69 )% 19,153 Discounted Cash Flow Discount Rate (7) 17.72 % - 30.13 % 24.46 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 85.00 % - 85.00 % 85.00 % 3,513 Other (6) Warrant Investments 12,479 Market Comparable Companies EBITDA Multiple (2) 12.4 x - 12.4 x 12.4 x Revenue Multiple (2) 0.6 x - 8.8 x 3.4 x Discount for Lack of Marketability (3) 8.11 % - 32.70 % 18.97 % 6,934 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.82 )% - 66.43 % ( 8.86 )% — Liquidation Revenue Multiple (2) 6.2 x - 6.2 x 6.2 x Discount for Lack of Marketability (3) 90.00 % - 90.00 % 90.00 % 6 Other (6) Total Level 3 Equity and Warrant Investments $ 85,966 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument. As of June 30, 2023 and December 31, 2022, the 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $ 24.70 and $ 24.59 per unit at par value. The par value at underwriting for the 2033 Notes was $ 25.00 per unit. Based on market quotations on or around June 30, 2023 and December 31, 2022, the 2031 Asset-Backed Notes were quoted for 0.932 and 0.951 . The fair values of the SBA debentures, July 2024 Notes, February 2025 Notes, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility are equal to their outstanding principal balances as of June 30, 2023 and December 31, 2022. The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 170,028 $ 146,395 $ — $ — $ 146,395 July 2024 Notes 104,680 103,447 — — 103,447 February 2025 Notes 49,809 47,754 — — 47,754 June 2025 Notes 69,676 65,121 — — 65,121 June 2025 3-Year Notes 49,694 47,831 — — 47,831 March 2026 A Notes 49,747 46,038 — — 46,038 March 2026 B Notes 49,725 46,105 — — 46,105 September 2026 Notes 321,849 274,835 — — 274,835 January 2027 Notes 345,269 301,265 — — 301,265 2031 Asset-Backed Notes 148,251 139,740 — 139,740 — 2033 Notes 38,880 39,520 — 39,520 — MUFG Bank Facility (1) 61,000 61,000 — — 61,000 SMBC Facility 130,000 130,000 — — 130,000 Total $ 1,588,608 $ 1,449,051 $ — $ 179,260 $ 1,269,791 (in thousands) December 31, 2022 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 169,738 $ 155,257 $ — $ — $ 155,257 July 2024 Notes 104,533 102,019 — — 102,019 February 2025 Notes 49,751 47,044 — — 47,044 June 2025 Notes 69,595 64,198 — — 64,198 June 2025 3-Year Notes 49,616 47,528 — — 47,528 March 2026 A Notes 49,700 45,512 — — 45,512 March 2026 B Notes 49,673 45,588 — — 45,588 September 2026 Notes 321,358 269,509 — — 269,509 January 2027 Notes 344,604 296,826 — — 296,826 2031 Asset-Backed Notes 147,957 142,620 — 142,620 — 2033 Notes 38,826 39,344 — 39,344 — MUFG Bank Facility (1) 107,000 107,000 — — 107,000 SMBC Facility 72,000 72,000 — — 72,000 Total $ 1,574,351 $ 1,434,445 $ — $ 181,964 $ 1,252,481 (1) In June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments

Investments	6 Months Ended
	Jun. 30, 2023
Schedule of Investments [Abstract]
Investments	4. Investments Control and Affiliate Investments As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds. The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and six months ended June 30, 2023 and 2022. (in thousands) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Portfolio Company (1) Type Fair Value as of June 30, 2023 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 297 $ — $ — $ 41 $ — $ — $ — $ ( 22 ) $ — Gibraltar Acquisition LLC (3) Control 44,392 731 19 2,667 — 1,527 38 6,402 — Hercules Adviser LLC Control 39,161 152 — 2,566 — 302 — 8,008 — Tectura Corporation Control 7,073 172 — ( 701 ) — 342 — ( 969 ) — Total Control Investments $ 90,923 $ 1,055 $ 19 $ 4,573 $ — $ 2,171 $ 38 $ 13,419 $ — (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Portfolio Company (1) Type Fair Value as of June 30, 2022 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 422 $ — $ — $ ( 192 ) $ — $ — $ — $ ( 143 ) $ — Gibraltar Business Capital, LLC Control 39,064 844 17 ( 3,578 ) — 1,678 33 ( 4,805 ) — Hercules Adviser LLC Control 35,181 128 — 8,637 — 239 — 11,191 — Tectura Corporation Control 8,208 172 — ( 139 ) — 342 — ( 61 ) — Total Control Investments $ 82,875 $ 1,144 $ 17 $ 4,728 $ — $ 2,259 $ 33 $ 6,182 $ — Affiliate Investments Black Crow AI, Inc. (2) Affiliate $ — $ — $ — $ — $ — $ — $ — $ ( 120 ) $ 3,772 Pineapple Energy LLC (2) Affiliate 3,613 76 — ( 1,295 ) — 1,123 — ( 422 ) — Total Affiliate Investments $ 3,613 $ 76 $ — $ ( 1,295 ) $ — $ 1,123 $ — $ ( 542 ) $ 3,772 Total Control & Affiliate Investments $ 86,488 $ 1,220 $ 17 $ 3,433 $ — $ 3,382 $ 33 $ 5,640 $ 3,772 (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 . (2) As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC were no longer affiliates as defined under the 1940 Act. (3) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. Portfolio Composition The following table shows the fair value of the Company’s portfolio of investments by asset class as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 2,878,923 92.5 % $ 2,741,388 92.5 % Unsecured Debt 59,019 1.9 % 54,056 1.8 % Preferred Stock 41,249 1.4 % 41,488 1.4 % Common Stock 94,931 3.0 % 92,484 3.1 % Warrants 34,314 1.1 % 30,646 1.1 % Investment Funds & Vehicles 4,353 0.1 % 3,893 0.1 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 % A summary of the Company’s investment portfolio, at value, by geographic location as of June 30, 2023 and December 31, 2022 is shown as follows: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of United States $ 2,755,178 88.5 % $ 2,670,520 90.1 % United Kingdom 200,455 6.5 % 171,629 5.8 % Netherlands 87,664 2.8 % 88,915 3.0 % Israel 53,019 1.7 % 9,052 0.3 % Canada 11,264 0.4 % 19,472 0.7 % Denmark 3,767 0.1 % — 0.0 % Germany 999 0.0 % 990 0.0 % Other 443 0.0 % 573 0.0 % Ireland — 0.0 % 2,804 0.1 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 % The following table shows the fair value of the Company’s portfolio by industry sector as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,137,725 36.5 % $ 1,150,707 38.8 % Software 891,438 28.6 % 798,264 26.9 % Consumer & Business Services 459,276 14.8 % 439,384 14.8 % Healthcare Services, Other 220,673 7.1 % 198,763 6.7 % Communications & Networking 105,343 3.4 % 101,833 3.4 % Diversified Financial Services 94,077 3.0 % 68,569 2.3 % Information Services 73,306 2.4 % 60,759 2.0 % Manufacturing Technology 49,596 1.6 % 46,109 1.6 % Biotechnology Tools 33,465 1.1 % 32,825 1.1 % Electronics & Computer Hardware 20,727 0.7 % 21,517 0.7 % Media/Content/Info 11,542 0.4 % 35 0.0 % Sustainable and Renewable Technology 11,333 0.4 % 15,486 0.5 % Consumer & Business Products 1,294 0.0 % 2,821 0.1 % Semiconductors 1,188 0.0 % 21,921 0.7 % Medical Devices & Equipment 1,052 0.0 % 1,834 0.1 % Surgical Devices 731 0.0 % 3,038 0.1 % Drug Delivery 23 0.0 % 90 0.0 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 % No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of June 30, 2023 or December 31, 2022. Concentrations of Credit Risk The Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development", "Software”, “Consumer & Business Services”, “Healthcare Services, Other”, and “Communications & Networking" sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies. As of June 30, 2023 and December 31, 2022, the Company’s ten largest portfolio companies represented approximately 30.3 % and 29.0 % of the total fair value of the Company’s investments in portfolio companies, respectively. As of June 30, 2023 and December 31, 2022, the Company had six and eight portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of June 30, 2023, the Company had four equity investments representing approximately 52.6 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2022, the Company had four equity investments which represented approximately 39.8 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of such investments. Investment Collateral In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of June 30, 2023 and December 31, 2022: Percentage of debt investments (at fair value), as of June 30, 2023 December 31, 2022 Senior Secured First Lien All assets including intellectual property 50.3 % 42.0 % All assets with negative pledge on intellectual property 21.1 % 26.1 % “Last-out” with security interest in all of the assets 11.7 % 11.6 % Total senior secured first lien position 83.1 % 79.7 % Second lien 14.9 % 18.4 % Unsecured 2.0 % 1.9 % Total debt investments at fair value 100.0 % 100.0 % Derivative Instruments The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of June 30, 2023 and December 31, 2022: (in thousands) Fair Value Derivative Instrument Statement Location June 30, 2023 December 31, 2022 Foreign currency forward contract Other assets $ ( 554 ) $ — Total $ ( 554 ) $ — Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and six months ended June 30, 2023 and 2022 are in the following locations in the Consolidated Statements of Operations: (in thousands) Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Statement Location 2023 2022 2023 2022 Foreign currency forward contract Net realized gain (loss) - Non-control / Non-affiliate investments $ — $ — $ — $ — Foreign currency forward contract Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments ( 554 ) — ( 554 ) — Total $ ( 554 ) $ — $ ( 554 ) $ — Investment Income The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows: (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Contractual interest income $ 86,147 $ 56,063 $ 168,938 $ 105,607 Exit fee interest income 14,054 6,655 23,436 13,381 PIK interest income 5,819 4,968 11,347 9,943 Other interest income (1) 2,966 1,045 5,162 2,052 Total interest income $ 108,986 $ 68,731 $ 208,883 $ 130,983 (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Recurring fee income $ 2,135 $ 1,907 $ 4,175 $ 3,686 Fee income - expired commitments 108 433 351 521 Accelerated fee income - early repayments 5,002 1,044 7,912 2,082 Total fee income $ 7,245 $ 3,384 $ 12,438 $ 6,289 (1) Other interest income includes OID interest income and interest recorded on other assets . As of June 30, 2023 and December 31, 2022, unamortized capitalized fee income was recorded as follows: (in millions) June 30, December 31, 2023 2022 Offset against debt investment cost $ 43.9 $ 43.1 Deferred obligation contingent on funding or other milestone 12.2 10.9 Total Unamortized Fee Income $ 56.1 $ 54.0 As of June 30, 2023 and December 31, 2022, loan exit fees receivable were recorded as follows: (in millions) June 30, December 31, 2023 2022 Included within debt investment cost $ 32.5 $ 32.5 Deferred receivable related to expired commitments 3.5 5.0 Total Exit Fees Receivable $ 36.0 $ 37.5

Debt

Debt	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt	5. Debt As of June 30, 2023 and December 31, 2022, the Company had the following available and outstanding debt: (in thousands) June 30, 2023 December 31, 2022 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures (2) $ 175,000 $ 175,000 $ 170,028 $ 175,000 $ 175,000 $ 169,738 July 2024 Notes 105,000 105,000 104,680 105,000 105,000 104,533 February 2025 Notes 50,000 50,000 49,809 50,000 50,000 49,751 June 2025 Notes 70,000 70,000 69,676 70,000 70,000 69,595 June 2025 3-Year Notes 50,000 50,000 49,694 50,000 50,000 49,616 March 2026 A Notes 50,000 50,000 49,747 50,000 50,000 49,700 March 2026 B Notes 50,000 50,000 49,725 50,000 50,000 49,673 September 2026 Notes 325,000 325,000 321,849 325,000 325,000 321,358 January 2027 Notes 350,000 350,000 345,269 350,000 350,000 344,604 2031 Asset-Backed Notes 150,000 150,000 148,251 150,000 150,000 147,957 2033 Notes 40,000 40,000 38,880 40,000 40,000 38,826 MUFG Bank Facility (2)(3) 400,000 61,000 61,000 545,000 107,000 107,000 SMBC Facility (2)(4) 400,000 130,000 130,000 225,000 72,000 72,000 Total $ 2,215,000 $ 1,606,000 $ 1,588,608 $ 2,185,000 $ 1,594,000 $ 1,574,351 (1) Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) In June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. (4) Includes $ 175.0 million of available commitment through the letter of credit facility. Debt issuance costs, net of accumulated amortization, were as follows as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 SBA Debentures $ 4,972 $ 5,262 July 2024 Notes 320 467 February 2025 Notes 191 249 June 2025 Notes 324 405 June 2025 3-Year Notes 306 384 March 2026 A Notes 253 300 March 2026 B Notes 275 327 September 2026 Notes 3,151 3,642 January 2027 Notes 4,731 5,396 2031 Asset-Backed Notes 1,749 2,043 2033 Notes 1,120 1,174 MUFG Bank Facility (1) 4,425 1,292 SMBC Facility (1) 2,135 1,701 Total $ 23,952 $ 22,642 (1) The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30. For the three and six months ended June 30, 2023, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,137 $ 146 $ — $ 1,283 $ — $ 2,262 $ 290 $ — $ 2,552 $ 2,262 July 2024 Notes 1,252 74 — 1,326 — 2,504 148 — 2,652 2,504 February 2025 Notes 535 28 — 563 — 1,070 57 — 1,127 1,070 June 2025 Notes 755 41 — 796 1,509 1,509 81 — 1,590 1,509 June 2025 3-Year Notes 750 39 — 789 1,500 1,500 78 — 1,578 1,500 March 2026 A Notes 562 23 — 585 — 1,125 47 — 1,172 1,125 March 2026 B Notes 568 26 — 594 — 1,137 52 — 1,189 1,138 September 2026 Notes 2,175 204 — 2,379 — 4,349 408 — 4,757 4,266 January 2027 Notes 3,078 207 — 3,285 — 6,157 414 — 6,571 5,906 2031 Asset-Backed Notes 1,904 100 — 2,004 1,857 3,807 200 — 4,007 3,713 2033 Notes 625 27 — 652 625 1,250 54 — 1,304 1,250 MUFG Bank Facility (2) 1,363 442 691 2,496 1,595 3,076 884 1,308 5,268 3,433 SMBC Facility 2,480 180 236 2,896 2,738 4,063 333 439 4,835 3,988 Total $ 17,184 $ 1,537 $ 927 $ 19,648 $ 9,824 $ 33,809 $ 3,046 $ 1,747 $ 38,602 $ 33,664 (1) Interest expense includes amortization of original issue discounts for the three months ended June 30, 2023 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2023, $ 83 thousand, $ 251 thousand, and $ 94 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. For the three and six months ended June 30, 2022, the components of interest expense and related fees and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,138 $ 146 $ — $ 1,284 $ — $ 1,688 $ 286 $ — $ 1,974 $ 749 2022 Notes (2) — — — — — 1,011 50 — 1,061 2,293 July 2024 Notes 1,252 74 — 1,326 — 2,504 148 — 2,652 2,504 February 2025 Notes 535 28 — 563 — 1,070 57 — 1,127 1,070 June 2025 Notes 755 41 — 796 1,509 1,509 81 — 1,590 1,509 June 2025 3-Year Notes 67 4 — 71 — 67 4 — 71 — March 2026 A Notes 562 24 — 586 — 1,125 48 — 1,173 1,125 March 2026 B Notes 568 26 — 594 — 1,137 52 — 1,189 1,138 September 2026 Notes 2,175 204 — 2,379 — 4,349 408 — 4,757 4,266 January 2027 Notes 3,078 207 — 3,285 — 5,473 368 — 5,841 — 2031 Asset-Backed Notes 169 9 — 178 — 169 9 — 178 — 2033 Notes 625 27 — 652 625 1,250 54 — 1,304 1,250 2022 Convertible Notes (2) — — — — — 923 149 — 1,072 5,004 MUFG Bank Facility (3) 1,369 175 395 1,939 1,215 1,483 412 962 2,857 1,215 SMBC Facility 405 64 68 537 283 587 113 133 833 519 Total $ 12,698 $ 1,029 $ 463 $ 14,190 $ 3,632 $ 24,345 $ 2,239 $ 1,095 $ 27,679 $ 22,642 (1) Interest expense includes amortization of original issue discounts for the three months ended June 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 4 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2022, $ 23 thousand, $ 112 thousand, $ 84 thousand, $ 223 thousand, and $ 4 thousand, related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) In February 2022, the Company has fully repaid the aggregate outstanding principal balances and retired 2022 Notes and 2022 Convertible Notes. (3) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. As of June 30, 2023 and December 31, 2022, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company’s debt. SBA Debentures The Company held the following SBA debentures outstanding principal balances as of June 30, 2023 and December 31, 2022: (in thousands) Maturity Date Interest Rate (1) June 30, 2023 December 31, 2022 March 26, 2021 September 1, 2031 1.58 % $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58 % 16,200 16,200 July 28, 2021 September 1, 2031 1.58 % 5,400 5,400 August 20, 2021 September 1, 2031 1.58 % 5,400 5,400 October 21, 2021 March 1, 2032 3.21 % 14,000 14,000 November 1, 2021 March 1, 2032 3.21 % 21,000 21,000 November 15, 2021 March 1, 2032 3.21 % 5,200 5,200 November 30, 2021 March 1, 2032 3.21 % 20,800 20,800 December 20, 2021 March 1, 2032 3.21 % 10,000 10,000 December 23, 2021 March 1, 2032 3.21 % 10,000 10,000 December 28, 2021 March 1, 2032 3.21 % 5,000 5,000 January 14, 2022 March 1, 2032 3.21 % 4,500 4,500 January 21, 2022 March 1, 2032 3.21 % 20,000 20,000 Total SBA Debentures $ 175,000 $ 175,000 (1) Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges. SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs compliance with SBA regulations. Our SBIC was in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of June 30, 2023 and December 31, 2022. HC IV received its license to operate as a SBIC on October 27, 2020. The license has a 10-year term. Through the license, HC IV has access to $ 175.0 million of capital through the SBA debenture program, that is in addition to the Company’s regulatory capital commitment of $ 87.5 million to HC IV. As of June 30, 2023 and December 31, 2022, HC IV has issued a total of $ 175.0 million in SBA guaranteed debentures. As of June 30, 2023, the Company held investments in HC IV in 21 companies with a fair value of approximately $ 312.7 million, accounting for approximately 10.0 % of the Company’s total investment portfolio. Further, HC IV held approximately $ 319.2 million in tangible assets which accounted for approximately 9.9 % of the Company’s total assets as of June 30, 2023. As of December 31, 2022, the Company held investments in HC IV in 21 companies with a fair value of approximately $ 343.7 million, accounting for approximately 11.6 % of the Company’s total investment portfolio. Further, HC IV held approximately $ 348.6 million in tangible assets which accounted for approximately 11.5 % of the Company’s total assets as of December 31, 2022. July 2024 Notes On July 16, 2019, the Company issued $ 105.0 million in aggregate principal amount of 4.77 % interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering . Interest on the July 2024 Notes is due semiannually . The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. February 2025 Notes On February 5, 2020, the Company issued $ 50.0 million in aggregate principal amount of 4.28 % interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes is due semiannually . The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 Notes On June 3, 2020, the Company issued $ 70.0 million in aggregate principal amount of 4.31 % interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. June 2025 3-Year Notes On June 23, 2022, the Company issued $ 50.0 million in aggregate principal amount of 6.00 % interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes is due semiannually. The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 A Notes On November 4, 2020, the Company issued $ 50.0 million in aggregate principal amount of 4.5 % interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering . Interest on the March 2026 A Notes is due semiannually . The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. March 2026 B Notes On March 4, 2021, the Company issued $ 50.0 million in aggregate principal amount of 4.55 % interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. The sale of the March 2026 B Notes generated net proceeds of approximately $ 49.5 million. Aggregate offering expenses in connection with the transaction, including fees and commissions, were approximately $ 0.5 million. Interest on the March 2026 B Notes is due semiannually . The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. September 2026 Notes On September 16, 2021, the Company issued $ 325.0 million in aggregate principal amount of 2.625 % interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. The issuance of the September 2026 Notes generated net proceeds of approximately $ 320.1 million. The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $ 4.1 million of costs and $ 0.8 million related to the discount. Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year, commencing on March 16, 2022 . The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture. January 2027 Notes On January 20, 2022, the Company issued $ 350.0 million in aggregate principal amount of 3.375 % interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Note s”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. The issuance of the January 2027 Notes generated net proceeds of approximately $ 343.4 million. The aggregate offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $ 4.1 million of costs and $ 2.5 million related to the discount. Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year, commencing on July 20, 2022 . The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture. 2031 Asset-Backed Notes On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $ 150.0 million in aggregate principal amount of 4.95 % interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available. Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of June 30, 2023 and December 31, 2022, there was approximately $ 12.3 million and $ 10.1 million, respectively, of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. 2033 Notes On September 24, 2018, the Company issued $ 40.0 million in aggregate principal amount of 6.25 % interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year . The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023. Credit Facilities As of June 30, 2023 and December 31, 2022, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the six months ended June 30, 2023 and year ended December 31, 2022, the weighted average interest rate was 7.16 % and 4.51 % , respectively, and the average debt outstanding under the Credit Facilities was $ 209.0 million and $ 127.7 million, respectively. MUFG Bank Facility On January 13, 2023, the Company entered into a third amended credit facility agreement, which amends the agreement dated as of June 10, 2022. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. (formerly MUFG Union Bank and known as the “Union Bank Facility”) as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time. Under the MUFG Bank Facility, the lenders have made commitments of $ 400.0 million, which may be further increased via an accordion feature up to an aggregate $ 600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. Debt under the MUFG Bank Facility generally bears interest at a rate per annum equal to SOFR plus 2.75 % for SOFR loans. The MUFG Bank Facility matures on January 13, 2026 , plus a 12-month amortization period, unless sooner terminated in accordance with its terms. The MUFG Bank Facility is secured by all of the assets of Hercules Funding IV. The MUFG Bank Facility requires payment of a non-use fee during the revolving credit availability period. The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy. SMBC Facility On June 14, 2022, the Company entered into a second amendment to a revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of June 30, 2023 , the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $ 225.0 million, from which the Company may access subject to certain conditions. The SMBC Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $ 500.0 million, funded by existing or additional lenders and with the agreement of SMBC Bank and subject to other customary conditions. Availability under the SMBC Facility will terminate on November 7, 2025 , and the outstanding loans under the SMBC Facility will mature on November 9, 2026 . Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder. Additionally in January 2023, the Company entered into a Letter of Credit Facility Agreement (the “SMBC LC Facility”) with Sumitomo Mitsui Banking Corporation that provides for a letter of credit facility with a final maturity date ending on January 13, 2026 and a commitment amount of $ 175.0 million as amended. Further, the SMBC LC Facility includes an accordion provision to increase the commitment up to $ 400 million, subject to certain conditions. The Company’s obligations under the SMBC LC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and is primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and any subsidiary guarantors thereunder. Interest under the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CDOR, or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 0.875 % to 2.0 % per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375 % per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility. The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes To qualify as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders. As previously noted, the determination of taxable income pursuant to U.S. federal income tax regulations differs from U.S. GAAP. As a result, permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. During the year ended December 31, 2022, the Company reclassified $ 3.0 million from accumulated net realized gains (losses) to additional paid-in capital for book purposes primarily related to net realized gains from portfolio companies which are held in taxable subsidiaries and are not consolidated with the Company for income tax purposes. Taxable income for the three months ended June 30, 2023, was approximately $ 60.9 million or $ 0.43 per share. Taxable net realized gains for the same period were $ 20.2 million or approximately $ 0.14 per share. Taxable income for the three months ended June 30, 2022, was approximately $ 40.0 million or $ 0.32 per share. Taxable net realized gains for the same period were $( 1.7 ) million or approximately $( 0.02 ) per share. Taxable income for the six months ended June 30, 2023, was approximately $ 125.0 million or $ 0.90 per share. Taxable net realized gains for the same period were $ 27.4 million or approximately $ 0.20 per share. Taxable income for the six months ended June 30, 2022, was approximately $ 73.1 million or $ 0.60 per share. Taxable net realized gains for the same period were $ 2.0 million or approximately $ 0.02 per share. The aggregate gross unrealized appreciation of the Company’s investments over cost for U.S. federal income tax purposes was $ 92.5 million and $ 72.2 million, as of June 30, 2023 and December 31, 2022, respectively. The aggregate gross unrealized depreciation of the Company’s investments under cost for U.S. federal income tax purposes was $ 92.0 million and $ 112.0 million, as of June 30, 2023 and December 31, 2022, respectively. The net unrealized appreciation over cost for U.S. federal income tax purposes was $ 0.5 million as of June 30, 2023 and the net unrealized depreciation over cost for U.S. federal income tax purposes was $ 39.8 million as of December 31, 2022. The aggregate cost of securities for U.S. federal income tax purposes was $ 3.1 billion and $ 3.0 billion as of June 30, 2023 and December 31, 2022, respectively. As a RIC, the Company is subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years (the "Excise Tax Avoidance Requirement"). The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains). Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year or returns of capital. For the three and six months ended June 30, 2023, the Company paid approximately $ 0.4 million and $ 5.2 million of income tax, including excise tax, and had $ 3.4 million of accrued, but unpaid tax expense as of June 30, 2023. For the three and six months ended June 30, 2022, the Company paid approximately $ 0.2 million and $ 7.3 million of income tax, including excise tax, and had $ 2.4 million of accrued, but unpaid tax expense as of June 30, 2022. Additionally, the Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal U.S. federal tax rates based on its taxable income. In accordance with ASC 740, the Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes. Based on an analysis of the Company’s tax position, there are no uncertain tax positions that met the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2019 - 2021 federal tax years for the Company remain subject to examination by the Internal Revenue Service. The 2018 – 2021 state tax years for the Company remain subject to examination by the state taxing authorities.

Stockholders' Equity and Distri

Stockholders' Equity and Distributions	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity and Distributions	7. Stockholders’ Equity and Distributions The Company has issued and outstandi ng 144,641,540 and 133,044,602 shares of common stock as of June 30, 2023 and December 31, 2022, respectively. We currently sell shares through our equity distribution agreement with JMP Securities LLC (“JMP”) and Jefferies LLC (“Jefferies”) (the “2023 Equity Distribution Agreement”) entered into on May 5, 2023. The 2023 Equity Distribution Agreement provides that we may offer and sell up to 25.0 million shares of our common stock from time to time through JMP or Jefferies, as our sales agents. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The 2023 Equity Distribution Agreement replaced the ATM equity distribution agreement between us, JMP and Jefferies executed on May 9, 2022. The Company issued and sold the following shares of common stock during the six months ended June 30, 2023 and 2022: (in millions, except per share data) Six Months Ended June 30th, Number of Shares Issued Gross Proceeds Underwriting Fees/Offering Expenses Net Proceeds Average Price/Share 2022 8.9 $ 148.7 $ 1.6 $ 147.1 $ 16.5 2023 9.7 $ 132.3 $ 1.6 $ 130.7 $ 13.5 The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of June 30, 2023, approximately 23.8 million shares remain available for issuance and sale under the current equity distribution agreement. The Company currently pays quarterly distributions to its stockholders. The following table summarizes the Company’s distributions declared during the six months ended June 30, 2023 and year ended December 31, 2022: (in thousands, except per share data) Distribution Type Declared Date Record Date Payment Date Per Share Amount Total Amount Base February 16, 2022 March 9, 2022 March 16, 2022 $ 0.33 $ 39,794 Supplemental February 16, 2022 March 9, 2022 March 16, 2022 $ 0.15 $ 18,088 Base April 27, 2022 May 17, 2022 May 24, 2022 $ 0.33 $ 41,245 Supplemental April 27, 2022 May 17, 2022 May 24, 2022 $ 0.15 $ 18,748 Base July 20, 2022 August 9, 2022 August 16, 2022 $ 0.35 $ 44,765 Supplemental July 20, 2022 August 9, 2022 August 16, 2022 $ 0.15 $ 19,185 Base October 13, 2022 November 10, 2022 November 17, 2022 $ 0.36 $ 47,472 Supplemental October 13, 2022 November 10, 2022 November 17, 2022 $ 0.15 $ 19,780 Total distributions declared during the year ended December 31, 2022 $ 1.97 $ 249,077 Base February 9, 2023 March 2, 2023 March 9, 2023 $ 0.39 $ 53,749 Supplemental February 9, 2023 March 2, 2023 March 9, 2023 $ 0.08 $ 11,025 Base April 27, 2023 May 16, 2023 May 23, 2023 $ 0.39 $ 55,910 Supplemental April 27, 2023 May 16, 2023 May 23, 2023 $ 0.08 $ 11,469 Total distributions declared during the six months ended June 30, 2023 $ 0.94 $ 132,153 During the six months ended June 30, 2023, for income tax purposes, the distributions paid of $ 0.94 per share were comprised of ordinary income. As of June 30, 2023, the Company estimates that it has generated undistributed taxable earnings “spillover” of $ 1.02 per share. The undistributed taxable earnings spillover will be carried forward toward distributions to be paid in accordance with RIC requirements. The Company has a distribution reinvestment plan, whereby the Company may buy shares of its common stock in the open market or issue new shares in order to satisfy dividend reinvestment requests. When the Company issues new shares in connection with the dividend reinvestment plan, the issue price is equal to the closing price of its common stock on the dividend record date. During the six months ended June 30, 2023 and 2022, the Company issued 133,142 and 121,471 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.

Equity Incentive Plan

Equity Incentive Plan	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plan	8. Equity Incentive Plans The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018 and, unless earlier terminated by the Board, terminate on May 12, 2028. Subject to certain adjustments and permitted reversions of shares, the maximum aggregate number of shares that may be authorized for issuance under awards granted under the 2018 Plan and Director Plan is 9,261,229 shares and 300,000 shares, respectively. In connection with the issuance of shares under the 2018 Plan and Director Plan, the Company has registered, in aggregate, 18.7 million and 300,000 shares of common stock, respectively. Outstanding awards issued under plans that precede the 2018 Plan and Director Plan remain outstanding, unchanged and subject to the terms of such plans and their respective award agreements, until the vesting, expiration or lapse of such awards in accordance with their terms. The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock. The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended June 30, 2023, and 2022, the Company recognized $ 3.3 million and $ 3.7 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. For the six months ended June 30, 2023, and 2022, the Company recognized $ 6.5 million and $ 8.1 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. As of June 30, 2023, and 2022, approximately $ 24.6 million and $ 19.1 million of total unrecognized compensation costs expected to be recognized over the next 2.9 and 2.0 years, respectively. Service-Vesting Awards The Company grants equity-based awards which have service conditions, which generally begin to vest one-third after one year after the date of grant and ratably over the succeeding 2 years in accordance with the individual award terms. Certain awards have service conditions of longer duration and may begin to vest up to seven years after the date of grant. These equity-based awards which vest upon achievement of service conditions are collectively referred to as the “Service Vesting Awards”. The grant date fair value of Service Vesting Awards granted during the six months ended June 30, 2023, and 2022, were approximately $ 18.1 million, and $ 10.7 million, respectively. The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the six months ended June 30, 2023, and 2022, are summarized below: Six Months Ended June 30, 2023 2022 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 958,985 $ 16.35 1,037,848 $ 14.51 Granted 1,306,880 $ 13.81 610,541 $ 17.39 Vested (1) ( 414,634 ) $ 16.28 ( 463,408 ) $ 14.39 Forfeited ( 6,712 ) $ 16.17 ( 17,108 ) $ 15.89 Unvested Shares End of Period 1,844,519 $ 14.57 1,167,873 $ 16.05 (1) With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period. In addition to the restricted stock equity-based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the six months ended June 30, 2023 and 2022, was approximately $ 67,000 and 83,000 , respectively. During the six months ended June 30, 2023 and 2022, approximately $ 46,000 , and $ 30,000 , of share-based cost due to stock option grants was expensed, respectively. Performance-Vesting Awards The Company has granted equity-based awards, which have market and performance conditions in addition to a service condition (“Performance Awards”). The value of these awards may increase dependent on increases to the Company’s total stockholder return (“TSR”). The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted. The Performance Awards typically vest after four years, and generally may not be disposed until one year post vesting. The Company determines the fair values of the Performance Awards at the grant date using a Monte-Carlo simulation multiplied by the target payout level and is recognized over the service period. For certain Performance Awards, distribution equivalent units (“Performance DEUs”) will accrue in the form of additional shares, but will not be paid unless the Performance Awards to which such Performance DEUs relate actually vest. During the six months ended June 30, 2023 , no Performance Awards were granted or vested. During the six months ended June 30, 2022 , a total of 487,409 Performance Award shares vested. During the six months ended June 30, 2023, 54,858 sha res Performance DEUs were issued and vested immediately with an aggregate fair value of $ 0.7 million. During the six months ended June 30, 2022 , 241,770 Performance DEUs were issued with a grant date fair value of $ 4.0 million. As of June 30, 2023 and 2022 , there were no unvested Performance Awards. Liability Classified Awards The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). The remaining maximum total potential value of the Liability Awards granted is $ 3.1 millio n, which assumes all performance conditions are met for each Liability award. If the performance conditions are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The awards are recorded as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statement of Assets and Liabilities. Certain Liability Awards are structured similar to the Performance Awards, and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. As of June 30, 2023 , the Company determined that the weighted average expected probability of the performance conditions being met within each Liability Award was 100 %. The expected probability is re-evaluated each period, and may be adjusted to reflect changes in this assumption. These other Liability Awards vest over a three-year service term. As of June 30, 2023, all Liability Awards are unvested and there was approximately $ 1.2 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 0.8 years. For the six months ended June 30, 2023, there was approximately $ 0.7 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $ 1.9 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. During the six months ended June 30, 2023 and 2022 , $ 0 and $ 6.0 million, respectively of the Liability Awards vested. As of June 30, 2022, all Liability Awards are unvested and there was approximately $ 3.2 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 1.8 years. For the six months ended June 30, 2022, there was approximately $ 2.3 million of compensation expense related to the Liability Awards recognized in the Consolidated Statement of Operations and $ 2.0 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	9. Earnings Per Share Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator Net increase (decrease) in net assets resulting from operations $ 94,775 $ ( 10,318 ) $ 189,339 $ ( 13,654 ) Less: Total distributions declared ( 67,379 ) ( 59,993 ) ( 132,153 ) ( 117,875 ) Total Earnings (loss), net of total distributions 27,396 ( 70,311 ) 57,186 ( 131,529 ) Earnings (loss), net of distributions attributable to common shares 27,108 ( 70,311 ) 56,552 ( 131,529 ) Add: Distributions declared attributable to common shares 66,672 59,431 130,696 116,693 Numerator for basic and diluted change in net assets per common share $ 93,780 $ ( 10,880 ) $ 187,248 $ ( 14,836 ) Denominator Basic weighted average common shares outstanding 141,390 124,255 138,338 121,292 Common shares issuable 694 — 1,249 — Weighted average common shares outstanding assuming dilution 142,084 124,255 139,587 121,292 Change in net assets per common share: Basic $ 0.66 $ ( 0.09 ) $ 1.35 $ ( 0.12 ) Diluted $ 0.66 $ ( 0.09 ) $ 1.34 $ ( 0.12 ) In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share. For three and six months ended June 30, 2022, as the Company had a net loss, the effect of unvested stock options, restricted stock units and awards, and Performance Awards were anti-dilutive, and therefore have been excluded from the calculation of diluted loss per share. The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and six months ended June 30, 2023, and 2022, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three Months Ended June 30, Six Months Ended June 30, Anti-dilutive Securities 2023 2022 2023 2022 Unvested common stock options 3,146 16 2,499 24 Restricted stock units 9,555 2 8,714 17 Unvested restricted stock awards 65,346 — 59,854 — Performance awards* — 1,685 — 1,116 * Included in these amounts are shares related to certain equity-based awards, which fully vested in May 2022 and delivered in May 2023 and thus no longer outstanding for purposes of calculating earnings per share. As of June 30, 2023 and December 31, 2022 , the Company was authorized to issue 200.0 million shares of common stock with a par value of $ 0.001 . Each share of common stock entitles the holder to one vote.

Financial Highlights

Financial Highlights	6 Months Ended
	Jun. 30, 2023
Investment Company, Financial Highlights [Abstract]
Financial Highlights	10. Financial Highlights Following is a schedule of financial highlights for the six months ended June 30, 2023 and 2022: (in thousands, except per share data and ratios) Six Months Ended June 30, 2023 2022 Per share data (1) : Net asset value at beginning of period $ 10.53 $ 11.22 Net investment income 1.02 0.62 Net realized gain (loss) 0.06 ( 0.04 ) Net unrealized appreciation (depreciation) 0.29 ( 0.70 ) Total from investment operations 1.37 ( 0.12 ) Net increase (decrease) in net assets from capital share transactions (1) ( 0.01 ) 0.23 Distributions of net investment income (6) ( 0.96 ) ( 0.96 ) Stock-based compensation expense included in net investment income and other movements (2) 0.03 0.06 Net asset value at end of period $ 10.96 $ 10.43 Ratios and supplemental data: Per share market value at end of period $ 14.80 $ 13.49 Total return (3) 19.55 % ( 13.72 )% Shares outstanding at end of period 144,641 127,285 Weighted average number of common shares outstanding 138,338 121,292 Net assets at end of period $ 1,585,510 $ 1,327,740 Ratio of total expense to average net assets (4) 10.75 % 9.13 % Ratio of net investment income before investment gains and losses to average net assets (4) 18.95 % 11.30 % Portfolio turnover rate (5) 17.20 % 8.88 % Weighted average debt outstanding $ 1,614,522 $ 1,386,242 Weighted average debt per common share $ 11.69 $ 11.43 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, (3) The total return for the six months ended June 30, 2023, and 2022 equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the six months ended June 30, 2023, and 2022 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of June 30, 2023, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones. As of June 30, 2023, and December 31, 2022, the Company had approximately $ 381.1 million and $ 628.9 million, respectively, of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The amounts disclosed exclude unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements. As of June 30, 2023, and December 31, 2022, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company June 30, 2023 December 31, 2022 Debt Investments: Thumbtack, Inc. $ 40,000 $ 40,000 Automation Anywhere, Inc. 29,400 29,400 Axsome Therapeutics, Inc. 25,375 21,000 Skydio, Inc. 22,500 22,500 SeatGeek, Inc. 19,375 — Phathom Pharmaceuticals, Inc. 16,625 66,500 Carwow LTD 14,365 — Dragos 13,000 — Dronedeploy, Inc. 12,500 12,500 Iveric Bio, Inc. 12,375 — PathAI, Inc. 12,000 12,000 Locus Robotics Corp. 10,740 — Tipalti Solutions Ltd. 10,500 — Alamar Biosciences, Inc. 10,000 10,000 Aryaka Networks, Inc. 10,000 20,000 Next Insurance, Inc. 10,000 — Kura Oncology, Inc. 8,250 8,250 Tarsus Pharmaceuticals, Inc. 8,250 10,313 Elation Health, Inc. 7,500 7,500 Gritstone Bio, Inc. 7,500 7,500 TG Therapeutics, Inc. 6,500 — Nuvolo Technologies Corporation 5,700 5,970 Akero Therapeutics, Inc. 5,000 5,000 Cutover, Inc. 4,150 1,000 Leapwork ApS 4,100 — Saama Technologies, LLC 3,875 — Riviera Partners LLC 3,500 3,500 Babel Street 3,375 3,375 Modern Life, Inc. 3,250 — Signal Media Limited 3,000 5,250 Vida Health, Inc. 3,000 40,000 Zappi, Inc. 2,571 2,571 Brain Corporation 2,500 20,700 Yipit, LLC 2,250 2,250 Streamline Healthcare Solutions 2,200 — Sumo Logic, Inc. 2,000 — Ceros, Inc. 1,707 1,707 ThreatConnect, Inc. 1,600 1,600 (in thousands) Unfunded Commitments (1) as of Portfolio Company June 30, 2023 December 31, 2022 Debt Investments: RVShare, LLC $ 1,500 $ 1,500 Loftware, Inc. 1,423 — Dispatch Technologies, Inc. 1,250 1,250 3GTMS, LLC 1,222 — LogicSource 1,209 1,209 Zimperium, Inc. 1,088 1,088 Ikon Science Limited 1,050 1,050 Omeda Holdings, LLC 919 938 Khoros (p.k.a Lithium Technologies) 906 1,812 Fortified Health Security 840 840 Agilence, Inc. 800 800 Flight Schedule Pro, LLC 639 639 Constructor.io Corporation 625 625 Enmark Systems, Inc. 457 457 Alchemer LLC 445 890 Cybermaxx Intermediate Holdings, Inc. 390 390 Annex Cloud 386 386 ShadowDragon, LLC 333 333 Cytracom Holdings LLC 72 225 Provention Bio, Inc. — 40,000 Madrigal Pharmaceutical, Inc. — 34,000 Oak Street Health, Inc. — 33,750 HilleVax, Inc. — 28,000 Replimune Group, Inc. — 20,700 G1 Therapeutics, Inc. — 19,375 Alladapt Immunotherapeutics Inc. — 15,000 AppDirect, Inc. — 15,000 Viridian Therapeutics, Inc. — 12,000 Dashlane, Inc. — 10,000 Fever Labs, Inc. — 8,333 Fulfil Solutions, Inc. — 5,000 Demandbase, Inc. — 3,750 MacroFab, Inc. — 3,000 Mobile Solutions Services — 495 Total Unfunded Debt Commitments: 376,087 623,221 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 2,269 2,842 Forbion Growth Opportunities Fund II C.V. 2,748 2,811 Total Unfunded Commitments in Investment Funds & Vehicles: 5,017 5,653 Total Unfunded Commitments $ 381,104 $ 628,874 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds. The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) June 30, 2023 December 31, 2022 Unfunded Debt Commitments: Expiring during: 2023 $ 187,230 $ 461,296 2024 156,056 134,856 2025 1,294 720 2026 9,037 9,038 2027 15,152 15,171 2028 5,318 2,140 2030 2,000 — Total Unfunded Debt Commitments 376,087 623,221 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 2,269 2,842 2032 2,748 2,811 Total Unfunded Commitments in Investment Funds & Vehicles 5,017 5,653 Total Unfunded Commitments $ 381,104 $ 628,874 The following tables provide the Company’s contractual obligations as of June 30, 2023 and December 31, 2022: As of June 30, 2023: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,606,000 $ — $ 375,000 $ 866,000 $ 365,000 Lease and License Obligations (4) 27,493 2,922 6,617 6,223 11,731 Total $ 1,633,493 $ 2,922 $ 381,617 $ 872,223 $ 376,731 As of December 31, 2022: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,594,000 $ — $ 382,000 $ 847,000 $ 365,000 Lease and License Obligations (4) 8,641 2,723 2,259 2,452 1,207 Total $ 1,602,641 $ 2,723 $ 384,259 $ 849,452 $ 366,207 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of June 30, 2023. There was also $ 130.0 million outstanding under the SMBC Facility and $ 61.0 million outstanding under the MUFG Bank Facility as of June 30, 2023 . (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of December 31, 2022. There was also $ 72.0 million outstanding under the SMBC Facility and $ 107.0 million outstanding under the MUFG Bank Facility as of December 31, 2022 . Certain premises are leased or licensed under agreements which expire at various dates through March 2034. For the three and six months ended June 30, 2023 and 2022, total rent expense, including short-term leases, amounted to approximately $ 0.8 million and $ 1.6 million, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset. The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of June 30, 2023, and 2022: (in thousands) Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Total operating lease cost $ 606 $ 744 $ 1,304 $ 1,441 Cash paid for amounts included in the measurement of lease liabilities $ 1,127 $ 1,175 $ 1,736 $ 1,769 As of June 30, 2023 As of December 31, 2022 Weighted-average remaining lease term (in years) 8.62 5.48 Weighted-average discount rate 6.71 % 5.37 % The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of June 30, 2023: (in thousands) As of June 30, 2023 2023 $ 1,042 2024 3,034 2025 3,288 2026 3,383 Thereafter 16,623 Total lease payments 27,370 Less: imputed interest & other items ( 23,484 ) Total operating lease liability $ 3,886 The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions As disclosed in “Note 2 – Summary of Significant Accounting Policies”, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. Refer to “Note 4 – Investments” for information related to income, gains and losses recognized related to the Company’s investment. In 2021, the Adviser Subsidiary entered into investment management agreements with its privately offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds and may receive incentive fees based on the performance of the Adviser Funds. The Company has a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary has access to the Company's human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology). Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended June 30, 2023 and 2022, are net of expenses allocated to the Adviser Subsidiary of $ 2.4 million and $ 3.1 million, respectively. The Company’s total expenses for the six months ended June 30, 2023 and 2022, are net of expenses allocated to the Adviser Subsidiary of $ 5.1 million and $ 4.5 million, respectively. As of June 30, 2023 and December 31, 2022, there was $ 0.1 million receivable from the Adviser Subsidiary in each period. In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. During the six months ended June 30, 2023, $ 320.4 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds. During the six months ended June 30, 2023, fundings of $ 199.9 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $ 9.6 million from the Adviser Funds relating to the assigned investments during the six months ended June 30, 2023. During the six months ended June 30, 2022, $ 440.0 million of all investment commitments of the Company and the Adviser Subsidiary were assigned to or directly committed by the Adviser Funds, respectively. During the six months ended June 30, 2022, fundings of $ 189.8 million were assigned to, directly originated, or funded by the Adviser Funds. The Company received $ 88.2 million from the Adviser Funds relating to the assigned investments during the six months ended June 30, 2022 . Additionally, in May 2022, the Company sold $ 73.5 million of assets to the Adviser Funds and realized a $ 0.1 million gain.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events Dividend Distribution Declaration On July 28, 2023 , the Board declared a cash distribution of $ 0.40 per share to be paid on August 25, 2023 to stockholders of record as of August 18, 2023 . In addition to the cash distribution, and as part of the supplemental cash distribution of $ 0.32 per share to be paid in four quarterly distributions of $ 0.08 per share, the Board declared a supplemental cash distribution of $ 0.08 per share to be paid on August 25, 2023 to stockholders of record as of August 18, 2023 . Including the $ 0.08 per share supplemental cash distributions paid to stockholders of record as of March 9, 2023 and May 16, 2023, the Board has declared a total of $ 0.24 per share of the $ 0.32 per share supplemental cash distribution declared on February 9, 2023 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency. As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated. Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.
Principles of Consolidation	Principles of Consolidation The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE. To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE. The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework. The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.
Fair Value Measurements	Fair Value Measurements The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets. Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.
Valuation of Investments	Valuation of Investments The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded. As of June 30, 2023, approximately 96.5 % of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the valuation designee of the Board. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy established by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by the Company's Valuation Committee and approved by the Board may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material. In accordance with procedures established by its Board, the Company values investments on a quarterly basis following a multistep valuation process. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. The quarterly Board approved multi-step valuation process is described below: (1) The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment; (2) Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary; (3) The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board; (4) The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and (5) The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio. Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation. Debt Investments The Company’s debt securities are primarily invested in venture capital-backed and institutional-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. The Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives, and to the extent market quotations or other pricing indicators (i.e. broker quotes) are available, these investments are considered Level 1 or 2 assets in line with ASC Topic 820. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below. The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. For syndicated debt investments, for which sufficient market data is available and liquidity, the Company values debt securities using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis. The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost. When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment. Equity Securities and Warrants Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date. At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors. Investment Funds & Vehicles The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.
Derivative Instruments	Derivative Instruments The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. As of June 30, 2023, the Company held $ 2,258 thousa nd (Cost basis $ 2,204 thousand) of foreign cash. As of December 31, 2022, the Company held $ 1,178 thousand (Cost basis $ 1,168 thousand) of foreign cash. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).
Other Assets	Other Assets Other assets generally consist of prepaid expenses, debt issuance costs on our Credit Facilities net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables.
Escrow Receivables	Escrow Receivables Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date.
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.
Investment Income Recognition	Investment Income Recognition The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID. The OID received upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term. The Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
Realized Gains or Losses	Realized Gains or Losses Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries.
Secured Borrowings	Secured Borrowings The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value.
Equity Offering Expenses	Equity Offering Expenses The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.
Debt	Debt The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest , debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements.
Stock Based Compensation	Stock-Based Compensation The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock-based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, it may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax. The Company has elected to be treated as a RIC under Subchapter M of the Code. As such, the Company generally will not be subject to U.S. federal income tax on the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes. As a RIC, the Company will be subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the Excise Tax Avoidance Requirement. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains). Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or return of capital.
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.
Comprehensive Income	Comprehensive Income The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did no t have other comprehensive income for the three and six months ended June 30, 2023 or 2022 . The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.
Distributions	Distributions Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions.
Segments	Segments The Company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these loan and investment relationships has similar business and economic characteristics, they have been aggregated into a single reportable segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2022, the FASB issued ASU 2022-03, “Fair Value Measurement (Topic 820)  Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, which was issued to (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The new guidance is effective for interim and annual periods beginning after December 15, 2023. The Company does not anticipate the new standard will have a material impact to the consolidated financial statements and related disclosures.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Investments Measured at Fair Value on Recurring Basis	These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of June 30, 2023 and December 31, 2022. (in thousands) Balance as of Quoted Prices in Significant Significant Description 2023 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 803 $ — $ — $ 803 Investments Senior Secured Debt $ 2,878,923 $ — $ — $ 2,878,923 Unsecured Debt 59,019 — — 59,019 Preferred Stock 41,249 — — 41,249 Common Stock (1) 94,931 61,144 — 33,787 Warrants 34,314 — 13,134 21,180 $ 3,108,436 $ 61,144 $ 13,134 $ 3,034,158 Investment Funds & Vehicles measured at Net Asset Value (2) 4,353 Total Investments, at fair value $ 3,112,789 Derivative Instruments (3) $ ( 554 ) Total Investments, at fair value including derivative instruments $ 3,112,235 (in thousands) Balance as of Quoted Prices in Significant Significant Description 2022 (Level 1) (Level 2) (Level 3) Other assets Escrow Receivables $ 875 $ — $ — $ 875 Investments Senior Secured Debt $ 2,741,388 $ — $ — $ 2,741,388 Unsecured Debt 54,056 — — 54,056 Preferred Stock 41,488 — — 41,488 Common Stock 92,484 66,027 1,398 25,059 Warrants 30,646 — 11,227 19,419 $ 2,960,062 $ 66,027 $ 12,625 $ 2,881,410 Investment Funds & Vehicles measured at Net Asset Value (2) 3,893 Total Investments, at fair value $ 2,963,955 (1) Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock. (2) In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities. (3) Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy.
Summary of Reconciliation Changes for Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the six months ended June 30, 2023 and 2022. (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (3) Gross (3) Balance as of Investments Senior Secured Debt $ 2,741,388 $ ( 5,845 ) $ 19,330 $ 648,729 $ — $ ( 524,679 ) $ — $ — $ 2,878,923 Unsecured Debt 54,056 — 4,276 687 — — — — 59,019 Preferred Stock 41,488 ( 1,941 ) 1,702 — — — — — 41,249 Common Stock 25,059 — 8,322 1,000 ( 594 ) — — — 33,787 Warrants 19,419 ( 1,763 ) 722 2,809 ( 7 ) — — — 21,180 Other Assets Escrow Receivable 875 80 — — ( 152 ) — — — 803 Total $ 2,882,285 $ ( 9,469 ) $ 34,352 $ 653,225 $ ( 753 ) $ ( 524,679 ) $ — $ — $ 3,034,961 (in thousands) Balance as of Net Realized (1) Net Change in (2) Purchases (5) Sales Repayments (6) Gross (4) Gross (4) Balance as of Investments Senior Secured Debt $ 2,156,709 $ ( 1,883 ) $ ( 16,525 ) $ 599,596 $ ( 73,500 ) $ ( 164,254 ) $ — $ ( 3,504 ) $ 2,496,639 Unsecured Debt 52,890 — ( 2,025 ) 3,362 — — — — 54,227 Preferred Stock 69,439 2,867 ( 14,157 ) 2,903 ( 4,772 ) — — ( 6,422 ) 49,858 Common Stock 21,968 ( 93 ) 10,240 — — — 207 ( 3,942 ) 28,380 Warrants 27,477 409 ( 8,120 ) 4,391 ( 2,167 ) — — — 21,990 Other Assets Escrow Receivable 561 312 — 167 ( 398 ) — — — 642 Total $ 2,329,044 $ 1,612 $ ( 30,587 ) $ 610,419 $ ( 80,837 ) $ ( 164,254 ) $ 207 $ ( 13,868 ) $ 2,651,736 (1) Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. (2) Included in net change in unrealized appreciation (depreciation) in the ac companying Consoli dated Statements of Operations. (3) There were no transfers into or out of Level 3 during the six months ended June 30, 2023. (4) Transfers out of Level 3 during the six months ended June 30, 2022, related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the six months ended June 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares. (5) Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. (6) Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
Schedule of Quantitative Information of Fair Value Measurements	The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of June 30, 2023 and December 31, 2022. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable. Investment Type - Level 3 Fair Value as of Valuation Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 1,046,205 Market Comparable Companies Hypothetical Market Yield 11.72 % - 18.25 % 14.52 % Premium/(Discount) ( 1.00 )% - 3.50 % 0.10 % Technology 1,047,563 Market Comparable Companies Hypothetical Market Yield 12.87 % - 20.20 % 15.57 % Premium/(Discount) ( 0.75 )% - 3.00 % 0.39 % 22,407 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.22 % Sustainable and Renewable Technology 1,856 Market Comparable Companies Hypothetical Market Yield 11.10 % 11.10 % Premium/(Discount) 0.75 % 0.75 % Lower Middle Market 252,658 Market Comparable Companies Hypothetical Market Yield 14.07 % - 17.36 % 13.96 % Premium/(Discount) ( 0.75 )% - 1.75 % 0.23 % 7,073 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 255,144 Debt Investments originated within 6 months 142,446 Imminent Payoffs (4) 162,590 Debt Investments Maturing in Less than One Year $ 2,937,942 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Fair Value as of Valuation Techniques/Methodologies Unobservable Input (1) Range Weighted (2) Pharmaceuticals $ 903,427 Market Comparable Companies Hypothetical Market Yield 11.74 % - 19.04 % 15.17 % Premium/(Discount) ( 0.75 )% - 1.75 % 0.01 % Technology 967,108 Market Comparable Companies Hypothetical Market Yield 12.05 % - 18.53 % 15.21 % Premium/(Discount) ( 1.00 )% - 1.50 % 0.20 % 20,356 Convertible Note Analysis Probability weighting of alternative outcomes 1.00 % - 50.00 % 35.79 % 1,671 Liquidation (3) Probability weighting of alternative outcomes 5.00 % - 80.00 % 48.29 % Sustainable and Renewable Technology 3,006 Market Comparable Companies Hypothetical Market Yield 14.71 % - 14.71 % 14.71 % Premium/(Discount) 0.75 % - 0.75 % 0.75 % Lower Middle Market 328,393 Market Comparable Companies Hypothetical Market Yield 13.68 % - 18.49 % 14.82 % Premium/(Discount) ( 2.00 )% - 0.75 % ( 0.43 )% 8,042 Liquidation (3) Probability weighting of alternative outcomes 20.00 % - 80.00 % 80.00 % Debt Investments for which Cost Approximates Fair Value 392,168 Debt Investments originated within 6 months 77,676 Imminent Payoffs (4) 93,597 Debt Investments Maturing in Less than One Year $ 2,795,444 Total Level 3 Debt Investments (1) The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment. Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows: • Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries. • Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business • Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry. • Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified (2) The weighted averages are calculated based on the fair market value of each investment. (3) The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. (4) Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 35,966 Market Comparable Companies EBITDA Multiple (2) 13.3 x - 13.3 x 13.3 x Revenue Multiple (2) 0.6 x - 18.0 x 7.9 x Tangible Book Value Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 5.47 % - 32.11 % 23.35 % 8,882 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 83.47 )% - 13.33 % ( 13.31 )% 27,161 Discounted Cash Flow Discount Rate (7) 19.95 % - 31.68 % 26.14 % — Liquidation Revenue Multiple (2) 1.7 x - 1.7 x 1.7 x Discount for Lack of Marketability (3) 83.00 % - 83.00 % 83.00 % 3,027 Other (6) Warrant Investments 15,936 Market Comparable Companies EBITDA Multiple (2) 13.3 x - 13.3 x 13.3 x Revenue Multiple (2) 0.7 x - 9.9 x 3.9 x Discount for Lack of Marketability (3) 5.47 % - 32.50 % 22.91 % 5,244 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 63.49 )% - 23.93 % 6.56 % Total Level 3 Equity and Warrant Investments $ 96,216 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. Investment Type - Level 3 Equity and Warrant Investments Fair Value as of Valuation Techniques/ Unobservable Input (1) Range Weighted Average (5) Equity Investments $ 30,086 Market Comparable Companies EBITDA Multiple (2) 12.4 x - 12.4 x 12.4 x Revenue Multiple (2) 0.7 x - 16.1 x 7.4 x Tangible Book Value Multiple (2) 1.6 x - 1.6 x 1.6 x Discount for Lack of Marketability (3) 8.11 % - 28.90 % 19.79 % 13,795 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.82 )% - 16.34 % ( 16.69 )% 19,153 Discounted Cash Flow Discount Rate (7) 17.72 % - 30.13 % 24.46 % — Liquidation Revenue Multiple (2) 2.1 x - 2.1 x 2.1 x Discount for Lack of Marketability (3) 85.00 % - 85.00 % 85.00 % 3,513 Other (6) Warrant Investments 12,479 Market Comparable Companies EBITDA Multiple (2) 12.4 x - 12.4 x 12.4 x Revenue Multiple (2) 0.6 x - 8.8 x 3.4 x Discount for Lack of Marketability (3) 8.11 % - 32.70 % 18.97 % 6,934 Market Adjusted OPM Backsolve Market Equity Adjustment (4) ( 97.82 )% - 66.43 % ( 8.86 )% — Liquidation Revenue Multiple (2) 6.2 x - 6.2 x 6.2 x Discount for Lack of Marketability (3) 90.00 % - 90.00 % 90.00 % 6 Other (6) Total Level 3 Equity and Warrant Investments $ 85,966 (1) The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes. (2) Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. (3) Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. (4) Represents the range of changes in industry valuations since the portfolio company's last external valuation event. (5) Weighted averages are calculated based on the fair market value of each investment. (6) The fair market value of these investments is derived based on recent market transactions. (7) The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Schedule of Fair Value Hierarchy Of Outstanding Borrowings	The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 170,028 $ 146,395 $ — $ — $ 146,395 July 2024 Notes 104,680 103,447 — — 103,447 February 2025 Notes 49,809 47,754 — — 47,754 June 2025 Notes 69,676 65,121 — — 65,121 June 2025 3-Year Notes 49,694 47,831 — — 47,831 March 2026 A Notes 49,747 46,038 — — 46,038 March 2026 B Notes 49,725 46,105 — — 46,105 September 2026 Notes 321,849 274,835 — — 274,835 January 2027 Notes 345,269 301,265 — — 301,265 2031 Asset-Backed Notes 148,251 139,740 — 139,740 — 2033 Notes 38,880 39,520 — 39,520 — MUFG Bank Facility (1) 61,000 61,000 — — 61,000 SMBC Facility 130,000 130,000 — — 130,000 Total $ 1,588,608 $ 1,449,051 $ — $ 179,260 $ 1,269,791 (in thousands) December 31, 2022 Carrying Approximate Identical Assets Observable Inputs Unobservable Inputs Description Value Fair Value (Level 1) (Level 2) (Level 3) SBA Debentures $ 169,738 $ 155,257 $ — $ — $ 155,257 July 2024 Notes 104,533 102,019 — — 102,019 February 2025 Notes 49,751 47,044 — — 47,044 June 2025 Notes 69,595 64,198 — — 64,198 June 2025 3-Year Notes 49,616 47,528 — — 47,528 March 2026 A Notes 49,700 45,512 — — 45,512 March 2026 B Notes 49,673 45,588 — — 45,588 September 2026 Notes 321,358 269,509 — — 269,509 January 2027 Notes 344,604 296,826 — — 296,826 2031 Asset-Backed Notes 147,957 142,620 — 142,620 — 2033 Notes 38,826 39,344 — 39,344 — MUFG Bank Facility (1) 107,000 107,000 — — 107,000 SMBC Facility 72,000 72,000 — — 72,000 Total $ 1,574,351 $ 1,434,445 $ — $ 181,964 $ 1,252,481 (1) In June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Schedule of Investments [Line Items]
shedule of Investments in and Advances to Affiliates	The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and six months ended June 30, 2023 and 2022. (in thousands) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Portfolio Company (1) Type Fair Value as of June 30, 2023 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 297 $ — $ — $ 41 $ — $ — $ — $ ( 22 ) $ — Gibraltar Acquisition LLC (3) Control 44,392 731 19 2,667 — 1,527 38 6,402 — Hercules Adviser LLC Control 39,161 152 — 2,566 — 302 — 8,008 — Tectura Corporation Control 7,073 172 — ( 701 ) — 342 — ( 969 ) — Total Control Investments $ 90,923 $ 1,055 $ 19 $ 4,573 $ — $ 2,171 $ 38 $ 13,419 $ — (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Portfolio Company (1) Type Fair Value as of June 30, 2022 Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Interest Income Fee Income Net Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss) Control Investments Coronado Aesthetics, LLC Control $ 422 $ — $ — $ ( 192 ) $ — $ — $ — $ ( 143 ) $ — Gibraltar Business Capital, LLC Control 39,064 844 17 ( 3,578 ) — 1,678 33 ( 4,805 ) — Hercules Adviser LLC Control 35,181 128 — 8,637 — 239 — 11,191 — Tectura Corporation Control 8,208 172 — ( 139 ) — 342 — ( 61 ) — Total Control Investments $ 82,875 $ 1,144 $ 17 $ 4,728 $ — $ 2,259 $ 33 $ 6,182 $ — Affiliate Investments Black Crow AI, Inc. (2) Affiliate $ — $ — $ — $ — $ — $ — $ — $ ( 120 ) $ 3,772 Pineapple Energy LLC (2) Affiliate 3,613 76 — ( 1,295 ) — 1,123 — ( 422 ) — Total Affiliate Investments $ 3,613 $ 76 $ — $ ( 1,295 ) $ — $ 1,123 $ — $ ( 542 ) $ 3,772 Total Control & Affiliate Investments $ 86,488 $ 1,220 $ 17 $ 3,433 $ — $ 3,382 $ 33 $ 5,640 $ 3,772 (1) In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 .
Schedule of Investment Collateral	Concentrations of Credit Risk The Company’s customers are primarily privately held companies and public companies which are active in the “Drug Discovery & Development", "Software”, “Consumer & Business Services”, “Healthcare Services, Other”, and “Communications & Networking" sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property. Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated among several portfolio companies. As of June 30, 2023 and December 31, 2022, the Company’s ten largest portfolio companies represented approximately 30.3 % and 29.0 % of the total fair value of the Company’s investments in portfolio companies, respectively. As of June 30, 2023 and December 31, 2022, the Company had six and eight portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of June 30, 2023, the Company had four equity investments representing approximately 52.6 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2022, the Company had four equity investments which represented approximately 39.8 % of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of such investments. Investment Collateral In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of June 30, 2023 and December 31, 2022: Percentage of debt investments (at fair value), as of June 30, 2023 December 31, 2022 Senior Secured First Lien All assets including intellectual property 50.3 % 42.0 % All assets with negative pledge on intellectual property 21.1 % 26.1 % “Last-out” with security interest in all of the assets 11.7 % 11.6 % Total senior secured first lien position 83.1 % 79.7 % Second lien 14.9 % 18.4 % Unsecured 2.0 % 1.9 % Total debt investments at fair value 100.0 % 100.0 % Derivative Instruments The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of June 30, 2023 and December 31, 2022: (in thousands) Fair Value Derivative Instrument Statement Location June 30, 2023 December 31, 2022 Foreign currency forward contract Other assets $ ( 554 ) $ — Total $ ( 554 ) $ — Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and six months ended June 30, 2023 and 2022 are in the following locations in the Consolidated Statements of Operations: (in thousands) Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Statement Location 2023 2022 2023 2022 Foreign currency forward contract Net realized gain (loss) - Non-control / Non-affiliate investments $ — $ — $ — $ — Foreign currency forward contract Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments ( 554 ) — ( 554 ) — Total $ ( 554 ) $ — $ ( 554 ) $ —
Summary Of Fair Value and Location Of The Company's Derivative Instruments	The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of June 30, 2023 and December 31, 2022: (in thousands) Fair Value Derivative Instrument Statement Location June 30, 2023 December 31, 2022 Foreign currency forward contract Other assets $ ( 554 ) $ — Total $ ( 554 ) $ —
Summary of Net realized and unrealized gains and losses	Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three and six months ended June 30, 2023 and 2022 are in the following locations in the Consolidated Statements of Operations: (in thousands) Three Months Ended June 30, Six Months Ended June 30, Derivative Instrument Statement Location 2023 2022 2023 2022 Foreign currency forward contract Net realized gain (loss) - Non-control / Non-affiliate investments $ — $ — $ — $ — Foreign currency forward contract Net change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments ( 554 ) — ( 554 ) — Total $ ( 554 ) $ — $ ( 554 ) $ —
Schedule of Investment Interest Income and Fee Income	The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows: (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Contractual interest income $ 86,147 $ 56,063 $ 168,938 $ 105,607 Exit fee interest income 14,054 6,655 23,436 13,381 PIK interest income 5,819 4,968 11,347 9,943 Other interest income (1) 2,966 1,045 5,162 2,052 Total interest income $ 108,986 $ 68,731 $ 208,883 $ 130,983 (in thousands) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Recurring fee income $ 2,135 $ 1,907 $ 4,175 $ 3,686 Fee income - expired commitments 108 433 351 521 Accelerated fee income - early repayments 5,002 1,044 7,912 2,082 Total fee income $ 7,245 $ 3,384 $ 12,438 $ 6,289 (1) Other interest income includes OID interest income and interest recorded on other assets .
Schedule of Unamortized Capitalized Fee Income	As of June 30, 2023 and December 31, 2022, unamortized capitalized fee income was recorded as follows: (in millions) June 30, December 31, 2023 2022 Offset against debt investment cost $ 43.9 $ 43.1 Deferred obligation contingent on funding or other milestone 12.2 10.9 Total Unamortized Fee Income $ 56.1 $ 54.0
Schedule of Loan Exit Fees Receivable	As of June 30, 2023 and December 31, 2022, loan exit fees receivable were recorded as follows: (in millions) June 30, December 31, 2023 2022 Included within debt investment cost $ 32.5 $ 32.5 Deferred receivable related to expired commitments 3.5 5.0 Total Exit Fees Receivable $ 36.0 $ 37.5
Industry Sector
Schedule of Investments [Line Items]
Investment Holdings, Schedule of Investments [Table Text Block]	The following table shows the fair value of the Company’s portfolio by industry sector as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of Drug Discovery & Development $ 1,137,725 36.5 % $ 1,150,707 38.8 % Software 891,438 28.6 % 798,264 26.9 % Consumer & Business Services 459,276 14.8 % 439,384 14.8 % Healthcare Services, Other 220,673 7.1 % 198,763 6.7 % Communications & Networking 105,343 3.4 % 101,833 3.4 % Diversified Financial Services 94,077 3.0 % 68,569 2.3 % Information Services 73,306 2.4 % 60,759 2.0 % Manufacturing Technology 49,596 1.6 % 46,109 1.6 % Biotechnology Tools 33,465 1.1 % 32,825 1.1 % Electronics & Computer Hardware 20,727 0.7 % 21,517 0.7 % Media/Content/Info 11,542 0.4 % 35 0.0 % Sustainable and Renewable Technology 11,333 0.4 % 15,486 0.5 % Consumer & Business Products 1,294 0.0 % 2,821 0.1 % Semiconductors 1,188 0.0 % 21,921 0.7 % Medical Devices & Equipment 1,052 0.0 % 1,834 0.1 % Surgical Devices 731 0.0 % 3,038 0.1 % Drug Delivery 23 0.0 % 90 0.0 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 %
Geographic Location
Schedule of Investments [Line Items]
Investment Holdings, Schedule of Investments [Table Text Block]	A summary of the Company’s investment portfolio, at value, by geographic location as of June 30, 2023 and December 31, 2022 is shown as follows: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of United States $ 2,755,178 88.5 % $ 2,670,520 90.1 % United Kingdom 200,455 6.5 % 171,629 5.8 % Netherlands 87,664 2.8 % 88,915 3.0 % Israel 53,019 1.7 % 9,052 0.3 % Canada 11,264 0.4 % 19,472 0.7 % Denmark 3,767 0.1 % — 0.0 % Germany 999 0.0 % 990 0.0 % Other 443 0.0 % 573 0.0 % Ireland — 0.0 % 2,804 0.1 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 %
Security Type Member
Schedule of Investments [Line Items]
Investment Holdings, Schedule of Investments [Table Text Block]	The following table shows the fair value of the Company’s portfolio of investments by asset class as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 Investments at Percentage of Investments at Percentage of Senior Secured Debt $ 2,878,923 92.5 % $ 2,741,388 92.5 % Unsecured Debt 59,019 1.9 % 54,056 1.8 % Preferred Stock 41,249 1.4 % 41,488 1.4 % Common Stock 94,931 3.0 % 92,484 3.1 % Warrants 34,314 1.1 % 30,646 1.1 % Investment Funds & Vehicles 4,353 0.1 % 3,893 0.1 % Total $ 3,112,789 100.0 % $ 2,963,955 100.0 %

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Schedule of Available and Outstanding Debt	As of June 30, 2023 and December 31, 2022, the Company had the following available and outstanding debt: (in thousands) June 30, 2023 December 31, 2022 Total Available Principal Carrying Value (1) Total Available Principal Carrying Value (1) SBA Debentures (2) $ 175,000 $ 175,000 $ 170,028 $ 175,000 $ 175,000 $ 169,738 July 2024 Notes 105,000 105,000 104,680 105,000 105,000 104,533 February 2025 Notes 50,000 50,000 49,809 50,000 50,000 49,751 June 2025 Notes 70,000 70,000 69,676 70,000 70,000 69,595 June 2025 3-Year Notes 50,000 50,000 49,694 50,000 50,000 49,616 March 2026 A Notes 50,000 50,000 49,747 50,000 50,000 49,700 March 2026 B Notes 50,000 50,000 49,725 50,000 50,000 49,673 September 2026 Notes 325,000 325,000 321,849 325,000 325,000 321,358 January 2027 Notes 350,000 350,000 345,269 350,000 350,000 344,604 2031 Asset-Backed Notes 150,000 150,000 148,251 150,000 150,000 147,957 2033 Notes 40,000 40,000 38,880 40,000 40,000 38,826 MUFG Bank Facility (2)(3) 400,000 61,000 61,000 545,000 107,000 107,000 SMBC Facility (2)(4) 400,000 130,000 130,000 225,000 72,000 72,000 Total $ 2,215,000 $ 1,606,000 $ 1,588,608 $ 2,185,000 $ 1,594,000 $ 1,574,351 (1) Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. (2) Availability subject to the Company meeting the borrowing base requirements. (3) In June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. (4) Includes $ 175.0 million of available commitment through the letter of credit facility.
Schedule of Debt Issuance Costs, Net of Accumulated Amortization	Debt issuance costs, net of accumulated amortization, were as follows as of June 30, 2023 and December 31, 2022: (in thousands) June 30, 2023 December 31, 2022 SBA Debentures $ 4,972 $ 5,262 July 2024 Notes 320 467 February 2025 Notes 191 249 June 2025 Notes 324 405 June 2025 3-Year Notes 306 384 March 2026 A Notes 253 300 March 2026 B Notes 275 327 September 2026 Notes 3,151 3,642 January 2027 Notes 4,731 5,396 2031 Asset-Backed Notes 1,749 2,043 2033 Notes 1,120 1,174 MUFG Bank Facility (1) 4,425 1,292 SMBC Facility (1) 2,135 1,701 Total $ 23,952 $ 22,642 (1) The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.
Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt	For the three and six months ended June 30, 2023, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,137 $ 146 $ — $ 1,283 $ — $ 2,262 $ 290 $ — $ 2,552 $ 2,262 July 2024 Notes 1,252 74 — 1,326 — 2,504 148 — 2,652 2,504 February 2025 Notes 535 28 — 563 — 1,070 57 — 1,127 1,070 June 2025 Notes 755 41 — 796 1,509 1,509 81 — 1,590 1,509 June 2025 3-Year Notes 750 39 — 789 1,500 1,500 78 — 1,578 1,500 March 2026 A Notes 562 23 — 585 — 1,125 47 — 1,172 1,125 March 2026 B Notes 568 26 — 594 — 1,137 52 — 1,189 1,138 September 2026 Notes 2,175 204 — 2,379 — 4,349 408 — 4,757 4,266 January 2027 Notes 3,078 207 — 3,285 — 6,157 414 — 6,571 5,906 2031 Asset-Backed Notes 1,904 100 — 2,004 1,857 3,807 200 — 4,007 3,713 2033 Notes 625 27 — 652 625 1,250 54 — 1,304 1,250 MUFG Bank Facility (2) 1,363 442 691 2,496 1,595 3,076 884 1,308 5,268 3,433 SMBC Facility 2,480 180 236 2,896 2,738 4,063 333 439 4,835 3,988 Total $ 17,184 $ 1,537 $ 927 $ 19,648 $ 9,824 $ 33,809 $ 3,046 $ 1,747 $ 38,602 $ 33,664 (1) Interest expense includes amortization of original issue discounts for the three months ended June 30, 2023 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2023, $ 83 thousand, $ 251 thousand, and $ 94 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. For the three and six months ended June 30, 2022, the components of interest expense and related fees and cash paid for interest expense for debt were as follows: (in thousands) Three Months Ended June 30, 2022 Six Months Ended June 30, 2022 Interest expense (1) Amortization of debt issuance cost (loan fees) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense Interest expense (1) Amortization of debt issuance cost (loan fees) (2) Unused facility and other fees (loan fees) Total interest expense and fees Cash paid for interest expense SBA Debentures $ 1,138 $ 146 $ — $ 1,284 $ — $ 1,688 $ 286 $ — $ 1,974 $ 749 2022 Notes (2) — — — — — 1,011 50 — 1,061 2,293 July 2024 Notes 1,252 74 — 1,326 — 2,504 148 — 2,652 2,504 February 2025 Notes 535 28 — 563 — 1,070 57 — 1,127 1,070 June 2025 Notes 755 41 — 796 1,509 1,509 81 — 1,590 1,509 June 2025 3-Year Notes 67 4 — 71 — 67 4 — 71 — March 2026 A Notes 562 24 — 586 — 1,125 48 — 1,173 1,125 March 2026 B Notes 568 26 — 594 — 1,137 52 — 1,189 1,138 September 2026 Notes 2,175 204 — 2,379 — 4,349 408 — 4,757 4,266 January 2027 Notes 3,078 207 — 3,285 — 5,473 368 — 5,841 — 2031 Asset-Backed Notes 169 9 — 178 — 169 9 — 178 — 2033 Notes 625 27 — 652 625 1,250 54 — 1,304 1,250 2022 Convertible Notes (2) — — — — — 923 149 — 1,072 5,004 MUFG Bank Facility (3) 1,369 175 395 1,939 1,215 1,483 412 962 2,857 1,215 SMBC Facility 405 64 68 537 283 587 113 133 833 519 Total $ 12,698 $ 1,029 $ 463 $ 14,190 $ 3,632 $ 24,345 $ 2,239 $ 1,095 $ 27,679 $ 22,642 (1) Interest expense includes amortization of original issue discounts for the three months ended June 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 4 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2022, $ 23 thousand, $ 112 thousand, $ 84 thousand, $ 223 thousand, and $ 4 thousand, related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. (2) In February 2022, the Company has fully repaid the aggregate outstanding principal balances and retired 2022 Notes and 2022 Convertible Notes. (3) The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.
SBA Debentures
Schedule of Available and Outstanding Debt	The Company held the following SBA debentures outstanding principal balances as of June 30, 2023 and December 31, 2022: (in thousands) Maturity Date Interest Rate (1) June 30, 2023 December 31, 2022 March 26, 2021 September 1, 2031 1.58 % $ 37,500 $ 37,500 June 25, 2021 September 1, 2031 1.58 % 16,200 16,200 July 28, 2021 September 1, 2031 1.58 % 5,400 5,400 August 20, 2021 September 1, 2031 1.58 % 5,400 5,400 October 21, 2021 March 1, 2032 3.21 % 14,000 14,000 November 1, 2021 March 1, 2032 3.21 % 21,000 21,000 November 15, 2021 March 1, 2032 3.21 % 5,200 5,200 November 30, 2021 March 1, 2032 3.21 % 20,800 20,800 December 20, 2021 March 1, 2032 3.21 % 10,000 10,000 December 23, 2021 March 1, 2032 3.21 % 10,000 10,000 December 28, 2021 March 1, 2032 3.21 % 5,000 5,000 January 14, 2022 March 1, 2032 3.21 % 4,500 4,500 January 21, 2022 March 1, 2032 3.21 % 20,000 20,000 Total SBA Debentures $ 175,000 $ 175,000 (1) Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.

Stockholders' Equity and Dist_2

Stockholders' Equity and Distributions (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of Common Stock Shares Issued and Sold	The Company issued and sold the following shares of common stock during the six months ended June 30, 2023 and 2022: (in millions, except per share data) Six Months Ended June 30th, Number of Shares Issued Gross Proceeds Underwriting Fees/Offering Expenses Net Proceeds Average Price/Share 2022 8.9 $ 148.7 $ 1.6 $ 147.1 $ 16.5 2023 9.7 $ 132.3 $ 1.6 $ 130.7 $ 13.5
Schedule of Dividends Declared	The following table summarizes the Company’s distributions declared during the six months ended June 30, 2023 and year ended December 31, 2022: (in thousands, except per share data) Distribution Type Declared Date Record Date Payment Date Per Share Amount Total Amount Base February 16, 2022 March 9, 2022 March 16, 2022 $ 0.33 $ 39,794 Supplemental February 16, 2022 March 9, 2022 March 16, 2022 $ 0.15 $ 18,088 Base April 27, 2022 May 17, 2022 May 24, 2022 $ 0.33 $ 41,245 Supplemental April 27, 2022 May 17, 2022 May 24, 2022 $ 0.15 $ 18,748 Base July 20, 2022 August 9, 2022 August 16, 2022 $ 0.35 $ 44,765 Supplemental July 20, 2022 August 9, 2022 August 16, 2022 $ 0.15 $ 19,185 Base October 13, 2022 November 10, 2022 November 17, 2022 $ 0.36 $ 47,472 Supplemental October 13, 2022 November 10, 2022 November 17, 2022 $ 0.15 $ 19,780 Total distributions declared during the year ended December 31, 2022 $ 1.97 $ 249,077 Base February 9, 2023 March 2, 2023 March 9, 2023 $ 0.39 $ 53,749 Supplemental February 9, 2023 March 2, 2023 March 9, 2023 $ 0.08 $ 11,025 Base April 27, 2023 May 16, 2023 May 23, 2023 $ 0.39 $ 55,910 Supplemental April 27, 2023 May 16, 2023 May 23, 2023 $ 0.08 $ 11,469 Total distributions declared during the six months ended June 30, 2023 $ 0.94 $ 132,153

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of unvested restricted stock equity	The activities for the Company's unvested restricted stock equity awards for each of the six months ended June 30, 2023, and 2022, are summarized below: Six Months Ended June 30, 2023 2022 Shares Weighted Average Grant Date Shares Weighted Average Grant Date Unvested Shares Beginning of Period 958,985 $ 16.35 1,037,848 $ 14.51 Granted 1,306,880 $ 13.81 610,541 $ 17.39 Vested (1) ( 414,634 ) $ 16.28 ( 463,408 ) $ 14.39 Forfeited ( 6,712 ) $ 16.17 ( 17,108 ) $ 15.89 Unvested Shares End of Period 1,844,519 $ 14.57 1,167,873 $ 16.05 (1) With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	Shares used in the computation of the Company’s basic and diluted earnings per share are as follows: (in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator Net increase (decrease) in net assets resulting from operations $ 94,775 $ ( 10,318 ) $ 189,339 $ ( 13,654 ) Less: Total distributions declared ( 67,379 ) ( 59,993 ) ( 132,153 ) ( 117,875 ) Total Earnings (loss), net of total distributions 27,396 ( 70,311 ) 57,186 ( 131,529 ) Earnings (loss), net of distributions attributable to common shares 27,108 ( 70,311 ) 56,552 ( 131,529 ) Add: Distributions declared attributable to common shares 66,672 59,431 130,696 116,693 Numerator for basic and diluted change in net assets per common share $ 93,780 $ ( 10,880 ) $ 187,248 $ ( 14,836 ) Denominator Basic weighted average common shares outstanding 141,390 124,255 138,338 121,292 Common shares issuable 694 — 1,249 — Weighted average common shares outstanding assuming dilution 142,084 124,255 139,587 121,292 Change in net assets per common share: Basic $ 0.66 $ ( 0.09 ) $ 1.35 $ ( 0.12 ) Diluted $ 0.66 $ ( 0.09 ) $ 1.34 $ ( 0.12 )
Schedule of Number of Anti-diluted Shares As Calculated Based on Weighted Average Closing Price of Common Stock	The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three and six months ended June 30, 2023, and 2022, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows: Three Months Ended June 30, Six Months Ended June 30, Anti-dilutive Securities 2023 2022 2023 2022 Unvested common stock options 3,146 16 2,499 24 Restricted stock units 9,555 2 8,714 17 Unvested restricted stock awards 65,346 — 59,854 — Performance awards* — 1,685 — 1,116 * Included in these amounts are shares related to certain equity-based awards, which fully vested in May 2022 and delivered in May 2023 and thus no longer outstanding for purposes of calculating earnings per share.

Financial Highlights (Tables)

Financial Highlights (Tables)	6 Months Ended
	Jun. 30, 2023
Investment Company, Financial Highlights [Abstract]
Schedule of Financial Highlights	Following is a schedule of financial highlights for the six months ended June 30, 2023 and 2022: (in thousands, except per share data and ratios) Six Months Ended June 30, 2023 2022 Per share data (1) : Net asset value at beginning of period $ 10.53 $ 11.22 Net investment income 1.02 0.62 Net realized gain (loss) 0.06 ( 0.04 ) Net unrealized appreciation (depreciation) 0.29 ( 0.70 ) Total from investment operations 1.37 ( 0.12 ) Net increase (decrease) in net assets from capital share transactions (1) ( 0.01 ) 0.23 Distributions of net investment income (6) ( 0.96 ) ( 0.96 ) Stock-based compensation expense included in net investment income and other movements (2) 0.03 0.06 Net asset value at end of period $ 10.96 $ 10.43 Ratios and supplemental data: Per share market value at end of period $ 14.80 $ 13.49 Total return (3) 19.55 % ( 13.72 )% Shares outstanding at end of period 144,641 127,285 Weighted average number of common shares outstanding 138,338 121,292 Net assets at end of period $ 1,585,510 $ 1,327,740 Ratio of total expense to average net assets (4) 10.75 % 9.13 % Ratio of net investment income before investment gains and losses to average net assets (4) 18.95 % 11.30 % Portfolio turnover rate (5) 17.20 % 8.88 % Weighted average debt outstanding $ 1,614,522 $ 1,386,242 Weighted average debt per common share $ 11.69 $ 11.43 (1) All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. (2) Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, (3) The total return for the six months ended June 30, 2023, and 2022 equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. (4) The ratios are calculated based on weighted average net assets for the relevant period and are annualized. (5) The portfolio turnover rate for the six months ended June 30, 2023, and 2022 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. (6) Includes distributions on unvested restricted stock awards.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2023
Other Commitments [Line Items]
Schedule of Unfunded Contractual Commitments and Unencumbered Unfunded Commitments	As of June 30, 2023, and December 31, 2022, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows: (in thousands) Unfunded Commitments (1) as of Portfolio Company June 30, 2023 December 31, 2022 Debt Investments: Thumbtack, Inc. $ 40,000 $ 40,000 Automation Anywhere, Inc. 29,400 29,400 Axsome Therapeutics, Inc. 25,375 21,000 Skydio, Inc. 22,500 22,500 SeatGeek, Inc. 19,375 — Phathom Pharmaceuticals, Inc. 16,625 66,500 Carwow LTD 14,365 — Dragos 13,000 — Dronedeploy, Inc. 12,500 12,500 Iveric Bio, Inc. 12,375 — PathAI, Inc. 12,000 12,000 Locus Robotics Corp. 10,740 — Tipalti Solutions Ltd. 10,500 — Alamar Biosciences, Inc. 10,000 10,000 Aryaka Networks, Inc. 10,000 20,000 Next Insurance, Inc. 10,000 — Kura Oncology, Inc. 8,250 8,250 Tarsus Pharmaceuticals, Inc. 8,250 10,313 Elation Health, Inc. 7,500 7,500 Gritstone Bio, Inc. 7,500 7,500 TG Therapeutics, Inc. 6,500 — Nuvolo Technologies Corporation 5,700 5,970 Akero Therapeutics, Inc. 5,000 5,000 Cutover, Inc. 4,150 1,000 Leapwork ApS 4,100 — Saama Technologies, LLC 3,875 — Riviera Partners LLC 3,500 3,500 Babel Street 3,375 3,375 Modern Life, Inc. 3,250 — Signal Media Limited 3,000 5,250 Vida Health, Inc. 3,000 40,000 Zappi, Inc. 2,571 2,571 Brain Corporation 2,500 20,700 Yipit, LLC 2,250 2,250 Streamline Healthcare Solutions 2,200 — Sumo Logic, Inc. 2,000 — Ceros, Inc. 1,707 1,707 ThreatConnect, Inc. 1,600 1,600 (in thousands) Unfunded Commitments (1) as of Portfolio Company June 30, 2023 December 31, 2022 Debt Investments: RVShare, LLC $ 1,500 $ 1,500 Loftware, Inc. 1,423 — Dispatch Technologies, Inc. 1,250 1,250 3GTMS, LLC 1,222 — LogicSource 1,209 1,209 Zimperium, Inc. 1,088 1,088 Ikon Science Limited 1,050 1,050 Omeda Holdings, LLC 919 938 Khoros (p.k.a Lithium Technologies) 906 1,812 Fortified Health Security 840 840 Agilence, Inc. 800 800 Flight Schedule Pro, LLC 639 639 Constructor.io Corporation 625 625 Enmark Systems, Inc. 457 457 Alchemer LLC 445 890 Cybermaxx Intermediate Holdings, Inc. 390 390 Annex Cloud 386 386 ShadowDragon, LLC 333 333 Cytracom Holdings LLC 72 225 Provention Bio, Inc. — 40,000 Madrigal Pharmaceutical, Inc. — 34,000 Oak Street Health, Inc. — 33,750 HilleVax, Inc. — 28,000 Replimune Group, Inc. — 20,700 G1 Therapeutics, Inc. — 19,375 Alladapt Immunotherapeutics Inc. — 15,000 AppDirect, Inc. — 15,000 Viridian Therapeutics, Inc. — 12,000 Dashlane, Inc. — 10,000 Fever Labs, Inc. — 8,333 Fulfil Solutions, Inc. — 5,000 Demandbase, Inc. — 3,750 MacroFab, Inc. — 3,000 Mobile Solutions Services — 495 Total Unfunded Debt Commitments: 376,087 623,221 Investment Funds & Vehicles: (2) Forbion Growth Opportunities Fund I C.V. 2,269 2,842 Forbion Growth Opportunities Fund II C.V. 2,748 2,811 Total Unfunded Commitments in Investment Funds & Vehicles: 5,017 5,653 Total Unfunded Commitments $ 381,104 $ 628,874 (1) For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. (2) For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.
Schedule of Contractual Obligations	The following tables provide the Company’s contractual obligations as of June 30, 2023 and December 31, 2022: As of June 30, 2023: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (2)(3) $ 1,606,000 $ — $ 375,000 $ 866,000 $ 365,000 Lease and License Obligations (4) 27,493 2,922 6,617 6,223 11,731 Total $ 1,633,493 $ 2,922 $ 381,617 $ 872,223 $ 376,731 As of December 31, 2022: Payments due by period (in thousands) Contractual Obligations (1) Total Less than 1 year 1 - 3 years 3 - 5 years After 5 years Debt (5)(3) $ 1,594,000 $ — $ 382,000 $ 847,000 $ 365,000 Lease and License Obligations (4) 8,641 2,723 2,259 2,452 1,207 Total $ 1,602,641 $ 2,723 $ 384,259 $ 849,452 $ 366,207 (1) Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. (2) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of June 30, 2023. There was also $ 130.0 million outstanding under the SMBC Facility and $ 61.0 million outstanding under the MUFG Bank Facility as of June 30, 2023 . (3) Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. (4) Facility leases and licenses including short-term leases. (5) Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of December 31, 2022. There was also $ 72.0 million outstanding under the SMBC Facility and $ 107.0 million outstanding under the MUFG Bank Facility as of December 31, 2022 .
Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases	The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of June 30, 2023, and 2022: (in thousands) Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 Total operating lease cost $ 606 $ 744 $ 1,304 $ 1,441 Cash paid for amounts included in the measurement of lease liabilities $ 1,127 $ 1,175 $ 1,736 $ 1,769 As of June 30, 2023 As of December 31, 2022 Weighted-average remaining lease term (in years) 8.62 5.48 Weighted-average discount rate 6.71 % 5.37 %
Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability	The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of June 30, 2023: (in thousands) As of June 30, 2023 2023 $ 1,042 2024 3,034 2025 3,288 2026 3,383 Thereafter 16,623 Total lease payments 27,370 Less: imputed interest & other items ( 23,484 ) Total operating lease liability $ 3,886
Unfunded Debt Commitments
Other Commitments [Line Items]
Schedule of Unfunded Contractual Commitments and Unencumbered Unfunded Commitments	The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type: (in thousands) June 30, 2023 December 31, 2022 Unfunded Debt Commitments: Expiring during: 2023 $ 187,230 $ 461,296 2024 156,056 134,856 2025 1,294 720 2026 9,037 9,038 2027 15,152 15,171 2028 5,318 2,140 2030 2,000 — Total Unfunded Debt Commitments 376,087 623,221 Unfunded Commitments in Investment Funds & Vehicles: Expiring during: 2030 2,269 2,842 2032 2,748 2,811 Total Unfunded Commitments in Investment Funds & Vehicles 5,017 5,653 Total Unfunded Commitments $ 381,104 $ 628,874

Schedule 12-14s - Summary of sc

Schedule 12-14s - Summary of schedule of investment (Tables)	6 Months Ended
	Jun. 30, 2023
Investments in and Advances to Affiliates [Abstract]
Schedule of Investments in and Advances to Affiliates	(in thousands) Investment (1) Amount of Interest and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of June 30, 2023 Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC (8) Preferred Stock $ — $ — $ 313 $ — — $ ( 21 ) $ 292 Common Stock — — 6 — — ( 1 ) 5 Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) (5) Unsecured Debt 1,565 — 21,700 46 — 2,867 24,613 Member Units — — 15,244 1,000 — 3,535 19,779 Hercules Adviser LLC (6) Unsecured Debt 302 — 12,000 — — — 12,000 Member Units — — 19,153 — — 8,008 27,161 Total Majority Owned Control Investments $ 1,867 $ — $ 68,416 $ 1,046 $ — $ 14,388 $ 83,850 Other Control Investments Tectura Corporation (7) Senior Debt $ 342 $ — $ 8,042 $ — $ — $ ( 969 ) $ 7,073 Preferred Stock — — — — — — — Common Stock — — — — — — — Total Other Control Investments $ 342 $ — $ 8,042 $ — $ — $ ( 969 ) $ 7,073 Total Control Investments $ 2,209 $ — $ 76,458 $ 1,046 $ — $ 13,419 $ 90,923 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. (6) Hercules Adviser LLC is a wholly owned subsidiary providing investment management and other services to the Adviser Funds and other External Parties. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. (8) As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES For the Six Months Ended June 30, 2022 (unaudited) (in thousands) Investment (1) Amount of Interest and Fees Credited to Income (2) Realized Gain (Loss) Fair Value as of Gross Additions (3) Gross Reductions (4) Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of June 30, 2022 Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC (10) Preferred Stock $ — $ — $ 500 $ — $ — $ ( 88 ) $ 412 Common Stock — — 65 — — ( 55 ) 10 Gibraltar Business Capital, LLC (5) Unsecured Debt 1,711 — 23,212 39 — ( 576 ) 22,675 Preferred Stock — — 19,393 — — ( 3,978 ) 15,415 Common Stock — — 1,225 — — ( 251 ) 974 Hercules Adviser LLC (6) Unsecured Debt 239 — 8,850 3,150 — — 12,000 Member Units — — 11,990 — — 11,191 23,181 Total Majority Owned Control Investments $ 1,950 $ — $ 65,235 $ 3,189 $ — $ 6,243 $ 74,667 Other Control Investments Tectura Corporation (7) Senior Debt $ 342 $ — $ 8,269 $ — $ — $ ( 61 ) $ 8,208 Preferred Stock — — — — — — — Common Stock — — — — — — — Total Other Control Investments $ 342 $ — $ 8,269 $ — $ — $ ( 61 ) $ 8,208 Total Control Investments $ 2,292 $ — $ 73,504 $ 3,189 $ — $ 6,182 $ 82,875 Affiliate Investments Black Crow AI, Inc. (8) Preferred Stock $ — $ 3,772 $ 1,120 $ — $ ( 1,000 ) $ ( 120 ) $ — Pineapple Energy LLC (9) Senior Debt 1,123 — 7,747 78 ( 4,781 ) ( 104 ) 2,940 Common Stock — — 591 400 — ( 318 ) 673 Total Affiliate Investments $ 1,123 $ 3,772 $ 9,458 $ 478 $ ( 5,781 ) $ ( 542 ) $ 3,613 Total Control and Affiliate Investments $ 3,415 $ 3,772 $ 82,962 $ 3,667 $ ( 5,781 ) $ 5,640 $ 86,488 (1) Stock and warrants are generally non-income producing and restricted. (2) Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. (3) Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. (4) Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. (5) As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. (6) Hercules Adviser LLC is a wholly-owned subsidiary providing investment management and other services to External Parties. (7) As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the (8) During the six months ended June 30, 2022, the Company sold its investments in Black Crow AI, Inc., as a result it is no longer an affiliate investment. (9) As of December 11, 2020, the Company's investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the voting securities of the portfolio company. (10) As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of June 30, 2023 (unaudited) (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal or Shares Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 292 Medical Devices & Equipment Common Stock 180,000 — 5 Total Coronado Aesthetics, LLC $ 250 $ 297 Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) (3) Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.50 % $ 25,000 24,613 24,613 Diversified Financial Services Member Units 1 29,006 19,779 Total Gibraltar Acquisition, LLC $ 53,619 $ 44,392 Hercules Adviser LLC Diversified Financial Services Unsecured Debt June 2025 Interest rate FIXED 5.00 % $ 12,000 12,000 12,000 Diversified Financial Services Member Units 1 35 27,161 Total Hercules Adviser LLC $ 12,035 $ 39,161 Total Majority Owned Control Investments ( 5.29 %)* $ 65,904 $ 83,850 Other Control Investments Tectura Corporation Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 23,703 $ 13,263 $ — Consumer & Business Services Senior Secured Debt July 2024 Interest rate FIXED 8.25 % $ 8,250 8,250 7,073 Consumer & Business Services Preferred Series BB Equity 1,000,000 — — Consumer & Business Services Common Stock 414,994,863 900 — Total Tectura Corporation $ 22,413 $ 7,073 Total Other Control Investments ( 0.44 %)* $ 22,413 $ 7,073 Total Control Investments ( 5.73 %)* $ 88,317 $ 90,923 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. (3) Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. Schedule 12 – 14 HERCULES CAPITAL, INC. CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES As of and for the year ended December 31, 2022 (in thousands) Industry Type of Investment (1) Maturity Date Interest Rate and Floor Principal Cost Value (2) Portfolio Company Control Investments Majority Owned Control Investments Coronado Aesthetics, LLC Medical Devices & Equipment Preferred Series A Equity 5,000,000 $ 250 $ 313 Medical Devices & Equipment Common Stock 180,000 — 6 Total Coronado Aesthetics, LLC $ 250 $ 319 Gibraltar Business Capital, LLC Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 14.50 % $ 15,000 14,715 12,802 Diversified Financial Services Unsecured Debt September 2026 Interest rate FIXED 11.50 % $ 10,000 9,852 8,898 Diversified Financial Services Preferred Series A Equity 10,602,752 26,122 14,137 Diversified Financial Services Common Stock 830,000 1,884 1,107 Total Gibraltar Business Capital, LLC $ 52,573 $ 36,944 Hercules Adviser LLC Diversified Financial Services Unsecured Debt June 2025 Interest rate FIXED 5.00 % $ 12,000 12,000 12,000 Diversified Financial Services Member Units 1 35 19,153 Total Hercules Adviser LLC $ 12,035 $ 31,153 Total Majority Owned Control Investments ( 4.88 %)* $ 64,858 $ 68,416 Other Control Investments Tectura Corporation Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 10,680 $ 240 $ — Consumer & Business Services Senior Secured Debt July 2024 Interest rate FIXED 8.25 % $ 8,250 8,250 8,042 Consumer & Business Services Senior Secured Debt July 2024 PIK Interest 5.00 % $ 13,023 13,023 — Consumer & Business Services Preferred Series BB Equity 1,000,000 — — Consumer & Business Services Common Stock 414,994,863 900 — Total Tectura Corporation $ 22,413 $ 8,042 Total Other Control Investments ( 0.58 %)* $ 22,413 $ 8,042 Total Control Investments ( 5.46 %)* $ 87,271 $ 76,458 * Value as a percent of net assets (1) Stock and warrants are generally non-income producing and restricted. (2) All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.

Description of Business - Addit

Description of Business - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Investment Company, Regulated Status [true false]	true

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total asset investment, Percentage	96.50%		96.50%
Cash and Cash Equivalents, Held in Foreign Currency, Acquisition Cost			$ 2,204		$ 1,168
Cash and Cash Equivalents, Held in Foreign Currency	$ 2,258		2,258		1,178
Fee Income	7,245	$ 3,384	12,438	$ 6,289
Total Exit Fees Receivable	36,000		36,000		37,500
Interest Income	108,986	68,731	$ 208,883	$ 130,983
Stock issued during period, shares, dividend reinvestment plan			133,142	121,471
Other comprehensive income	0	$ 0	$ 0	$ 0
Investment Company, Accounting and Reporting under Topic 946 [true false]			true
Deferred Fees [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Exit Fees Receivable	3,500		$ 3,500		5,000
Included in Cost [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total Exit Fees Receivable	$ 32,500		$ 32,500		$ 32,500

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Investments Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands		Jun. 30, 2023		Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		$ 3,108,436		$ 2,960,062
Escrow Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other assets		803		875
Senior Secured
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		2,878,923		2,741,388
Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		59,019		54,056
Private Equity Funds, Non-US
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	[1]	4,353		3,893
Excluding Cash And Cash Equivalent
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		3,112,789		2,963,955
Including Cash And Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		3,112,235
Derivative Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	[2]	(554)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		61,144		66,027
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		13,134		12,625
Level 3 significant unobservable inputs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		3,034,158		2,881,410
Level 3 significant unobservable inputs | Escrow Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other assets		803		875
Level 3 significant unobservable inputs | Senior Secured
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		2,878,923		2,741,388
Level 3 significant unobservable inputs | Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		59,019		54,056
Preferred Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		41,249		41,488
Preferred Note | Level 3 significant unobservable inputs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		41,249		41,488
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		94,931	[3]	92,484
Common Stock | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		61,144	[3]	66,027
Common Stock | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		0	[3]	1,398
Common Stock | Level 3 significant unobservable inputs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		33,787	[3]	25,059
Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		34,314		30,646
Warrants | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		13,134		11,227
Warrants | Level 3 significant unobservable inputs
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments		$ 21,180		$ 19,419
[1] In accordance with U.S. GAAP, certain investments are measured at fair value using the net asset value per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statement of Assets and Liabilities. Derivative Instruments are carried at fair value and a level 2 security within the Company's fair value hierarchy. Common Stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's Common Stock.

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Reconciliation of Changes for All Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - Level 3 significant unobservable inputs - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		$ 2,882,285	$ 2,329,044
Net Realized Gains (Losses)	[1]	(9,469)	1,612
Net Change in Unrealized Appreciation (Depreciation)	[2]	34,352	(30,587)
Purchases	[3]	653,225	610,419
Sales		753	80,837
Repayments	[4]	524,679	164,254
Gross Transfers into Level 3	[5]		207
Gross Transfers out of Level 3	[5]		(13,868)
Ending Balance		3,034,961	2,651,736
Senior Secured
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		2,741,388	2,156,709
Net Realized Gains (Losses)	[1]	(5,845)	(1,883)
Net Change in Unrealized Appreciation (Depreciation)	[2]	19,330	(16,525)
Purchases	[3]	648,729	599,596
Sales			73,500
Repayments	[4]	524,679	164,254
Gross Transfers out of Level 3	[5]		3,504
Ending Balance		2,878,923	2,496,639
Escrow Receivables
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		875	561
Net Realized Gains (Losses)	[1]	80	312
Net Change in Unrealized Appreciation (Depreciation)	[2]		0
Purchases	[3]		167
Sales		152	398
Ending Balance		803	642
Unsecured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		54,056	52,890
Net Change in Unrealized Appreciation (Depreciation)	[2]	4,276	(2,025)
Purchases	[3]	687	3,362
Ending Balance		59,019	54,227
Preferred Note
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		41,488	69,439
Net Realized Gains (Losses)	[1]	(1,941)	2,867
Net Change in Unrealized Appreciation (Depreciation)	[2]	(1,702)	(14,157)
Purchases	[3]		2,903
Sales			4,772
Gross Transfers out of Level 3	[5]		6,422
Ending Balance		41,249	49,858
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		25,059	21,968
Net Realized Gains (Losses)	[1]		(93)
Net Change in Unrealized Appreciation (Depreciation)	[2]	8,322	10,240
Purchases	[3]	1,000	0
Sales		594	0
Gross Transfers into Level 3	[5]		207
Gross Transfers out of Level 3	[5]		3,942
Ending Balance		33,787	28,380
Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance		19,419	27,477
Net Realized Gains (Losses)	[1]	(1,763)	409
Net Change in Unrealized Appreciation (Depreciation)	[2]	722	8,120
Purchases	[3]	2,809	4,391
Sales		7	2,167
Ending Balance		$ 21,180	$ 21,990
[1] Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations. Included in net change in unrealized appreciation (depreciation) in the ac companying Consoli dated Statements of Operations. Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of level 3 investments. Amounts are net of purchases assigned to the Adviser Funds. Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization. Transfers out of Level 3 during the six months ended June 30, 2022, related to the initial public offerings of Gelesis, Inc., Pineapple Energy, LLC, and the conversion of Level 3 debt investments into common stock investments. Transfers into Level 3 during the six months ended June 30, 2022 related to the decline of liquidity of Kaleido Biosciences, Inc. shares.

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments	$ 18,858	$ (48,316)	$ 39,963	$ (85,058)
2033 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value	$ 24.7		$ 24.7		$ 24.59
2031 Asset-Backed Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value	0.932		$ 0.932		$ 0.951
Debt | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			$ 23,000	17,700
Warrant Investment [Member] | Unobservable Inputs Level 3 | Depreciation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			(800)
Warrant Investment [Member] | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments				8,600
Common Stock Investment [Member] | Unobservable Inputs Level 3 | Appreciation
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			8,300	10,200
Preferred Stock Investment Member | Unobservable Inputs Level 3 | Depreciation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain (Loss) on Investments			$ (1,700)	$ (14,900)
Underwriting | 2033 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current Price Per Par Value	$ 25		$ 25

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Schedule of Quantitative Information of Fair Value Measurements (Details) - Level 3 significant unobservable inputs $ in Thousands		Jun. 30, 2023 USD ($)		Dec. 31, 2022 USD ($)
Equity and Warrant Investments
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 96,216		$ 85,966
Valuation Market Approach | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		35,966		30,086
Valuation Market Approach | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 15,936		$ 12,479
Valuation Market Approach | Minimum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[1]	0.0547
Valuation Market Approach | Maximum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[1]	0.3211
Market Comparable Companies | Minimum | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2]	12.4	[3]
Market Comparable Companies | Minimum | EBITDA Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2]	12.4	[3]
Market Comparable Companies | Minimum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.6	[2]	0.7	[3]
Market Comparable Companies | Minimum | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.7	[2]	0.6	[3]
Market Comparable Companies | Minimum | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2]	1.6	[3]
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[4]			0.0811
Market Comparable Companies | Minimum | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0547	[1]	0.0811	[4]
Market Comparable Companies | Maximum | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2]	12.4	[3]
Market Comparable Companies | Maximum | EBITDA Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2]	12.4	[3]
Market Comparable Companies | Maximum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		18	[2]	16.1	[5]
Market Comparable Companies | Maximum | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		9.9	[2]	8.8	[3]
Market Comparable Companies | Maximum | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2]	1.6	[3]
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[4]			0.289
Market Comparable Companies | Maximum | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.325	[1]	0.327	[4]
Market Comparable Companies | Weighted Average | EBITDA Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2],[6]	12.4	[3],[7]
Market Comparable Companies | Weighted Average | EBITDA Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		13.3	[2],[6]	12.4	[3],[7]
Market Comparable Companies | Weighted Average | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		7.9	[2],[6]	7.4	[3],[7]
Market Comparable Companies | Weighted Average | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		3.9	[2],[6]	3.4	[3],[7]
Market Comparable Companies | Weighted Average | Tangible Book Value Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2],[6]	1.6	[3],[7]
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2335	[1],[6]	0.1979	[4],[7]
Market Comparable Companies | Weighted Average | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2291	[1],[6]	0.1897	[4],[7]
Liquidation | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 0		$ 0
Liquidation | Minimum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2]	2.1	[3]
Liquidation | Minimum | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3]			6.2
Liquidation | Minimum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.83	[1]	0.85	[4]
Liquidation | Minimum | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[4]			90
Liquidation | Maximum | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2]	2.1	[3]
Liquidation | Maximum | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3]			6.2
Liquidation | Maximum | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.83	[1]	0.85	[4]
Liquidation | Maximum | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[4]			90
Liquidation | Weighted Average | Revenue Multiple | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		1.7	[2],[6]	2.1	[3],[7]
Liquidation | Weighted Average | Revenue Multiple | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[3],[7]			6.2
Liquidation | Weighted Average | Discount for Lack of Marketability | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.83	[1],[6]	0.85	[4],[7]
Liquidation | Weighted Average | Discount for Lack of Marketability | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[4],[7]			90
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.8347)	[5]	(0.9782)	[8]
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1333	[5]	0.1634	[8]
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.1331)	[5],[6]	(0.1669)	[7],[8]
Market Adjusted OPM Backsolve | Weighted Average | Market Equity Adjustment | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0656	[5],[6]	(0.0886)	[7],[8]
Market Adjusted OPM Backsolve | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 8,882		$ 13,795
Market Adjusted OPM Backsolve | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 5,244		$ 6,934
Market Adjusted OPM Backsolve | Minimum | Market Equity Adjustment | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.6349)	[5]	(0.9782)	[8]
Market Adjusted OPM Backsolve | Maximum | Market Equity Adjustment | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2393	[5]	0.6643	[8]
Discounted Cash Flow | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 27,161		$ 19,153
Discounted Cash Flow | Minimum | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1995	[9]	0.1772	[10]
Discounted Cash Flow | Maximum | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.3168	[9]	0.3013	[10]
Discounted Cash Flow | Weighted Average | Measurement Input, Discount Rate | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.2614	[6],[9]	0.2446	[7],[10]
Other | Equity Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[11]	$ 3,027		$ 3,513
Other | Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments				6
Investments [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		2,937,942		2,795,444
Investments [Member] | Debt Maturing Within One Year
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		162,590		93,597
Investments [Member] | Debt Investments - Imminent Payoff
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[12]	142,446		77,676
Investments [Member] | Valuation Cost Approach
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		255,144		392,168
Investments [Member] | Valuation Market Approach | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		1,046,205		903,427
Investments [Member] | Valuation Market Approach | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		1,047,563		967,108
Investments [Member] | Valuation Market Approach | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		1,856		3,006
Investments [Member] | Valuation Market Approach | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		252,658		328,393
Investments [Member] | Liquidation | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments	[13]			1,671
Investments [Member] | Liquidation | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 7,073	[13]	$ 8,042
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13]			0.05
Investments [Member] | Liquidation | Minimum | Probability weighting of alternative outcomes | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13]	0.20		0.20
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13]			0.80
Investments [Member] | Liquidation | Maximum | Probability weighting of alternative outcomes | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13]	0.80		0.80
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13],[14]			0.4829
Investments [Member] | Liquidation | Weighted Average | Probability weighting of alternative outcomes | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[13],[14]	0.80		0.80
Investments [Member] | Valuation Income Approach | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Investments		$ 22,407		$ 20,356
Investments [Member] | Valuation Income Approach | Minimum | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.01		0.01
Investments [Member] | Valuation Income Approach | Maximum | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.50		0.50
Investments [Member] | Valuation Income Approach | Weighted Average | Probability weighting of alternative outcomes | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.3522		0.3579
Investments [Member] | Market Comparable Companies | Hypothetical Market Yield | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.111
Investments [Member] | Market Comparable Companies | Premium/(Discount) | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0075
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1172		0.1174
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1287		0.1205
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.1471
Investments [Member] | Market Comparable Companies | Minimum | Hypothetical Market Yield | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1407		0.1368
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.01)		(0.0075)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.0075)		(0.01)
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.0075
Investments [Member] | Market Comparable Companies | Minimum | Premium/(Discount) | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		(0.0075)		(0.02)
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1825		0.1904
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.202		0.1853
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.1471
Investments [Member] | Market Comparable Companies | Maximum | Hypothetical Market Yield | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.1736		0.1849
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.035		0.0175
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.03		0.015
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input				0.0075
Investments [Member] | Market Comparable Companies | Maximum | Premium/(Discount) | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input		0.0175		0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.1452		0.1517
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.1557		0.1521
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.111		0.1471
Investments [Member] | Market Comparable Companies | Weighted Average | Hypothetical Market Yield | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.1396		0.1482
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Pharmaceuticals
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.001		0.0001
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.0039		0.002
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Sustainable And Renewable Technology
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.0075		0.0075
Investments [Member] | Market Comparable Companies | Weighted Average | Premium/(Discount) | Lower Middle Market
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Alternative Investment, Measurement Input	[14]	0.0023		(0.0043)
[1] Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments. Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments. Represents the range of changes in industry valuations since the portfolio company's last external valuation event. Weighted averages are calculated based on the fair market value of each investment. Weighted averages are calculated based on the fair market value of each investment. Represents the range of changes in industry valuations since the portfolio company's last external valuation event. The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments. The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices. Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date. The significant unobservable input used in the fair value measurement of impaired debt securities is the probability weighting of alternative outcomes. The weighted averages are calculated based on the fair market value of each investment.

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy Of Outstanding Borrowings (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		$ 1,588,608	$ 1,574,351
Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		1,588,608	1,574,351
Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		1,449,051	1,434,445
SBA Debentures | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		170,028	169,738
SBA Debentures | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		146,395	155,257
July 2024 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		104,680	104,533
July 2024 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		103,447	102,019
February 2025 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,809	49,751
February 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,754	47,044
June 2025 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		69,676	69,595
June 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		65,121	64,198
March 2026 A Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,747	49,700
March 2026 A Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		46,038	45,512
March 2026 B Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,725	49,673
March 2026 B Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		46,105	45,588
June 2025 3-Year Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		49,694	49,616
June 2025 3-Year Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,831	47,528
January 2027 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		345,269	344,604
January 2027 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		301,265	296,826
September 2026 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		321,849	321,358
September 2026 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		274,835	269,509
2031 Asset-Backed Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		148,251	147,957
2031 Asset-Backed Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		139,740	142,620
2033 Notes | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		38,880	38,826
2033 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		39,520	39,344
MUFG Bank Facility | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt	[1]	61,000	107,000
MUFG Bank Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value	[1]	61,000	107,000
SMBC Facility | Carrying Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Other Long-Term Debt		130,000	72,000
SMBC Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		130,000	72,000
Observable Inputs Level 2 | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		179,260	181,964
Observable Inputs Level 2 | 2031 Asset-Backed Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		139,740	142,620
Observable Inputs Level 2 | 2033 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		39,520	39,344
Unobservable Inputs Level 3 | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		1,269,791	1,252,481
Unobservable Inputs Level 3 | SBA Debentures | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		146,395	155,257
Unobservable Inputs Level 3 | July 2024 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		103,447	102,019
Unobservable Inputs Level 3 | February 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,754	47,044
Unobservable Inputs Level 3 | June 2025 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		65,121	64,198
Unobservable Inputs Level 3 | March 2026 A Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		46,038	45,512
Unobservable Inputs Level 3 | March 2026 B Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		46,105	45,588
Unobservable Inputs Level 3 | June 2025 3-Year Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		47,831	47,528
Unobservable Inputs Level 3 | January 2027 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		301,265	296,826
Unobservable Inputs Level 3 | September 2026 Notes | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		274,835	269,509
Unobservable Inputs Level 3 | MUFG Bank Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value	[1]	61,000	107,000
Unobservable Inputs Level 3 | SMBC Facility | Fair Value
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Approximate fair value		$ 130,000	$ 72,000
[1] June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Investments - Additional Inform

Investments - Additional Information (Details) - Firm	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Percentage of portfolio investment fair value	0%	0%
Percentage of fair value investment in portfolio companies	30.30%	29%
Count greater five percent fair value equity	4	4
Percentage of equity investments held in portfolio companies	52.60%	39.80%
Concentrations of Credit Risk
Schedule of Investments [Line Items]
Number of portfolio companies	6	8
Revenue Benchmark | Collateral Type Concentration Risk
Schedule of Investments [Line Items]
Concentration Risk, Percentage	100%	100%

Investments - Schedule of Reali

Investments - Schedule of Realized Gains and Losses and Changes in Unrealized Appreciation and Depreciation on Control and Affiliate investments (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022		Dec. 31, 2022		Dec. 31, 2021
Schedule Of Investments [Line Items]
Total investments, at fair value		$ 3,112,789				$ 3,112,789				$ 2,963,955
Interest Income		108,986		$ 68,731		208,883		$ 130,983
Fee Income		7,245		3,384		12,438		6,289
Total net change in unrealized appreciation (depreciation)		18,858		(48,316)		39,963		(85,058)
Total net realized gain (loss)		217		(2,133)		8,177		(4,514)
Affiliate Investments
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]			3,613				3,613
Interest Income	[1]			76				1,123
Fee Income	[1]			0				0
Total net change in unrealized appreciation (depreciation)	[1]			(1,295)				(542)
Total net realized gain (loss)	[1]			0				3,772
Investment, Affiliated Issuer [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value				86,488				86,488				$ 82,962
Interest Income		0		76		0		1,123
Total net change in unrealized appreciation (depreciation)								5,640
Total net realized gain (loss)								3,772
Investment, Affiliated Issuer, Controlled [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value		90,923	[1],[2]	82,875	[1]	90,923	[1],[2]	82,875	[1]	$ 76,458	[3]	73,504
Interest Income	[1]	1,055		1,144		2,171		2,259
Fee Income	[1]	19		17		38		33
Total net change in unrealized appreciation (depreciation)	[1]	4,573		4,728		13,419		6,182
Total net realized gain (loss)	[1]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics, LLC
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]	297		422		297		422
Interest Income	[1]	0		0		0		0
Fee Income	[1]	0		0		0		0
Total net change in unrealized appreciation (depreciation)	[1]	(41)		(192)		(22)		(143)
Total net realized gain (loss)	[1]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital, LLC
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]	44,392	[4]	39,064		44,392	[4]	39,064
Interest Income	[1]	731	[4]	844		1,527	[4]	1,678
Fee Income	[1]	19	[4]	17		38	[4]	33
Total net change in unrealized appreciation (depreciation)	[1]	2,667	[4]	(3,578)		6,402	[4]	(4,805)
Total net realized gain (loss)	[1]	0	[4]	0		0	[4]	0
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser LLC
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]	39,161		35,181		39,161		35,181
Interest Income	[1]	152		128		302		239
Fee Income	[1]	0		0		0		0
Total net change in unrealized appreciation (depreciation)	[1]	2,566		8,637		8,008		11,191
Total net realized gain (loss)	[1]	0		0		0		0
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]	7,073		8,208		7,073		8,208
Interest Income	[1]	172		172		342		342
Fee Income	[1]	0		0		0		0
Total net change in unrealized appreciation (depreciation)	[1]	(701)		(139)		(969)		(61)
Total net realized gain (loss)	[1]	0		0		0		0
Control and Affiliate Issuer Investments [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value	[1]			86,488				86,488
Interest Income	[1]			1,220				3,382
Fee Income	[1]			17				33
Total net change in unrealized appreciation (depreciation)	[1]			3,433				5,640
Total net realized gain (loss)	[1]			0				3,772
Investment, Affiliated Issuer, Noncontrolled [Member]
Schedule Of Investments [Line Items]
Total investments, at fair value				3,613				3,613				$ 9,458
Interest Income		107,931		67,511		206,712		127,601
Total net change in unrealized appreciation (depreciation)		0		(1,295)		0		(542)
Total net realized gain (loss)		$ 0		0		$ 0		3,772
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow AI, Inc. affiliates
Schedule Of Investments [Line Items]
Total investments, at fair value	[1],[5]			0				0
Interest Income	[1],[5]			0				0
Fee Income	[1],[5]			0				0
Total net change in unrealized appreciation (depreciation)	[1],[5]			0				(120)
Total net realized gain (loss)	[1],[5]			0				3,772
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy LLC
Schedule Of Investments [Line Items]
Total investments, at fair value	[1],[5]			3,613				3,613
Interest Income	[1],[5]			76				1,123
Fee Income	[1],[5]			0				0
Total net change in unrealized appreciation (depreciation)	[1],[5]			(1,295)				(422)
Total net realized gain (loss)	[1],[5]			$ 0				$ 0
[1] In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 . All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC were no longer affiliates as defined under the 1940 Act.

Investments - Schedule of Rea_2

Investments - Schedule of Realized Gains and Losses and Change in Unrealized Appreciation and Depreciation on Control and Affiliate Investment (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Investments [Line Items]
Net Income	$ 94,775	$ (10,318)	$ 189,339	$ (13,654)
Hercules Adviser LLC
Schedule of Investments [Line Items]
Total Revenue			3,500
Operating Income			(1,900)
Net Income			$ (1,800)

Investments - Schedule of Fair

Investments - Schedule of Fair Value Portfolio of Investments by Asset Class (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,112,789	$ 2,963,955
Senior Secured
Schedule Of Investments [Line Items]
Investments at Fair Value	2,878,923	2,741,388
Unsecured Debt
Schedule Of Investments [Line Items]
Investments at Fair Value	59,019	54,056
Investment Funds And Vehicles
Schedule Of Investments [Line Items]
Investments at Fair Value	4,353	3,893
Preferred Stock | Equity
Schedule Of Investments [Line Items]
Investments at Fair Value	41,249	41,488
Common Stock | Equity
Schedule Of Investments [Line Items]
Investments at Fair Value	94,931	92,484
Warrants | Warrant
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 34,314	$ 30,646
Geographic Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Investment Type Concentration Risk | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Investment Type Concentration Risk | Revenue Benchmark | Senior Secured
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	92.50%	92.50%
Investment Type Concentration Risk | Revenue Benchmark | Unsecured Debt
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.90%	1.80%
Investment Type Concentration Risk | Revenue Benchmark | Investment Funds And Vehicles
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0.10%
Investment Type Concentration Risk | Preferred Stock | Revenue Benchmark | Equity
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.40%	1.40%
Investment Type Concentration Risk | Common Stock | Revenue Benchmark | Equity
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3%	3.10%
Investment Type Concentration Risk | Warrants | Revenue Benchmark | Warrant
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.10%	1.10%

Investments - Schedule of Fai_2

Investments - Schedule of Fair Value Portfolio of Investments by Geographic Location (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,112,789	$ 2,963,955
United States
Schedule Of Investments [Line Items]
Investments at Fair Value	2,755,178	2,670,520
United Kingdom
Schedule Of Investments [Line Items]
Investments at Fair Value	200,455	171,629
Netherlands
Schedule Of Investments [Line Items]
Investments at Fair Value	87,664	88,915
Canada
Schedule Of Investments [Line Items]
Investments at Fair Value	11,264	19,472
Israel
Schedule Of Investments [Line Items]
Investments at Fair Value	53,019	9,052
Denmark
Schedule Of Investments [Line Items]
Investments at Fair Value	3,767	0
Ireland
Schedule Of Investments [Line Items]
Investments at Fair Value	0	2,804
Germany
Schedule Of Investments [Line Items]
Investments at Fair Value	999	990
Other
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 443	$ 573
Geographic Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Geographic Concentration Risk [Member] | Revenue Benchmark | United States
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	88.50%	90.10%
Geographic Concentration Risk [Member] | Revenue Benchmark | United Kingdom
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	6.50%	5.80%
Geographic Concentration Risk [Member] | Revenue Benchmark | Netherlands
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	2.80%	3%
Geographic Concentration Risk [Member] | Revenue Benchmark | Canada
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.40%	0.70%
Geographic Concentration Risk [Member] | Revenue Benchmark | Israel
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.70%	0.30%
Geographic Concentration Risk [Member] | Revenue Benchmark | Denmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.10%	0%
Geographic Concentration Risk [Member] | Revenue Benchmark | Ireland
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0.10%
Geographic Concentration Risk [Member] | Revenue Benchmark | Germany
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0%
Geographic Concentration Risk [Member] | Revenue Benchmark | Other
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0%

Investments - Schedule of Fai_3

Investments - Schedule of Fair Value Portfolio By Industry Sector (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 3,112,789	$ 2,963,955
Drug Discovery & Development
Schedule Of Investments [Line Items]
Investments at Fair Value	1,137,725	1,150,707
Software
Schedule Of Investments [Line Items]
Investments at Fair Value	891,438	798,264
Consumer & Business Services
Schedule Of Investments [Line Items]
Investments at Fair Value	459,276	439,384
Healthcare Services Other
Schedule Of Investments [Line Items]
Investments at Fair Value	220,673	198,763
Communications & Networking
Schedule Of Investments [Line Items]
Investments at Fair Value	105,343	101,833
Diversified Financial Services
Schedule Of Investments [Line Items]
Investments at Fair Value	94,077	68,569
Information Services
Schedule Of Investments [Line Items]
Investments at Fair Value	73,306	60,759
Manufacturing Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	49,596	46,109
Biotechnology Tools
Schedule Of Investments [Line Items]
Investments at Fair Value	33,465	32,825
Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Investments at Fair Value	20,727	21,517
Sustainable And Renewable Technology
Schedule Of Investments [Line Items]
Investments at Fair Value	11,333	15,486
Media/Content/Info
Schedule Of Investments [Line Items]
Investments at Fair Value	11,542	35
Surgical Devices
Schedule Of Investments [Line Items]
Investments at Fair Value	731	3,038
Consumer & Business Products
Schedule Of Investments [Line Items]
Investments at Fair Value	1,294	2,821
Medical Devices & Equipment
Schedule Of Investments [Line Items]
Investments at Fair Value	1,052	1,834
Semiconductors
Schedule Of Investments [Line Items]
Investments at Fair Value	1,188	21,921
Drug Delivery
Schedule Of Investments [Line Items]
Investments at Fair Value	$ 23	$ 90
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Discovery & Development
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	36.50%	38.80%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Software
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	28.60%	26.90%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Consumer & Business Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	14.80%	14.80%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Healthcare Services Other
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	7.10%	6.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Communications & Networking
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3.40%	3.40%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Diversified Financial Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	3%	2.30%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Information Services
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	2.40%	2%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Manufacturing Technology
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.60%	1.60%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Biotechnology Tools
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	1.10%	1.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Electronics & Computer Hardware
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.70%	0.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Sustainable And Renewable Technology
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.40%	0.50%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Media/Content/Info
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0.40%	0%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Surgical Devices
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Consumer & Business Products
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Medical Devices & Equipment
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0.10%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Semiconductors
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0.70%
Industry Sub Sector Concentration Risk [Member] | Revenue Benchmark | Drug Delivery
Schedule Of Investments [Line Items]
Concentration Risk, Percentage	0%	0%

Investments - Schedule of Inves

Investments - Schedule of Investment Collateral (Details) - Revenue Benchmark - Collateral Type Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Concentration Risk, Percentage	100%	100%
Senior Secured First Lien [Member]
Schedule of Investments [Line Items]
Concentration Risk, Percentage	83.10%	79.70%
Second Lien
Schedule of Investments [Line Items]
Concentration Risk, Percentage	14.90%	18.40%
Unsecured [Member]
Schedule of Investments [Line Items]
Concentration Risk, Percentage	2%	1.90%
All Assets Including Intellectual Property [Member] | Senior Secured First Lien [Member]
Schedule of Investments [Line Items]
Concentration Risk, Percentage	50.30%	42%
All Assets with Negative Pledge on Intellectual Property [Member] | Senior Secured First Lien [Member]
Schedule of Investments [Line Items]
Concentration Risk, Percentage	21.10%	26.10%
Last-out with Security Interest in all of the Assets [Member] | Senior Secured First Lien [Member]
Schedule of Investments [Line Items]
Concentration Risk, Percentage	11.70%	11.60%

Investments - Schedule of Inv_2

Investments - Schedule of Investment Interest Income and Fee Income (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule of Investments [Line Items]
Interest Income		$ 108,986	$ 68,731	$ 208,883	$ 130,983
Fee Income		7,245	3,384	12,438	6,289
Contractual Interest Income
Schedule of Investments [Line Items]
Interest Income		86,147	56,063	168,938	105,607
Exit fee interest income
Schedule of Investments [Line Items]
Interest Income		14,054	6,655	23,436	13,381
PIK interest income
Schedule of Investments [Line Items]
Interest Income		5,819	4,968	11,347	9,943
Other Interest Income
Schedule of Investments [Line Items]
Interest Income	[1]	2,966	1,045	5,162	2,052
Recurring Fee Income
Schedule of Investments [Line Items]
Fee Income		2,135	1,907	4,175	3,686
Accelerated Fee Income - Expired Commitments
Schedule of Investments [Line Items]
Fee Income		108	433	351	521
Accelerated Fee Income - Early Repayments
Schedule of Investments [Line Items]
Fee Income		$ 5,002	$ 1,044	$ 7,912	$ 2,082
[1] Other interest income includes OID interest income and interest recorded on other assets .

Investments - Schedule of Unamo

Investments - Schedule of Unamortized Capitalized Fee Income (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	$ 56.1	$ 54
Included in Cost [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	43.9	43.1
Deferred Fees [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Unamortized Fee Income	$ 12.2	$ 10.9

Investments - Schedule of Loan

Investments - Schedule of Loan Exit Fees Receivable (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	$ 36	$ 37.5
Included in Cost [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	32.5	32.5
Deferred Fees [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total Exit Fees Receivable	$ 3.5	$ 5

Investments - Schedule of Deriv

Investments - Schedule of Derivative Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Summary of Investment Holdings [Line Items]
Total	$ (554)	$ 0	$ (554)	$ 0
Foreign Exchange Forward Member
Summary of Investment Holdings [Line Items]
Total	(554)		(554)		$ 0
Net realized (gain) loss on derivative investments	0	0	0	0
Net change in unrealized gain loss on derivatives investments	(554)	$ 0	(554)	$ 0
Foreign Exchange Forward Member | Other assets
Summary of Investment Holdings [Line Items]
Total	$ (554)		$ (554)		$ 0

Debt - Schedule of Available an

Debt - Schedule of Available and Outstanding Debt (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Outstanding balance		$ 2,215,000	$ 2,185,000
Principal		1,606,000	1,594,000
Carrying Value	[1]	1,588,608	1,574,351
SBA Debentures
Debt Instrument [Line Items]
Outstanding balance	[2]	175,000	175,000
Principal	[2]	175,000	175,000
Carrying Value	[1],[2]	170,028	169,738
July 2024 Notes
Debt Instrument [Line Items]
Outstanding balance		105,000	105,000
Principal		105,000	105,000
Carrying Value	[1]	104,680	104,533
February 2025 Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,809	49,751
June 2025 Notes
Debt Instrument [Line Items]
Outstanding balance		70,000	70,000
Principal		70,000	70,000
Carrying Value	[1]	69,676	69,595
June 2025 3-Year Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,694	49,616
March 2026 A Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,747	49,700
March 2026 B Notes
Debt Instrument [Line Items]
Outstanding balance		50,000	50,000
Principal		50,000	50,000
Carrying Value	[1]	49,725	49,673
September 2026 Notes
Debt Instrument [Line Items]
Outstanding balance		325,000	325,000
Principal		325,000	325,000
Carrying Value	[1]	321,849	321,358
January 2027 Notes
Debt Instrument [Line Items]
Outstanding balance		350,000	350,000
Principal		350,000	350,000
Carrying Value	[1]	345,269	344,604
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Outstanding balance		150,000	150,000
Principal		150,000	150,000
Carrying Value	[1]	148,251	147,957
2033 Notes
Debt Instrument [Line Items]
Outstanding balance		40,000	40,000
Principal		40,000	40,000
Carrying Value	[1]	38,880	38,826
MUFG Bank Facility
Debt Instrument [Line Items]
Outstanding balance	[2],[3]	400,000	545,000
Principal	[2],[3]	61,000	107,000
Carrying Value	[1],[2],[3]	61,000	107,000
SMBC Facility
Debt Instrument [Line Items]
Outstanding balance	[2],[4]	400,000	225,000
Principal	[2],[4]	130,000	72,000
Carrying Value	[1],[2],[4]	$ 130,000	$ 72,000
[1] Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. Availability subject to the Company meeting the borrowing base requirements. In June 2022 the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. Includes $ 175.0 million of available commitment through the letter of credit facility.

Debt - Schedule of Debt Issuanc

Debt - Schedule of Debt Issuance Costs, Net of accumulated Amortization (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Net of debt issuance costs		$ 23,952	$ 22,642
SBA Debentures
Debt Instrument [Line Items]
Net of debt issuance costs		4,972	5,262
July 2024 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		320	467
February 2025 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		191	249
June 2025 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		324	405
June 2025 3-Year Notes
Debt Instrument [Line Items]
Net of debt issuance costs		306	384
March 2026 A Notes
Debt Instrument [Line Items]
Net of debt issuance costs		253	300
March 2026 B Notes
Debt Instrument [Line Items]
Net of debt issuance costs		275	327
September 2026 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		3,151	3,642
January 2027 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		4,731	5,396
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Net of debt issuance costs		1,749	2,043
2033 Notes
Debt Instrument [Line Items]
Net of debt issuance costs		1,120	1,174
MUFG Bank Facility
Debt Instrument [Line Items]
Net of debt issuance costs	[1]	4,425	1,292
SMBC Facility
Debt Instrument [Line Items]
Net of debt issuance costs	[1]	$ 2,135	$ 1,701
[1] The MUFG Bank Facility (f.k.a. Union Bank Facility) and SMBC Facility, are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.

Debt - Components of Interest E

Debt - Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended
		Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022
Debt Instrument [Line Items]
Interest expense		$ 17,184	[1]	$ 12,698	[2]	$ 33,809	[1]	$ 24,345	[2]
Amortization of debt issuance cost (loan fees)		1,537		1,029		3,046		2,239	[3]
Total interest expense and fees		19,648		14,190		38,602		27,679
Cash paid for interest expense		9,824		3,632		33,664		22,642
Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		927		463		1,747		1,095
SBA Debentures
Debt Instrument [Line Items]
Interest expense		1,137	[1]	1,138	[2]	2,262	[1]	1,688	[2]
Amortization of debt issuance cost (loan fees)		146		146		290		286	[3]
Total interest expense and fees		1,283		1,284		2,552		1,974
Cash paid for interest expense		0		0		2,262		749
SBA Debentures | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2022 Notes
Debt Instrument [Line Items]
Interest expense	[2],[3]			0				1,011
Amortization of debt issuance cost (loan fees)	[3]			0				50
Total interest expense and fees	[3]			0				1,061
Cash paid for interest expense	[3]			0				2,293
2022 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)	[3]			0				0
July 2024 Notes
Debt Instrument [Line Items]
Interest expense		1,252	[1]	1,252	[2]	2,504	[1]	2,504	[2]
Amortization of debt issuance cost (loan fees)		74		74		148		148	[3]
Total interest expense and fees		1,326		1,326		2,652		2,652
Cash paid for interest expense		0		0		2,504		2,504
July 2024 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
February 2025 Notes
Debt Instrument [Line Items]
Interest expense		535	[1]	535	[2]	1,070	[1]	1,070	[2]
Amortization of debt issuance cost (loan fees)		28		28		57		57	[3]
Total interest expense and fees		563		563		1,127		1,127
Cash paid for interest expense		0		0		1,070		1,070
February 2025 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
June 2025 Notes
Debt Instrument [Line Items]
Interest expense		755	[1]	755	[2]	1,509	[1]	1,509	[2]
Amortization of debt issuance cost (loan fees)		41		41		81		81	[3]
Total interest expense and fees		796		796		1,590		1,590
Cash paid for interest expense		1,509		1,509		1,509		1,509
June 2025 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
June 2025 3-Year Notes
Debt Instrument [Line Items]
Interest expense		750	[1]	67	[2]	1,500	[1]	67	[2]
Amortization of debt issuance cost (loan fees)		39		4		78		4	[3]
Total interest expense and fees		789		71		1,578		71
Cash paid for interest expense		1,500		0		1,500		0
June 2025 3-Year Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
March 2026 A Notes
Debt Instrument [Line Items]
Interest expense		562	[1]	562	[2]	1,125	[1]	1,125	[2]
Amortization of debt issuance cost (loan fees)		23		24		47		48	[3]
Total interest expense and fees		585		586		1,172		1,173
Cash paid for interest expense		0		0		1,125		1,125
March 2026 A Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
March 2026 B Notes
Debt Instrument [Line Items]
Interest expense		568	[1]	568	[2]	1,137	[1]	1,137	[2]
Amortization of debt issuance cost (loan fees)		26		26		52		52	[3]
Total interest expense and fees		594		594		1,189		1,189
Cash paid for interest expense		0		0		1,138		1,138
March 2026 B Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
September 2026 Notes
Debt Instrument [Line Items]
Interest expense		2,175	[1]	2,175	[2]	4,349	[1]	4,349	[2]
Amortization of debt issuance cost (loan fees)		204		204		408		408	[3]
Total interest expense and fees		2,379		2,379		4,757		4,757
Cash paid for interest expense		0		0		4,266		4,266
September 2026 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
January 2027 Notes
Debt Instrument [Line Items]
Interest expense		3,078	[1]	3,078	[2]	6,157	[1]	5,473	[2]
Amortization of debt issuance cost (loan fees)		207		207		414		368	[3]
Total interest expense and fees		3,285		3,285		6,571		5,841
Cash paid for interest expense		0				5,906		0
January 2027 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Interest expense		1,904	[1]	169	[2]	3,807	[1]	169	[2]
Amortization of debt issuance cost (loan fees)		100		9		200		9	[3]
Total interest expense and fees		2,004		178		4,007		178
Cash paid for interest expense		1,857		0		3,713		0
2031 Asset-Backed Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2033 Notes
Debt Instrument [Line Items]
Interest expense		625	[1]	625	[2]	1,250	[1]	1,250	[2]
Amortization of debt issuance cost (loan fees)		27		27		54		54	[3]
Total interest expense and fees		652		652		1,304		1,304
Cash paid for interest expense		625		625		1,250		1,250
2033 Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		0		0		0		0
2022 Convertible Notes
Debt Instrument [Line Items]
Interest expense	[3]			0				923	[2]
Amortization of debt issuance cost (loan fees)	[3]			0				149
Total interest expense and fees	[3]			0	[2]			1,072
Cash paid for interest expense	[3]			0				5,004
2022 Convertible Notes | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)	[3]			0				0
MUFG Bank Facility
Debt Instrument [Line Items]
Interest expense		1,363	[1],[4]	1,369	[2],[5]	3,076	[1],[4]	1,483	[2],[5]
Amortization of debt issuance cost (loan fees)		442	[4]	175	[5]	884	[4]	412	[3],[5]
Total interest expense and fees		2,496	[4]	1,939	[5]	5,268	[4]	2,857	[5]
Cash paid for interest expense		1,595	[4]	1,215	[5]	3,433	[4]	1,215	[5]
MUFG Bank Facility | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		691	[4]	395	[5]	1,308	[4]	962	[5]
SMBC Facility
Debt Instrument [Line Items]
Interest expense		2,480	[1]	405	[2]	4,063	[1]	587	[2]
Amortization of debt issuance cost (loan fees)		180		64		333		113	[3]
Total interest expense and fees		2,896		537		4,835		833
Cash paid for interest expense		2,738		283		3,988		519
SMBC Facility | Unused Facility Other Fees [Member]
Debt Instrument [Line Items]
Unused facility and other fees (loan fees)		$ 236		$ 68		$ 439		$ 133
[1] Interest expense includes amortization of original issue discounts for the three months ended June 30, 2023 of $ 42 thousand, $ 126 thousand, and $ 47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2023, $ 83 thousand, $ 251 thousand, and $ 94 thousand, related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. Interest expense includes amortization of original issue discounts for the three months ended June 30, 2022 of $ 42 thousand, $ 126 thousand, and $ 4 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. For the six months ended June 30, 2022, $ 23 thousand, $ 112 thousand, $ 84 thousand, $ 223 thousand, and $ 4 thousand, related to the 2022 Notes, 2022 Convertible Notes, September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively. In February 2022, the Company has fully repaid the aggregate outstanding principal balances and retired 2022 Notes and 2022 Convertible Notes. The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender. The June 2022 amendment of the MUFG Bank Facility replaced the Union Bank Facility via an amendment which changed the lead lender.

Debt - Components of Interest_2

Debt - Components of Interest Expense, Related Fees, Losses on Debt Extinguishment and Cash Paid for Interest Expense for Debt (Parentheticals) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
September 2026 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	$ 42	$ 42	$ 83	$ 84
January 2027 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	126	126	251	223
2031 Asset-Backed Notes
Debt Instrument [Line Items]
Amortization of original issue discounts	$ 47	$ 4	$ 94	4
2022 Notes
Debt Instrument [Line Items]
Amortization of original issue discounts				23
2022 Convertible Notes
Debt Instrument [Line Items]
Amortization of original issue discounts				$ 112

Debt - Schedule of SBA Debentur

Debt - Schedule of SBA Debentures Outstanding Principal Balances (Details) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Outstanding Principal Balances		$ 1,606,000	$ 1,594,000
SBA Debentures Issued on March 26, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Mar. 26, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 37,500	37,500
SBA Debentures Issued on June 25, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Jun. 25, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 16,200	16,200
SBA Debentures Issued on July 28, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Jul. 28, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 5,400	5,400
SBA Debentures Issued on August 20, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Aug. 20, 2021
Maturity Date		Sep. 01, 2031
Interest Rate	[1]	1.58%
Outstanding Principal Balances		$ 5,400	5,400
SBA Debentures Issued on October 21, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Oct. 21, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 14,000	14,000
SBA Debentures Issued on November 1, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 01, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 21,000	21,000
SBA Debentures Issued on November 15, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 15, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 5,200	5,200
SBA Debentures Issued on November 30, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Nov. 30, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 20,800	20,800
SBA Debentures Issued on December 20, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 20, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 10,000	10,000
SBA Debentures Issued on December 23, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 23, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 10,000	10,000
SBA Debentures Issued on December 28, 2021
Debt Instrument [Line Items]
Issuance/Pooling Date		Dec. 28, 2021
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 5,000	5,000
SBA Debentures Issued on January 14, 2022
Debt Instrument [Line Items]
Issuance/Pooling Date		Jan. 14, 2022
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 4,500	4,500
SBA Debentures Issued on January 21, 2022
Debt Instrument [Line Items]
Issuance/Pooling Date		Jan. 21, 2022
Maturity Date		Mar. 01, 2032
Interest Rate	[1]	3.21%
Outstanding Principal Balances		$ 20,000	20,000
SBA Debentures
Debt Instrument [Line Items]
Outstanding Principal Balances	[2]	$ 175,000	$ 175,000
[1] Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges. Availability subject to the Company meeting the borrowing base requirements.

Debt - Additional Information (

Debt - Additional Information (Details) $ in Thousands

3 Months Ended

6 Months Ended

12 Months Ended

Jan. 13, 2023 USD ($)

Jun. 23, 2022 USD ($)

Jan. 20, 2022 USD ($)

Sep. 16, 2021 USD ($)

Mar. 04, 2021 USD ($)

Oct. 27, 2020 USD ($)

Jun. 30, 2023 USD ($)

Jun. 30, 2022 USD ($)

Jun. 30, 2023 USD ($) Firm

Jun. 30, 2022 USD ($)

Dec. 31, 2022 USD ($) Firm

Jun. 22, 2022 USD ($)

Dec. 31, 2021 USD ($)

Nov. 04, 2020 USD ($)

Jun. 03, 2020 USD ($)

Feb. 05, 2020 USD ($)

Jul. 16, 2019 USD ($)

Sep. 24, 2018 USD ($)

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 2,215,000

$ 2,215,000

$ 2,185,000

Investment Owned, Fair Value

3,112,789

3,112,789

2,963,955

Gain (loss) on extinguishment of debt

0

$ 0

0

$ (3,686)

Restricted cash

12,339

$ 3,371

12,339

$ 3,371

10,079

Variable Interest Entity, Primary Beneficiary [Member]

Debt Instrument [Line Items]

Restricted cash

12,339

$ 12,339

10,079

MUFG Bank Facility

Debt Instrument [Line Items]

Line of Credit Facility, Covenant Terms

these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV.

Line of credit facility, maturity date

Jan. 13, 2026

Line of Credit Facility, Maximum Borrowing Capacity

400,000

$ 400,000

Maximum borrowing capacity

400,000

$ 400,000

Line of Credit Facility, Description

funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions.

MUFG Bank Facility | 1-month SOFR

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

2.75%

Secured Credit Facility with M U F G Bank Ltd. (M U F G) | Maximum

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

600,000

$ 600,000

Maximum borrowing capacity

600,000

$ 600,000

SMBC Facility

Debt Instrument [Line Items]

Line of credit facility, maturity date

Nov. 07, 2025

SMBC Facility

Debt Instrument [Line Items]

Line of credit facility, maturity date

Nov. 09, 2026

Line of Credit Facility, Maximum Borrowing Capacity

225,000

$ 225,000

Maximum borrowing capacity

225,000

$ 225,000

Line of Credit Facility, Description

Availability under the SMBC Facility will terminate on November 7, 2025, and the outstanding loans under the SMBC Facility will mature on November 9, 2026.

Line of credit facility, unused capacity, commitment fee percentage

0.375%

SMBC Facility | Minimum

Debt Instrument [Line Items]

Interest rate plus applicable margin adjustment

0.875%

SMBC Facility | Maximum

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

500,000

$ 500,000

Maximum borrowing capacity

500,000

$ 500,000

Interest rate plus applicable margin adjustment

2%

SMBC LC Facility

Debt Instrument [Line Items]

Line of credit facility, maturity date

Jan. 13, 2026

Line of Credit Facility, Maximum Borrowing Capacity

$ 175,000

175,000

$ 175,000

Maximum borrowing capacity

175,000

$ 175,000

175,000

Credit Facility

Debt Instrument [Line Items]

Debt average amount outstanding

$ 209,000

$ 127,700

Line of credit interest rate

7.16%

4.51%

Additional Face Amount | SMBC LC Facility

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

400,000

Maximum borrowing capacity

$ 400,000

July 2024 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 105,000

Debt instrument, interest rate

4.77%

4.77%

Debt Instrument, Maturity Date

Jul. 16, 2024

Debt Instrument, redemption, description

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the July 2024 Notes is due semiannually

Debt Instrument, Collateral

The July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

February 2025 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt instrument, interest rate

4.28%

4.28%

Debt Instrument, Maturity Date

Feb. 05, 2025

Debt Instrument, redemption, description

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.28% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the February 2025 Notes is due semiannually

Debt Instrument, Collateral

The February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 70,000

Debt instrument, interest rate

4.31%

4.31%

Debt Instrument, Maturity Date

Jun. 03, 2025

Debt Instrument, redemption, description

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.31% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the June 2025 Notes is due semiannually.

Debt Instrument, Collateral

The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

June 2025 3-Year Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt instrument, interest rate

6%

6%

Debt Instrument, Maturity Date

Jun. 23, 2025

Debt Instrument, redemption, description

On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.00% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering.

Debt instrument, payment terms, description

Interest on the June 2025 3-Year Notes is due semiannually.

Debt Instrument, Collateral

The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 A Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt instrument, interest rate

4.50%

4.50%

Debt Instrument, Maturity Date

Mar. 04, 2026

Debt Instrument, redemption, description

On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.5% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering

Debt instrument, payment terms, description

Interest on the March 2026 A Notes is due semiannually

Debt Instrument, Collateral

The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

March 2026 B Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 50,000

Debt instrument, interest rate

4.55%

4.55%

Debt Instrument, Maturity Date

Mar. 04, 2026

Debt Instrument, redemption, description

On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.55% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering.

Debt instrument, payment terms, description

Interest on the March 2026 B Notes is due semiannually

Net proceeds from sale of Notes

49,500

Aggregate Debt Issuance Cost

$ 500

Debt Instrument, Collateral

The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

September 2026 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 325,000

Debt instrument, interest rate

2.625%

2.625%

Debt Instrument, Maturity Date

Sep. 16, 2026

Debt Instrument, redemption, description

The Company may redeem some or all of the September 2026 Notes at any time, or from time to time, at the redemption price set forth under the terms of the September 2026 Notes Indenture.

Debt instrument, payment terms, description

Interest on the September 2026 Notes is payable semi-annually in arrears on March 16 and September 16 of each year, commencing on March 16, 2022

Net proceeds from sale of Notes

320,100

Aggregate Debt Issuance Cost

4,100

Aggregate Discount On Issuance

$ 800

Debt Instrument, Collateral

The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

January 2027 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 350,000

Debt instrument, interest rate

3.375%

3.375%

Debt Instrument, Maturity Date

Jan. 20, 2027

Debt Instrument, redemption, description

The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.

Debt instrument, payment terms, description

Interest on the January 2027 Notes is payable semi-annually in arrears on January 20 and July 20 of each year, commencing on July 20, 2022

Net proceeds from sale of Notes

343,400

Aggregate Debt Issuance Cost

4,100

Aggregate Discount On Issuance

$ 2,500

Debt Instrument, Collateral

The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

2031 Asset-Backed Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 150,000

Debt instrument, interest rate

4.95%

4.95%

Debt Instrument, Maturity Date

Jul. 20, 2031

Debt instrument, payment terms, description

Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.

2031 Asset-Backed Notes | Variable Interest Entity, Primary Beneficiary [Member]

Debt Instrument [Line Items]

Restricted cash

$ 12,300

$ 12,300

$ 10,100

2033 Notes

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 40,000

Debt instrument, interest rate

6.25%

6.25%

Debt Instrument, Maturity Date

Oct. 30, 2033

Debt Instrument, redemption, description

The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023.

Debt instrument, payment terms, description

Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year

Debt Instrument, Collateral

The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

HC IV

Debt Instrument [Line Items]

License term

10 years

Debt Instrument, license description

HC IV received its license to operate as a SBIC on October 27, 2020. The license has a 10-year term.

Regulatory capital commitment amount

$ 87,500

Debt Instrument, Face Amount

$ 175,000

$ 175,000

$ 175,000

Investments held by number of companies | Firm

21

21

Investment Owned, Fair Value

$ 312,700

$ 312,700

$ 343,700

Percentage of total investment portfolio

10%

10%

11.60%

Tangible Assets

$ 319,200

$ 319,200

$ 348,600

Percentage of total assets held

9.90%

9.90%

11.50%

Line of Credit Facility, Maximum Borrowing Capacity

175,000

Maximum borrowing capacity

$ 175,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Tax Contingency [Line Items]
Taxable income	$ 60,900	$ (40,000)	$ 125,000	$ (73,100)
Taxable income per share	$ 0.43	$ 0.32	$ 0.9	$ 0.6
Taxable net realized gains	$ 20,200	$ (1,700)	$ 27,400	$ 2,000
Taxable net realized gains per share	$ 0.14	$ 0.02	$ 0.2	$ 0.02
Income tax, including excise tax, paid	$ 400	$ 200	$ 5,151	$ 7,281
Taxes payable	3,400	$ 2,400	3,400	$ 2,400
Tax basis of investments, gross, unrealized appreciation	92,500		92,500		$ 72,200
Tax basis of investments, gross, unrealized depreciation	92,000		92,000		112,000
Tax basis of investments, unrealized appreciation (depreciation), net	500		500		39,800
Tax basis of investments, cost for income tax purposes	$ 3,100,000		$ 3,100,000		3,000,000
Taxable Subsidiary [Member]
Income Tax Contingency [Line Items]
Adjustments to Additional Paid in Capital, Other					$ 3,000

Stockholders' Equity and Dist_3

Stockholders' Equity and Distributions - Schedule of Common Stock Shares Issued and Sold (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Class of Stock [Line Items]
Number of Shares Issued			9.7	8.9
Accumulated proceeds from issuance of shares	$ 65,406	$ 61,855	$ 130,748	$ 147,104
Average Price/Share	$ 13.5	$ 16.5	$ 13.5	$ 16.5
Common - Gross Proceeds
Class of Stock [Line Items]
Accumulated proceeds from issuance of shares			$ 132,300	$ 148,700
Common - Offering Expenses
Class of Stock [Line Items]
Accumulated proceeds from issuance of shares			$ 1,600	$ 1,600

Stockholders' Equity and Dist_4

Stockholders' Equity and Distributions - Schedule of Dividends Declared (Details) - USD ($) $ / shares in Units, $ in Thousands							3 Months Ended		6 Months Ended		12 Months Ended
	May 23, 2023	Mar. 09, 2023	Nov. 17, 2022	Aug. 16, 2022	May 24, 2022	Mar. 16, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Dividends Payable [Line Items]
Distributions of net investment income							$ 0.47	$ 0.48	$ 0.94	$ 0.96	$ 1.97
Less: Distributions declared-common and restricted shares							$ 67,379	$ 59,993	$ 132,153	$ 117,875	$ 249,077
Dividend Declared One [Member]
Dividends Payable [Line Items]
Distribution Type									Base		Base
Declared Date									Feb. 09, 2023		Feb. 16, 2022
Record Date									Mar. 02, 2023		Mar. 09, 2022
Payment Date									Mar. 09, 2023		Mar. 16, 2022
Distributions of net investment income		$ 0.39				$ 0.33
Less: Distributions declared-common and restricted shares		$ 53,749				$ 39,794
Dividend Declared Two [Member]
Dividends Payable [Line Items]
Distribution Type									Supplemental		Supplemental
Declared Date									Feb. 09, 2023		Feb. 16, 2022
Record Date									Mar. 02, 2023		Mar. 09, 2022
Payment Date									Mar. 09, 2023		Mar. 16, 2022
Distributions of net investment income		$ 0.08				$ 0.15
Less: Distributions declared-common and restricted shares		$ 11,025				$ 18,088
Dividend Declared Three [Member]
Dividends Payable [Line Items]
Distribution Type									Base		Base
Declared Date									Apr. 27, 2023		Apr. 27, 2022
Record Date									May 16, 2023		May 17, 2022
Payment Date									May 23, 2023		May 24, 2022
Distributions of net investment income	$ 0.39				$ 0.33
Less: Distributions declared-common and restricted shares	$ 55,910				$ 41,245
Dividend Declared Four [Member]
Dividends Payable [Line Items]
Distribution Type									Supplemental		Supplemental
Declared Date									Apr. 27, 2023		Apr. 27, 2022
Record Date									May 16, 2023		May 17, 2022
Payment Date									May 23, 2023		May 24, 2022
Distributions of net investment income	$ 0.08				$ 0.15
Less: Distributions declared-common and restricted shares	$ 11,469				$ 18,748
Dividend Declared Five [Member]
Dividends Payable [Line Items]
Distribution Type											Base
Declared Date											Jul. 20, 2022
Record Date											Aug. 09, 2022
Payment Date											Aug. 16, 2022
Distributions of net investment income				$ 0.35
Less: Distributions declared-common and restricted shares				$ 44,765
Dividend Declared Six [Member]
Dividends Payable [Line Items]
Distribution Type											Supplemental
Declared Date											Jul. 20, 2022
Record Date											Aug. 09, 2022
Payment Date											Aug. 16, 2022
Distributions of net investment income				$ 0.15
Less: Distributions declared-common and restricted shares				$ 19,185
Dividend Declared Seven [Member]
Dividends Payable [Line Items]
Distribution Type											Base
Declared Date											Oct. 13, 2022
Record Date											Nov. 10, 2022
Payment Date											Nov. 17, 2022
Distributions of net investment income			$ 0.36
Less: Distributions declared-common and restricted shares			$ 47,472
Dividend Declared Eight [Member]
Dividends Payable [Line Items]
Distribution Type											Supplemental
Declared Date											Oct. 13, 2022
Record Date											Nov. 10, 2022
Payment Date											Nov. 17, 2022
Distributions of net investment income			$ 0.15
Less: Distributions declared-common and restricted shares			$ 19,780

Stockholders' Equity and Dist_5

Stockholders' Equity and Distributions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	May 05, 2023
Class Of Stock [Line Items]
Common stock, shares outstanding		144,641,000		144,641,000		133,045,000
Distributions of net investment income		$ 0.47	$ 0.48	$ 0.94	$ 0.96	$ 1.97
Stock issued during period, shares, dividend reinvestment plan				133,142	121,471
Number of Shares Issued				9,700,000	8,900,000
Offering expenses on issuance of shares				$ 1,581	$ 1,617
Common Stock
Class Of Stock [Line Items]
Common stock, shares issued		144,641,540		144,641,540		133,044,602
Stock issued during period, shares, dividend reinvestment plan		72,000	61,000	133,000	121,000
Number of Shares Issued		5,062,000	4,061,000	9,721,000	8,921,000
Equity distribution agreement remaining available shares 2022		23,800,000		23,800,000
2023 Equity Distribution Agreement [Member] | Common Stock
Class Of Stock [Line Items]
Equity distribution agreement available shares							25,000,000
Spillover amount per share [Member]
Class Of Stock [Line Items]
Undistributed taxable earnings		$ 1.02		$ 1.02
Ordinary Income
Class Of Stock [Line Items]
Distributions of net investment income	[1],[2]			$ 0.96	$ 0.96
[1] All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. Includes distributions on unvested restricted stock awards.

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional information (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jun. 28, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation		$ 3,300,000	$ 3,700,000
Employee benefits and share-based compensation		3,325,000	3,661,000	$ 6,511,000	$ 8,085,000
Unrecognized compensation costs		$ 24,600,000	$ 19,100,000	$ 24,600,000	$ 19,100,000
Total unrecognized compensation costs expected to be recognized, Period				2 years 10 months 24 days	2 years
Performance Award shares vested	[1]			414,634	463,408
Distribution equivalent units				1,306,880	610,541
Unvested Performance Awards		1,844,519	1,167,873	1,844,519	1,167,873	958,985	1,037,848
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				$ 46,000	$ 30,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted				67,000	83,000
Service vesting awards granted				$ 67,000	83,000
Service-Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards				2 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted				$ 18,100,000	10,700,000
Service vesting awards granted				$ 18,100,000	$ 10,700,000
Performance Vesting Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Service vesting awards				The total compensation will be determined by the Company’s TSR relative to specified BDCs during a specified performance period. Depending on the results achieved during the specified performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the target shares granted.
Performance Award shares vested				0
Unvested Performance Awards		0	0	0	0
Performance Deu Member
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance Award shares vested				54,858	241,770
Distribution equivalent units (“DEUs”) were issued with a grant date fair value				$ 700,000	$ 4,000,000
Performance Vesting Award Member
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance Award shares vested					487,409
Liability Classified Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation				700,000	$ 2,300,000
Unrecognized compensation costs		$ 1,200,000	$ 3,200,000	$ 1,200,000	$ 3,200,000
Total unrecognized compensation costs expected to be recognized, Period				9 months 18 days	1 year 9 months 18 days
Remaining max award value		$ 3,100,000		$ 3,100,000
Weighted average performance conditions in liability		100%		100%
Accounts payable and accrued liabilities		$ 1,900,000	$ 2,000,000	$ 1,900,000	$ 2,000,000
Liability award vested				$ 0	$ 6,000,000
Two Thousand Eighteen Plan And Director Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								18,700,000
Two Thousand Eighteen Plan And Director Plan | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								300,000
2018 Plan | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								9,261,229
Director Plan | Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized								300,000
[1] With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.

Equity Incentive Plans - Unvest

Equity Incentive Plans - Unvested Restricted Stock Equity Awards (Details) - $ / shares		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Unvested Shares Beginning of Period		958,985	1,037,848
Granted		1,306,880	610,541
Vested (1)	[1]	(414,634)	(463,408)
Forfeited		(6,712)	(17,108)
Unvested Shares End of Period		1,844,519	1,167,873
Unvested Shares Beginning of Period		$ 16.35	$ 14.51
Granted		13.81	17.39
Vested (1)	[1]	16.28	14.39
Forfeited		16.17	15.89
Unvested Shares End of Period		$ 14.57	$ 16.05
[1] With respect to certain restricted stock equity awards granted prior to January 1, 2019, receipt of the shares of the Company’s common stock underlying vested restricted stock equity awards will be deferred for four years from grant date unless certain conditions are met. Accordingly, such vested restricted stock equity awards will not be issued as common stock upon vesting until the completion of the deferral period.

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Numerator
Net Income (Loss)	$ 94,775	$ (10,318)	$ 189,339	$ (13,654)
Distributions	(67,379)	(59,993)	(132,153)	(117,875)	$ (249,077)
Total Earnings, net of total distributions	(27,396)	70,311	(57,186)	131,529
Numerator for basic and diluted change in net assets per common share	$ 93,780	$ (10,880)	$ 187,248	$ (14,836)
Denominator
Basic	141,390	124,255	138,338	121,292
Common shares issuable	694	0	1,249	0
Weighted average common shares outstanding assuming dilution	142,084	124,255	139,587	121,292
Change in net assets per common share
Basic	$ 0.66	$ (0.09)	$ 1.35	$ (0.12)
Diluted	$ 0.66	$ (0.09)	$ 1.34	$ (0.12)
Common Stock [Member]
Numerator
Distributions	$ 66,672	$ 59,431	$ 130,696	$ 116,693
Numerator for basic and diluted change in net assets per common share	$ 27,108	$ (70,311)	$ 56,552	$ (131,529)

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Number of Anti-diluted Shares As Calculated Based on Weighted Average Closing Price of Common Stock (Details) - shares		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Unvested Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		3,146	16	2,499	24
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		9,555	2	8,714	17
Unvested Restricted Stock Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		65,346	0	59,854	0
Performance Awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	[1]	0	1,685	0	1,116
[1] Included in these amounts are shares related to certain equity-based awards, which fully vested in May 2022 and delivered in May 2023 and thus no longer outstanding for purposes of calculating earnings per share.

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, voting rights	Each share of common stock entitles the holder to one vote.

Financial Highlights - Schedule

Financial Highlights - Schedule of Financial Highlights of the Company (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Net investment income before investment gains and losses per common share:
Net Asset Value Per Share, Beginning Balance				$ 10.53	$ 11.22	$ 11.22
Net investment income before investment gains and losses per common share: Basic		$ 0.53	$ 0.32	1.01	0.62
Total from investment operations	[1]			1.37	(0.12)
Investment Company, Share Issuance, Per Share	[1]				0.23
Investment Company, Share Repurchase, Per Share	[1]			(0.01)
Distributions of net investment income		(0.47)	(0.48)	(0.94)	(0.96)	(1.97)
Stock-based compensation expense included in net investment income and other movements	[1],[2]			0.03	0.06
Net Asset Value Per Share, Ending Balance		10.96	10.43	10.96	10.43	$ 10.53
Ratios and supplemental data (in thousands, except per share data):
Per share market value at end of period		$ 14.8	$ 13.49	$ 14.8	$ 13.49
Total return	[3]			19.55%	(13.72%)
Shares outstanding at end of period		144,641	127,285	144,641	127,285
Basic		141,390	124,255	138,338	121,292
Net assets at end of period		$ 1,585,510	$ 1,327,740	$ 1,585,510	$ 1,327,740	$ 1,401,459
Ratio of total expense to average net assets	[4]			10.75%	9.13%
Ratio of net investment income before investment gains and losses to average net assets	[4]			18.95%	11.30%
Investment Company, Portfolio Turnover	[5]			17.20%	8.88%
Weighted average debt outstanding				$ 1,614,522	$ 1,386,242
Weighted average debt per common share				$ 11.69	$ 11.43
Realized
Net investment income before investment gains and losses per common share:
Net gain (loss)	[1]			0.06	(0.04)
Unrealized
Net investment income before investment gains and losses per common share:
Net gain (loss)	[1]			0.29	(0.7)
Net Investment Income
Net investment income before investment gains and losses per common share:
Net gain (loss)	[1]			1.02	0.62
Ordinary Income
Net investment income before investment gains and losses per common share:
Distributions of net investment income	[1],[6]			$ (0.96)	$ (0.96)
[1] All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date. Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to net asset value. Pursuant to ASC Topic 718, The total return for the six months ended June 30, 2023, and 2022 equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors. The ratios are calculated based on weighted average net assets for the relevant period and are annualized. The portfolio turnover rate for the six months ended June 30, 2023, and 2022 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized. Includes distributions on unvested restricted stock awards.

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	$ 381,104		$ 381,104		$ 628,874
Total rent expense		$ 800	$ 1,600	$ 800	$ 1,600
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	$ 381,104	$ 628,874
Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	5,017	5,653
Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	376,087	623,221
Phathom Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	16,625	66,500
Vida Health | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,000	40,000
Skydio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	22,500	22,500
SeatGeek, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	19,375	0
Oak Street Health, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	33,750
HilleVax, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	28,000
Axsome Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	25,375	21,000
Automation Anywhere, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	29,400	29,400
Iveric Bio Gene Therapy LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	12,375	0
Aryaka Networks, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	10,000	20,000
G1 Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	19,375
Dragos | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	13,000	0
Alladapt Immunotherapeutics Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	15,000
Dronedeploy Incorporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	12,500	12,500
Locus Robotics Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	10,740	0
R V Share Limited Liability Company | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,500	1,500
App Direct Incorporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	15,000
Nuvolo Technologies Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	5,700	5,970
Elation Health, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	7,500	7,500
Gritstone Bio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	7,500	7,500
Viridian Therapeutics Inc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	12,000
Tarsus Pharmaceuticals, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	8,250	10,313
Dashlane, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	10,000
Akero Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	5,000	5,000
Alamar Biosciences, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	10,000	10,000
Fulfil Solutions Inc [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	5,000
Brain Corporation | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	2,500	20,700
Ceros, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,707	1,707
Demandbase, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	3,750
Riviera Partners LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,500	3,500
Signal Media Limited [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,000	5,250
Yipit, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	2,250	2,250
Saama Technologies | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,875	0
Khoros (p.k.a Lithium Technologies) | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	906	1,812
ThreatConnect, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,600	1,600
Dispatch Technologies, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,250	1,250
Logic Source | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,209	1,209
Ikon Science Limited | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,050	1,050
Omeda Holdings, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	919	938
Alchemer LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	445	890
3GTMS, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,222	0
Agilence, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	800	800
Constructor.io Corporation [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	625	625
Mobile Solutions Services | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	495
Enmark Systems, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	457	457
Zimperium, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	1,088	1,088
Cybermaxx Intermediate Holdings, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	390	390
ShadowDragon, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	333	333
Cytracom Holdings LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	72	225
Annex Cloud | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	386	386
Thumbtack, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	40,000	40,000
Madrigal Pharmaceutical Inc [Member] | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	34,000
TG Therapeutics, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	6,500	0
Sumo Logic | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	2,000	0
Carwow LTD | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	14,365	0
Forbion Growth Opportunities Fund I C V | Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	2,269	2,842
Streamline Healthcare Solutions | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	2,200	0
Forbion Growth Opportunities Fund I I C V | Investment Funds And Vehicles
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	2,748	2,811
Tipalti Solutions Ltd. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	10,500	0
Next Insurance, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	10,000	0
FeverLabsInc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	8,333
Kura Oncology, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	8,250	8,250
MacroFab, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	3,000
Zappi, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	2,571	2,571
Cutover, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	4,150	1,000
Fortified Health Security | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	840	840
Flight Schedule Pro, LLC | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	639	639
ReplimuneGroupInc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	20,700
Pathai Inc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	12,000	12,000
Leapwork ApS | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	4,100	0
Provention Bio, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	0	40,000
BabelStreet | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,375	3,375
Modern Life, Inc. | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	3,250	0
Loftware, Inc | Debt Investments
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1]	$ 1,423	$ 0
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Unfunded Contractual Commitments (Parenthetical) (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount	[1],[2]	$ 381,104	$ 628,874
Adviser Funds
Loss Contingencies [Line Items]
Investment Company, Financial Support to Investee Contractually Required, Not Provided, Amount		$ 127,900	$ 173,500
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Additional Information on Unecumbered Unfunded Commitments (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Total Unfunded Debt Commitments	[1],[2]	$ 381,104	$ 628,874
Debt Investments
Commitments And Contingencies [Line Items]
2023		187,230	461,296
2024		156,056	134,856
2025		1,294	720
2026		9,037	9,038
2027		15,152	15,171
2028		5,318	2,140
2030		2,000	0
Total Unfunded Debt Commitments	[1]	376,087	623,221
Investment Funds And Vehicles
Commitments And Contingencies [Line Items]
2030		2,269	2,842
2032		2,748	2,811
Total Unfunded Debt Commitments		$ 5,017	$ 5,653
[1] For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $ 127.9 million and $ 173.5 million of unfunded commitments as of June 30, 2023, and December 31, 2022 , respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Contractual Obligations (Details) - USD ($) $ in Thousands		Jun. 30, 2023		Dec. 31, 2022
Commitments And Contingencies [Line Items]
Long-Term Debt, Total	[1]	$ 1,588,608		$ 1,574,351
Lessee, Operating Lease, Liability, to be Paid, Year One		3,383
Total lease payments		27,370
Contractual Obligation, to be Paid, Year One	[2]	2,922		2,723
Contractual Obligation, to be Paid, Year Two and Three	[2]	381,617		384,259
Contractual Obligation, to be Paid, Year Four and Five	[2]	872,223		849,452
Contractual Obligation, to be Paid, after Year Five	[2]	376,731		366,207
Contractual Obligations, Total	[2]	1,633,493		1,602,641
Debt Investments [Member]
Commitments And Contingencies [Line Items]
Long-Term Debt, Maturity, Year One	[2],[3]	0	[4]	0	[5]
Long-Term Debt, Maturity, Year Two and Three	[2],[3]	375,000	[4]	382,000	[5]
Long-Term Debt, Maturity, Year Four and Five	[2],[3]	866,000	[4]	847,000	[5]
Long-Term Debt, Maturity, after Year Five	[2],[3]	365,000	[4]	365,000	[5]
Long-Term Debt, Total	[3]	1,606,000	[4]	1,594,000	[5]
Lease and License Obligations
Commitments And Contingencies [Line Items]
Lessee, Operating Lease, Liability, to be Paid, Year One	[2],[6]	2,922		2,723
Lessee, Operating Lease, Liability, to be Paid, Year Two and Three	[2],[6]	6,617		2,259
Lessee, Operating Lease, Liability, to be Paid, Year Four and Five	[2],[6]	6,223		2,452
Lessee, Operating Lease, Liability, to be Paid, after Year Five	[2],[6]	11,731		1,207
Total lease payments	[2],[6]	$ 27,493		$ 8,641
[1] Except for the SMBC Facility and MUFG Bank Facility (f.k.a. Union Bank Facility), all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date. Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds. Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”. Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of June 30, 2023. There was also $ 130.0 million outstanding under the SMBC Facility and $ 61.0 million outstanding under the MUFG Bank Facility as of June 30, 2023 . Includes $ 175.0 million in principal outstanding under the SBA Debentures, $ 105.0 million of the July 2024 Notes, $ 50.0 million of the February 2025 Notes, $ 70.0 million of the June 2025 Notes, $ 50.0 million of the June 2025 3-Year Notes, $ 50.0 million of the March 2026 A Notes, $ 50.0 million of the March 2026 B Notes, $ 150.0 million of the 2031 Asset-Backed Notes, $ 40.0 million of the 2033 Notes, $ 325.0 million of the September 2026 Notes and $ 350.0 million of the January 2027 Notes as of December 31, 2022. There was also $ 72.0 million outstanding under the SMBC Facility and $ 107.0 million outstanding under the MUFG Bank Facility as of December 31, 2022 . Facility leases and licenses including short-term leases.

Commitments and Contingencies_5

Commitments and Contingencies - Schedule of Contractual Obligations (Parenthetical) (Details) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
Commitments And Contingencies [Line Items]
Principal		$ 1,606,000	$ 1,594,000
SMBC Facility
Commitments And Contingencies [Line Items]
Principal		130,000	72,000
MUFG Bank Facility
Commitments And Contingencies [Line Items]
Principal		61,000	107,000
SBA Debentures
Commitments And Contingencies [Line Items]
Principal	[1]	175,000	175,000
July 2024 Notes
Commitments And Contingencies [Line Items]
Principal		105,000	105,000
February 2025 Notes
Commitments And Contingencies [Line Items]
Principal		50,000	50,000
June 2025 Notes
Commitments And Contingencies [Line Items]
Principal		70,000	70,000
June 2025 3-Year Notes
Commitments And Contingencies [Line Items]
Principal		50,000	50,000
March 2026 A Notes
Commitments And Contingencies [Line Items]
Principal		50,000	50,000
March 2026 B Notes
Commitments And Contingencies [Line Items]
Principal		50,000	50,000
2031 Asset-Backed Notes
Commitments And Contingencies [Line Items]
Principal		150,000	150,000
2033 Notes
Commitments And Contingencies [Line Items]
Principal		40,000	40,000
September 2026 Notes
Commitments And Contingencies [Line Items]
Principal		325,000	325,000
January 2027 Notes
Commitments And Contingencies [Line Items]
Principal		$ 350,000	$ 350,000
[1] Availability subject to the Company meeting the borrowing base requirements.

Commitments and Contingencies_6

Commitments and Contingencies - Summary of Information Related to Measurement of Operating Lease Liabilities and Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Total operating lease cost	$ 606	$ 744	$ 1,304	$ 1,441
Cash paid for amounts included in the measurement of lease liabilities	$ 1,127	$ 1,175	$ 1,736	$ 1,769
Weighted-average remaining lease term (in years)	8 years 7 months 13 days		8 years 7 months 13 days		5 years 5 months 23 days
Weighted-average discount rate	6.71%		6.71%		5.37%

Commitments and Contingencies_7

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Operating Leases and Reconciliation to Operating Lease Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
2023	$ 1,042
2024	3,383
2025	3,034
2026	3,288
Thereafter	16,623
Total lease payments	27,370
Less: imputed interest	(23,484)
Operating lease liability	$ 3,886	$ 5,506

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Adviser Subsidiary
Related Party Transaction [Line Items]
Receivable from related party		$ 0.1		$ 0.1		$ 0.1
Related party transactions amount		$ 2.4	$ 3.1	5.1	$ 4.5
Adviser Funds
Related Party Transaction [Line Items]
Adviser subsidiary investment commitments				320.4	440
Adviser subsidiary investment funding				199.9	189.8
Sales to related party	$ 73.5
Gain(Loss) on sales to related party	$ 0.1
Related party transactions amount				$ 9.6	$ 88.2

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - $ / shares	Aug. 22, 2023	Aug. 15, 2023	Jul. 27, 2023	May 16, 2023	Mar. 09, 2023	Jun. 30, 2023	Jun. 30, 2022
Subsequent Event [Line Items]
Cash distribution, per share					$ 0.08
Quarterly distribution, per share					0.08
Share price						$ 14.8	$ 13.49
Base Dividend
Subsequent Event [Line Items]
Dividends payable, date to be paid	Aug. 25, 2023
Cash distribution, per share	$ 0.4
Quarterly distribution, per share	$ 0.4
Dividends payable, date of record		Aug. 18, 2023
Supplemental Dividend
Subsequent Event [Line Items]
Dividends payable, date declared				Feb. 09, 2023
Dividends payable, date to be paid	Aug. 25, 2023
Cash distribution, per share	$ 0.08
Quarterly distribution, per share	$ 0.08
Dividends payable, date of record		Aug. 18, 2023
Total Supplemental Dividends Amount to be Paid			$ 0.32
Supplemental Dividends Declared to Date				$ 0.32	$ 0.24
Supplemental Dividends Amount to be Paid Each Quarter			$ 0.08
Base and Supplemental Dividend
Subsequent Event [Line Items]
Dividends payable, date declared			Jul. 28, 2023

Schedule 12-14s - Summary of _2

Schedule 12-14s - Summary of schedule of investment (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended				12 Months Ended
		Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022		Dec. 31, 2022		Dec. 31, 2021
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating		$ 116,231		$ 72,115		$ 221,321		$ 137,272
Realized Gain (Loss)		217		(2,133)		8,177		(4,514)
Investment cost		3,114,097				3,114,097				$ 3,005,696
Investment Owned, Fair Value		3,112,789				3,112,789				2,963,955
Net Change in Unrealized Appreciation (Depreciation)		18,858		(48,316)		39,963		(85,058)
Coronado Aesthetics L L C [Member] | Preferred Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[1],[2]					0
Medical Devices And Equipment [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		1,052				1,052				1,834
Diversified Financial Services [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		94,077				94,077				68,569
Consumer And Business Services [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		459,276				459,276				439,384
Sustainable And Renewable Technology [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		11,333				11,333				15,486
Senior Secured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		2,878,923				2,878,923				2,741,388
Unsecured Debt [Member]
Investments in and Advances to Affiliates [Line Items]
Investment Owned, Fair Value		59,019				59,019				54,056
Investment, Affiliated Issuer [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3]							3,415
Realized Gain (Loss)								3,772
Investment Owned, Fair Value				86,488				86,488				$ 82,962
Gross Additions	[4]							3,667
Gross reductions	[5]							5,781
Net Change in Unrealized Appreciation (Depreciation)								5,640
Investment, Affiliated Issuer, Controlled [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						2,209	[2]	2,292	[3]
Realized Gain (Loss)	[6]	0		0		0		0
Investment cost		88,317				88,317				87,271
Investment Owned, Fair Value		90,923	[6],[7]	82,875	[6]	90,923	[6],[7]	82,875	[6]	76,458	[8]	73,504
Gross Additions						1,046	[9]	3,189	[4]
Gross reductions						0	[10]	0	[5]
Net Change in Unrealized Appreciation (Depreciation)	[6]	4,573		4,728		13,419		6,182
Investment, Affiliated Issuer, Controlled [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						1,867	[2]	1,950	[3]
Realized Gain (Loss)								0
Investment cost		65,904				65,904				64,858
Investment Owned, Fair Value		83,850	[7]	74,667		83,850	[7]	74,667		68,416	[8]	65,235
Gross Additions						1,046	[9]	3,189	[4]
Gross reductions						0	[10]	0	[5]
Net Change in Unrealized Appreciation (Depreciation)						14,388		6,243
Investment, Affiliated Issuer, Controlled [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						342	[2]	342	[3]
Realized Gain (Loss)						0	[9]	0
Investment cost		22,413				22,413				22,413
Investment Owned, Fair Value		7,073	[7]	8,208		7,073	[7]	8,208		8,042	[8]	8,269
Gross Additions						0	[9]	0	[4]
Gross reductions						0	[10]	0	[5]
Net Change in Unrealized Appreciation (Depreciation)						(969)		(61)
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6]	0		0		0		0
Investment Owned, Fair Value	[6]	39,161		35,181		39,161		35,181
Net Change in Unrealized Appreciation (Depreciation)	[6]	2,566		8,637		8,008		11,191
Investment, Affiliated Issuer, Controlled [Member] | Hercules Adviser L L C [Member] | Member Units [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[2],[11]	0	[3],[12]
Realized Gain (Loss)						0	[9],[11]	0	[12]
Investment Owned, Fair Value		27,161	[11]	23,181	[12]	27,161	[11]	23,181	[12]	19,153	[11]	11,990	[12]
Gross Additions						0	[9],[11]	0	[4],[12]
Gross reductions						0	[10],[11]	0	[5],[12]
Net Change in Unrealized Appreciation (Depreciation)						8,008	[11]	11,191	[12]
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6]	0		0		0		0
Investment Owned, Fair Value	[6]	297		422		297		422
Net Change in Unrealized Appreciation (Depreciation)	[6]	(41)		(192)		(22)		(143)
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics L L C [Member] | Common Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						0	[2]	0	[3],[13]
Realized Gain (Loss)						0	[1],[9]	0	[13]
Investment Owned, Fair Value		5	[1]	10	[13]	5	[1]	10	[13]	6	[1]	65	[13]
Gross Additions						0	[1],[9]	0	[4],[13]
Gross reductions						0	[1],[10]	0	[5],[13]
Net Change in Unrealized Appreciation (Depreciation)						(1)	[1]	(55)	[13]
Investment, Affiliated Issuer, Controlled [Member] | Coronado Aesthetics L L C [Member] | Preferred Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[13]							0
Realized Gain (Loss)						0	[1]	0	[13]
Investment Owned, Fair Value		292	[1]	412	[13]	292	[1]	412	[13]	313	[1]	500	[13]
Gross Additions						0	[1],[9]	0	[4],[13]
Gross reductions						0	[1],[10]	0	[5],[13]
Net Change in Unrealized Appreciation (Depreciation)						(21)	[1]	(88)	[13]
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6]	0		0		0		0
Investment Owned, Fair Value	[6]	7,073		8,208		7,073		8,208
Net Change in Unrealized Appreciation (Depreciation)	[6]	(701)		(139)		(969)		(61)
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation [Member] | Common Stock [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[14]					0
Investment Owned, Fair Value	[14]									0
Gross Additions	[9],[14]					0
Net Change in Unrealized Appreciation (Depreciation)	[14]					0
Investment, Affiliated Issuer, Controlled [Member] | Tectura Corporation [Member] | Preferred Stock [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[14]					0
Investment Owned, Fair Value	[14]									0
Gross Additions	[9],[14]					0
Net Change in Unrealized Appreciation (Depreciation)	[14]					0
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6]	0	[15]	0		0	[15]	0
Investment Owned, Fair Value	[6]	44,392	[15]	39,064		44,392	[15]	39,064
Net Change in Unrealized Appreciation (Depreciation)	[6]	2,667	[15]	(3,578)		6,402	[15]	(4,805)
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital L L C [Member] | Common Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[16]							0
Realized Gain (Loss)	[16]							0
Investment Owned, Fair Value	[16]			974				974				1,225
Gross Additions	[4],[16]							0
Gross reductions	[5],[16]							0
Net Change in Unrealized Appreciation (Depreciation)	[16]							(251)
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital L L C [Member] | Preferred Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[16]							0
Realized Gain (Loss)	[16]							0
Investment Owned, Fair Value	[16]			15,415				15,415				19,393
Gross Additions	[4],[16]							0
Gross reductions	[5],[16]							0
Net Change in Unrealized Appreciation (Depreciation)	[16]							(3,978)
Investment, Affiliated Issuer, Controlled [Member] | Gibraltar Business Capital L L C [Member] | Member Units [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[2],[17]					0
Investment Owned, Fair Value		19,779	[17]			19,779	[17]			15,244	[10]
Gross Additions	[9],[17]					1,000
Net Change in Unrealized Appreciation (Depreciation)	[17]					3,535
Investment, Affiliated Issuer, Controlled [Member] | Medical Devices And Equipment [Member] | Coronado Aesthetics L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		250				250				250
Investment Owned, Fair Value		297	[7]			297	[7]			319	[8]
Investment, Affiliated Issuer, Controlled [Member] | Medical Devices And Equipment [Member] | Coronado Aesthetics L L C [Member] | Preferred Series A | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 250				$ 250				$ 250
Shares		5,000,000				5,000,000				5,000,000
Investment Owned, Fair Value		$ 292	[7]			$ 292	[7]			$ 313	[8]
Investment, Affiliated Issuer, Controlled [Member] | Medical Devices And Equipment [Member] | Coronado Aesthetics L L C [Member] | Common Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 0				$ 0				$ 0
Shares		180,000				180,000				180,000
Investment Owned, Fair Value		$ 5	[7]			$ 5	[7]			$ 6	[8]
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Hercules Adviser L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		12,035				12,035				12,035
Investment Owned, Fair Value		39,161	[7]			39,161	[7]			31,153	[8]
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Hercules Adviser L L C [Member] | Member Units [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 35				$ 35				$ 35
Shares		1				1				1,000
Investment Owned, Fair Value		$ 27,161	[7]			$ 27,161	[7]			$ 19,153	[8]
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		53,619				53,619				52,573
Investment Owned, Fair Value		44,392	[7]			44,392	[7]			36,944	[8]
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Preferred Series A | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost										$ 26,122
Shares										10,602,752
Investment Owned, Fair Value	[8]									$ 14,137
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Common Stock [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost										$ 1,884
Shares										830,000
Investment Owned, Fair Value	[8]									$ 1,107
Investment, Affiliated Issuer, Controlled [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Member Units [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 29,006				$ 29,006
Shares		1				1
Investment Owned, Fair Value	[7]	$ 19,779				$ 19,779
Investment, Affiliated Issuer, Controlled [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		22,413				22,413				22,413
Investment Owned, Fair Value		7,073	[7]			7,073	[7]			8,042	[8]
Investment, Affiliated Issuer, Controlled [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Preferred Series BB | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 0				$ 0				$ 0
Shares		1,000,000				1,000,000				1,000,000
Investment Owned, Fair Value		$ 0	[7]			$ 0	[7]			$ 0	[8]
Investment, Affiliated Issuer, Controlled [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Common Stock [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment cost		$ 900				$ 900				$ 900
Shares		414,994,863				414,994,863				414,994,863
Investment Owned, Fair Value		$ 0	[7]			$ 0	[7]			$ 0	[8]
Investment, Affiliated Issuer, Controlled [Member] | Senior Secured Debt [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						342	[2],[14]	342	[3],[18]
Realized Gain (Loss)	[18]							0
Investment Owned, Fair Value		$ 7,073	[14]	8,208	[18]	7,073	[14]	8,208	[18]	$ 8,042	[14]	8,269	[18]
Gross Additions						0	[9],[14]	0	[4],[18]
Gross reductions						0	[10],[14]	0	[5],[18]
Net Change in Unrealized Appreciation (Depreciation)						$ (969)	[14]	(61)	[18]
Investment, Affiliated Issuer, Controlled [Member] | Senior Secured Debt [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Kind		5%				5%				5%
Investment cost		$ 13,263				$ 13,263				$ 240
Principal Amount		23,703				$ 23,703				$ 10,680
Maturity Date						2024-07				2024-07
Investment Owned, Fair Value		0	[7]			$ 0	[7]			$ 0	[8]
Investment, Affiliated Issuer, Controlled [Member] | Unsecured Debt [Member] | Hercules Adviser L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						302	[2],[11]	239	[3],[12]
Realized Gain (Loss)						0	[9],[11]	0	[12]
Investment Owned, Fair Value		12,000	[11]	12,000	[12]	12,000	[11]	12,000	[12]	12,000	[11]	8,850	[12]
Gross Additions	[4],[12]							3,150
Gross reductions						0	[10],[11]	0	[5],[12]
Net Change in Unrealized Appreciation (Depreciation)						0	[9],[11]	0	[12]
Investment, Affiliated Issuer, Controlled [Member] | Unsecured Debt [Member] | Gibraltar Business Capital L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating						1,565	[2],[17]	1,711	[3],[16]
Realized Gain (Loss)	[16]							0
Investment Owned, Fair Value		$ 24,613	[17]	22,675	[16]	24,613	[17]	22,675	[16]	$ 21,700	[10]	23,212	[16]
Gross Additions						46	[9],[17]	39	[4],[16]
Gross reductions						0	[10],[17]	0	[5],[16]
Net Change in Unrealized Appreciation (Depreciation)						$ 2,867	[17]	(576)	[16]
Investment, Affiliated Issuer, Controlled [Member] | Unsecured Debt [Member] | Diversified Financial Services [Member] | Hercules Adviser L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		5%				5%				5%
Investment cost		$ 12,000				$ 12,000				$ 12,000
Principal Amount		12,000				$ 12,000				$ 12,000
Maturity Date						2025-06				2023-05
Investment Owned, Fair Value		$ 12,000	[7]			$ 12,000	[7]			$ 12,000	[8]
Investment, Affiliated Issuer, Controlled [Member] | Unsecured Debt [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		11.50%				11.50%				14.50%
Investment cost		$ 24,613				$ 24,613				$ 14,715
Principal Amount		25,000				25,000				$ 15,000
Maturity Date										2026-09
Investment Owned, Fair Value		$ 24,613	[7]			$ 24,613	[7]			$ 12,802	[8]
Investment, Affiliated Issuer, Controlled [Member] | Unsecured Debt One [Member] | Diversified Financial Services [Member] | Gibraltar Business Capital L L C [Member] | Majority Owned Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash										11.50%
Investment cost										$ 9,852
Principal Amount										$ 10,000
Maturity Date						2026-09				2026-09
Investment Owned, Fair Value	[8]									$ 8,898
Investment, Affiliated Issuer, Controlled [Member] | Senior Secured Debt One [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Cash		8.25%				8.25%				8.25%
Investment cost		$ 8,250				$ 8,250				$ 8,250
Principal Amount		8,250				$ 8,250				$ 8,250
Maturity Date						2024-07				2024-07
Investment Owned, Fair Value		7,073	[7]			$ 7,073	[7]			$ 8,042	[8]
Investment, Affiliated Issuer, Controlled [Member] | Senior Secured Debt Two [Member] | Consumer And Business Services [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment, Interest Rate, Paid in Kind										5%
Investment cost										$ 13,023
Principal Amount										$ 13,023
Maturity Date										2024-07
Investment Owned, Fair Value	[8]									$ 0
Investment, Affiliated Issuer, Noncontrolled [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3]							1,123
Realized Gain (Loss)		0		0		0		3,772
Investment Owned, Fair Value				3,613				3,613				9,458
Gross Additions	[4]							478
Gross reductions	[5]							5,781
Net Change in Unrealized Appreciation (Depreciation)		$ 0		(1,295)		0		(542)
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6],[19]			0				0
Investment Owned, Fair Value	[6],[19]			3,613				3,613
Net Change in Unrealized Appreciation (Depreciation)	[6],[19]			(1,295)				(422)
Investment, Affiliated Issuer, Noncontrolled [Member] | Pineapple Energy L L C [Member] | Common Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[20]							0
Realized Gain (Loss)	[20]							0
Investment Owned, Fair Value	[20]			673				673				591
Gross Additions	[4],[20]							400
Gross reductions	[5],[20]							0
Net Change in Unrealized Appreciation (Depreciation)	[20]							(318)
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow A I Inc [Member]
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[6],[19]			0				3,772
Investment Owned, Fair Value	[6],[19]			0				0
Net Change in Unrealized Appreciation (Depreciation)	[6],[19]			0				(120)
Investment, Affiliated Issuer, Noncontrolled [Member] | Black Crow A I Inc [Member] | Preferred Stock [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[21]							0
Realized Gain (Loss)	[21]							3,772
Investment Owned, Fair Value	[21]			0				0				1,120
Gross Additions	[4],[21]							0
Gross reductions	[5],[21]							(1,000)
Net Change in Unrealized Appreciation (Depreciation)	[21]							(120)
Investment, Affiliated Issuer, Noncontrolled [Member] | Senior Secured Debt [Member] | Pineapple Energy L L C [Member]
Investments in and Advances to Affiliates [Line Items]
Gross Investment Income, Operating	[3],[20]							1,123
Realized Gain (Loss)	[20]							0
Investment Owned, Fair Value	[20]			$ 2,940				2,940				$ 7,747
Gross Additions	[4],[20]							78
Gross reductions	[5],[20]							(4,781)
Net Change in Unrealized Appreciation (Depreciation)	[20]							$ (104)
Investment, Affiliated Issuers Controlled, Not Majority-Owned [Member] | Senior Secured Debt [Member] | Tectura Corporation [Member] | Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Realized Gain (Loss)	[9],[14]					$ 0
[1] As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment. Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of June 30, 2023, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”. As of June 30, 2022, the Hercules Adviser, LLC qualified as a significant subsidiary pursuant to Rule 10-01(b)(1). The total revenue, operating income, and net income were $ 3.5 million, $( 1.9 ) million, and $( 1.8 ) million for the six months ended June 30, 2022 . All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs. Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities. Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period. Hercules Adviser LLC is a wholly owned subsidiary providing investment management and other services to the Adviser Funds and other External Parties. Hercules Adviser LLC is a wholly-owned subsidiary providing investment management and other services to External Parties. As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. As of March 31, 2018, the Company's investment in Gibraltar Business Capital, LLC became classified as a control investment as a result of obtaining a controlling financial interest. As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC (p.k.a. Gibraltar Business Capital, LLC) became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively. As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the As of September 30, 2022, Black Crow AI, Inc. and Pineapple Energy LLC were no longer affiliates as defined under the 1940 Act. As of December 11, 2020, the Company's investment in Pineapple Energy LLC became classified as an affiliate investment as a result of obtaining more than 5% but less than 25% of the voting securities of the portfolio company. During the six months ended June 30, 2022, the Company sold its investments in Black Crow AI, Inc., as a result it is no longer an affiliate investment.

Schedule 12-14s - Summary of _3

Schedule 12-14s - Summary of schedule of investment (Parenthetical) (Details) - Investment, Affiliated Issuer, Controlled [Member]	Jun. 30, 2023	[1]	Dec. 31, 2022	[2]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	(5.73%)		5.46%
Other Control Investments
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	(0.44%)		0.58%
Majority Owned Control Investments [Member]
Investments in and Advances to Affiliates [Line Items]
Investment owned, percent of net assets	(5.29%)		4.88%
[1] * Value as a percent of net assets * Value as a percent of net assets